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1. SUMMARY 
 
 MicroRNAs (miRNAs) are a large family of small noncoding RNAs that extensively 
regulate gene expression in animals, plants and protozoa. The first miRNA was identified in the 
early 1990s, but it took almost a decade until miRNAs were recognized as key post-
transcriptional regulators of gene expression. Despite the rapidly growing list of miRNA-
regulated physiological and pathological processes, intracellular membrane trafficking has 
attracted little interest from scientific miRNA community. Membrane trafficking defines a 
complex network of pathways, including biosynthetic trafficking and endocytosis that are 
indispensable for normal cellular functions. Previous studies have analyzed a few miRNAs 
involved in insulin secretion, however, no systematic investigation of miRNAs as important 
regulators of membrane trafficking has been performed.  
 The overall aim of this study was to identify miRNAs and their biologically relevant 
target genes involved in the regulation of membrane trafficking. As tools to modulate miRNA 
functions, we used synthetic miRNA mimics (pre-miRs) and inhibitors (anti-miRs) to enhance 
(gain-of-function) and to suppress (loss-of-function) the activity of cellular miRNAs, 
respectively. As proof of principle, we demonstrated that increased activity of miR-17 family 
miRNAs accelerates the biosynthetic cargo protein (ts-O45-G) transport and reduces the cellular 
internalization of DiI-LDL ligand.      
Taking the advantage of available technological platforms, we designed a gain-of-
function large-scale screening to identify miRNAs that affect biosynthetic ts-O45-G transport 
rate. We showed that 44 out of 470 tested miRNAs induced significant changes in cargo 
trafficking. Using image analysis platform, we further identified eight miRNAs (miR-30b, -382,        
-432, -517a, -517b, -517c, -637 and -765) that also showed significant effects on Golgi complex 
integrity. Importantly, the majority of identified miRNAs are not endogenously expressed in 
HeLa cells, indicating the need for validation studies in other experimental systems. 
To identify functionally relevant target genes, we selected miR-17 and miR-517a and 
performed genome-wide transcriptome analysis 12h, 24h and 48h after transfection with the 
respective pre-miRs. We identified TBC1D2 and LDLR genes as novel functional miR-17 targets 
and confirmed that they exert the miR-17-mediated regulation of endocytosis. Further studies are 
needed to identify target genes responsible for the miR-17-governed acceleration of ts-O45-G to 
the plasma membrane. In case of miR-517a, we found a set of target genes with functions in 
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membrane trafficking system, however, their functional interplay with miR-517a remains to be 
confirmed. 
Bioinformatics analysis of transcriptome profiling data confirmed that the presence of 
miRNA seed binding site in the 3´UTRs of human mRNAs is an important determinant for 
functional miRNA:mRNA interaction. Additionally, we demonstrated that the sets of transcripts 
downregulated at early time points after transfection with pre-miRs have substantially higher 
fractions of transcripts with miRNA binding sites in their 3´UTRs compared to the transcripts 
downregulated at late time points. We believe that these findings could contribute to the 
development of more accurate miRNA target prediction tool, also allowing identification of 
nonconserved miRNA targets.   
In conclusion, we have established an experimental platform that consists of (i) a 
functional screening module to identify miRNAs that affect membrane trafficking, (ii) a 
microarray module to identify miRNA target genes, (iii) a statistics and bioinformatics module 
for data analysis and integration and (iv) a target validation module to validate functional links 
between targets and miRNAs. Using this platform, we identified numerous miRNAs with novel 
functions in membrane trafficking system. Moreover, we identified and confirmed TBC1D2 and 
LDLR genes as novel functional targets of miR-17.  
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2. ZUSAMMENFASSUNG 
 
MicroRNAs (miRNAs) sind eine große Familie kleiner nichtcodierender RNAs, die 
weitgehend die Genexpression in Tieren, Pflanzen und Protozoen regulieren. Die erste miRNA 
wurde in den frühen 1990ern identifiziert, aber es dauerte beinahe ein Jahrzehnt bis die miRNAs 
als Schlüssel-posttranskriptionale Regulatoren der Genexpression begriffen wurden. Trotz der 
schnell wachsenden Liste von miRNA-regulierten physiologischen und pathologischen Prozesse  
hat der intrazelluläre Membrantransport  wenig Interesse bei der  wissenschaftlichen miRNA 
Gemeinschaft geweckt. Membrantransport definiert ein komplexes Netzwerk von Bahnen, die 
den biosynthetischen Transport und Endocytose beinhalten, die unentbehrlich für normale 
zelluläre Funktionen sind. Frühere Studien haben einige miRNAs analysiert, die an der Insulin-
Sekretion beteiligt waren, jedoch wurde keine systematische Erforschung von miRNAs als 
wichtige Regulatoren von Membrantransport durchgeführt. 
Das allgemeine Ziel dieser Studie war es, miRNAs und ihre biologisch relevanten 
Zielgene, die in der Regulation des Membrantransports involviert sind, zu identifizieren. Als 
Werkzeuge zur Modellierung der miRNA-Funktionen verwendeten wir synthetische miRNA 
mimics (pre-miRs) und Inhibitoren (anti-miRs), um die Aktivität der zellulären miRNAs zu 
erhöhen (Anstieg der Funktion) oder entsprechend abzuschalten (Verlust der Funktion). Als 
Beweis zeigten wir, daß die  erweiterte Aktivität der miR-17 Familie mRNAs  den 
biosynthetischen Cargo-Protein (ts-O45-G) Transport beschleunigt und die  zelluläre 
Internalisierung von Dil-LDL Liganden  reduziert. 
Indem wir den Vorteil einer verfügbaren Technologieplattform nutzten, entwickelten wir 
ein gain-of function Hochdurchsatzscreen, um miRNAs zu identifizieren, die eine Auswirkung 
auf die biosynthetische ts-O45-G-Transportrate haben. Wir zeigten, daß 44 von 470 getesteten 
miRNAs signifikante Veränderungen im Cargotransport induzierten. Durch Nutzung der 
Bildanalyse-Plattform identifizierten wir weitere acht miRNAs (miR-30b, -382, -432, -517a, -
517b, -517c, -637, -und -765) die auch signifikante Effekte auf die Golgikomplexintegrität 
zeigten. Es ist wichtig, daß die Mehrheit der identifizierten miRNAs, die  nicht endogen in Hela-
Zellen exprimiert werden, die Notwendigkeit für Validierungsstudien in anderen experimentellen 
Systemen zeigen. 
Um funktionell relevante Zielgene zu identifizieren, selektierten wir miR-17 und miR-
517a und führten eine genomweite Transkriptionsanalyse 12h, 24h und 48h nach Transfektion 
mit den entsprechenden pre-miRs durch. Wir identifizierten TBC1D2- und LDLR-Gene als neue 
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funktionelle miR-17 targets und bestärkten, daß sie die miR-17 -herbeigeführte Regulation der 
Endozytose gebrauchen. Weitere Studien sind notwendig, um Zielgene zu identifizieren, die 
verantwortlich sind für die miR-17-beeinflußte Beschleunigung von ts-O45-G zur 
Plamamembran. Im Fall von miR-517a fanden wir ein Set von Zielgenen mit Funktionen im 
Membrantransportsystem, jedoch bleibt ihre funktionelle Wechselwirkung mit miR-517a zu 
bestätigen. 
Bioinformatikanalyse von Transkriptionsprofildaten bekräftigten, daß die Anwesendheit 
von miRNA “seed“-Bindungstellen an den 3´UTRs von humanen mRNAs eine wichtige 
Determinante für miRNA:mRNA funktionelle Interaktion ist. Zusätzlich zeigten wir, daß die Sets 
von Transkripten, die zu frühen Zeitpunkten nach Transfektion mit pre-miRs  substanziell höhere 
Fraktionen von Transkripten mit miRNA-Bindungsstellen in ihren 3´UTRs aufweisen, verglichen 
mit den Transkripten, die zu späteren Zeitpunkten runterreguliert wurden. Wir glauben, daß diese 
Ergebnisse zur Entwicklung von genaueren miRNA Vorhersagetools beitragen könnten,  auch 
könnte es die Identifizierung von unkonservierten miRNA-Targets erlauben. 
Zum Abschluß etablierten wir eine experimentelle Plattform, die aus einem funktionellen 
Screening-Modul besteht, um miRNAs zu identifizieren, die eine Auswirkung auf den 
Memrantransport haben, ein microarray-Modul zur Identifizierung von miRNA Targetgenen, ein 
statistisches und Bioinformatik-Modul zur Datenanalyse und Integration, ein Target-Modul zur 
Validierung eines funktionellen Links zwischen Targets und miRNAs zu erzielen. Mittels dieser 
Plattform identifizierten wir eine Anzahl von miRNAs mit neuen Funktionen im 
Membrantransportsystem. Außerdem identifizierten und bestätigten wir TBC1D2 und LDLR-
Gene als neue funktionelle Targets von miR-17. 
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3. INTRODUCTION 
 
3.1. miRNAs and their discovery 
 
 MicroRNAs (miRNAs) are a family of small ~21-nucleotide-long noncoding single-
stranded endogenous RNA molecules that regulate gene expression post-transcriptionally by 
base-pairing to target mRNAs. Bioinformatics and experimental approaches have revealed that 
~30-75% of human protein-coding genes can be potentially targeted by miRNAs (Baek et al, 
2008; Bartel, 2009; Friedman et al, 2009; Lewis et al, 2005; Selbach et al, 2008). Originally 
recognized as regulators of fundamental processes at cellular and organism level, including 
development (Bernstein et al, 2003; Lee et al, 1993; Olsen & Ambros, 1999), cell proliferation 
(Johnson et al, 2007), differentiation (Chen et al, 2004) and apoptosis (Brennecke et al, 2003; 
Chan et al, 2005; Cimmino et al, 2005), miRNAs have now been demonstrated to modulate 
cholesterol metabolism (Krutzfeldt et al, 2005), stress response (Huang et al, 2009), neuronal 
plasticity (Schratt et al, 2006; Siegel et al, 2009) and immune response (Xiao & Rajewsky, 
2009). Furthermore, aberrant miRNA expression has been linked to various diseases, such as 
diabetes (Guay et al, 2011), cancer (Croce, 2009; Lynam-Lennon et al, 2009), hepatitis C 
(Jopling et al, 2005) and mental disorders (Xu et al, 2010). 
 Historically, the first hint about miRNAs as novel regulatory genes in C. elegans was 
published by Chalfie and colleagues in 1981 (Chalfie et al, 1981). However, only in 1993 
Ambros, Lee and Feinbaum discovered that lin-14 gene is regulated by a short 22-nt RNA 
encoded by the lin-4 gene in C. elegans. The lin-4 miRNA sequence was found to be partially 
complementary to the multiple sequences in the 3´untranslated region (3´UTR) of the lin-14 
mRNA (Lee et al, 1993). The second miRNA let-7, which inhibits the expression of lin-41, lin-
14, lin-28, lin-42 and daf-12 genes during development of C. elegans, was characterized by 
Ruvkun and colleagues 7 years later (Reinhart et al, 2000). Although originally thought to be a 
genetic oddity of nematodes, let-7 and some other C. elegans miRNAs were soon shown to be 
conserved in other metazoans including human (Pasquinelli et al, 2000). Finally, in 2001, 
miRNAs burst on the stage with three landmark articles published in a single issue of Science, 
reporting the discovery of over a hundred novel miRNAs in nematodes, flies and mammals 
(Lagos-Quintana et al, 2001; Lau et al, 2001; Lee & Ambros, 2001). These papers introduced the 
term “microRNA” to refer to a family of small non-coding RNAs with similar genomic features.  
 16 
During the following years, thousands of miRNAs have been and are still being 
characterized in almost all studied organisms, ranging from viruses (Cai et al, 2006) and green 
algae (Molnar et al, 2007) to complex animal species (Lagos-Quintana et al, 2001). To date, there 
are 21 643 mature miRNAs identified in 168 species including 1 527 miRNAs found in human 
genome annotated in miRBase 18 release (http://www.mirbase.org/). miRNAs are located in 
diverse regions of the genome including both protein-coding and non-coding transcription units. 
Computational analysis revealed 55 and 51 distinct miRNA clusters encoding approximately 46% 
and 47% of known by that time human and mouse miRNAs, respectively (Griffiths-Jones et al, 
2008; Yuan et al, 2009). Analysis of the primary miRNA transcripts (pri-miRNAs) indicated that 
clusters can contain from 2 to 46 tandemly encoded miRNA hairpins (Baskerville & Bartel, 2005; 
Bortolin-Cavaille et al, 2009). By mapping miRNA genomic coordinates to genomic position of 
all annotated human genes, Hinske and colleagues demonstrated that 42.6% miRNAs are located 
within intronic regions, 5.3% within exonic regions and the remaining 52.1% are intergenic 
miRNAs. Interestingly, genomic distribution of miRNAs in other surveyed species with well-
annotated protein-coding genes is very similar to the one in humans (Hinske et al, 2010). 
 
3.2. Biological functions of animal miRNAs 
 
Many fundamental biological processes were shown to be regulated by miRNAs. The first 
evidence of miRNA involvement in regulation of developmental timing came from studies of lin-
4 gene mutantion in C. elegans (Lee et al, 1993). As identified later, lin-4 encodes a miRNA that 
is partially complementary to seven motifs in the 3´UTR of the transcription factor lin-14 
messenger RNA. lin-4 miRNA (ortholog of mammalian miR-125) binds to lin-14 mRNA and 
controls the developmental transition from the L1 to L2 larval stage by promoting lin-14 mRNA 
degradation. Loss-of-function mutation in lin-4 miRNA results in the repeated cell division and 
failed differentiation (Bagga et al, 2005; Lee et al, 1993; Wightman et al, 1993). Other four 
members of let-7 family (let-7, miR-48, miR-84 and miR-241) were shown to control the 
developmental transition from the L2 to the L3 stage by regulation of the transcription factors 
HBL-1 and DAF-2 (Abbott et al, 2005; Hammell et al, 2009; Li et al, 2005). The terminal 
transition from the L4 larval stage to the adult nematode is conferred by upregulation of the let-7 
miRNA in the L4 stage, which downregulates LIN-41 and thereby upregulates the transcription 
factor LIN-29 (Reinhart et al, 2000; Rougvie & Ambros, 1995). Considering that both lin-4 and 
let-7 miRNA families are broadly conserved, they might have similar functions in other 
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organisms. Consistent with this notion, Pasquinelli and colleagues discovered that let-7 
expression is temporally regulated during development in different animal species (Pasquinelli et 
al, 2000). Moreover, the evolutionary conserved roles for temporally regulated miRNAs, 
particularly the let-7 family, have been confirmed during terminal differentiation of fly wing 
imaginal discs and proliferation of mammalian stem cells during both normal development and 
cancer (reviewed in Nimmo & Slack, 2009; Tennessen & Thummel, 2008). 
The loss of lin-4 and the let-7 miRNA function causes clear cell differentiation defects 
associated with cell proliferation. In addition to numerous studies investigating the biological 
roles of miRNAs in organogenesis in nematodes (Johnston & Hobert, 2003), flies (Lai et al, 
2005) and zebrafish (Giraldez et al, 2005), an elaborate knockout work of miR-17-92 cluster in 
mice revealed that deletion of this cluster leads to neonatal lethality. Furthermore, deletion of this 
cluster impairs normal development of heart, lungs and B cells. The proapoptotic Bim gene was 
identified as target of the cluster and likely partially responsible for the phenotypes caused by 
knockout of miR-17-92. Authors also showed that concomitant deletion of miR-17-92 and 
paralogue miR-106b-25 cluster causes more severe cardiac defects, increased apoptosis and 
embryonic death by midgestation, indicating functional cooperation between related miRNA 
clusters (Ventura et al, 2008).  
Since genetic loss-of-function mutations are unavailable for most of miRNAs, dicer 
knockout mutants have been particularly useful models for studying miRNA functions during 
embryogenesis and early development. Observations that depletion of Dicer by RNAi in C. 
elegans leads to developmental phenotypes reminiscent of the lin-4 and let-7 mutants (Grishok et 
al, 2001) clearly indicate a crucial role of miRNAs in early animal development. Moreover, loss 
of Dicer also causes developmental arrest in zebrafish (Giraldez et al, 2005) and depletion of 
stem cells in mice (Bernstein et al, 2003). 
Functional studies have demonstrated that miRNAs are involved in the regulation of 
almost every investigated cellular process. In most cases, however, these findings come from the 
examination of pathological samples. Thus, our understanding, regarding the physiologic 
functions of most of the identified miRNAs, remains very fragmented. A number of previous 
studies have revealed the high degree of similarity between dysregulation of developmental 
processes and malignant transformation. Importantly, a set of miRNAs have been implicated in 
both pathological conditions. Aberrant miRNA expression profiles have been detected in most 
tumors examined (Hayashita et al, 2005; Volinia et al, 2006). These findings have highlighted the 
potential of miRNA profiling in cancer diagnosis, progressions and outcome (Jay et al, 2007; Lu 
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et al, 2005). In this context, the definition of oncogenes and tumor suppressors has been 
expanded from the protein-coding genes to include miRNAs (Garzon et al, 2006; Wu et al, 
2007). 
Due to particular focus of this project on miR-17-92 cluster, recent advances in 
understanding the role of this cluster in tumorigenesis will be reviewed in the next section. 
 
3.2.1. miR-17-92 cluster and cancer 
 
 One of the best-characterized polycistronic miRNA cluster, miR-17-92, resides in the 
C13orf25 gene locus on chromosome 13 and gives rise to six mature miRNAs: miR-17, miR-18, 
miR-19a, miR-20a, miR-19b and miR-92a (Ota et al, 2004; Tanzer & Stadler, 2004). The six 
miRNAs can be grouped into three distinct seed families according to their seed sequences: the 
miR-17 seed family (miR-17 and miR-20a), the miR-18 seed family (miR-18a), the miR-19 family 
(miR-19a and miR-19b) and the miR-92 family (miR-92a). Other paralogous miRNAs encoded by 
miR-106a-363 and miR-106b-25 clusters can also be grouped into these families. Most likely, 
paralogous miR-106a-363 and miR-106b-25 clusters originated via a series of duplications and 
deletions of C13orf25 locus during early vertebrate evolution (Tanzer & Stadler, 2004; Ventura 
et al, 2008). 
 The high-level amplification of 13q31-q32, a locus of miR-17-92, has been observed in 
several hematopoietic malignancies and solid tumors, including lung carcinoma, Burkitt’s 
lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, glioma, bladder cancer, 
squamous-cell carcinoma of the head and neck, liposarcoma and colon carcinomas, just to 
mention a few (Ota et al, 2004; Volinia et al, 2006). Some of the first functional data indicating 
the oncogenic activity of miR-17-92 cluster came from a mouse B-cell lymphoma model, in 
which overexpression of truncated miR-17-92 cluster (lacking miR-92a) functionally cooperates 
with c-MYC oncogene to accelerate the progression of malignant lymphomas (He et al, 2005). 
Dysregulated expression of c-MYC due to mutation or amplification is one of the most common 
abnormalities in human cancers (Cole & McMahon, 1999). As low degree of apoptosis was 
observed in tumors resulting from combined c-MYC and truncated miR-17-92 expression, the 
cluster inhibits apoptotic factors induced by c-MYC oncoprotein. This collaboration leads to 
highly malignant, disseminated B-cell lymphomas. Inspired by these findings, authors coined the 
term “oncomiR”, with miR-17-92 being oncomiR-1, to denote miRNAs with a role in 
tumorigenesis (He et al, 2005). The anti-apoptotic effects of miR-17-92 cluster can be at least 
 19 
partially explained by inhibition of pro-apoptotic BIM and PTEN expression. An elegant study of 
functional dissection of the individual miRNA in B-cell lymphoma model revealed that miR-19a 
and miR-19b are essential and sufficient to recapitulate the oncogenic activity of the entire cluster 
through repression of apoptosis by inhibiting PTEN (Mu et al, 2009). Consistent with results 
observed in a mouse B-cell lymphoma model, upregulation of BIM and PTEN most likely 
contributes to the increased apoptosis rate during pro-B to pre-B transition in miR-17-92 deficient 
animals during both fetal and adult B-cell development (Ventura et al, 2008; Xiao et al, 2008).  
 The direct interaction between miR-17-92 and c-MYC was initially underlined by the 
finding that c-MYC binds directly to the genomic locus of miR-17-92 and induces its 
transcription (O'Donnell et al, 2005). At the same time, it has been shown that E2F transcription 
factors, E2F1, E2F2 and E2F3, are negatively regulated by miR-17 and miR-20a. Despite the fact 
that the 3´UTRs of all three transcription factors contain miR-17/miR-20a binding sites, the 
downregulation of E2F1 protein level is stronger than for the other two (O'Donnell et al, 2005; 
Sylvestre et al, 2007). E2Fs are essential factors in the regulation of the cell cycle and, in 
particular E2F1, can induce apoptosis in response to DNA damage (Lin et al, 2001). Since c-
MYC and E2Fs have been demonstrated to activate each other transcriptionally, O'Donnell et al. 
uncovered a tighly controlled and unusually structured network in which c-MYC activates the 
transcription of E2Fs while simultaneously limits their translation via induction of miR-17 and 
miR-20a (Fig. I.3) (O'Donnell et al, 2005; Sylvestre et al, 2007). Furthermore, E2F transcription 
factors also activate the transcription of miR-17-92 cluster, with E2F3 being the major 
transcription activator of the cluster as demonstrated by chromatin immunoprecipitation (Woods 
et al, 2007). Taken all these evidences together, a complex interaction network of c-MYC, E2Fs 
and the miR-17-92 cluster is proposed; miR-17-92 exerts its oncogenic activity by shifting the 
E2F transcriptional balance away from the pro-apoptotic E2F1 toward the proliferative E2F3 
transcriptional network, thereby assisting the DNA-damaged cells to avoid the programmed cell 
death (Fig. I.3). 
 Apart from E2Fs, BIM and PTEN, the oncogenic activity of the miR-17-92 cluster was 
attributed to the downregulation of tumor suppressors such as Retinoblastoma-like protein 2 
(RBL2) (Lu et al, 2007) or cyclin-dependent kinase inhibitor (CDKN1A, also known as p21) 
(Fontana et al, 2008). Moreover, Cloonan and colleagues discovered that miR-17 inhibits the 
expression of mitogen-activated kinase JNK2, which results in an increased cyclin D1 expression 
and cell cycle progression (Cloonan et al, 2008). Whereas miR-17, miR-20a and miR-19a/b are 
important regulators of proliferation and apoptosis of transformed cells, miR-18a induces tumor 
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neovascularization via downregulation of anti-angiogenic proteins such as connective tissue 
growth factor (CTGF) and trombospondin-1 (TSP1) (Fig. I.3) (Dews et al, 2006). Recent data 
from breast cancer cell lines showed that miR-19 also downregulates expression of the tissue 
factor (TF) which is recognized as an important regulator of tumor angiogenesis and metastasis 
(Zhang et al, 2011).  
 
In contrast to the above cited studies, accumulating evidences indicate that the miR-17-92 
cluster also acts as a tumor suppressor in some circumstances. Loss of heterozygosity of miR-17-
92 correlates with multiple tumor progression, including breast cancer, nasopharyngeal 
carcinoma, retinoblastoma, hepatocellular carcinoma and squamous cell carcinoma of the larynx 
(reviewed in Coller et al, 2007). miR-17 exerts its tumor-suppressive activity by limiting the 
expression of Nuclear receptor coactivator 3 (NCOA3), which in turn activates the PI3K/Akt 
signaling pathway resulting in increased expression levels of downstream targets like cyclin D1 
(Hossain et al, 2006). Cyclin D1 is a key regulator of the G1-S phase transition. Importantly, 
overexpression of this oncoprotein is observed in ~50% of human breast cancers (Fu et al, 2004). 
Consistently, Yu and colleagues (Yu et al, 2008) demonstrated that miR-17 and miR-20a repress 
cyclin D1 expression and identified a novel cyclin D1-miRNA regulatory feedback loop. They 
showed that the cyclin D1 binds to the regulatory region of miR-17-92 promoter and induces the 
cluster transcription.   
Fig. I.3: The interactions among c-MYC, E2Fs and the miR-17-92 cluster. Depending 
on both cell type and physiological context, miR-17-92 can promote proliferation, inhibit 
apoptosis and increase neoangiogenesis through the post-transcriptional inhibition of a number 
of target mRNAs. Modified from (Olive et al, 2010). 
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 In summary, a central role of miR-17-92 in control of proliferative signals and thereby 
tumorigenesis is emphasized by the fact that at least four key regulatory proteins (c-MYC, E2F3, 
AML1 and cyclin D1) converge on the cluster promoter region to create important regulatory 
feedback loops (Fontana et al, 2007; Yu et al, 2008; O'Donnell et al, 2005; Sylvestre et al, 2007). 
The findings that miR-17-92 cluster acts both as oncogene and tumor suppressor is likely 
dependent on the cell type, the expression pattern and/or the levels of the target mRNAs 
(Cloonan et al, 2008). 
 
3.2.2. miRNAs and membrane trafficking 
 
Much of the progress in understanding the essential roles of miRNAs in homeostatic 
processes such as development, cell proliferation and death has been made over the last decade. 
However, our knowledge of how miRNAs might regulate exocytic and endocytic machineries in 
eukaryotic cells is limited to only a few reports showing the effects of some miRNAs on 
regulated insulin secretion (Lovis et al, 2008; Plaisance et al, 2006; Poy et al, 2004). Despite the 
specific control mechanisms that are essential for a strict regulation of induced cargo secretion, 
the core exocytic machinery of both constitutive and regulated secretion pathways is conserved. 
The first evidence that miRNAs are actively involved in the regulation of secretory cargo 
trafficking came from a report on miR-375 function in the murine pancreatic β-cell line MIN6. 
The authors demonstrated that pancreatic islet-specific miR-375 effectively inhibits glucose-
stimulated insulin secretion through downregulation of myotrophin (MTPN) protein level (Poy et 
al, 2004). The functions of MTPN have not been investigated in β-cells, but it has been shown 
that this protein is implicated in vesicle transport and neurotransmitter catecholamine release in 
neurons (Yamakuni et al, 2002). It is possible that MTPN causes changes in the actin network by 
interacting with the actin-capping protein CAPZ, thereby influencing secretory granule docking 
and fusion (Taoka et al, 2003). Recently, Li and colleagues confirmed Mtpn as a physiological 
target of miR-375 and showed that it acts as an anti-apoptotic gene in β-cell lipoapoptosis, 
suggesting that miR-375 could regulate both function and viability of pancreatic β-cells (Li et al, 
2010).        
 In addition to miR-375, other miRNAs, including miR-124a and miR-96 have been 
identified to modulate the expression of several other proteins involved in insulin exocytosis in 
MIN6 β-cells. Among them, only RAB27A seems to be directly targeted by miR-124a, whereas 
dysregulation of SNAP-25, RAB3A, synapsin-1A and NOC2 is potentially caused by secondary 
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miR-124a-mediated mechanisms such as regulation of transcription factors (Baroukh et al, 2007; 
Lovis et al, 2008). The effects of miR-96 on insulin exocytosis are mediated through increased 
mRNA and protein levels of granuphilin and decreased level of NOC2 (Lovis et al, 2008). 
Granuphilin is RAB3A and RAB27A effector protein which is associated with insulin secretory 
granules and negatively regulates their docking to the plasma membrane (Coppola et al, 2002; Yi 
et al, 2002). In contrast, NOC2 positively regulates insulin secretion by inhibiting Gi/o signaling 
(Matsumoto et al, 2004). Moreover, it was shown that another miRNA, miR-9, downregulates the 
expression of granuphilin targeting directly its transcription factor ONECUT-2 (Plaisance et al, 
2006). 
Taken together, these findings in murine cells provide a strong basis for speculation that 
miRNAs can also actively regulate vesicle transport pathways in human cells.  
 
3.3. Principles of miRNA-mRNA interactions: an overview 
 
 Once incorporated into miRISC, the miRNA brings the complex to its target messenger 
RNAs by interacting with complementary binding sites, which can be present in multiple copies 
(Park et al, 2009; Tian et al, 2010). An individual miRNA can regulate expression of hundreds of 
transcripts and, as a consequence, level of multiple proteins (Baek et al, 2008; Lewis et al, 2005; 
Selbach et al, 2008). On the other hand, multiple miRNAs can repress expression of an individual 
target mRNA (Du et al, 2009; le Sage et al, 2007; Lewis et al, 2005; Wu et al, 2010). Animal 
miRNAs preferentially bind to the 3´UTRs of transcripts (Grimson et al, 2007), while the 
majority of plant miRNA binding sites are located in the protein-coding sequences (CDS) 
(Rhoades et al, 2002). However, recent experimental evidences prove the existence of a new 
class of animal miRNA targets that contain binding sites in their 5´UTRs (Lee et al, 2009; Lytle 
et al, 2007; Orom et al, 2008) or within the CDS (Elcheva et al, 2009). Although animal miRNA 
binding sites in the CDS were demonstrated to be less potent than the 3´UTR binding sequences 
(Baek et al, 2008; Selbach et al, 2008), both types of sites act synergistically when present in the 
same transcript (Fang & Rajewsky, 2011). 
 miRNAs interact with their targets via Watson-Crick base pairing. Target identification 
by animal miRNAs is achieved mainly through complementarity to the 5´-proximal so called 
“seed” sequence. The minimal size of the seed sequence sufficient to trigger target silencing has 
been subject to ongoing debate. Grimson and colleagues have initially classified experimentally 
identified miRNA binding sites into four distinct groups. These groups include 6mer (miRNA 
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positions 2-7), 7mer-m8 (positions 2-8), 7mer-A1 (positions 1-7 and adenosine is located across 
position 1 of the miRNA) and 8mer (miRNA nucleotides 1-8 and adenosine is located across 
position 1 of the miRNA). Importantly, comparison of 11 experimental data sets revealed that a 
majority (75%) of the downregulated mRNAs possesses sequences complementary to the 7mer-
m8 type seed region of examined miRNAs (Grimson et al, 2007). Of course, there is an exception 
to every rule: functional miRNA:target interactions containing mismatches or bulges in the seed 
region, such as Lin-41 mRNA and let-7 miRNA pair in C. elegans, have also been identified 
(Didiano & Hobert, 2006; Vella et al, 2004). 
In contrast to animal miRNAs, most of the plant miRNAs form complementary or nearly 
complementary hybrids with target mRNAs. It allows Ago proteins to cleave target mRNA 
between the nucleotides paired at positions 10 and 11 of the interacting miRNA (Llave et al, 
2002), in a manner similar to siRNA-directed cleavage. The cleavage products are degraded by 
the exosome and the 5´-3´ exonuclease XRN4 (Souret et al, 2004). Animal miRNAs inhibit target 
mRNA expression either by repressing protein translation and/or by inducing deadenylation and 
subsequent degradation (reviewed in Huntzinger & Izaurralde, 2011). However, recently several 
groups have reported that miRNAs are capable of activating rather than inhibiting target 
expression under certain conditions (Orom et al, 2008; Vasudevan et al, 2007; Vasudevan et al, 
2008). In summary, transcriptome analyses confirmed that target mRNA degradation by 
endonucleolytic cleavage is a prominent mechanism of miRNA-mediated gene silencing in plants 
(Schwab et al, 2005), while exonucleolytic degradation is a dominant way promoting decay of 
animal miRNA targeted mRNAs (discussed in details below). 
 The most relevant aspects concerning animal miRNA-mediated degradation, translational 
repression and some examples of translational target mRNA activation are discussed in details in 
the following sections.    
 
3.3.1. miRNA-mediated target degradation 
  
 A number of previous observations supports the idea that animal miRNA-mediated gene 
silencing is frequently accomplished by target mRNA degradation. These observations come 
from a series of transcriptome studies showing that the abundance of dozens of validated or 
predicted miRNA targets inversely correlates with the level of miRNA (Baek et al, 2008; 
Giraldez et al, 2006; Guo et al, 2010; Hendrickson et al, 2009; Lim et al, 2005; Selbach et al, 
2008). Moreover, combining ribosome profiling with mRNA microarray data revealed that at 
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least 84% of decreased protein production can be attributable to decreased mRNA levels rather 
than to reduced translational efficiency (Guo et al, 2010). Hence, although initially miRNAs were 
considered to repress protein translation with modest or no effect on mRNA level (Olsen & 
Ambros, 1999; Wightman et al, 1993), genome-wide studies proved that mRNA degradation is a 
widespread mode of miRNA action in animal cells.  
 Although animal miRNAs can generally direct mRNA cleavage catalyzed by AGO2 
(Yekta et al, 2004), they rarely do so due to the fact that the majority of miRNA-target pairs are 
only partially complementary or contain bulges, which inhibits the slicer activity of Ago2. 
miRNA-mediated destabilization of mRNA is predominantly initiated through deadenylation, 
which promotes de-capping followed by exonucleolytic decay (Behm-Ansmant et al, 2006; 
Eulalio et al, 2008; Piao et al, 2010). Deadenylation is performed by CAF1-CCR4-NOT 
deadenylase complex recruited to repressed mRNAs via interaction with GW182, a component of 
miRISC, while the de-capping complex DCP1-DCP2 is required for the removal of the cap 
structure (Behm-Ansmant et al, 2006). The importance of mRNA degradation factors in miRNA-
based target destabilization has been demonstrated by depletion of components of the CAF1-
CCR4-NOT and the DCP1-DCP2 complexes. For example, knockdown of DCP1 and DCP2 
prevents mRNA degradation, but results in an accumulation of deadenylated, translational 
repressed targets (Behm-Ansmant et al, 2006). Following deadenylation, repressed mRNAs are 
rapidly degraded either from their 3´ ends by the exosome, or after subsequent de-capping, by the 
cytoplasmic 5´-3´ exonuclease XRN1 (reviewed in Parker & Song, 2004).  
 
3.3.2. miRNA-mediated translational repression 
  
 Translational inhibition can be defined as a phenomenon when the decrease in protein 
expression exceeds the level of mRNA degradation. Translation can be generally divided into 
initiation, elongation and termination. Initiation is the most common target for translational 
regulation of eukaryotic genes. Briefly, initiation starts with the assembly of eukaryotic 
translation initiation factor 4F (eIF4F, which is comprised of eIF4E, eIF4G and eIF4A subunits) 
on 5´-terminal m
7
G cap of the mRNA. This assembly is followed by mRNA circularization 
induced by eIF4G subunit interaction with the polyadenylate-binding protein C1 (PABPC1, also 
known as PABP1) and subsequent formation of the active 80S ribosome (reviewed in Kapp & 
Lorsch, 2004). 
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miRNA-mediated translational repression in animals has been proposed to occur via 
inhibition of translation initiation. However, early observations in C. elegans (Olsen & Ambros, 
1999; Seggerson et al, 2002) together with more recent experiments in mammalian cells (Nottrott 
et al, 2006; Petersen et al, 2006) demonstrated that miRNA-targeted mRNAs possess the same 
polysomal profile as non-repressed messages. Contrary to the concept of miRNA-mediated 
repression, these polysomes are sensitive to various translational inhibitors suggesting that they 
are actively engaged in translation (Nottrott et al, 2006; Petersen et al, 2006). Due to divergent 
experimental data, different models for miRNA-guided translational repression were proposed: 
(i) co-translational degradation of nascent polypeptide chain, (ii) inhibition of translation 
elongation and (iii) translation termination due to miRNA-induced drop off of ribosomes 
prematurely. The model of co-transcriptional peptide degradation was proposed by Nottrott and 
colleagues (Nottrott et al, 2006), however, no further model validation by other laboratories was 
reported. Initially proposed by Petersen and colleagues (Petersen et al, 2006), the premature 
translation termination model characterized by miRNA-mediated dissociation of ribosomes was 
supported by the finding that translation, initiated through an internal ribosome entry site (IRES), 
is still susceptible to miRNA-guided repression (Lytle et al, 2007). 
In contrast to these observations, other studies concluded that miRNAs inhibit translation 
at the initiation step. Pillai and colleagues (Pillai et al, 2005) showed that miRISC-bound mRNAs 
do not co-sediment with polysomes in sucrose sedimentation gradient, but shift towards lighter 
fractions. In addition to that, messenger RNAs containing IRES were immune to repression by 
miRNAs (Pillai et al, 2005). A series of experiments in cell-free extracts of rabbit reticulocytes, 
Drosophila and mammalian cell lines also showed that m
7
G structure is required for repression, 
further supporting the model that miRNA-mediated translational inhibition occurs at the initiation 
step (Thermann & Hentze, 2007; Wakiyama et al, 2007; Wang et al, 2006). The observation that 
molecular tethering of human Ago proteins to the 3’UTR of the reporter mRNA still suppressed 
translation (Pillai et al, 2004) promped researchers to investigate how miRISC proteins interact 
with translational machinery. The early work of Kiriakidou and colleagues proposed that 
mammalian AGO2 binds to m
7
G cap directly via its MC domain and in this way prevents 
translation initiation by competing with eIF4E subunit (Kiriakidou et al, 2007). However, follow-
up structure modeling (Kinch & Grishin, 2009) and other experimental studies (Eulalio et al, 
2008) disproved the proposed model. Instead, the mutation of two phenylalanines predicted to 
mediate cap binding was shown to actually abolish the AGO1 interaction with both GW182 and 
miRNAs in D. melanogaster (Eulalio et al, 2008). These findings suggested that GW182, a 
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cellular factor known to be essential for miRNA-mediated repression, not only promotes 
deadenylation of miRISC-bound target mRNA but also interferes with protein translation.  
 In summary, these evidences suggest that miRNA-mediated translational repression, 
besides target degradation, occurs predominantly at the initiation step. 
 
3.3.3. Translational activation by miRNAs 
 
 Several reports indicating that miRNAs can enhance rather than repress expression of 
specific mRNAs under certain conditions further expand the functional repertoire of these small 
RNAs. Vasudevan and colleagues reported that AGO2-miR-369-3 complex stimulates TNFα 
mRNA translation in quiescent cells arrested in G0/G1 phase (Vasudevan et al, 2007). More 
recently, the same laboratory found that xlmiR-16 (Xenopus laevis miR-16) is required for 
upregulated expression of cell cycle regulator Myt1 kinase in prophase I-arrested immature X. 
laevis oocytes (Mortensen et al, 2011). It should also be noted that AGO association with Fragile 
X Related Protein (FRX1) was required for translational activation in both studies.  
Further examples of miRNA-mediated translational activation involve miR-10a and miR-
122. miR-10a was reported to bind to the 5´UTR immediately downstream of the regulatory 
5´TOP motif located in mRNAs encoding ribosomal proteins and to enhance their translation 
under amino acid starvation conditions. Furthermore, authors speculate that miR-10a might 
positively regulate global protein synthesis via stimulation of ribosomal protein expression and 
potentially affect processes of cellular transformation (Orom et al, 2008). Liver-specific miR-122 
was shown to stimulate replication of Hepatitis C virus (HCV) RNA in hepatoma cells by 
binding to it’s 5´UTR (Jopling et al, 2005). Recent findings suggest that miR-122 might also 
enhance HCV RNA translation (Henke et al, 2008). However, additional experiments are 
required to elucidate whether this function is AGO- or GW182-dependent and does not occur due 
to any conformational changes of HCV RNA that facilitates ribosome loading. 
 
3.4. miRNA biogenesis 
 
 The biogenesis pathway in animals consists of a series of several biochemical steps that 
process pri-miRNAs into biologically active, mature miRNAs (Fig. I.1). The miRNA genes are 
initially transcribed by RNA polymerase II (Lee et al, 2004). It has been proposed that the largest 
human miRNA gene cluster C19MC encoding 59 miRNAs is exclusively transcribed by RNA 
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polymerase III (Borchert et al, 2006). However, a recent study revealed that most likely C19MC 
is also transcribed by RNA polymerase II (Bortolin-Cavaille et al, 2009). Similar to other 
protein-coding mRNAs, primary transcripts of intergenic human miRNAs are 3´ polyadenylated 
and bear a 5´ terminal 7-methyl guanylate cap (Cai et al, 2004). The majority of primary 
transcipts are from 3 to 4 kb in length (Saini et al, 2007). The conventional miRNA biogenesis 
pathway is characterized by two sequential cleavage reactions mediated by RNase III family 
enzymes. The first endonucleolytic reaction occurs in the nucleus where pri-miRNAs are 
recognized and cleaved by a multi-protein complex, called microprocessor, liberating ~70-nt long 
stem-loop structured precursor-miRNAs (pre-miRNAs). The two essential components of the 
minimal microprocessor complex are RNase III enzyme Drosha and the double-stranded RNA 
binding protein DiGeorge critical region 8 (DGCR8, also known as Pasha in D. melanogaster and 
C. elegans) (Denli et al, 2004). The larger microprocessor complex contains many accessory 
proteins such as heterogeneous nuclear ribonucleoproteins (hnRNPs), DEAD-box helicases p68 
and p72 and Ewing’s sarcoma proteins (Gregory et al, 2004). The two double-stranded RNA-
binding domains of DGCR8/Pasha stably interact with the pri-miRNAs and determine the precise 
cleavage site (Han et al, 2006), whereas RNase domains cleave the 5´ and 3´ arms of the pri-
miRNA hairpin structure (Han et al, 2004). 
 After nuclear processing, the 2-nt 3´overhang of pre-miRNA is recognized by exportin-5 
in complex with GTP-bound Ran cofactor and the pre-miRNA hairpin is exported from the 
nucleus (Yi et al, 2003). 
 In the cytoplasm, pre-miRNAs are further processed by a second RNase III enzyme Dicer. 
Dicer cleaves off the terminal loop by cutting both strands of the pre-miRNAs, leaving a 
transient, roughly 20-nt long, miRNA/miRNA* duplex with 2-nt overhangs at each 3´ end. 
Overall hairpin length and loop size influence the efficiency of Dicer processing, and the 
imperfect nature of the miRNA/miRNA* pairing also affects cleavage (Park et al, 2011). Similar 
to Drosha, Dicer is a member of a multi-protein complex, called miRNA RISC loading complex 
(miRLC), which additionally contains other double-stranded RNA binding proteins, Tar RNA 
binding protein (TRBP, Chendrimada et al, 2005), protein activator of PKR (PACT, Lee et al, 
2006) and Argonaute-2 (Ago2, Gregory et al, 2005). In contrast to Drosha-DGCR8 complex, 
TRBP and PACT are not essential for Dicer activity, however, they facilitate the cleavage of 
terminal loop, stabilize Dicer protein and recruit Ago2 to the miRLC (Chendrimada et al, 2005; 
Gregory et al, 2005; Lee et al, 2006). Noteworthy, the exported pre-miRNA hairpin binds already 
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preassembled miRLC in the cytoplasm (Gregory et al, 2005). The formation of miRLC is an 
ATP-independent process (Maniataki & Mourelatos, 2005).  
Following cleavage, Dicer and interacting proteins TRBP or PACT dissociate from the 
miRLC initiating the transition of the miRLC into the active miRISC. This transition is further 
continued by the immediate separation of the miRNA/miRNA* duplex into the functional 
 
 
Fig. I.1: Animal miRNA 
biogenesis and effect on target 
mRNAs. miRNA genes are transcribed 
to generate primary miRNA (pri-
miRNA) molecules that fold into 
hairpin structures. After excision from 
pri-miRNAs by the microprocessor 
complex (Drosha-DGCR8), a hairpin 
(pre-mRNA) is exported to the 
cytoplasm and further processed by the 
Dicer-TRBP complex to yield a 
miRNA/miRNA* duplex. Following 
processing, the miRNA duplex 
liberates the mature miRNA to 
assemble into a miRISC comprised of 
core Ago proteins and other auxiliary 
proteins. The incorporated miRNA 
guides miRISC to the target mRNAs 
and inhibit protein synthesis by either 
repressing translation or promoting 
mRNA deadenylation followed by 
decay. Alternative miRNA biogenesis 
pathways such as of mirtrons, ac-pre-
miRNA and pre-miR-451 are also 
depicted. Adapted from (Krol et al, 
2010). 
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mRNA-targeting mature miRNA strand (guide strand), which is complementary to the target 
mRNA, and the miRNA* strand (passenger strand). It was assumed that miRNA* is usually 
degraded, however, recent studies have demonstrated that passenger strands are not always by-
products and a substantial cohort of miRNA* species are functionally active (Chiang et al, 2010; 
Yang et al, 2011). Although many helicases such as p68, p72, RNA helicase A, Mov10 (Gregory 
et al, 2004; Meister et al, 2005) have been attributed to the miRNA biogenesis, a common 
enzyme responsible for miRNA/miRNA* unwinding has not been identified yet. In some cases, 
specific helicases are found in complex with distinct miRNAs such as let-7 (Salzman et al, 2007), 
on the other hand, the formation of active miRISC in the absence of ATP suggests that helicases 
might be generally dispensable (Maniataki & Mourelatos, 2005).  
As mentioned, the miRNA/miRNA* duplex can be a source of two different mature 
miRNAs. However, the thermodynamic stability of the miRNA duplex 5´ ends determines which 
strand is preferentially incorporated into miRISC; usually, the retained is the one that has less 
stable base pair at its 5´ end in the duplex (Khvorova et al, 2003). In addition to the processing of 
miRNA precursor molecules, Drosha and Dicer also have a significant impact on miRNA loading 
into miRISC. Notably, cleavage of some precursor miRNAs by these enzymes is not very 
accurate and results in miRNA variants with heterogenic termini. Hence, cleavage heterogeneity 
can result into different 5´ end stability and, consequently, alter active miRNA strand selection 
(Carthew & Sontheimer, 2009). 
  The mammalian Ago/miRNA complex is associated with a number of different proteins 
such as Gemin3, Gemin4, Mov10, Imp8 and GW182 (Meister et al, 2005; Weinmann et al, 
2009). In addition, studies in human, worms and flies indicate that the minimal 
Ago/miRNA/GW182 complex is sufficient for miRNA-mediated gene silencing (Ding & 
Grosshans, 2009; Eulalio et al, 2008; Liu et al, 2005) (Fig. I.1).  
 
3.4.1. Alternative miRNA biogenesis pathways 
 
 In addition to the well-defined conventional miRNA biogenesis pathway that governs the 
maturation of most miRNAs in animals, several alternative maturation pathways were identified 
that do not generally require Drosha or Dicer cleavage. The most prominent alternative 
mechanism uses splicing machinery and the lariat-debranching enzyme to generate pre-miRNA 
hairpins, thereby bypassing the initial Drosha cut. Such short-hairpin introns are known as 
mitrons; although they were initially thought to exist only in flies and nematodes (Okamura et al, 
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2007; Ruby et al, 2007), Berezikov and colleagues identified them also in mammals (Berezikov 
et al, 2007). In contrast to the canonically processed intronic miRNAs, mitrons are located within 
very short introns and the ends of the hairpin are determined by the splice sites of such introns. 
Following RNA refolding, mitrons are subjected to exportin-5-Ran-mediated transport to the 
cytoplasm where they are further processed by Dicer (Okamura et al, 2007; Ruby et al, 2007). 
 Most recently, a Dicer-independent biogenesis pathway of blood-specific miR-451 has 
been identified (Cheloufi et al, 2010; Cifuentes et al, 2010). pre-miR-451, which has shorter stem 
part compared to other pre-miRNAs, is cleaved by AGO2 RNase H-like endonuclease activity. 
The 3´ end of functional miR-451 is generated by exonucleolytic trimming by a cellular nuclease 
independently of Dicer (Cheloufi et al, 2010; Cifuentes et al, 2010). In addition to its central role 
in miRNA-mediated gene repression, AGO2 has been reported to cleave some, but not all, pre-
miRNAs to an additional processing intermediate called AGO2-cleaved pre-miRNA or ac-pre-
miRNA (Diederichs & Haber, 2007). AGO2 nicks the prospective passenger miRNA strand 12 
nucleotides from its 3´ end before Dicer cleavage, however, the physiological functions of this 
intermediate remain unknown (Diederichs & Haber, 2007). The alternative miRNA maturation 
pathways are depicted in Figure I.1.          
 
3.4.2. Regulation of miRNA biogenesis 
 
 miRNA biogenesis can be controlled by the regulation of miRNA gene transcription and 
post-transcriptional processing. The similar features of intergenic miRNA and mRNA promoters 
and the common DNA binding factors required for the transcription of both indicate that 
transcription of miRNA genes is regulated by similar mechanisms to those of protein-coding 
genes (Corcoran et al, 2009). For example, the proto-oncogene c-MYC is a transcription factor, 
which regulates 10 to 15% of human genes, modulates transcription of the miR-17-92 cluster (He 
et al, 2005) through binding to E-boxes within its promoter (O'Donnell et al, 2005). On the 
contrary, expression of several tumor suppressor miRNA genes, including the miR-15a, -29, -34 
and let-7 families, is inhibited by the same c-MYC transcription factor (Chang et al, 2008). 
Another example of regulated miRNA gene transcription is the tumor suppressor miR-34a which 
expression is increased by p53 in response to genotoxic stress (Raver-Shapira et al, 2007). 
Additionally, regulation of miRNA gene transcription is a major level of control 
responsible for spatiotemporal expression of miRNAs as well as the same rule is valid for tissue- 
or development-specific expression of protein-coding genes. The orchestrated spatiotemporal 
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expression of miRNAs with mRNAs is exemplified in Figure I.2 and is also discussed in details 
in recent reviews (Davis & Hata, 2009; Schanen & Li, 2011). 
Post-transcriptional processing of miRNA consists of many maturation steps and each 
stage of biogenesis provides a broad spectrum of regulatory options to generate individual 
miRNA differently. Some of the major options are: (i) editing of pri- or pre-miRNAs by 
adenosine deaminases (ADARs) that catalyze the A-to-I transition in double stranded RNA and 
thereby block further processing of edited sequences by Drosha (Yang et al, 2006) or Dicer 
(Kawahara et al, 2007); (ii) positive regulation of Drosha activity by RNA helicases p68 and p72 
(Fukuda et al, 2007) and p68-interacting SMAD proteins (Davis et al, 2010; Hata & Davis, 
2011); (iii) competition of Lin-28 and Dicer for interaction with let-7 family pre-miRNAs 
Fig. I.2: Transcription factor – miRNA regulatory circuits. (1) Expression of miR-17-
92 cluster is positively regulated by both c-Myc and E2F1 transription factors, whereas miR-17 
inhibits translation of the important cell cycle regulator E2F1. Consistent with activation of 
proto-oncogenic c-Myc, this feed-back circuit is often found deregulated in tumors. (2) 
Transcription of several myocyte-specific miRNAs, including miR-1 and miR-133, is upregulated 
by MEF2, MyoD and SRF during myogenesis. (3-5) A number of single-negative miRNA 
autoregulatory loops with transcription factors have been described in differentiating 
hematopoietic progenitor cells (c-Myb-miR-15a, Runx1-miR-27a) or dopaminergic neurons 
(Pitx3-miR-133b). Adapted from (Davis & Hata, 2009). 
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(Lightfoot et al, 2011; Rybak et al, 2008) and (iv) inhibition of Dicer activity by other yet-
unknown factors (Obernosterer et al, 2006). Although recent studies have provided deeper 
insights into regulation of miRNA biogenesis (Davis & Hata, 2009; Krol et al, 2010; Siomi & 
Siomi, 2010; Suzuki & Miyazono, 2010), this topic is not the focus of the project, therefore, it is 
not discussed in details here. 
 
3.5. High-content screening approaches for studying miRNA functions  
  
Despite the recent rapid accumulation of experimental data and the emergence of 
functional models, the complexity of miRNA-based regulation is still far from being well 
understood. In particular, there is a lack of comprehensive knowledge concerning which cellular 
processes are regulated by which miRNAs or how temporal and spatial interactions between 
miRNAs and their targets occur. In this regard, results from large-scale functional analyses have 
immense potential to address these questions. 
The established infrastructure for siRNA/shRNA screenings (robotics for large-scale 
sample preparation, automated data acquisition and analysis, data storage capacities) can easily 
be applied for high-throughput studies of miRNA function. As for siRNA library screenings, 
lipid-based transfection is most commonly used to achieve a transient overexpression (Lam et al, 
2010) or inhibition (Cheng et al, 2005) of miRNAs in cell culture. The advantages of the solid-
phase reverse transfection method, in combination with an automated liquid handling system, 
have been also applied in miRNA screenings by several groups with a high success rate 
(Ovcharenko et al, 2007; Whittaker et al, 2010). Several miRNA screenings have been completed 
under conditions of miRNA stable overexpression achieved by transduction with retroviral 
vectors encoding specific miRNAs (Huang et al, 2008; le Sage et al, 2007; Nagel et al, 2009; 
Voorhoeve et al, 2006).  
A number of miRNA library screenings have been completed during the last 5 years 
(reviewed in Serva et al, 2011). Two major groups of biological processes have been investigated 
so far, namely, (i) cell viability, proliferation and apoptosis, and (ii) gene expression and/or 
activity regulation. Many miRNAs that regulate cell proliferation and apoptosis has been 
identified by using high-throughput approaches (Lam et al, 2010; Voorhoeve et al, 2006; 
Whittaker et al, 2010) since Cheng and colleagues (Cheng et al, 2005) reported the first large-
scale screen to identify mammalian miRNAs involved in these processes. In 2007, Ovcharenko 
and colleagues (Ovcharenko et al, 2007) performed a screening of 187 miRNAs in order to 
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capture the modulators of TRAIL-induced apoptotic pathway. miRNAs regulating expression of 
BCL-2 family protein MCL1 were identified by screening a library of 810 human miRNAs for 
their ability to sensitize cancer cells to ABT-263, an inhibitor of BCL-2 family members (Lam et 
al, 2010). As a result, 10 miRNAs were shown to bind directly to the 3´UTR of MCL1 mRNA 
and thereby inhibit protein expression. These examples demonstrate the potency of large-scale 
screenings in identifying miRNAs that regulate proliferation or modulate sensitivity to 
chemotherapeutic agents, and this knowledge contributes to the development of novel miRNA-
based anti-cancer therapeutics. The feasibility of proliferation-focused miRNA screenings has 
been significantly improved by the development of quantification methods from straightforward 
cell counting (Cheng et al, 2005) to recording of electrical impedance over 96 hours (Cole et al, 
2008).  
miRNAs that regulate the expression of gene of interest are usually identified in so-called 
“target-based” screenings. In the most cases, luciferase or fluorescent protein reporters bearing 
3´UTR of gene of interest are employed and the intensity of the detected signal is used to 
quantify gene expression level upon modulation of miRNAs (Nagel et al, 2009; Park et al, 2009; 
Tian et al, 2010; Wu et al, 2010). For instance, using a functional genetic approach with stable 
expression of individual miRNAs, miR-221 and miR-222 were identified to specifically regulate 
expression of tumour suppressor p27
Kip1
 (le Sage et al, 2007). 
Apart from two major groups of processes mentioned above, the repertoire of cellular 
processes analysed by miRNA functional screenings is expanding rapidly (reviewed in Serva et 
al, 2011). Conducting miRNA library screenings in appropriate cellular contexts, for instance, 
screening for miRNAs regulating steroidogenesis in ovarian cells (Sirotkin et al, 2009) or 
screening for miRNAs regulating lipid droplet formation in hepatocytes (Whittaker et al, 2010), 
ensures acquisition of physiologically relevant information. 
There are virtually no reasons why the read-out strategies in miRNA screenings should be 
different from the ones established in siRNA-based screenings. Nevertheless, fluorescence 
microscopy-based approaches are considered to be highly advantageous over biochemical 
techniques in large-scale miRNA screenings. Features that make fluorescence microscopy ideal 
to analyse regulatory potential of miRNAs include (i) rapid collection of large amount of data, 
(ii) feasibility of phenotype multiplexing, (iii) possibility to acquire quantitative data on a single 
cell and/or population levels and (iv) detection of subtle phenotypes (Pepperkok & Ellenberg, 
2006; Sacher et al, 2008). The pioneers in applying this approach for functional miRNA 
investigation were Sirotkin and colleagues (Sirotkin et al, 2010), who performed a fluorescence 
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microscopy-based miRNA screening in order to identify miRNAs regulating cell proliferation 
and apoptosis. Primary human ovarian cells were transfected with synthetic miRNA mimics and 
immufluorescence of proliferating cell nuclear antigen (PCNA) and Cyclin-B1 were used to 
determine miRNA effects on cell proliferation. Immunofluorescence of BAX was used to 
estimate apoptosis rate. Additionally, Whittaker and colleagues (Whittaker et al, 2010) 
demonstrated that the sensitivity of fluorescence microscopy technique in measuring lipid 
dropled formation in hepatocytes upon overexpression of miRNAs is a high as of laborious 
biochemical assay. Using an automated image acquisition platform combined with image 
analysis software, authors identified 11 out of 327 screened miRNAs as the most potent 
regulators of intracellular lipid content.          
 
3.6. Membrane trafficking in mammalian cells 
 
Eukaryotic cells have a highly evolved membrane trafficking organization. The evolution 
of eukaryotic cells introduced a major challenge to traffic a vast array of different cargoes (for 
example, hormones, matrix and serum proteins, digestive enzymes, antibodies and growth 
factors) between distinct membranous organelles in a specific and regulated manner. Moreover, 
membrane trafficking is involved in controlling size, shape and molecular composition of most 
cellular organelles. Functionally, membrane trafficking routes are broadly divided into the 
biosynthetic pathway responsible for the transport of cargoes synthesized in the endoplasmic 
reticulum (ER) to the cell surface, or to other endomembrane organelle, and the endocytic 
pathway. The latter is responsible for the internalization of compounds from the extracellular 
space to be utilized for cellular metabolism. Both biosynthetic transport and endocytosis are 
multistep processes involving cargo selection and vesicle formation at the donor membrane, 
vesicle transport, tethering and fusion with the target membrane. To carry out so many diverse 
tasks, membrane trafficking system relies on an array of membranous organelles, including the 
ER, the Golgi complex, different types of endosomes, lysosomes, the plasma membrane and 
secretory granules in specialized secretory cells (Fig. I.4). In addition to structural components, 
different cargo trafficking processes are coordinated by a sophisticated regulatory machinery that 
is estimated to comprise thousands of proteins (Gilchrist et al, 2006).  
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3.6.1 Biosynthetic membrane trafficking 
 
The biosynthetic transport of membrane and secretory proteins initiates at their site 
synthesis, the ER, whose environment is especially suited to facilitate the proper folding of newly 
synthesized proteins and the initial steps of their N-linked glycosylation (Ellgaard & Helenius, 
2003). While some of the proteins are able to fold into their native structures during co-
translational insertion into the ER, others require more assistance from a complex folding 
machinery that includes chaperones and other folding enzymes (Kleizen & Braakman, 2004). 
Folding is essential for protein transport to the Golgi complex, and if this step can not be 
completed, misfolded proteins are retained in the ER and are degraded by the ER-associated 
degradation machinery (Sitia & Braakman, 2003). After folding, post-translational modifications 
and quality control, mature proteins enter ER exit sites (ERES), where they are sorted into 
budding vesicles interacting directly with components of the coat protein complex II (COPII) or 
indirectly through interactions with specific cargo receptors such as the lectin ERGIC53 (Kuehn 
et al, 1998; Schrag et al, 2003).  
Sequential polymerization of COPII subcomplexes (Sec23–Sec24 and Sec13p–Sec31p) 
causes the membrane curvature required for the formation of the vesicle and potentially induces 
the subsequent scission of the budding COPII-coated vesicles from the ER (Barlowe, 2002; 
Stephens, 2003). COPII vesicles rapidly uncoat and fuse to form the ER-Golgi intermediate 
compartment (ERGIC). From there, coat protein complex I (COPI)-coated vesicular carriers are 
transported towards the cis-Golgi complex along microtubules by the dynein motor protein 
(Appenzeller-Herzog & Hauri, 2006; Bannykh et al, 1998). From ERGIC, ER resident proteins 
that participate in the formation of anterograde carriers are recycled back to the ER by COPI-
mediated retrograde transport (Scales et al, 1997).  
Once in the Golgi complex, cargo proteins migrate through the multiple stacks of this 
organelle, to emerge at the trans-Golgi network (TGN). The Golgi complex is a highly dynamic 
organelle comprising from three to eight cisternae. Fuctionally, the Golgi complex is devided in 
cis-Golgi, medial-Golgi and TGN, each part containing different resident enzymes that act at 
early, intermediate and late steps of secretory cargo processing, respectively (Rabouille et al, 
1995). Although several models have been proposed for intra-Golgi cargo transport, COPI-
mediated transport appears to play a central role in Golgi function (Glick & Nakano, 2009). 
However, the directionality of COPI-dependent transport remains an open question; while several 
groups have reported that COPI vesicles are responsible for the anterograde intra-Golgi 
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movement of cargo (Orci et al, 1997; Rothman, 1994), others failed to detect secretory cargo in 
COPI vesicles (Martinez-Menarguez et al, 2001), suggesting that these vesicles are not involved 
in anterograde cargo transport. Similarly, conflicting data comes from studies about anterograde 
transport of resident Golgi glycosylation enzymes (Cosson et al, 2002; Martinez-Menarguez et 
al, 2001), indicating that new methods might be necessary to resolve these controversies.  
Fig. I.4: Biosynthetic and endocytic membrane trafficking pathways in mammalian 
cells. The transport of newly synthesized secretory proteins as well as proteins that reside in 
membrane trafficking system starts from the ER, where they are packaged into COPII-coated 
carriers that fuse to form the ER-Golgi intermediate compartment (ERGIC). In the Golgi 
apparatus, the cargoes enter the cis-Golgi network, move through the Golgi stack, and are sorted 
at the trans-Golgi network (TGN). COPI-mediated retrograde transport recycles Golgi resident 
proteins from upstream compartments as well as ER proteins from the ERGIC and Golgi 
complex. From TGN, different types of carriers transport sorted cargoes to various final 
destinations. Most plasma membrane proteins and extracellular cargoes are internalized through 
clathrin-dependent or -independent endocytosis. The endocytic vesicles fuse with each other to 
form the early endosomes from where cargoes can be transferred to the lysosomes via the late 
endosomes or to the TGN, or recycled back to the plasma membrane. Macropinocytosis and 
phagocytosis pathways for the uptake of large extracellular fluid volumes and solid particles, 
respectively, are shown. Adapted from (De Matteis & Luini, 2011)         
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After passing through the medial-Golgi complex, different cargoes are sorted in the TGN 
and packaged in specialized carriers for delivery to their respective destinations. For instance, 
clathrin-coated vesicles (CCVs) transport certain cargoes from the TGN to endosomes. Most 
lysosomal enzymes contain a mannose-6-phosphate tag and are sorted by mannose-6-phosphate 
receptor (M6PR) into CCVs that deliver cargo to the late endosomes (Braulke & Bonifacino, 
2009; Hille-Rehfeld, 1995). Many secretory proteins are loaded into large pleiomorphic carriers 
and delivered to the plasma membrane by a variety of routes (Bossard et al, 2007). Apart from 
secretory proteins that utilize the constitutive biosynthetic pathway, certain specialized cells sort 
specific cargoes (hormones, neurotransmitters) into secretory granules that accumulate in the 
cytoplasm until their secretion is triggered by physiological signals (Burgoyne & Morgan, 2003). 
In addition to serving as cargo sorting and exit site of the Golgi, the TGN is also central to the 
recycling pathway of various endosomal and plasma membrane proteins. This can be illustrated 
by the fact that many of these proteins are found in both endosomes and TGN (Pavelka et al, 
1998; Shen et al, 2006). Thus, the TGN represents the interface between the biosynthetic and 
endocytic pathways.  
 
3.6.1 Endocytic membrane trafficking 
 
The endocytic pathway is comprised of various vesicular organelles, including 
early/sorting endosomes, recycling endosomes, multivesucular bodies, late endosomes and 
lysosomes. Similarly to post-Golgi biosynthetic trafficking, endocytosis includes several distinct 
pathways. Besides clathrin-mediated endocytosis (CME), which accounts for a large proportion 
of endocytic events, an array of clathrin-independent pathways has been identified. These 
pathways include caveolin1-dependent endocytosis, ARF6-dependent endocytosis, flotillin-
dependent endocytosis, macropinocytosis, phagocytosis and trans-endocytosis (Doherty & 
McMahon, 2009). Although a list of cargoes that have been shown to undergo clathrin-
independent endocytosis is rapidly expanding (Kirkham & Parton, 2005), molecular mechanisms 
and physiological functions of CME is the best-understood. 
CCV formation occurs through five stages: initiation, cargo selection, coat assembly, 
scission and uncoating. Clathrin coats are made up of clathrin triskelia that do not possess any 
affinity for biological membranes. Therefore, many transmembrane receptors and their ligands 
are packaged into CCVs only in complex with adaptor proteins, such as AP2, and cargo-specific 
accessory proteins, such as AP180 and epsin. Noteworthy, specific adaptor complexes are 
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required for CCV formation at the TGN and at the plasma membrane (Traub, 2005). There are 
six different adaptor complexes in mammals (AP-1-6), however, AP-2 is a core adaptor for the 
formation of CCVs at the plasma membrane (Ohno, 2006). The uptake of the best-characterized 
clathrin-dependent cargoes, such as transferrin, epidermal growth factor and low-density 
lipoprotein has been shown to require AP-2 (Boucrot et al, 2010; Huang et al, 2004). AP-2 and 
other accessory proteins are recruited at sites of the plasma membrane, which are destined to be 
internalized, by the putative nucleation module (Henne et al, 2010; Stimpson et al, 2009). Once 
at the plasma membrane, these proteins bind to the cytoplasmic tails of transmembrane cargo 
molecules and subsequently initiate clathrin coat assembly by recruiting clathrin triskelia directly 
from the cytosol. Following the formation of CCV, the membrane scission GTPase dynamin 
twists around the connective neck and mediates membrane fission releasing the vesicle from the 
donor plasma membrane (Sweitzer & Hinshaw, 1998). After pinching off from the plasma 
membrane, CCVs are uncoated by the ATPase heat shock cognate 70 (HSC70) and its cofactor, 
auxilin (Schlossman et al, 1984; Ungewickell et al, 1995), and naked vesicles generally fuse to 
the RAB5-positive early endosomes (Nielsen et al, 1999). 
Similar to the TGN, endosomes represent a major sorting compartment in mammalian 
cells. Sorting of internalized material within the endosomal system is complex, involving ligands 
being released from their receptors for degradation in the lysosomes and recycling of receptors to 
the plasma membrane (Maxfield & McGraw, 2004). Endocytosed membrane proteins, including 
the epidermal growth factor receptor, that are tagged for degradation by ubiquitylation are 
collected in multivesicular bodies, also referred to as a form of late endosomes, through the 
action of ESCRT-I, -II and –III complexes (Felder et al, 1990; Katzmann et al, 2002). The 
formation of late endosomes from early endosomes requires the conversion from a RAB5-
positive compartment into a RAB7-positive compartment, a process regulated by the SAND-1-
CCZ-1 complex (Kinchen & Ravichandran, 2010; Poteryaev et al, 2010).  
Besides previously mentioned biosynthetic cargo trafficking pathways between the TGN 
and the endosomal system, there are at least two main retrograde transport routes between these 
membranous compartments. The pathway between the early endosomes and the TGN is used by, 
for example, Shiga toxin to reach the Golgi complex and the ER (Mallard et al, 1998), and cargo 
receptor TGN38, which is transported to the TGN before recycling back to the plasma membrane 
(Chapman & Munro, 1994). The second endosome-to-TGN pathway implicates late endosomes. 
This route is involved in the retrograde transport of, for example, furin (Mallet & Maxfield, 
1999) and M6PR (Hille-Rehfeld, 1995). Thus, the endosomal system is a sophisticated and 
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dynamic network through which different cargoes and resident proteins are transported following 
diverse anterograde and retrograde pathways. 
 
3.7. Core regulatory proteins in membrane trafficking 
 
  Many regulatory and structural proteins that are involved in the membrane trafficking 
process have been characterized: adaptor proteins for specific cargo sequestration, proteins 
responsible for vesicle budding and scission, motor proteins that transport vesicular carriers along 
cytoskeletal components and the vesicle coat proteins. However, the molecular mechanisms by 
which the membrane trafficking is coordinated to maintain both the fidelity and the efficiency of 
the cargo transport remains a significant focus of research. GTPases of the Ras superfamily have 
come to the frontline as key regulatory factors that play a critical role in membrane trafficking. 
These GTPases are classified into five families: Ras, Rho, Rab, Arf and Ran. Members of Rab 
and Arf families are of particular importance as they, in complexes with numerous effector 
proteins, participate in the regulation of almost all vesicular transport steps in eukaryotic cells, 
starting from the vesicle formation, trafficking to and fusion with target membranes (Donaldson 
& Jackson, 2011; Stenmark, 2009). GTPases are small monomeric GTP-binding proteins that 
cycle between the cytoplasmic GDP-bound inactive and the membrane-associated GTP-bound 
active forms providing a major mechanism to regulate assembly and disassembly of functional 
membrane domains in the biosynthetic and endocytic membrane trafficking pathways. The 
activation and inactivation of Rab and Arf GTPases are controlled by guanine nucleotide 
exchange factors (GEFs) and GTPase-activating proteins (GAPs), respectively. GDP dissociation 
inhibitors (GDIs) represents the third type of regulators specific to Rabs (Bernards, 2003; Jackson 
& Casanova, 2000; Matsui et al, 1990; Randazzo & Hirsch, 2004). 
Besides GTPases, heterogeneous tethering factors and highly conserved SNAP receptors 
(SNAREs) have been show to drive tethering of vesicular carrier to and fusion with acceptor 
membranes as well as to contribute specificity of membrane trafficking.  
 
3.7.1. Arf GTPases 
 
The small ADP-ribosylation factor (Arf) GTPases are major regulators of vesicle 
biogenesis process. The Arf family consists of Sar1, ARF1-6, Arf-like (Arl) and Arf-related 
(Arp) proteins. Sar1 GTPase plays central role in COPII coat assembly and cargo selection at 
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ERES and thereby is an essential protein for ER-to-Golgi transport (Nakano & Muramatsu, 
1989). After activation by GEF Sec12, Sar1 inserts into ER membrane and recruits a 
heterodimeric Sec23/24 complex, which is a part of COPII coatomer (Bielli et al, 2005; Hicke et 
al, 1992; Nakano et al, 1988). Subsequently recruited Sec13/31 complex forms a structural cage 
around the budding vesicle acting as a scaffold for the outer layer subunits of the COPII coat 
(Stagg et al, 2006). 
While Sar1 regulates COPII coat assembly at ER, the Arf GTPases control biogenesis of 
COPI and clathrin coats at the Golgi, endosomes and plasma membrane (D'Souza-Schorey & 
Chavrier, 2006). Based on sequence homology, the six mammalian Arfs can be divided into three 
classes (Kahn et al, 2006). Class I Arf proteins (ARF1, ARF2 and ARF3) control the assembly of 
different types of vesicle coat complexes onto budding vesicles along the biosynthetic pathway. 
Class II Arf proteins (ARF4 and ARF5) are thought to play a role in early Golgi transport, 
whereas ARF6, the sole member of class III, is involved in the regulation of endosomal 
membrane trafficking and actin cytoskeleton remodelling at the cell periphery (Bonifacino & 
Glick, 2004; Claude et al, 1999; D'Souza-Schorey et al, 1995; Radhakrishna et al, 1996). All 
Arfs and Arls, but not Sar1, are co-translationally myristoylated at the second Gly residue of the 
N-terminus and this modification is required for membrane binding as well as for biological 
activity. In contrast to Rab GTPases, ARFs require activation by specific GEFs prior to 
membrane binding via the myristoyl group and associated N-terminal amphipathic helix 
(Antonny et al, 1997). Activated ARFs recruit cargo sorting proteins, coat proteins, lipid-
modifying enzymes and other effector molecules that affect cargo packaging and coated vesicle 
maturation (Gillingham & Munro, 2007). For example, GTP-bound ARF1 interacts with 
cytosolic β-COP and ε-COP subunits and recruits them to the Golgi complex promoting cargo 
sorting into and formation of COPI-coated carriers (Lippincott-Schwartz et al, 1998; Zhao et al, 
1997; Zhao et al, 1999). It has been shown that ARF1 binds to membrin, a mammalian ER-Golgi 
SNARE located on COPI-coated vesicles (Honda et al, 2005). Moreover, ARF1 also interacts 
with GS15 and YKT6 SNAREs involved in retrograde membrane trafficking (Lee et al, 2005), 
suggesting that interplays between the GTPase and tethering factors might function on ARF1 
targeting to Golgi complex and on vesicle tethering at Golgi. ARF1 also regulates the formation 
of CCV at the TGN and endosomal compartments through the recruitment of AP-1, AP-3 and 
AP-4 complexes (Boehm et al, 2001; Ooi et al, 1998; Stamnes & Rothman, 1993), as well as 
Golgi-localized γ-ear-containing ARF-binding (GGA) proteins (Shiba et al, 2003). These 
 41 
examples illustrate that ARF1 is an important regulator of both anterograde and retrograde cargo 
trafficking. 
As mentioned previously, ARF6 GTPase plays a distinct role in endocytic membrane 
trafficking. ARF6 has been shown to recruit and activate type I phosphatidylinositol-4-phosphate 
5-kinase (PIP5K) (Krauss et al, 2003), leading to increased levels of phosphatidylinositol 4,5-
biphosphate (PI(4,5)P2) at the cell periphery. It is well known that PI(4,5)P2 regulates clathrin-
mediated endocytosis  (Haucke, 2005; Wenk & De Camilli, 2004) and cooperates with ARF6 to 
translocate AP-2 complex to the membrane (Paleotti et al, 2005), pointing towards a major role 
for ARF6 in AP-2/clathrin coat assembly. Moreover, PI(4,5)P2 regulates actin polymerization 
(Miki et al, 1996), mediating ARF6 function in the cytoskeleton remodelling. ARF6 also 
participates in at least one clathrin-independent pathway responsible for the endocytosis of 
cargoes including IL2Rβ, CD59, MHC class I and carboxypeptidase E (Arnaoutova et al, 2003; 
Donaldson, 2003)           
 
3.7.2. Rab GTPases 
 
Rabs are compartment-specific GTPases that play a crucial role in regulating each of the 
five major steps in membrane trafficking: vesicle budding, uncoating, delivery to their destination 
compartment, tethering and fusion with the target membrane (Fig. I.5). Rab GTPases constitute 
the largest family of the Ras superfamily with 11 genes identified in yeast and almost 70 in 
humans (Pereira-Leal & Seabra, 2001). While some of the Rabs are tissue-specific, many are 
ubiquitously expressed (Miaczynska & Zerial, 2002 and references therein). Rab proteins are 
reversibly associated with the surfaces of distinct membranous compartments by hydrophobic 
geranylgeranyl groups that are attached to one or, in most cases, two Cys residues in CAAX box 
at the C-terminus (Andres et al, 1993; Desnoyers et al, 1996). Following prenylation, GDI binds 
modified Rabs and assists their targeting to the relevant membranous compartments. 
Additionally, GDI can act as a Rab recycling factor. If the Rab fails to encounter its effectors or 
after the delivery of vesicle to its destination, GDI can detach GTPase from the membrane and 
deliver it to another compartment; here the Rab-GDI complex is recognized and dissociated by 
membrane-associated GDI displacement factors (GDFs). Although Rab targeting to the 
membrane is not yet fully understood, GDFs have been proposed to be at the apex of a hierarchy 
that defines membrane identity through the recruitment of specific Rab-GDI (Sivars et al, 2003; 
Soldati et al, 1994; Ullrich et al, 1994) (Fig. I.5). 
 42 
 
 
Once inserted into the membrane, Rabs are activated by specific GEFs. Following 
activation, Rabs recruit or activate distinct sets of effector proteins, including cargo sorting 
adaptors, kinases, phosphatases, motor proteins or their adaptors and tethering factors (Fig. I.5). 
The best example of Rabs involved in cargo selection and vesicle formation process is RAB9, 
which regulates membrane trafficking between late endosomes and the TGN (Lombardi et al, 
1993). Diaz and Pfeffer identified TIP47 protein that binds to the cytoplasmic tail of mannose-6-
phosphate receptors (M6PRs) and is required for their recycling from late endosomes back to the 
Golgi (Diaz & Pfeffer, 1998). TIP47 also binds RAB9 and this interaction increases the affinity 
Fig. I.5: Functions of Rab GTPases in membrane trafficking. (a) An active GTP-
bound Rab activates a sorting adaptor to sort a cargo into a vesicle, which is subsequently coated 
with cargo-specific coat complexes. (b) Rabs recruit phosphoinositide (PI) kinases or 
phosphatases that may alter PI compositions and thereby lead to vesicle uncoating. (c) Rabs 
mediate vesicle transport along actin- or microtubule-based cytoskeletal structures by interacting 
with motor adaptors, such as RAB11FIP2, or by binding directly to motors, such as kinesin 
KIF20A. (d) Rabs control vesicle tethering by recruiting tethering factors, such as SNAREs, 
which induce vesicle fusion with the target membrane. (e) Following membrane fusion and cargo 
release, Rabs are converted into the inactive state through hydrolysis of GTP and, in complex 
with GDI, recycled back to the donor membrane, where they can be reactivated by specific GEFs 
for another cycle of vesicle transport. Adapted from (Stenmark, 2009). 
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of TIP47 for M6PRs, which leads to enrichment of the M6PRs within the budding vesicle 
(Carroll et al, 2001). In contrast to previously described ARF6-mediated clathrin coat formation 
on budding vesicle, RAB5 regulates clathrin-coated vesicle uncoating after fission from the donor 
membrane. Uncoating can be activated in two ways: (i) RAB5 induces displacement of µ2 kinase 
from AP-2 and (ii) RAB5 accelerates PI(4,5)P2 turnover through the recruitment of effectors such 
as PI phosphatases (Semerdjieva et al, 2008; Shin et al, 2005). Rabs also recruit effector proteins 
that are necessary for vesicle transport along actin- or microtubule-based cytoskeletal structures 
(Fig. I.5). For example, RAB11 efector RAB11FIP2 acts as adaptor for RAB11-positive 
recycling endosomes to bind myosin Vb motor (Hales et al, 2002). Some kinesins can directly 
interact with active Rabs; for instance, KIF20A binds to the Golgi-localized RAB6 (Echard et al, 
1998). Several examples of Rab functions in vesicle tethering are described in the following 
section. The exact role of Rabs in vesicular carrier fusion with the target membrane is less 
understood; however, it is known that Rab-effector complexes interact with SNAREs and might 
affect their activity membrane fusion (Collins et al, 2005; Subramanian et al, 2004).       
After delivery of the cargo-loaded vesicle to the acceptor membrane, Rab is deactivated 
through GTP hydrolysis to GDP, which is not only accomplished by the intrinsic GTPase activity 
of the Rab, but also accelerated by GAPs (Bernards, 2003). More than 40 different GAPs are 
present in humans and mice. Most of them share a conserved TBC1 (Tre-2/Cdc16/Bub2) domain 
(Fukuda, 2011; Strom et al, 1993). Importantly, GEFs and GAPs as well as Rab effectors are 
thought to restrict either spatial or temporal activity of Rabs and thereby, in combination with 
GDFs, they might assist in establishing Rab-specific compartment identity (Pfeffer, 2005; Rink et 
al, 2005). This compartment identity is an essential prerequisite to ensure the fidelity of the entire 
membrane trafficking system. 
 
3.7.3. Tethering factors and SNAREs 
 
One of the fundamental issues in vesicular transport is how a given cargo carrier is able to 
bind and fuse to its specific acceptor membrane. Eukaryotic cells have developed an elaborate 
system that involves Rab GTPases, tethering factors and SNAREs. While GTP-bound Rabs 
activate tethering factors that are required for the initial vesicle binding, the subsequent 
membrane fusion is determined by membrane-embedded SNARE proteins. Tethers are thought to 
bridge membranes binding both to Rabs and SNAREs, and thus prepare membranes for fusion. In 
contrast to highly conserved SNAREs, tethering factors are much more conserved and are 
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divided into two broad groups: coiled-coil filamentous tethering proteins and multisubunit 
tethering complexes (MTCs). Coiled-coil tethers form long, rod-like complexes spanning up to 
200nm distances and bridging vesicle and target membranes. Most of the tethers belonging to the 
first group are integral membrane proteins of Golgi complex and, therefore, are termed golgins. 
One of the best-studied golgins is p115. It is important for the clustering of COPII-coated 
vesicles as well as the docking of COPI- and COPII-coated carriers to the cis-Golgi network 
(Moyer et al, 2001; Weide et al, 2001). In order to perform these functions, p115 interacts with a 
number of Golgi SNAREs, including syntaxin-5, membrin, GOS-28 and BET1 (Shorter et al, 
2002), and other golgins, such as GM130 and giantin (Nakamura et al, 1997b; Nelson et al, 
1998). Apart from being predominantly located at the cis-Golgi, p115 is also recruited to COPII 
vesicles by GTP-bound RAB1 (Allan et al, 2000). The functional relevance of p115 in 
biosynthetic membrane trafficking is exemplified by the finding that siRNA-based RNAi of p115 
leads to Golgi complex fragmentation and blocks VSV-G transport to the plasma membrane 
(Puthenveedu & Linstedt, 2004). Another well-characterized coiled-coil tether early endosomal 
antigen 1 (EEA1) is recruited by active RAB5 and together with SNAREs, such as syntaxin-13, 
participates in homotypic fusion of early endosomes (Christoforidis et al, 1999; McBride et al, 
1999). 
   Currently, there are at least nine different MTCs that act throughout the membrane 
trafficking system and at the plasma membrane in eukaryotic cells (Brocker et al, 2010). 
Similarly to coiled-coil tethering factors, MTCs bridge the recognition of vesicles via specific 
Rabs and SNARE-mediated membrane fusion processes. The Dsl1p MTC is located at the ER 
and regulates retrograde Golgi-ER transport by tethering COPI-coated vesicles (Andag et al, 
2001). The COG complex is responsible for COPI-mediated intra-Golgi transport and 
maintenance of Golgi structure (Oka et al, 2004; Ungar et al, 2002). The TGN-associated GARP 
complex cooperates with RAB6 in tethering vesicles derived from both early and late endosomes 
to the TGN (Siniossoglou & Pelham, 2001). Secretory cargo-loaded vesicles are tethered to the 
plasma membrane by the octameric exocyst complex (Wiederkehr et al, 2004). Two MTCs 
operate sequentially between endosomes and lysosomes. The CORVET is required for tethering 
of TGN-derived vesicles to endosomes and one of the complex subunits (Vps8) interacts with 
RAB5 as its effector (Chen & Stevens, 1996; Markgraf et al, 2009). Vps39 subunit of the HOPS 
complex has been proposed to act as GEF for RAB7 during early-to-late endosome maturation 
(Rink et al, 2005), however, this model was disproved by recent findings that RAB7 is activated 
by the RAB5-recruited SAND-1-CCZ-1 complex (Kinchen & Ravichandran, 2010; Poteryaev et 
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al, 2010). Nevertheless, the HOPS complex is implicated in several fusion events at the late 
endosome and the vacuole, including the fusion of multivesicular bodies, Golgi-derived AP-3-
positive vesicles and the homotypic fusion of vacuoles (Nakamura et al, 1997a). The TRAPP is 
found in three forms (I, II, III) and has been described as a multisubunit GEF for yeast Rabs Ypt1 
(a homolog of human RAB1 GTPases) and Ypt31/32. (Jones et al, 2000). Apart from acting as 
GEFs, TRAPP complexes also promote vesicle tethering. The best example is the TRAPPI 
complex, which tethers ER-derived vesicles to the cis-Golgi by binding to COPII coat subunit 
Sec23 (Cai et al, 2007). Due to their oligomeric composition of different proteins (3 – 10 
subunits), MTCs, in particular TRAPPI-III, can carry out additional regulatory functions at 
different organelles (Brocker et al, 2010).    
The final step of vesicle trafficking is its fusion with the acceptor membrane driven by 
SNARE proteins. There are 36 SNAREs identified in humans. SNAREs are functionally 
classified into v- and t-SNAREs, because they reside on opposing membrane, usually on a 
transport vesicle and a target membrane, respectively (Jahn & Scheller, 2006). t-SNAREs form 
oligomeric complexes to acquire specificity for different v-SNAREs (Parlati et al, 2002). 
Following tethering, SNAREs from opposing membranes generates trans-SNARE complexes or 
SNAREpins, which bring two bilayers into close proximity and induce membrane fusion (Weber 
et al, 1998). A functional t-SNARE complex provides the template for v-SNARE binding and is a 
prerequisite for SNAREpin assembly. The assembly of SNAREpin is also regulated by so-called 
SM (Sec1/Munc1) proteins. SM proteins directly interact with v- and t-SNARE complexes at 
different transport steps and thereby stimulate specific membrane fusion and confer additional 
specificity to membrane trafficking (Peng & Gallwitz, 2002; Shen et al, 2007). Moreover, distinct 
SM proteins can augment the SNAREpin-mediated membrane fusion process (Scott et al, 2004). 
After fusion, the trans-SNARE complexes are often referred to as cis-SNARE pairs because they 
reside in a single lipid bilayer (Jahn & Scheller, 2006). The cis-SNARES are dissociated and 
recycled to different membranous compartments by cytosolic SNAP and NSF proteins for 
another round of cargo transport (Block et al, 1988).  
 
Membrane trafficking is a highly coordinated multistep process involving the formation 
of vesicular carriers loaded with defined sets of cargo, their transport between compartments and 
the fusion with the target membranes. The fidelity of membrane trafficking relies on an array of 
regulatory proteins and on their interactions with effector molecules. Despite the fact that 
different groups of regulatory proteins can regulate the same steps of membrane traffic, their 
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successive roles in this process can be discerned. While Arf GTPases are the central regulators of 
vesicle biogenesis, Rab GTPases play crucial roles in defining membrane identity, which is 
essential for specific cargo selection, vesicle transport and targeting to the correct cellular 
compartment. Finally, tethering factors and SNAREs are responsible for vesicular carrier docking 
to and fusion with the specific target membranes. Recent recognition of miRNAs as important 
regulators of virtually all investigated physiological and pathological processes suggests that 
these RNA molecules can potentially constitute the additional level of membrane trafficking 
regulation. Indeed, this notion has been supported by recent finding that miR-92a regulates the 
expression of RAB14, which is involved in surfactant secretion in lung cells (Gou et al, 2008; 
Kanzaki et al, 2011).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 47 
4. OBJECTIVES 
 
 The overall goal of this study was to identify miRNAs and their biologically relevant 
target genes involved in the regulation of membrane trafficking. Considering the evidence to 
date, miRNAs seem to be responsible for fine regulation of numerous target genes. We envisage 
that miRNAs act as novel adaptive regulators of membrane trafficking, providing robustness to 
this complex cellular process. Previous studies have analyzed a few miRNAs involved in insulin 
secretion, however, no systematic investigation of miRNAs as regulators of membrane trafficking 
has been performed. 
 
 For this reason, the following aims of this study were proposed: 
 
1. To apply quantitative approaches for detection of miRNA-mediated changes in 
biosynthetic trafficking and endocytosis; 
2. To identify miRNAs involved in the regulation of membrane trafficking; 
3. To identify and validate novel functionally relevant targets that exert miRNA-
mediated regulation of membrane trafficking.      
 
To implement proposed aims, the following approaches were applied:  
Aim 1. miRNA-mediated changes in biosynthetic trafficking efficiency were evaluated 
using a fluorescence intensity-based ts-O45-G protein transport assay. A quantitative 
fluorescence intensity-based DiI-LDL internalization assay was applied for quantification of 
endocytosis efficiency. Synthetic miRNA mimics (pre-miRs) and miRNA inhibitors were used to 
modulate the activity of endogenous miRNAs. 
Aim 2. In order to identify miRNAs involved in the regulation of biosynthetic cargo 
trafficking, large-scale functional screening of Pre-miR
TM
 miRNA Precursor Library was 
performed. Hit miRNAs were confirmed in small-scale ts-O45-G transport assay and further 
investigated for their effects on the Golgi complex integrity. 
Aim 3. In order to identify membrane trafficking-related miRNA targets, genome-wide 
mRNA expression profiling in combination with bioinformatics analysis was conducted. 
Functional relevance of potential targets was confirmed by siRNA-based RNAi. Novel miRNA 
targets were validated by luciferase reporter assay, qRT-PCR and western blot approaches.    
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5. MATERIALS AND METHODS 
 
5.1. Materials 
 
5.1.1. siRNAs, miRNAs and miRNA library 
 
 siRNAs targeting human α-COP (SI00351491 and SI04157419), TBC1D2 (SI02807518 
and SI04239494), ASAP2 (SI00360619 and SI04151784), M6PR (SI00626052 and SI03069920), 
LDLR (SI00011186 and SI03024525) and non-silencing control siRNA “All Stars” (SI03650318) 
were purchased from Qiagen. Cy3-labeled siRNA targeting INCENP (28431) was purchased 
from Ambion.  
Synthetic double-stranded RNA molecules mimicking human endogenous miRNAs (pre-
miRs) and single-stranded inhibitors for endogenous miRNAs (anti-miRs) were purchased from 
Ambion; miR-17 (products PM12412 and AM12412), miR-18a (PM12973 and AM12973), miR-
19a (PM10649 and AM10649), miR-20a (PM10057 and AM10057), miR-20b (PM10975 and 
AM10975), miR-92a (PM10916 and AM10916), miR-93 (PM10951 and AM10951), miR-320a 
(PM11621 and AM11621) and negative control pre-miR (PNC) and anti-miR (ANC) (AM17120 
and AM17011). Synthetic DNA/LNA anti-miR for miR-20b (410133-00) and DNA/LNA anti-
miR negative control (199004-00) were from Exiqon. miRZip-20b expression plasmid 
(MZIP20b-PA-1) and plasmid expressing control miRZIP (MZIP000-PA-1) were purchased from 
System Biosciences. Large-scale pre-miR library (Pre-miR
TM
 miRNA Precursor Library – 
Human v3, 4385830) of 470 human miRNAs based on Sanger miRBase v9.2 was purchased from 
Ambion. List of the miRNAs included in the library is in Appendix I.  
 
5.1.2. Luciferase reporter plasmids 
 
A panel of dual-luciferase reporter plasmids was prepared and used in this project to 
measure human miRNA activity and miRNA regulatory effect on target gene expression: 
1. psiCheck
TM
-2-miR-17 
2. psiCheck
TM
-2-miR-20a 
3. psiCheck
TM
-2-miR-92a 
4. psiCheck
TM
-2-miR-320a 
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5. psiCheck
TM
-2-TBC1D2-3´UTR 
6. psiCheck
TM
-2-TBC1D2-3´UTR-mut 
7. psiCheck
TM
-2-TBC1D2-3´UTR-mut 
8. psiCheck
TM
-2-LDLR-3´UTR 
A luciferase reporter vector psiCheck
TM
-2 (Promega, a generous gift from Dr. D. Grimm, 
BioQuant, University of Heidelberg) was used to generate dual-luciferase reporters. In order to 
measure the activity of miRNAs, DNA fragments encoding single completely complementary 
miRNA-binding site for specific miRNAs were cloned into XhoI- and NotI-digested psiCheck
TM
-
2 vector immediately downstream of the top codon of Renilla luciferase gene (no.1 throught no.4 
plasmids). The DNA fragments were obtained by annealing two synthetic oligonucleotides. The 
sequences of oligonucleotides used to generate human miRNA-specific reporters are as follows: 
 
1. For miR-17 binding site in psiCheck
TM
-2-miR-17 plasmid: 
 FWD 5’-TCGAGCTACCTGCACTGTAAGCACTTTGTCTAGAGC-3’  
REV 5’-GGCCGCTCTAGACAAAGTGCTTACAGTGCAGGTAGC-3’ 
 
2. For miR-20a binding site in psiCheck
TM
-2-miR-20a plasmid: 
 FWD 5’-TCGAGCTACCTGCACTATAAGCACTTTATCTAGAGC-3’ 
REV  5’-GGCCGCTCTAGATAAAGTGCTTATAGTGCAGGTAGC-3’ 
 
3. For miR-92a in psiCheck
TM
-2-miR-92a plasmid:  
FWD 5’-TCGAGACAGGCCGGGACAAGTGCAATATCTAGAGC-3’ 
REV  5’-GGCCGCTCTAGATATTGCACTTGTCCCGGCCTGTC-3’ 
 
4. For miR-320a in psiCheck
TM
-2-miR-320a plasmid: 
FWD 5’-TCGAGTCGCCCTCTCAACCCAGCTTTTTCTAGAGC-3’ 
REV  5’-GGCCGCTCTAGAAAAAGCTGGGTTGAGAGGGCGAC-3’ 
 
For plasmids to measure miR-17 regulatory effect on target gene expression, the 352-bp 
and 2534-bp full-length TBC1D2 and LDLR 3´UTRs, respectively, were PCR-amplified from the 
genomic DNA of HeLa cells. The primer sequences used for PCR are as follows: 
 
5. For TBC1D2-3´UTR: 
FWD 5’-ATACTCGAGCTTGGCCACCTCCCCTCCCCAC-3’ 
REV 5’-ATAGCGGCCGCTGAATGATTTCCACCATTTACA-3’ 
 
6. For LDLR-3´UTR: 
FWD 5’-ATACTCGAGACATCTGCCTGGAGTCCCGTCC-3’ 
REV 5’-GCGGCGGCCGCTTTAGACAAATTGGTTCATTTA-3’ 
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PCR products were cleaved with XhoI and NotI restriction endonucleases and cloned into 
XhoI- and NotI-digested psiCheck
TM
-2 vector immediately downstream of the top codon of 
Renilla luciferase gene. The resulting plasmids were entitled psiCheck-2-TBC1D2-3´UTR and 
psiCheck-2-LDLR-3´UTR. To mutate or delete a predicted miR-17 binding site in the 3´UTR of 
TBC1D2 mRNA, psiCheck-2-TBC1D2-3´UTR was used as a template plasmid for Phusion site-
directed mutagenesis kit (Finnzymes). The following 5´-phosphorylated primers were used: 
 
7. For psiCheck
TM
-2-TBC1D2-3´UTR-mut: 
FWD 5’-Pho-CCTCTTCCACAGTCGTGAAACGCATGTAAACAA-3’ 
REV 5’-Pho-TGACGAAAGGGTGGCATCCCTGGGTAAGTA-3’ 
 
8. For psiCheck
TM
-2-TBC1D2-3´UTR-mut: 
FWD 5’-Pho-GCATGTAAACAAGCAAGAGCACTGC-3’ 
REV 5’-Pho-GACGAAAGGGTGGCATCCCTGGGTA-3’ 
 
5.1.3 Antibodies and other reagents 
 
The mouse monoclonal anti-ts-O45-G antibody recognizing the extracellular epitope of 
ts-O45-G protein was a generous gift from Prof. M.D. K. Simons (MPI-CBG, Germany). 
Polyclonal rabbit anti-TBC1D2 antibody was a kind gift from Dr. V. Braga (Imperial College 
London, UK). Polyclonal rabbit anti-LDLR antibody was purchased from Cayman Chemicals. 
Monoclonal mouse anti-GM130 (clone 35/GM130) was purchased from BD Transduction 
Laboratories. Alexa647 conjugate of lectin Concanavalin A was from Invitrogen. Secondary anti-
mouse and anti-rabbit IgG HRP-conjugated antibodies were purchased from R&D Systems. 
Secondary goat Alexa647/Cy3-conjugated anti-mouse IgG antibody was purchased from 
Invitrogen. Transfection reagent Lipofectamine™ 2000 was purchased from Invitrogen. 
qRT-PCR TaqMan
®
 miRNA expression assays (ID 002308 for miR-17, ID 000580 for 
miR-20a, ID 000430 for miR-92a, ID 002277 for miR-320a and ID 001093 for endogenous 
control small nuclear RNU6B RNA) were purchased from Applied Biosystems. qRT-PCR 
TaqMan
®
 mRNA expression assays (ID Hs00917985_m1 for TBC1D2, ID Hs00181192_m1 for 
LDLR and ID Hs99999905_m1 for endogenous control GAPDH mRNAs) were also purchased 
from Applied Biosystems. Dil-LDL was purchased from Invitrogen. 
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5.2. Methods 
 
5.2.1. Cell culture and media 
 
Human epithelial carcinoma cells (HeLa) and HIV-infectible HeLa-CD4 (Clavel & 
Charneau, 1994) cells were cultured in Growth Medium (GM) consisting of Dulbecco's Modified 
Eagle Medium (DMEM, Invitrogen) supplemented with 10% (v/v) fetal calf serum (PAA 
Laboratories), 2mM L-glutamine (Invitrogen), 50 g/ml streptomycin and 50U/ml penicillin 
(Invitrogen). HeLa and HeLa-CD4 cells were cultured in 10cm culture dishes and split on a 
regular basis every three days to maintain optimal growth conditions. For splitting, cells were 
washed with pre-warmed phosphate-buffered saline (PBS) solution to remove traces of GM and 
incubated in 1ml 0.25% trypsin-EDTA (Invitrogen) solution for 5min at 37°C. Cells were then 
resuspended in fresh GM and 1/8 part of cell suspension plated in culture dishes. Unless 
otherwise indicated, cells were maintained at 37°C in a humidified atmosphere with 5% CO2. 
Starvation Medium (SM) consisting of DMEM supplemented with 2mM L-glutamine, 
50 g/ml streptomycin and 50U/ml penicillin and Imaging Medium (IM, pH 7.4) consisting of 
Modified Eagle Medium without phenol red (MEM, Invitrogen) supplemented with 30mM 
HEPES and 0.5g/l sodium bicarbonate were used for DiI-LDL internalization experiments. 
Transfection Medium (TM) consisting of DMEM supplemented with 10% (v/v) fetal calf serum 
and 2mM L-glutamine was used for tranfection with pre-miRs, anti-miRs and siRNAs. 
 
5.2.2 Transfection with pre-miRs, anti-miRs and siRNAs 
 
Transfection of HeLa cells with pre-miRs, anti-miRs or siRNAs was performed either by 
means of the liquid-phase direct transfection or solid-phase reverse transfection. For both types of 
transfection, the Lipofectamine™ 2000 was used as transfection reagent. While all small-scale 
experiments described in this work were based on liquid-phase transfection, a large-scale 
screening of a human pre-miR library was performed by using reverse transfection approach 
described elsewhere (Erfle et al, 2007; Erfle et al, 2008). For reverse transfection, 5µl of the 
respective pre-miR or siRNA 30µM stock solution was mixed with 4.75µl OptiMEM I + 
GlutaMAX I (Invitrogen)/0.4M sucrose (USB) solution and 1.75µl Lipofectamine™ 2000. This 
mixture was incubated for 30min at room temperature. Next, 7.25µl of a 0.08% (w/v) gelatin 
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(Sigma-Aldrich) solution containing 3.5 x 10
-4
% (v/v) human fibronectin (Sigma-Aldrich) was 
added reaching a total volume of 18.75µl. Finally, transfection solution was diluted in 450µl of 
MilliQ water and 25µl of this solution was transferred into each well of 96-well µ-plates (Ibidi). 
The plates were dried for 2.5h in the Speed Vac. In this way, a pre-miR library of 470 pre-miRs 
was distributed over 10 different layouts of 96-well µ-plates replicated 18 times, with a final 
amount of 8pmol of respective pre-miR or siRNA per well. Three wells containing siRNA 
against human α-COP were distributed over each layout and used as positive control for reverse 
transfection efficiency. Additionally, five wells with PNC were distributed over each layout and 
used as negative control in ts-O45-G-based library screening.  
In case of liquid-phase transfection with pre-miRs, anti-miRs and siRNAs, 
Lipofectamine™ 2000 was used according to the manufacture’s instructions. The solutions of 
respective oligonucleotide/OptiMEM I + GlutaMAX I/Lipofectamine 2000 were applied to cells 
growing in TM. Unless otherwise indicated, pre-miRs, anti-miRs and siRNAs were transfected at 
final concentration of 50nM. 
  
5.2.3. Total DNA and RNA isolation 
 
 Total DNA from HeLa cell culture was purified by DNeasy® Blood & Tissue Kit 
(Qiagen) according to the manufacturer’s recommendations. 
Total RNA was isolated using mirVana
TM
 miRNA Isolation Kit (Ambion) according to 
the manufacturer’s instructions. The kit is designed to purify total RNA including very small 
RNA species, such as miRNAs. Briefly, HeLa cells were washed 2 – 3 times with ice-cold PBS 
and lysed in Lysis/Binding Solution. Lysates were collected, mixed with 1/10 volume of miRNA 
Homogenate Additive and incubated for 10min on ice. Next, the equal volume of acid 
phenol:chloroform solution was added to lysates, followed by centrifugation for 5 min at 
maximum speed. The upper aqueous phase was collected and mixed with 1.25 volumes of 100% 
ethanol. The lysate/ethanol mixtures were filtered through Filter Cartridge by centrifugation, 
followed by one washing step with miRNA Wash Solution 1 and two washing steps with Wash 
Solution 2/3. The Filter Cartridges were transferred into fresh collection tubes and total RNA 
recovered in 100μL of pre-heated (95°C) nuclease-free water. 
All buffers, washing solutions and filter cartridges required for total DNA and RNA 
extraction were provided in isolation kits. 
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5.2.4. Biosynthetic ts-O45-G trafficking assay 
 
To evaluate effects of miRNAs on the biosynthetic trafficking, well-described ts-O45-G 
transport assay (Starkuviene & Pepperkok, 2007) was applied. In order to screen pre-miR library 
of 470 miRNAs, 5.5 x 10
3
 of actively growing HeLa cells in 250µl/TM were plated into prepared 
96-well µ-plates with pre-miRs. For small-scale assays, cells were seeded on 8-well μ-slides (7 x 
10
3
/well) and transfected either with pre-miRs or anti-miRs or respective control oligonucleotides 
at a final concentration of 50nM on the next day. Next, cells were incubated with recombinant 
adenovirus encoding ts-O45-G-YFP (hereafter, ts-O45-G) 42h after transfection. After 45min 
incubation at 37°C, cells were washed and incubated for 6h at 39.5°C in a humidified atmosphere 
with 5% CO2. The synchronized release of ts-O45-G from ER was achieved by moving cells to a 
permissive temperature, 32°C, in the presence of 100μg/ml cycloheximide (Sigma-Aldrich). One 
hour later, cells were fixed with 3% paraformaldehyde and plasma membrane-traversed ts-O45-G 
was immunostained with a primary mouse anti-ts-O45-G antibody, followed by immunostaining 
with a secondary Alexa647-conjugated goat anti-mouse IgG antibody. Nuclei were stained with 
0.3μg/ml Hoechst 33342. Images were acquired by ScanˆR Acquisition module (Olympus) on 
IX81 motorized inverted fluorescence microscope (Olympus) using 10x UplanSApo objective 
(NA 0.4); 20 images/well or 36 images/well were acquired from 96-well µ-plates or 8-well µ-
slides, respectively. The total fluorescence intensity of single cell-associated plasma membrane 
(PM)-incorporated fraction of ts-O45-G (Alexa647 channel) and the total fluorescence intensity 
of expressed ts-O45-G (YFP channel) were measured by means of the image analysis software 
ScanˆR Analysis module (Olympus), and extracted data were further analyzed as described in 
“Statistical data analysis”. 
Depending on the experimental format, 7 500 – 10 000 cells were analyzed for each 
transfected RNA molecule. 
 
5.2.5. DiI-LDL internalization assay 
 
For analysis of cellular uptake of fluorescently labeled low-density lipoprotein (3,3'-
dioctadecylindocarboncyanine-labelled LDL, DiI-LDL, Invitrogen), HeLa cells were seeded on 
8-well μ-slides (Ibidi) in GM (1x104 cells/well). The next day, cells were transfected with pre-
miRs or anti-miRs, or siRNAs at a final concentration of 50nM. Transfected cells were cultured 
in GM for 24h and medium was then exchanged for SM supplemented with 0.2% (w/v) bovine 
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serum albumin (BSA) for additional 24h. DiI-LDL internalization assay was carried out as 
described elsewhere (Gilbert et al, 2009). Briefly, 48h after transfection, cells were exposed for 
45min at 37°C to 10mg/ml 2-hydroxy-β-cyclodextrin (HPCD, Sigma-Aldrich) and 0.2% (w/v) 
BSA added to SM, followed by washing with ice-cold IM supplemented with 0.2% (w/v) BSA. 
Next, cells were labeled with 50µg/ml Dil-LDL for 30min at 4°C and Dil-LDL internalization 
was stimulated for 20min at 37°C. Cells were washed with ice-cold acidic IM (pH 3.5) for 1min 
in order to strip off residual DiI-LDL on plasma membrane. Cells were fixed in 3% 
paraformaldehyde for 20min on ice. Nuclei were stained with 0.3μg/ml Hoechst 33342 and 49 
images/well were acquired as described in “Biosynthetic ts-O45-G trafficking assay”. The total 
fluorescence intensity of single cell-associated DiI-LDL was measured by means of the image 
analysis software ScanˆR Analysis module (Olympus), and extracted data were further analyzed 
as described in “Statistical data analysis”. On average, 8 700 cells were analyzed for each 
transfected RNA molecule. 
 
5.2.6. Dual-luciferase reporter assay 
 
The day before transfection, Hela cells were seeded into 24-well plates (4 x 10
4
 
cells/well). The next day, cells were co-transfected with 10ng of the respective luciferase reporter 
vector and either with pre-miRs or anti-miRs at a final concentration of 50nM. Dual-luciferase 
reporter assay (Promega) was performed 24h after transfection following the manufacturer’s 
protocol with minor changes. Briefly, before lysis, cells were washed once with ice-cold PBS and 
100μl of 1x Passive Lysis Buffer was applied per well. The plates were mounted on a rocking 
platform for 15min rocking at room temperature to complete cell lysis. Later, lysates were 
collected and stored at -20°C. Before luciferase activity measurement, lysates were thawed on 
ice, centrifuged briefly to pellet cell debris and 5μl of lysates were transferred into a white 96-
well plate (Greiner Bio-One). The read-out of luminescence signal was performed with a Glomax 
96-microplate luminometer (Promega) equipped with two injectors and primed with LARII and 
Stop&Glo
®
 reagents. The activity of firefly luciferase was initiated by automatically injecting 
25μl of LARII and luminescence acquired for 10s. After, the luminescence of firely luciferase 
was quenched by injecting 25μl of Stop&Glo® reagent, which also initiated Renilla luciferase 
activity. Luminescence of Renilla luciferase was measured for another 10s. Luminescence 
intensity of Renilla luciferase depends on the protein expression level, which is regulated by 
intracellular miRNAs. In order to determine the effect of miRNAs on reporter protein expression, 
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luminescence intensity of Renilla luciferase was normalized to the intensity of firefly luciferase 
used as internal transfection control. 
 
5.2.7. qRT-PCR mRNA and miRNA expression assays       
 
qRT-PCR TaqMan
®
 miRNA expression assays specific for each miRNA of interest were 
performed as previously described (Chen et al, 2005). Briefly, Hela cells were seeded in 24-well 
plates. The next day cells were transfected with either pre-miRs or anti-miRs at a final 
concentration of 50nM, or mock-transfected (only Lipofectamine 2000). Total RNA was isolated 
24h, 48h and 72h after transfection. TaqMan
®
 miRNA assays were used to reverse transcribe 
15ng of total RNA. Each 15µl reverse transcription reaction mix contained 50nM miRNA-
specific stem-loop Reverse Transcription primer, 100 mM dNTPs, 1x Reverse Transcription 
buffer, 0.25 U/μl RNase Inhibitor and 3.33 U/μl of MultiScribeTM Reverse Transcriptase and 
nuclease-free water. The reaction mixes were kept on ice for 5 min, then incubated in the MJ 
Mini thermocycler (Bio-Rad) at 16°C for 30 min, at 42°C for 30 min, at 85°C for 5 min and 
finally were held at 4°C. qRT-PCR reactions were carried out in 96-well ABgene® PCR Plates 
(Thermo Fisher Scientific) using the Real Time PCR 7500 system (Applied Biosystems). Each 
20µl reaction mix contained 1.33 μl of cDNA beforehand diluted 1:10, 1x TaqMan® Universal 
Master Mix, 1 μl of TaqMan® miRNA assay mix containing TaqMan® primer, forward and 
reverse primers and nuclease-free water. The 2
-ΔΔCT
 method for miRNA expression quantification 
was applied as described elsewhere (Livak & Schmittgen, 2001) using expression level of 
RNU6B RNA as a reference for normalization. 
For qRT-PCR of TBC1D2 and LDLR mRNAs, HeLa cells were transfected with pre-miR-
17, siRNAs targeting TBC1D2 and LDLR, or with respective controls at final concentration of 
50nM in 24-well plates. Total RNA was extracted at 12h, 24h and 48h after transfection. Total 
RNA (500ng) was reverse transcribed to cDNA using TaqMan
®
 Reverse Transcription Reagents 
(Applied Biosystems) with random hexamers. The qRT-PCR of TBC1D2 and LDLR mRNAs was 
carried out in the Applied Biosystems StepOnePlus Real-Time PCR system (Applied 
Biosystems) using 65ng of cDNAs with the respective TaqMan
®
 mRNA assay in accordance 
with the manufacturer’s protocol. Relative expression level of TBC1D2 and LDLR mRNAs was 
calculated by applying 2
-∆∆CT
 method and using expression level of GAPDH mRNA as a 
reference for normalization.  
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Expression profiling experiments for each miRNA and mRNA were performed with two-
three biological samples, two replicates of reverse transcription reaction per sample and two 
replicates of real-time PCR per reverse transcription reaction. 
 
5.2.8. Western blotting 
 
For human TBC1D2 and LDLR western blot analysis, HeLa cells were transfected with 
pre-miR-17, siRNAs against TBC1D2 or LDLR and appropriate negative controls in 24-well 
plates. Forty-eight hours post-transfection, cells for TBC1D2 protein analysis were lysed in 30µl 
of pre-heated (95°C) Laemmli lysis buffer (Laemmli, 1970) supplemented with 10mM DTT and 
proteins separated on 8% SDS-PAGE gels. Cells for LDLR protein analysis were lysed in 100µl 
lysis buffer (2.9% glycerol, 0.66mM DTT, 1% SDS, 20.8mM Tris-HCl, pH6.8, 1mM PMSF, 
0.0025% Bromophenol Blue) and proteins were separated on 7% SDS-PAGE gels. Before 
electrophoresis, all lysates were treated with benzonase nuclease (Sigma-Aldrich) in order to 
degrade nucleic acids. Proteins were blotted on PVDF Immobilon-P membranes (Millipore) and 
non-specific antibody binding was blocked with 5% non-fat milk in TBS buffer. Blots were 
probed with primary anti-TBC1D2 or anti-LDLR antibodies in TBS-0.1% Tween-20 solution 
overnight at 4°C to detect TBC1D2 and LDLR proteins, respectively. In order to detect tubulin-α, 
blots were probed with anti-tubulin antibody in TBS-0.1 % Tween-20 solution for 1h at room 
temperature. Next, all blots were probed with secondary HRP-conjugated antibodies in TBS-
0.1% Tween-20 solution for 1h at room temperature and chemiluminescence signals were 
detected using the enhanced chemiluminescence (ECL) reagents (GE Healthcare). Protein-
specific chemiluminescence signals were acquired by a Chemiluminescence Detection System 
(Intas) and quantified by means of the ImageJ software (NIH, Abramoff et al, 2004). The total 
chemiluminescence intensity of TBC1D2-specific bands was normalized to the tubulin-α-specific 
chemiluminescence intensity and the LDLR-specific signal was normalized to the signal of cross-
reacting band of the anti-LDLR antibody used (~63kDa). 
 
5.2.9. mRNA microarray analysis 
 
 For mRNA expression profiling upon transfection with pre-miR-17, in HeLa-CD4 cells 
were plated in 24-well plates at a density of 4 x 10
4
 cells/well. The following day, cells were 
transfected with pre-miR-17 or PNC at a final concentration of 50nM. 
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 For mRNA expression profiling upon transfection with pre-miR-517a, HeLa cells were 
seeded in 12-well plates at different densities depending on the incubation period: 6 x 10
4
 for 12h 
and 24h, 3 x 10
4
 for 48h experiments. The next day, cells were transfected with pre-miR-517a or 
PNC at a final concentration of 50nM. 
Total RNA of two biological replicates of each experimental condition was isolated 12h, 
24h and 48h after transfection as described in “Biosynthetic ts-O45-G trafficking assay” and 
submitted for expression profiling at the Microarray Core Facility at German Cancer Research 
Center (DKFZ, Heidelberg). Briefly, the quality of total RNA was checked by gel analysis on the 
Agilent 2100 Bioanalyzer (Agilent Technologies) and estimated by calculating the 28S/18S ratio 
of ribosomal RNAs by RIN algorithm (Schroeder et al, 2006). Only samples with RIN index 
value greater than 8.5 were selected for further expression profiling. Next, 250ng of total RNA 
was used for complementary DNA (cDNA) synthesis, followed by an amplification/labeling step 
(in vitro transcription) in order to synthesize biotin-labeled complementary RNA (cRNA) using 
the MessageAmp II aRNA Amplification kit (Ambion) in accordance with the manufacturer’s 
protocol. The cRNA was column-purified by using the TotalPrep RNA Amplification Kit and 
quality was controlled using the RNA Nano Chip Assay on Agilent 2100 Bioanalyzer. 
Human Sentrix-8 BeadChip
®
 arrays (Illumina) and HumanHT-12 v4 BeadChip
®
 arrays 
(Illumina) were used for hybridization of biotin-labeled cRNA samples obtained from miR-17 
and miR-517a experiments, respectively. Hybridization was carried out in GEX-HCB buffer 
(Illumina) at a concentration of 100ng cRNA/µl for 20h at 58°C. Spike-in controls for low, 
medium and highly abundant mRNAs as well as mismatch control and biotinylation control 
oligonucleotides were added. The arrays were scanned on Beadstation array scanner (Illumina). 
Data extraction was done for all beads individually. Differentially regulated genes were defined 
by further analysis as described in “Statistical data analysis”.  
 
5.2.10. miRNA microarray analysis 
 
 HeLa cells were plated at a density of 4 x 10
4
 cells/well in 12-well plates. The cells were 
treated under three different conditions: (I) cells were incubated for 49h at 37°C in a humidified 
atmosphere with 5% CO2; (II) cells were incubated for 42h at 37°C and then moved for another 
7h at 39.5°C; (III) cells were incubated for 42h at 37°C, then transduced with recombinant 
adenoviral vector, which encodes ts-O45-G protein as described in “Biosynthetic ts-O45-G 
trafficking assay”, and incubated for another 6h at 39.5°C. Independently to the type of treatment, 
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the total RNA was isolated 49h after cell seeding and samples were submitted for miRNA 
expression profiling at the Genomics Core Facility at European Molecular Biology Laboratory 
(EMBL, Heidelberg). The total RNA samples were processed and hybridized on the glass slide 
formatted with 8 high definition human miRNA microarrays (Agilent) following the 
manufacturer’s protocol. Arrays were based on Sanger miRBase v14.0. The steady-state 
expressed miRNAs in HeLa cells under condition (I) and miRNAs affected by temperature 
change or viral transduction under conditions (II) and (III), respectively, were defined by further 
analysis as described in “Statistical data analysis”. Due to the limited number of 8 miRNA 
microarrays per glass slide, four biological replicates of samples treated under condition (I) and 
two biological replicates of each condition (II) and condition (III) were used for miRNA 
expression profiling. 
 
5.2.11. Automated classification of nuclei in apoptosis and proliferation assay 
 
Effects of miRNAs on cell proliferation were determined by applying automated image 
analysis of cell nuclei in collaboration with Dr. Nathalie Harder (Biomedical Computer Vision 
group, Dr. Karl Rohr). The following steps were used: (i) segmentation of cell nuclei, (ii) gray 
value normalization, (iii) feature extraction and (iv) nuclei classification. To segment cell nuclei 
in apoptosis, mitosis, or interphase, a gradient based thresholding approach was extended for the 
segmentation of cell nuclei as described previously (Matula et al, 2009). In this approach, bright 
sides of edges of all objects were detected by taking connected sets of pixels (connected 
components) with negative Laplacian that contained pixels with high gradient magnitude. Each 
connected component was morphologically closed with a small 3x3 pixel structuring element and 
the holes in the components were filled. In order to correctly segment apoptotic cell nuclei, an 
additional step was introduced, in which small connected components within a short distance 
were combined into one component. Each component was treated as a cell nucleus in later steps. 
Since the images of different experiments had highly differing gray value ranges, normalization 
of the gray values was performed before feature extraction. For nuclei normalization, 
characteristics of the gray value distribution of the foreground pixels (histogram of the nuclues 
pixels), such as the location and the width of the maximum peak, were determined for each 
experiment. Next, the mean of the extracted histogram characteristics over all experiments and 
the parameters to transform each individual distribution to this mean distribution was determined. 
These parameters were used to shift and scale the gray values of all images into a common gray 
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value range. After normalization, a set of 354 features were extracted for each cell nucleus. The 
feature set contained features, such as size, shape, mean and standard deviation (SD) of gray 
values, texture-related features (for example, Haralick texture features and wavelet features) and 
moment-based features (for example, Zernike moments). Based on the extracted features, cell 
nuclei were classified into four classes, namely, (i) interphase, (ii) mitosis, (iii) apoptosis and (iv) 
artefacts (e.g., clusters of nuclei, background artefacts). Weighted support vector machines 
(SVMs) with a radial basis function kernel were used for classification. Furthermore, for training 
of the classifier, a set of 577 manually annotated samples were taken from six different 
experiments. Before applying the classifier to unseen data, the performance of the classifier was 
tested by using four-fold cross validation on the training set. More details on the feature 
extraction and classification steps can be found in work of Harder and colleagues (Harder et al, 
2008). As a final result, the percentage of nuclei per class for each experiment was determined. 
 
5.2.12. Automated quantification of Golgi complex integrity 
 
Effects of miRNAs on the integrity of the Golgi complex were determined by an 
automated image analysis approach developed in collaboration with Jan-Philip Bergeest 
(Biomedical Computer Vision group, Dr. Karl Rohr). HeLa cells were transfected with either pre-
miRs or siRNA against α-COP, or non-targeting siRNA on 8-well μ-slides (7x103 cells/well) and 
incubated for 48h. After incubation, cells were fixed with 3% paraformaldehyde, permeabilized 
with PBS-0.1% Triton X-100 solution. The Golgi complex was immunostained with a primary 
mouse anti-GM130 antibody, followed by immunostaining with a secondary Cy3-conjugated 
goat anti-mouse antibody. Additional staining of cellular glycoproteins with an Alexa647-
conjugated lectin Concanavalin A (ConA) was used to determine cell regions. Finally, nuclei 
were stained with 0.3μg/ml Hoechst 33342 and 20 images/well of three fluorescence channels 
were acquired by ScanˆR Acquisition module (Olympus) on IX81 motorized inverted 
fluorescence microscope (Olympus) using 20x UplanSApo objective (NA 0.75). Next, 
microscopic images were segmented in three steps: (i) segmentation of cell nuclei based on 
Hoechst 33342 channel, (ii) segmentation of cell regions based on ConA-Alexa647 channel and 
(iii) Golgi segmentation based on GM130-Cy3 channel. First, in order to segment cell nuclei, an 
edge-based segmentation approach was used as previously described (Matula et al, 2009). 
Apoptotic cells were identified as decribed above and removed from further analysis. Second, 
cell regions were segmented on a basis of ConA immunostaining applying a seeded watershed 
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transform, where the segmented cell nuclei were used as seeds. The resulting watershed basins 
were referred to as influence zones for each cell nuclei. Then, region growing was performed in 
each influence zone, starting from the pixels at the edge of cell nucleus. All pixels with intensities 
within a certain range and with a connection to the edge of nucleus were included as cell region 
(Matula et al, 2009). Third, noise artifacts in images of GM130-Cy3 channel were reduced by 
applying a morphological top-hat transform (Soille, 2004) and Golgi complex was segmented by 
using the triangle thresholding approach within each segmented cell region (Zack et al, 1977). 
Each resulting connected region was considered as a separate Golgi fragment. Next, the Golgi 
complex was quantified in terms of (i) number of Golgi fragments, (ii) size of fragments, (iii) 
distance between the Golgi fragment center and the center of the nucleus and (iv) 
immunofluorescence intensity of GM130 protein. The maximum distance of Golgi fragment from 
the nucleus was considered as the distance between the center of the outermost Golgi fragment 
and the center of nucleus in each cell. The average fluorescence intensity of GM130 protein was 
calculated as ratio of the total GM130 fluorescence intensity to the total size (pixels) of Golgi 
complex in each cell. All features were extracted on a cell-by-cell basis and averaged for all cells 
transfected with individual pre-miRs or siRNAs. The image analysis approach was implemented 
in MATLAB (Mathworks, USA) using the DIPImage Toolbox (Delft University of Technology, 
Netherlands) and the Image Processing Toolbox (Mathworks, USA). 
 
5.2.13. Statistical data analysis 
 
a.) Statistical data analysis of biosynthetic ts-O45-G trafficking assay 
 
ts-O45-G transport assay was performed either on 8-well µ-slides or in 96-well µ-plates 
and 36 or 20 images/well were acquired, respectively. The image quality was visually inspected 
for the quality control and total intensity thresholds were defined for each experiment separately. 
Specifically, the cells with the highest total intensity of expressed ts-O45-G (~7.5% of analyzed 
cells) and cells that were not transduced with the adenoviral vector (~5% of analyzed cells) were 
removed from further analysis. ts-O45-G transport rate in a single cell was estimated by the ratio 
of the total grey values of PM-incorporated to the total grey values of the total amount of 
expressed protein. Next, the mean of ts-O45-G transport rates for each experimental sample was 
calculated over all cells in the corresponding images. The R programming language (http://cran.r-
project.org/) and the “RNAither” (Rieber et al, 2009) package from Bioconductor 
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(http://www.bioconductor.org/) were used for normalization of experimental data. For 
normalization of experiments carried out on 8-well µ-slides, the mean of the transport rate in the 
negative controls (control siRNA, PNC or ANC) was subtracted from the mean of the transport 
rate in each experimental sample and variance was adjusted by dividing by the standard transport 
rate deviation of the negative controls as defined by the equation (1): 
 
 
where x is the mean of ts-O45-G transport rate in experimental sample, i is the well of 
experimental sample, and µ(ctl) and σ(ctl) are the mean and the standard deviation of ts-O45-G 
transport rate in cells transfected with respective negative controls on the µ-slide, respectively. 
The thresholds of +/- 2 SDs of the normalized ts-O45-G transport rate compared to the mean 
transport rate in negative control-transfected cells were used to define effector miRNAs in ts-
O45-G transport assay performed on 8-well µ-slides. 
Since the screening of pre-miR library was carried out in 96-well µ-plates, Z-score 
normalization was used to identify hit miRNAs as defined by the equation (2): 
 
where x is the mean of ts-O45-G transport rate in experimental sample, i is the well of 
experimental sample, and µ(plate) and σ(plate) are the mean and the standard deviation of overall 
ts-O45-G transport rate in the experimental µ-plate, respectively. The thresholds of +/- 1.5 of the 
Z-score-normalized trafficking rate were used to identify hit miRNAs in the pre-miR library 
screening.  
Finally, positive values indicate acceleration of ts-O45-G transport rate and negative 
values represent inhibition of ts-O45-G transport rate. 
 
b.) Statistical data analysis of DiI-LDL internalization assay 
 
DiI-LDL internalization assay was performed on 8-well µ-slides and 49 images/well were 
acquired. Similar to ts-O45-G trafficking assay, the total grey values of internalized DiI-LDL 
fluorescence intensity in single cells were taken for calculations and the efficiency of ligand 
uptake was normalized to the respective negative controls as defined by the equation (1). 
Consequently, positive values indicate increased amount of internalized DiI-LDL and negative 
values represent reduced amount of internalized DiI-LDL compared to negative control samples. 
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The thresholds of +/- 1 SD of normalized intracellular DiI-LDL amount compared to the mean 
internalized amount in negative control-transfected cells were used to identify the effector 
miRNAs in DiI-LDL assay. 
 
c.) Statistical data analysis of mRNA microarrays 
 
Data analysis of Illumina mRNA microarrays was accomplished by normalization of the 
averaged signals of all specific probe replicates using the quantile normalization algorithm 
without background substraction. Analysis was performed by means of the Chipster analysis 
platform v1.4.7 (http://chipster.csc.fi/). Expression level fold change (log2) of the respective 
transcript was defined as difference between the normalized mean intensity of the respective 
probes from samples transfected with pre-miR-17 or pre-miR-517a and negative control samples. 
The statistical significance of expression level fold changes was estimated by calculating a p-
value using empiricalBayes method (a modification of t-test) and Benjamini-Hochberg multiple 
testing correction method. Next, the log2 expression fold changes were transformed to linear 
expression fold changes and cutoff values of +/- 1.5 corresponding to an adjusted p-value ≤ 0.05 
(in case of pre-miR-517a, p-value ≤ 0.01) were applied to identify significantly deregulated 
transcripts. 
 
d.) Statistical data analysis of miRNA microarrays 
  
Data analysis of Agilent miRNA microarrays was achieved by normalization of the 
averaged signals of all miRNA-specific probe replicates using the median normalization 
algorithm after background substraction. The background signal of each microarray was 
determined by averaging the intensities of “Negative control” probes distributed over the 
microarray. Median-normalized intensities of miRNAs from samples treated under condition (i) 
were used to determine the steady-state expression levels of individual miRNAs. Fold changes of 
individual miRNA expression levels under different experimental conditions were defined as 
normalized intensity ratios between samples prepared under conditions (I) and (II), and samples 
prepared under conditions (I) and (III). The statistical significance was estimated by using 
empiricalBayes method and Benjamini-Hochberg multiple testing correction method. 
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e.) Statistical significance 
 
Statistical data significance of ts-O45-G transport, DiI-LDL uptake, qRT-PCR, luciferase 
reporter assays and western blot analyses was tested using a two-tailed Student’s t-test. p-values 
lower than 0.05 were considered as significant. 
  
5.2.14. Bioinformatics analysis 
 
Human 3´UTRs, 5´UTRs and protein coding sequences (CDS) based on RefSeq database 
were obtained from UCSC Genome Browser (http://genome.ucsc.edu/). If multiple RefSeq 
identifiers were mapped to a single Entrez Gene ID present in the mRNA microarray data, the 
RefSeq with the longest 3´UTR was used for further analysis. Next, the 3´UTRs, 5´UTRs and 
CDS of miR-17- and miR-517a-affected mRNAs were searched for 5´-GCACUUU-3´ and 5´-
UGCACGA-3´ heptamers, respectively. These heptamers are reverse complementary to the 
defined seed sequences (miRNA positions 2-8) of investigated miRNAs. The overall frequency 
of potential miRNA binding sites (heptamers) in human transcriptome was referred to as 
background rate and determined by searching all obtained transcript sequences for the presence 
of the indicated heptamers. 
Transcriptome-wide enrichment analysis for nucleotide motifs of mRNA expression data 
upon transfection with pre-miR-17 or pre-miR-517a was performed with Sylamer algorithm 
(http://www.ebi.ac.uk/enright/sylamer/).  
 miRNA target predictions were queried in three web-based prediction tools: (i) 
MicroCosm Targets v5, which uses miRanda algorithm to identify potential miRNA binding sites 
(http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/info.html), (ii) Diana-microT v3.0 
(http://diana.cslab.ece.ntua.gr/microT/) and (iii) TargetScanHuman release 5.2 
(http://www.targetscan.org/vert_50/). Predictions were queried using default parameters (for 
TargetScanHuman only conserved miRNA binding sites were used).  
Membrane trafficking-related genes that are directly annotated to the Gene Ontology 
terms of “Protein transport” (GO:0015031), “Endocytosis” (GO:0006897) and “Protein 
secretion” (GO:0009306) were queried in two databases: (i) Ensembl 
(http://www.ensembl.org/biomart/) and (ii) AmiGO (http://amigo.geneontology.org/). 
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6. RESULTS 
 
6.1. Proof of principle: application of pre-miRs and anti-miRs for membrane 
trafficking assays 
 
Gain-of-function (overexpression) and/or loss-of-function (inhibition) approaches are two 
the most often used methods to elucidate the regulatory miRNA mechanisms of gene expression. 
Much of the progress in investigating miRNA functions has been gained from loss-of-function 
studies with synthetic miRNA antisense RNA oligonucleotides (hereafter, anti-miRs). Anti-miRs 
sterically block the mature miRNA and sequester it from participating in miRISC-associated 
inhibition of target mRNAs. RNA molecules that mimics mature miRNA (hereafter, pre-miRs) 
have been widely used to achieve de novo or to increase the expression of specific miRNAs 
(Borgdorff et al, 2010; Cheng et al, 2005; Davis et al, 2006; Davis et al, 2009; Lam et al, 2010).  
Chemical modifications are necessary to protect synthetic anti-miRs and pre-miRs from 
serum and intracellular nucleases when administrated to animals or cell cultures. Other properties 
of chemically modified RNA molecules include enhanced hybridization affinity for the target 
miRNA (in case of anti-miRs) or mRNA (in case of pre-miRs) and improved activation of 
RNase H or other proteins involved in the miRNA-mediated regulation (Esau, 2008). Moreover, 
specific modifications contribute to enhanced tissue and cellular uptake (Krutzfeldt et al, 2005). 
The potency of anti-miRs containing different chemical modifications was recently investigated 
in HeLa cells by Lennox and Behlke (Lennox & Behlke, 2010).  
Considering that various chemical modifications might confer substantially different 
functional features to oligonucleotides, we performed a set of proof of principle experiments to 
evaluate transfection efficiency, activity and stability of pre-miRs and anti-miRs used in this 
project. Noteworthy, the exact chemical modifications and structural characteristics of pre-miRs 
and anti-miRs are undisclosed (patent pending products of Ambion), further highlighting the need 
for proof of principle experiments.  
 
6.1.1. Transfection efficiency of synthetic pre-miRs and anti-miRs 
  
In order to determine the optimal transfection conditions for synthetic pre-miRs and anti-
miRs, four widely used adherent cell lines (HeLa, HeLa-CD4, A549 and NIH 3T3) were 
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transfected with Cy3-labeled negative controls of pre-miRs (PNC) and anti-miRs (ANC). Two 
different transfection approaches were tested: the liquid-phase direct transfection and the solid-
phase reverse transfection. The latter strategy, in combination with automated multi-channel 
fluorescence microscopy, is more suitable for large-scale high-throughput studies as well as it 
effectively shortens the duration of cellular assays (Erfle et al, 2007). To evaluate the efficiency 
of liquid-phase direct transfection, different cell lines were transfected with Cy3-labeled PNC or 
ANC at a final concentration of 50nM. Lipofectamine 2000 was used as a transfection reagent. 
More than 80% of cells were transfected in all tested cell lines 24h after transfection and no 
significant difference was observed between PNC and ANC transfection efficiency. 
Delivery of PNC and ANC by solid-phase reverse transfection was evaluated in 96-well 
µ-plates and 384-spot cell arrays. In this set of experiments, 8pmol of PNC or ANC were used 
per well or spot (Erfle et al, 2008). Transfection efficiency was examined in four cell lines and 
found to be comparable to that of direct transfection. 
In conclusion, it was showed that synthetic pre-miRs and anti-miRs can be delivered 
efficiently into four adherent cell lines using Lipofectamine 2000 as a transfection reagent. 
Furthermore, delivery of pre-miRs and anti-miRs can be achieved using either liquid-phase or 
solid-phase reverse transfection approaches.    
Transfection experiments were performed by the master student U. Neniškytė (previous 
member of Screening of Cellular Networks laboratory); therefore, results are not visually 
presented in this thesis. 
 
6.1.2. Functionality tests of pre-miRs and anti-miRs 
 
To investigate whether transfected pre-miRs and anti-miRs can effectively increase or 
decrease intracellular levels of specific miRNAs, respectively, we conducted quantitative real-
time PCR (qRT-PCR) and luciferase reporter assays. For these experiments, we selected three 
human miRNAs encoded by extensively studied polycistronic miR-17-92 cluster, namely miR-17, 
miR-20a and miR-92a (Tanzer & Stadler, 2004), and unrelated miR-320a. In line with previously 
published data (Chen et al, 2008), our microarray-based miRNA profiling results, which are 
discussed later (Appendix II), confirmed that all four selected miRNAs are expressed in HeLa 
cells. To examine the potency of pre-miRs and anti-miRs to modulate the expression levels of the 
selected miRNAs, respective pre-miRs and anti-miRs were transfected into HeLa cells. Levels of 
mature miRNAs were assayed by qRT-PCR 24h, 48h and 72h after transfection. Relative miRNA 
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expression changes were calculated by using a critical threshold (C(T)) method, also known as   
2
-ΔΔCT
 (Livak & Schmittgen, 2001). Expression level of abundant small nuclear U6B RNA 
(RNU6B) was used as a reference for normalization throughout the experiments. We detected 
significantly increased levels of all tested miRNAs (2.7- to 6-fold, log2) in the cells transfected 
with respective pre-miRs compared to the mock-transfected cells (Fig. R.1 A). Importantly, very 
similar results were obtained up to 72h after transfection (Fig. R.1 B), indicating a high degree of 
pre-miR resistance to serum and intracellular nucleases. 
Quantification of miRNA expression in the cells transfected with anti-miRs showed no 
significant changes in miR-17, miR-20a and miR-320a levels. Anti-miR-92a was an exception: 
we observed nearly 3-fold (log2) reduction of miR-92a in the cells transfected with anti-miR-92a 
compared to the mock-transfected cells (Fig. R.1 A). This data is somewhat in contrast to 
previously published results showing an effective target miRNA degradation induced by anti-
miRs (Davis et al, 2006; Esau et al, 2006; Krutzfeldt et al, 2007). On the other hand, anti-miRs 
containing specific chemical modifications can sequester target miRNA into a stable complex 
and inhibit its activity without detectable degradation (Davis et al, 2009; Elmen et al, 2008). 
Moreover, some high affinity chemical modifications, which stabilize the anti-miR:miRNA 
duplex, can significantly interfere with miRNA detection by qRT-PCR methods (Davis et al., 
2009). Taken together, profiling of miRNA expression is not a reliable method to evaluate the 
extent of miRNA inhibition by anti-miRs used in this study.  
In order to directly evaluate functional potency of pre- and anti-miRs, we applied a dual-
luciferase reporter assay, which has been successfully used to measure miRNA activity in cell 
cultures (Davis et al, 2006; Lennox & Behlke, 2010). The assay is based on the expression of 
luciferase gene cloned into psiCHECK
TM
-2 vector (Promega), which was used as a template to 
generate specific reporter constructs for miR-17, miR-20a, miR-92a and miR-320a. Each 
construct contained a single perfect complementary binding site for miRNA of interest in the 
3´UTR of the Renilla luciferase gene. Firefly luciferase gene cloned in the same vector was used 
as an internal transfection efficiency reporter. The miRNA-specific luciferase reporter constructs 
were co-transfected with respective pre-miRs or anti-miRs into HeLa cells. Cells were lysed 24h 
post-transfection and assayed for Renilla and firefly luciferase activities. In accordance with the 
data obtained by miRNA qRT-PCR, miRNA overexpression by pre-miRs led to a significant 
downregulation of Renilla luciferase protein level compared to the cells co-transfected with 
reporter construct and PNC. Normalized decrease in luciferase level varied from 2- to 3-fold, 
depending on overexpressed miRNA (Fig. R.1 C). In contrast, inhibition of miRNAs by anti-
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miRs resulted in a derepression of the Renilla luciferase mRNA and thereby a markedly 
upregulated luciferase protein expression. Notably, anti-miR-92a, which was the most effective 
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Figure R.1: Proof of principle: evaluation of functional potency of pre-miRs and 
anti-miRs. (A) Quantitative RT-PCR was used to quantify changes in the miRNA expression 
levels after transfection with pre- or anti-miRs. HeLa cells were transfected with the indicated 
pre- or anti-miRs and qRT-PCR was performed 48h after transfection. Expression levels of miR-
17, miR-20a, miR-92a, and miR-320a in mock-transfected cells (only transfection reagent 
Lipofectamine 2000) were adjusted to 0 and used as a reference to normalize miRNA expression 
changes in the cells transfected with corresponding pre- or anti-miRs. CTL represents PNC or 
ANC. Results are shown as normalized expression mean values from 3 independent transfection 
experiments (n=3) ± S.E.M. (B) Representative time-course qRT-PCR experiment in the cells 
transfected with pre-miR-17 or PNC. Results are normalized and represented as in (A). (C) Dual 
luciferase reporter assay was performed in HeLa cells co-transfected with respective reporter 
constructs and pre- or anti-miRs. Renilla and firefly luciferase activities were measured 24h post-
transfection. Renilla expression level was determined by Renilla/firefly luciferase activity ratio 
and normalized against the control cells (CTL) co-transfected with respective reporter construct 
and PNC or ANC. Results are shown as mean values of normalized Renilla/firefly luciferase 
ratios from three independent experiments (n = 3) ± S.E.M.  
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anti-miR in qRT-PCR, also was the most potent inhibitor in luciferase assay. It induced an 8-fold 
higher Renilla luciferase expression compared to ANC (Fig. R.1 C). To conclude, these results 
demonstrate that synthetic pre-miRs and anti-miRs are functionally potent, respectively, to 
enhance or to inhibit the activity of endogenous miRNAs in HeLa cells. Moreover, we show that 
these compounds, at least pre-miRs, are resistant to nuclease degradation up to 72h post-
transfection. 
 
6.1.3. Quantitative investigation of the biosynthetic membrane trafficking 
 
To investigate whether miRNAs are actively involved in the regulation of biosynthetic 
membrane trafficking, we employed a well-described quantitative fluorescence intensity-based 
protein transport assay (Starkuviene et al, 2004; Starkuviene & Pepperkok, 2007). The key 
component of this assay is a fluorescent protein-tagged temperature-sensitive glycoprotein 
mutant of vesicular stomatitis virus (ts-O45-G). This ectopically expressed chimeric 
transmembrane protein remains in misfolded state at 39.5°C and, therefore, accumulates in the 
endoplasmic reticulum (ER) (Zilberstein et al, 1980). The synchronized release of ts-O45-G is 
achieved by moving cells to the permissive temperature of 32°C; the protein passes through the 
biosynthetic trafficking system and incorporates into the plasma membrane. ts-O45-G transport 
rate is estimated by the ratio between ts-O45-G specific fluorescence on the plasma membrane 
and the total amount of the expressed protein on a single cell basis (see Methods). An automated 
image acquisition and analysis, a similar approach to the one used by Starkuviene and Pepperkok 
(Starkuviene and Pepperkok 2007), enabled us to collect information from 8 000 – 10 000 cells 
for each experiment, ensuring the reliability of the data. We further applied an elaborate 
statistical data analysis that allowed normalizing and comparing data across different 
experiments. For this purpose, we used the R programming language and the  “RNAither” 
package from Bioconductor (Rieber et al, 2009).  
As mentioned in the introduction, human miRNAs encoded by one of the best-
characterized miR-17-92 cluster and its paralogous miR-106a-363 and miR-106b-25 clusters can 
be grouped into four separate miRNA families according to their seed sequences (Fig. R.2 A). 
We selected miR-17, miR-18a, miR-19a and miR-92a as representative members of each seed 
family and investigated whether overexpression or inhibition of each of them can have any effect 
on biosynthetic cargo trafficking. miR-320a was also used in this assay as miRNA unrelated to 
the paralogous clusters. We performed a ts-O45-G transport assay with five selected miRNAs in 
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HeLa and HeLa-CD4 cell lines on 8-well µ-slides. Respective pre-miRs and anti-miRs were 
introduced by liquid-phase direct transfection. Additionally, siRNA targeting α-COP mRNA was 
included as positive control in each µ-slide. α-COP is a subunit of the oligomeric COPI coatomer 
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17 CAAAGUGCUUACAGUGCAGGUAG
20a UAAAGUGCUUAUAGUGCAGGUAG
20b CAAAGUGCUCAUAGUGCAGGUAG
93 CAAAGUGCUGUUCGUGCAGGUAG
106a AAAAGUGCUUACAGUGCAGGUAG
106b UAAAGUGCUGACAGUGCAGAU
18a UAAGGUGCAUCUAGUGCAGAUAG
18b UAAGGUGCAUCUAGUGCAGUUAG
19a UGUGCAAAUCUAUGCAAAACUGA
19b UGUGCAAAUCCAUGCAAAACUGA
92a UAUUGCACUUGUCCCGGCCUGU
25 CAUUGCACUUGUCUCGGUCUGA
363 AAUUGCACGGUAUCCAUCUGUA
B. C. 
A. 
Figure R.2: Overexpression of miR-17 induces significant changes in biosynthetic ts-
O45-G trafficking in HeLa cells. (A) Sequence comparison of mature miRNAs encoded by the 
three paralogous clusters in mammals. miRNAs are grouped into four families according to their 
seed sequences (nucleotides 2-8). (B) Representative images of ts-O45-G transport assay in HeLa 
cells. While no changes in ts-O45-G secretion rate were obtained in cells transfected with control 
siRNA (upper row), knockdown of α-COP with specific siRNA resulted in a strong inhibition of 
cargo trafficking (middle row) 48h post-transfection. Importantly, transfection with pre-miR-17 
significantly increased the fraction of PM-incorporated ts-O45-G (lower row). Scale bar 
represents 20 μm. (C) Quantification of fluorescence intensity-based ts-O45-G biosynthetic 
transport assay. HeLa cells were transfected with siRNAs, pre- and anti-miRs, and the respective 
controls on the 8-well µ-slides. After 48h, ts-O45-G transport assay was performed and 
quantified as described in Methods. The ts-O45-G transport rate was normalized against the 
control siRNA-transfected cells. CTL represents either PNC or ANC, dashed lines cutoff values. 
Results are shown as normalized ts-O45-G transport rate mean values from at least three 
independent experiments (n ≥ 3) ± S.E.M. ***, p<0.001. PM, the plasma membrane. 
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complex that is essential for both anterograde and retrograde vesicular trafficking in the ER-
Golgi segment (Gerich et al, 1995; Letourneur et al, 1994; Orcl et al, 1993). The results of our 
functional assay revealed that overexpression of miR-17 significantly accelerated ts-O45-G 
transport in both HeLa (Fig. R.2 B and C) and HeLa-CD4 (data not shown) cells 48h after 
transfection, indicating that miR-17 is an active regulator of biosynthetic trafficking. In contrast 
to miR-17, overexpression of miR-19a inhibited cargo trafficking compared to PNC; however, the 
effect of miR-19b was less pronounced than the one induced by miR-17. While overexpression of 
miR-17 and miR-19a caused reproducible phenotypes of cargo trafficking, we could not observe 
any significant effect on cargo transport after inhibition of these miRNAs by anti-miRs (Fig. R.2 
C). In line with previous studies (Erfle et al, 2004), knockdown of α-COP significantly 
compromised biosynthetic cargo trafficking. Importantly, data normalization showed that a 
strong inhibition of ts-O45-G transport in α-COP siRNA-transfected cells is represented by more 
than 4 standard deviations (SDs) from the mean of protein transport rate in control siRNA-
transfected cells (Fig. R.2 B and C). Based on this observation, we set stringent thresholds at +/- 
2 SDs from the mean of ts-O45-G transport rate observed for negative controls in order to 
identify miRNAs that induce biologically significant changes in biosynthetic cargo trafficking. 
We further confirmed miRNA-mediated ts-O45-G transport phenotypes in reverse-
transfected HeLa cells in 96-well plates. Consistent with the results obtained after liquid-phase 
transfection with pre-miRs, overexpression of miR-17 resulted in more than 2 SDs increased 
transport rate of model cargo protein (data not shown). 
These results indicate that miRNAs are active regulators of biosynthetic cargo trafficking 
in mammalian cells. Specifically, we showed that overexpression of miR-17 significantly 
increases cargo trafficking rate and this effect is not specific to the single cell type since it was 
observed both in HeLa and HeLa-CD4 cell lines. 
 
6.1.4. Quantitative investigation of the endocytosis 
 
In order to measure miRNA-mediated effects on endocytosis, an opposite process of 
protein secretion, we employed a low-density lipoprotein (LDL) internalization assay. This assay 
is based on a fluorescently labeled LDL (DiI-LDL; LDL conjugated to 3,3'- 
dioctadecylindocarboncyanine) that is internalized into cells via clathrin-mediated endocytosis 
upon binding to the LDL receptor (LDLR). Following internalization, DiI-LDL distributes within 
endosomal compartments where the amount of internalized ligand molecules can be measured 
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quantifying their fluorescence intensity (Ghosh et al, 1994). To this end, we transfected HeLa 
cells with pre-miRs or anti-miRs for selected miRNAs by liquid-phase transfection on 8-well µ-
slides. Since depletion of LDLR has been reported to compromise DiI-LDL internalization 
(Gilbert et al, 2009), siRNA targeting LDLR mRNA was chosen as a positive control. DiI-LDL 
internalization was stimulated 48h post-transfection and total single cell-associated fluorescence 
intensity was measured and quantified as described in Methods. The endocytosis assay revealed 
that overexpression of miR-17 significantly reduced DiI-LDL uptake compared to PNC (Fig. 
R.3), indicating that this miRNA has also an active role in endocytosis regulation. Although we 
observed reduced DiI-LDL internalization in cells transfected with pre-miR-18 in separate 
experimental replicas, the overall result was not significant due to high data variability (Fig. R.3 
C
o
n
tr
o
l 
s
iR
N
A
L
D
L
R
 s
iR
N
A
C
T
L
m
iR
-1
7
m
iR
-1
8
a
m
iR
-1
9
a
m
iR
-9
2
a
m
iR
-3
2
0
a
-3
-2
-1
0
1
2
siRNAs
Pre-miRs
Anti-miRs
***
***N
o
rm
a
li
z
e
d
 D
iI
-L
D
L
 i
n
te
n
s
it
y
 (
S
D
)
A. B. 
Figure R.3: Overexpression of miR-17 leads to significantly reduced internalization 
of DiI-LDL in HeLa cells. (A) Representative images of DiI-LDL internalization assay in HeLa 
cells. In contrast to unaffected DiI-LDL uptake in control siRNA-transfected cells (upper row), 
ligand internalization was strongly reduced in LDLR siRNA- (middle row) and pre-miR-17-
transfected cells (lower row). Scale bar represents 20 μm. (B) Quantification of internalized DiI-
LDL fluorescence intensity in cells transfected with indicated siRNAs, pre-miRs and anti-miRs. 
Single cell-associated total intensity of DiI-LDL was measured and normalized to the respective 
controls (LDLR siRNA to control siRNA, pre-miRs to PNC and anti-miRs to ANC) as described 
in Methods. CTL represents either PNC or ANC, dashed lines cutoff values. Results are shown 
as normalized mean DiI-LDL intensity values from three to six independent experiments (3 ≤ n ≤ 
6) ± S.E.M. ***, p<0.001. 
 
 72 
B). Unfortunately, the inhibition of miRNAs with anti-miRs had no significant influence on 
cellular DiI-LDL uptake. In agreement with published data (Gilbert et al, 2009), knockdown of 
LDLR resulted in a strong reduction of internalized DiI-LDL (Fig. R.3 B). Importantly, data 
analysis showed that DiI-LDL amount in LDLR siRNA-transfected HeLa cells was reduced by 
more than 2 SDs from the mean of DiI-LDL fluorescence intensity in negative control siRNA-
transfected cells (Fig. R.3 B). Based on this finding, we set cutoff values at +/- 1 SD from the 
mean of internalized ligand amount in negative controls in order to identify miRNAs that cause 
biologically significant changes in DiI-LDL uptake. Taken together, these experiments suggest 
that miRNAs are also potent regulators of endocytosis process with miR-17 being involved in 
LDL internalization.  
 
6.1.5. Members of the miR-17 family regulate membrane trafficking  
 
miRNAs with identical seed sequences are predicted to have a highly overlapping set of 
targets and, therefore, it is possible that they regulate the same biological processes (Bartel, 2009; 
Lewis et al, 2005; Sethupathy et al, 2006). Indeed, several experimental studies have supported 
this prediction on target gene (Doebele et al, 2010; O'Donnell et al, 2005; Uhlmann et al, 2010; 
Wu et al, 2010; Xu et al, 2007) or biological process (Borgdorff et al, 2010) level. Therefore, we 
hypothesized that other members of miR-17 seed family also could be implicated in the 
regulation of biosynthetic ts-O45-G transport and DiI-LDL internalization. To address this 
hypothesis, we performed ts-O45-G transport and DiI-LDL uptake assays in HeLa cells 
transfected with pre-miRs or anti-miRs for other three miR-17 family members, namely, miR-
20a, miR-20b and miR-93. As seen in Figure R.4 A, individual overexpression of all three 
miRNAs resulted in a significantly accelerated ts-O45-G transport rate. Consistently, transfection 
with pre-miRs markedly reduced the amount of internalized DiI-LDL (Fig. R.4. B). Again, 
inhibition of these miRNAs did not induce phenotypic changes that significantly differ from the 
control ANC in any assay (Fig. R.4), indicating the systematic difficulties to obtain cellular 
phenotypes after miRNA inhibition under used experimental conditions. 
Together with previously reported observations, our findings further support the 
hypothesis that miRNAs with the same seed sequence have redundant functions in regulating 
distinct biological processes. Moreover, we demonstrated that miR-17 seed family members are 
novel regulators of biosynthetic cargo transport and endocytosis.         
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6.1.6. Overexpression of miR-320a inhibits cell proliferation 
 
Numerous independent studies have demonstrated a role of miRNAs in cell proliferation 
and apoptosis (Cheng et al, 2005; Schaar et al, 2009). In accordance with the tumorigenic activity 
of the miR-17-92 cluster, it has been extensively reported as an important regulator of cellular 
growth and apoptosis (Hayashita et al, 2005; He et al, 2005; Mu et al, 2009; O'Donnell et al, 
2005). In is well known that membrane trafficking is ceased in mitotic (Misteli & Warren, 1995; 
Warren, 1993) and apoptotic cells (Nozawa et al, 2002). To examine whether miRNA-mediated 
changes in membrane trafficking are associated with altered cell proliferation or apoptosis, we set 
a microscopy-based nuclei classification assay. HeLa cells were transfected with pre-miRs or 
anti-miRs for miR-17, miR-20a, miR-92a, miR-93 and miR-320a. PNC and ANC were included 
as negative controls; siRNA against the inner centromere protein (INCENP) mRNA was used as 
positive control. It has been shown that depletion of INCENP leads to abnormal spindle 
midzone/midbody formation during mitosis and thereby results in bi- and multinucleated arrested 
cells (Neumann et al, 2006; Zhu et al, 2005). For our assay, we stained nuclei with 0.3μg/ml 
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Figure R.4: miR-17 seed family members regulate biosynthetic ts-O45-G transport 
and DiI-LDL uptake in HeLa cells. (A) Quantification of ts-O45-G transport assay in cells 
transfected with indicated pre-miRs and anti-miRs. (B) Quantification of DiI-LDL uptake assay 
48h after transfection as in (A). CTL represents either PNC or ANC, dashed lines cutoff values. 
Both assays were quantified and normalized to the respective controls (pre-miRs to PNC and 
anti-miRs to ANC) as described in Methods. Results are represented as mean values of 
normalized ts-O45-G transport rates (A) or means of normalized DiI-LDL intensity values (B) 
from at least three independent experiments (n ≥ 3) ± S.E.M. *, p<0.05; **, p<0.01; ***, 
p<0.001. 
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Hoechst 33342 and performed live cell imaging 48h after transfection. Having achieved the 96% 
accuracy of the automated nuclei segmentation (data not shown), we further classified nuclei into 
four distinct classes, namely, (i) interphase, (ii) mitosis, (iii) apoptosis and (iv) so called 
“artefacts” (for example, multinucleated cells, clusters of nuclei, background artefacts). 
Classification was accomplished by the extended approach described by Harder et al (Harder et 
al, 2008). By normalizing the nuclei intensity across the individual experiments, we achieved an 
accuracy of 97.6% for classifying interphase cells and 82% for classifying mitotic cells (Fig. 5A). 
The accuracy of the assay was demonstrated by the substantially reduced mitotic events in the 
INCENP siRNA-transfected cells (Fig. 5B). In line with previous observations (Schaar et al, 
2009), classification of cell nuclei revealed that overexpression of miR-320a decreased the 
fraction of mitotic cells. Cell proliferation was also modestly decreased in response to 
overexpression of miR-17, miR-20a and miR-93, the effectors of ts-O45-G transport rate and 
cellular DiI-LDL internalization; however, difference from control cells was not significant (Fig. 
5B). In contrast to recent studies (Tsuchida et al, 2011), modulation of miR-92a activity had no 
impact on proliferation, further supporting the context-dependent functions of miR-17-92 cluster 
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A. 
Figure R.5: Microscopy-based nuclei 
classification assay. (A) Representative 
images of four nuclei classes considered in the 
automated image analysis are represented in 
upper row. Confusion matrix for classification 
of nuclei using a weighted SVM classifier with 
fourfold cross-validation and accuracy of the 
results are given in lower row. (B) 
Quantification of HeLa cell proliferation 48h 
after transfection with indicated RNA 
molecules. CTL represents either PNC or 
ANC. Results are represented as mean values 
of percentage of mitotic cells from three 
independent experiments (n = 3) ± S.E.M.    
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(Cloonan et al, 2008; Hossain et al, 2006). Similar to our results from functional membrane 
trafficking assays, inhibition of miRNAs had no effect on cell proliferation (Fig. 5B). Despite 
accurate classification of apoptotic nuclei (Fig. 5A), we found quantification of apoptosis not 
reliable due to frequently observed loss of adherence of dying cells under the used experimental 
conditions. Unfortunately, we did not measure the effect of miR-19a which has been recently 
reported as a key compotent to exert the oncogenic activity of the cluster by promoting cell 
survival (Mu et al, 2009; Olive et al, 2009). 
Altogether, automated nuclei analysis confirmed an anti-proliferative effect of miR-320a. 
These results also demonstrated that membrane trafficking phenotypes induced by 
overexpression of miR-17 family members are direct effects, rather than consequence of altered 
cell proliferation.   
 
6.1.7. Alternative approaches for inhibition of endogenous miRNAs 
 
 An approach that effectively inhibits miRNA activity is important for performing a 
comprehensive functional analysis of miRNAs. Multiple steps in miRNA biogenesis pathway can 
be targeted with antisense oligonucleotides that inhibit miRNA maturation and/or function. 
Nevertheless, one of the most straightforward methods for determining the function of a mature 
miRNA is to block its activity in miRNA-induced silencing complex (miRISC). Considering that 
turnover of mature miRNAs is relatively slow (Lee et al, 2003), this strategy gains an advantage 
over others for short-term studies. Consistently, many investigators have demonstrated an 
effective targeting of mature miRNAs with antisense oligonucleotides in a variety of cultured 
cells (Davis et al, 2006; Hutvagner et al, 2004; Meister et al, 2004). 
 To investigate further whether inhibition of miRNAs can cause significant phenotypic 
changes in membrane trafficking, we applied two alternative strategies for inhibition of 
endogenous miR-20b in HeLa cells. We selected miR-20b because its overexpression led to the 
most significant acceleration of ts-O45-G transport and reduction of internalized DiL-LDL 
amount compared to other investigated miR-17 family members (Fig. R.4). The first alternative 
miRNA inhibition strategy is based on the single-stranded DNA oligonucleotides with locked 
nucleic acid (LNA) backbone modifications incorporated at specific positions. These antisense 
oligonucleotides, referred to as DNA/LNA anti-miRs, have increased resistance to nuclease 
degradation, higher affinity to target miRNA and are more potent in inhibiting miRNA activity in 
cell cultures compared to the classical 2´-O-methyl-modified anti-miRs (Davis et al, 2006; Orom 
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et al, 2006). The second alternative miRNA inhibition approach is based on the transient 
expression of shRNA from a lentiviral expression vector. The asymmetric shRNAs are 
recognized by the RNase III enzyme Dicer and processed to functional single-stranded anti-miRs, 
referred to as miRZips, which bind to endogenous miRNAs and inhibit their function. To 
measure the extent of miR-20b inhibition by these two different approaches, we co-transfected 
HeLa cells with either DNA/LNA anti-miR-20b or miRZip-20b expression vector and the 
reporter plasmid. The reporter plasmid contained luciferase gene with the perfect complementary 
miR-20b binding site in the 3´UTR as described previously for other miRNAs. A negative control 
DNA/LNA oligonucleotide and a miRZip expression vector encoding non-targeting shRNA were 
used as negative controls for DNA/LNA anti-miR-20b or miRZip-20b transfections, respectively. 
We tested different concentrations of DNA/LNA anti-miR-20b (range from 10nM to 50nM) and 
different amounts of miRZip-20b expression vector (range from 10ng to 900ng/well in 24-well 
plate). We found that DNA/LNA anti-miR-20b at 50nM concentration and 100ng/well of 
miRZip-20b construct induced the most pronounced effects in luciferase reporter assay (Fig. R.6 
A). As expected, inhibition of miR-20b by both DNA/LNA anti-miR-20b and miRZip-20b 
resulted in an upregulated luciferase expression. Importantly, anti-miR-20b, containing the same 
chemical modifications as other anti-miRs previously tested in membrane trafficking assays, 
showed the strongest effect on the reporter gene expression (Fig. R.6 A).  
To examine whether miR-20b inhibition by DNA/LNA anti-miR-20b leads to changes in 
biosynthetic trafficking, we transfected cells with DNA/LNA anti-miR-20b or control 
oligonucleotide and measured ts-O45-G transport rate 48h later. Similar to our previous findings 
(Fig. R.4 A), we did not observe biologically significant changes in cargo transport rate in the 
DNA/LNA anti-miR-20b-transfected cells compared to the control cells (Fig. R.6 B). 
These results indicate that although different inhibition approaches are efficient in 
suppressing miRNA activity in luciferase reporter assay, they induce none to modest phenotypic 
effects in our functional membrane trafficking assays. Perfect complementarity between miRNA 
of interest and luciferase mRNA allows AGO2-mediated cleavage of reporter transcript. Thus, 
completely complementary miRNA binding sites increase sensitivity and dynamic range of the 
luciferase reporter assay (Esau, 2008; Yekta et al, 2004). However, this type of binding sites is 
less sensitive to other miRNAs containing the same seed sequence as the miRNA of interest but 
with different nucleotides in other positions. We showed that the specific inhibition of the 
miRNA by anti-miRs leads to a significant upregulation of the reporter gene expression. 
However, considering that miRNAs with the same seed sequence have a highly overlapping set 
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of targets, the less complementary natural target mRNAs remain suppressed by other seed family 
miRNAs. This would explain why anti-miRs are efficient in reporter assay, but have a poor 
performance in functional assays.                    
 
 Conclusions: The results from previous experiments in our laboratory showed that 
synthetic pre-miR and anti-miR molecules can be efficiently introduced into different types of 
adherent cells by liquid-phase or solid-phase reverse transfection approaches using 
Lipofectamine 2000 as a transfection reagent. As proof of principle, we showed that pre-miRs 
and anti-miRs are efficient in enhancing or suppressing activity of cellular miRNAs, respectively, 
as determined by qRT-PCR and/or luciferase reporter assays. Moreover, we identified miRNAs 
of miR-17 family as novel regulators of biosynthetic trafficking and endocytosis. We confirmed 
that overexpression of miR-320a suppresses cell proliferation. Despite the fact that efficient 
inhibition of individual miRNAs was achieved by different approaches, we could not observe 
C
TL
A
nt
i-m
iR
-2
0b
A
nt
i-m
iR
-2
0b
, D
N
A
/L
N
A
m
iR
Zi
p-
20
b
0.0
0.5
1.0
1.5
2.0
2.5
N
o
rm
a
li
z
e
d
 R
L
u
c
/F
L
u
c
 r
a
ti
o
(f
o
ld
 c
h
a
n
g
e
)
A
N
C
, 
D
N
A
/L
N
A
A
n
ti
-m
iR
-2
0
b
, 
D
N
A
/L
N
A
-1
0
1
N
o
rm
a
li
z
e
d
 t
s
-O
4
5
-G
 t
ra
n
s
p
o
rt
 r
a
te
 (
S
D
)
B. A. 
Figure R.6: Inhibition of miR-20b by alternative approaches (A) Luciferase reporter 
assay in HeLa cells co-transfected with miR-20b reporter construct and indicated anti-miRs 
(50nM final concentration) or miRZip expression vectors (100ng/well) in 24-well plates. Renilla 
and firefly luciferase activities were measured 24h post-transfection and their ratio normalized 
against the control cells. CTL represents cells co-transfected with miR-20b reporter construct and 
ANC or DNA/LNA negative control, or control miRZip expression vector. (B) Quantification of 
ts-O45-G transport assay in cells transfected with DNA/LNA anti-miR-20b or control 
oligonucleotides. The experiment was quantified and normalized to the control cells as described 
in Methods. Results are shown as mean values of normalized Renilla/firefly luciferase ratios (A) 
or normalized ts-O45-G transport rates (B) from three experiments (n = 3) ± S.E.M. 
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significant cellular phenotypes induced by suppression of investigated miRNAs. Therefore, the 
majority of the results in this project were obtained using gain-of-function miRNA approach. 
 
6.2. Large-scale identification of miRNAs regulating biosynthetic cargo trafficking 
 
 Although significant progress has been made in understanding important regulatory roles 
of miRNAs in a wide range of biological processes (Bartel, 2009; Krol et al, 2010), the miRNA-
mediated regulatory mechanisms of membrane trafficking have never been systematically 
investigated. Our understanding of the miRNA-mediated regulation of this cellular process is 
limited to a small number of reports on insulin secretion (Lovis et al, 2008; Plaisance et al, 2006; 
Poy et al, 2004) and to our findings on miR-17 family miRNAs described earlier in this thesis. 
Application of high-content sample preparation technology (Erfle et al, 2008), in combination 
with automated image acquisition and analysis modules, has led to a number of successful 
genome-wide functional screenings of miRNAs (Serva et al, 2011). Having successfully 
completed proof of principle experiments and taking the advantage of available technological 
platforms, we next designed a gain-of-function large-scale screening to identify miRNAs 
involved in the regulation of biosynthetic ts-O45-G trafficking.  
 
6.2.1. Functional screening identifies multiple miRNAs as potential regulators of 
biosynthetic trafficking 
 
The primary screening of Pre-miR
TM
 miRNA Precursor Library (Ambion) of 470 human 
miRNAs annotated in miRBase v9.2 (Appendix I) was conducted in HeLa cells in 96-well plate 
experimental format. Pre-miRs were distributed across 10 different layouts of 96-well µ-plates 
and prepared for solid-phase reverse transfection as described in Methods. Additionally, each 
layout contained 3 wells with siRNAs against α-COP and 5 wells with PNC used as controls. 
Following library preparation, we seeded 5 500 cells per well. The cargo trafficking assay was 
performed 48h after cell seeding. Total plasma membrane-traversed ts-O45-G and overall 
expressed cargo protein fluorescence intensities were determined at single cell level from three 
independent experimental replicas. An average of 7 500 cells were analysed for each miRNA. 
Changes in biosynthetic ts-O45-G transport rate caused by overexpression of individual miRNAs 
were Z-score-normalized against the mean transport rate of the plate. Mean transport rate was 
computed over all wells in the plate except wells with α-COP siRNA and PNC. Then, Z-scores of 
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Table 1: miRNAs that inhibited cargo transport.  Table 2: miRNAs that accelerated cargo 
transport.  
Figure R.7: Schematic representation of quantitative pre-miR library screening in 
order to identify miRNAs involved in regulation of biosynthetic trafficking. Of 470 tested 
miRNAs, 44 significantly affected transport rate of ts-O45-G protein under overexpression 
conditions. 
 
Z -score S.E.M.
Fold 
change
S.E.M.
MIMAT0002888 miR-532 -4.14 0.61 0.70 0.05
MIMAT0002852 miR-517a -3.70 0.76 0.88 0.05
MIMAT0003307 miR-637 -3.20 0.14 0.79 0.16
MIMAT0002857 miR-517b -3.16 0.22 0.84 0.07
MIMAT0000074 miR-19b -2.59 0.91 0.94 0.06
MIMAT0003330 miR-654 -2.54 0.79 0.80 0.20
MIMAT0000275 miR-218 -2.43 0.24 1.00 0.04
MIMAT0000267 miR-210 -2.42 0.28 1.18 0.07
MIMAT0003276 miR-608 -2.35 0.43 0.94 0.11
MIMAT0001636 miR-452* -2.31 0.32 0.79 0.08
MIMAT0003317 miR-647 -2.15 0.12 0.56 0.09
MIMAT0003945 miR-765 -2.09 0.52 0.81 0.06
MIMAT0000423 miR-125b -2.06 0.34 0.59 0.21
MIMAT0000710 miR-365 -2.04 0.07 0.98 0.10
MIMAT0000737 miR-382 -1.90 0.19 1.13 0.08
MIMAT0000773 miR-346 -1.89 0.30 1.03 0.11
MIMAT0002866 miR-517c -1.86 0.48 0.94 0.05
MIMAT0003326 miR-663 -1.83 0.37 0.98 0.11
MIMAT0000259 miR-182 -1.73 0.12 1.16 0.03
MIMAT0000422 miR-124a -1.71 0.18 1.01 0.33
MIMAT0000095 miR-96 -1.67 0.19 0.95 0.08
MIMAT0003272 miR-604 -1.67 0.97 0.83 0.06
MIMAT0000443 miR-125a -1.66 0.12 0.79 0.37
MIMAT0003239 miR-574 -1.65 0.35 1.02 0.03
MIMAT0000420 miR-30b -1.62 0.26 1.07 0.10
MIMAT0002173 miR-483 -1.62 0.57 1.00 0.05
MIMAT0002814 miR-432 -1.58 0.38 0.92 0.09
MIMAT0003216 miR-553 -1.55 0.33 0.43 0.08
MIMAT0001080 miR-196b -1.55 0.53 0.81 0.12
MIMAT0000462 miR-206 -1.54 0.18 0.93 0.06
MIMAT0002174 miR-484 -1.54 0.27 0.88 0.03
ts-O45-G 
transport
Cell growth
Accession number 
in miRBase v9.2
miRNA ID
Z -score S.E.M.
Fold 
change
S.E.M.
MIMAT0000676 miR-128b 3.06 0.11 0.72 0.14
MIMAT0000686 miR-34c 2.17 0.33 1.02 0.11
MIMAT0000681 miR-29c 2.07 0.10 0.95 0.02
MIMAT0000227 miR-197 2.01 0.25 0.94 0.07
MIMAT0000452 miR-154 1.81 0.18 0.88 0.08
MIMAT0000453 miR-154* 1.68 0.49 1.14 0.02
MIMAT0002805 miR-489 1.68 0.41 0.77 0.04
MIMAT0003263 miR-595 1.68 0.14 0.86 0.13
MIMAT0001413 miR-20b 1.65 0.22 0.96 0.13
MIMAT0004450 miR-297 1.62 1.02 1.19 0.06
MIMAT0000255 miR-34a 1.61 0.24 0.73 0.03
MIMAT0003299 miR-630 1.56 0.20 0.93 0.09
MIMAT0002804 miR-488 1.54 0.16 0.55 0.09
Accession number 
in miRBase v9.2
miRNA ID
ts-O45-G 
transport
Cell growth
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three replicas were averaged to a single value for each miRNA (Fig. R.7). Following data 
normalization, only miRNAs that accelerated or inhibited ts-O45-G transport rate by more than 
1.5 Z-scores were considered as primary hit miRNAs. In total, our primary gain-of-function 
screen identified 44 miRNAs that significantly affected cargo transport rate, comprising about 
10% of the library. Out of these, overexpression of 31 miRNAs inhibited (Table 1), whereas 
overexpression of other 13 miRNAs accelerated cargo trafficking rate (Table 2). Among the top 
inhibitory miRNAs we identified members of miR-517 family (Table 1). Overexpression of miR-
34 family miRNAs, miR-34c and miR-34a, significantly accelerated ts-O45-G transport rate 
(Table 2). In strong agreement with the results of biosynthetic transport assay with miR-17 
family miRNAs (Fig. R.4), overexpression of miR-20b also significantly increased ts-O45-G 
transport rate (1.65 Z-scores) in library screening (Table 2). To our knowledge, no publications 
are available reporting on the interplay between our hit miRNAs and biosynthetic trafficking. 
This indicates the potency of our large-scale screening in identifying miRNAs with novel 
functions in the regulation of biosynthetic pathway. 
 Apart from quantification of ts-O45-G transport rate, image analysis on a cell-by-cell 
basis allowed us to estimate the changes in cell growth induced by miRNA overexpression 
(Table 1 and 2). Since this estimation was based on a total number of analyzed cells, we could 
not discern between miRNA-induced changes in apoptosis or proliferation rates. The total 
numbers of cells transfected with individual pre-miRs were normalized against the PNC, which 
was adjusted to 1, and the differences represented as fold changes in cell growth (Table 1 and 2). 
Similar to previous study where the same approach was applied for identification of miRNAs 
involved in cell growth (Cheng et al, 2005), we set fold change cutoff values at 0.8 and 1.2. 
miRNAs outside this range were considered as effectors of cell growth.  
 To confirm the results obtained from the large-scale screening, we performed a ts-O45-G 
transport assay with a representative set of the inhibitory miRNAs. For this purpose, we used a 
set of six pre-miRs from a different batch and introduced them by liquid-phase transfection into 
cells on 8-well µ-slides. Except for miR-553, we observed a strong correlation between the data 
from library screening and from the validation assay (Fig. R.8). Importantly, miR-553 was one of 
the weakest ts-O45-G transport inhibitory hits as well as it was the strongest cell growth inhibitor 
among all screened miRNAs (Table 1). This suggests that miR-553-mediated inhibition of 
protein transport in the large-scale screening is likely a consequence of reduced cell growth, 
rather than specific effect on membrane trafficking. Noteworthy, the different extent of cargo 
transport inhibition between the screening and the validation assay might be due to different data 
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normalization methods (normalization to plate mean was used for the data from the screening and 
normalization to PNC for the data from the validation assay). Together, these results validate the 
functional activity of pre-miRs of human Pre-miR
TM
 library and further demonstrate that our 
functional screening is an efficient strategy to identify miRNAs that regulate biosynthetic cargo 
trafficking.  
 
6.2.2. Analysis of Golgi complex integrity confirms hit miRNAs 
 
The Golgi complex is a highly dynamic organelle that serves as a major sorting and 
modification center of cellular proteins (Donaldson & Lippincott-Schwartz, 2000; Rodriguez-
Boulan & Musch, 2005). Moreover, it regulates transport of cargo proteins via different 
membrane trafficking pathways (Bonifacino & Rojas, 2006; Pavelka et al, 2008). miRNAs can 
virtually affect any process or cellular structure involved in membrane trafficking system. 
Therefore, we next investigated whether miRNA-mediated phenotypes of ts-O45-G transport are 
associated with corresponding changes in the Golgi complex morphology. To this end, we 
developed a fully automated image analysis platform for quantification of the Golgi complex in 
single cells from microscopic images as described in Methods (Fig. R.9). The approach, which 
determines cell boundaries on a basis of nuclear location, nuclear size and lectin Concanavalin A 
distribution pattern, was designed to extract primary parameters of the Golgi complex. These 
parameters are as follow: 
1. Number of Golgi fragments 
2. Size of Golgi fragments 
3. Distance of Golgi fragments from nuclear center 
4. Fluorescence intensity of immunostained Golgi markers, such as GM130 protein 
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Figure R.8: Small-scale ts-O45-G 
transport assay validates primary miRNA hits. 
HeLa cells were liquid-phase transfeted with pre-
miRs for six inhibitory miRNAs identified in 
library screening. The cargo trafficking assay was 
perfomed 48h post-transfection and the transport 
rate was normalized to PNC-transfected cells as 
described in Methods. Results are represented as 
mean values of normalized ts-O45-G transport rates 
from two independent experiments (n= 2) ± S.E.M. 
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In order to measure the effects of primary hit miRNAs (Table 1 and 2) on these Golgi 
complex parameters, we transfected cells with the respective pre-miRs. Transfection with siRNA 
against α-COP and non-targeting siRNA were used as positive and negative controls, 
respectively. To meet the temporal conditions of the large-scale miRNA screening, cells were 
fixed 48h after transfection. Following fixation, we immunostained cellular DNA, lectin 
Concanavalin A and cis-Golgi matrix protein GM130 for acquisition of microscopic images of 
nuclei, cell regions and Golgi complexes, respectively. In accordance with the functional 
screening data, the Golgi complex analysis revealed a markedly increased number of Golgi 
fragments in the cells transfected with pre-miRs of miR-517 family members (Fig. R.10 A and 
B). Quantification of Golgi fragments showed more than 4-fold higher fragmentation in the pre-
miR-517a or -517b, or -517c-transfected cells compared to the control cells, indicating that all 
three miRNAs have similar effect on Golgi structure. By applying cutoff values of 0.75 and 1.75 
to the normalized numbers of Golgi fragments, we selected in total eight miRNAs whose 
overexpression significantly altered Golgi complex integrity (Fig. R.10 B). Whereas transfection 
with seven pre-miRs led to increased fragmentation, overexpression of miR-382 induced 
condensation of Golgi complex (Fig. R.10 A and B). We focused further on these eight miRNAs 
to examine whether they cause other changes in the Golgi apparatus. Image analysis revealed that 
number of Golgi fragments negatively correlated with the average size of fragments (Fig. R.10 
C) and positively correlated with the distribution area of the Golgi complex. The distribution area 
was defined by the distance between the outermost Golgi fragment and the nuclear center in each 
cell (Fig. R.10 D). To investigate whether overexpression of miRNAs can affect the level of 
Golgi protein GM130, we measured immunofluorescence intensity of this protein in the cells 
Cell region (Concanavalin A) Detection of nucleus and cell 
region
Golgi complex (GM130) Attribution of Golgi complex 
to the cell 
Figure R.9: Automated analysis of Golgi complex integrity. Simplified representation 
of automated image analysis process to quantify morphological changes in Golgi complex on a 
cell-by-cell basis. A detailed description of image segmentation and feature extraction steps is 
available in Methods. 
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Figure R.10: Multi-parametric analysis of Golgi complex reveals phenotypic changes 
in Golgi complex induced by overexpression of miRNAs. (A) Representative images of Golgi 
complex. Two opposite effects of miRNA overexpression on Golgi morphology are shown; while 
transfection with pre-miR-382 leads to the condensation, delivery of pre-miR-517a significantly 
increases Golgi complex fragmentation. siRNA and α-COP siRNA was used positive control. 
Scale bar represents 20 μm. (B-E) Quantification of Golgi complex in the cells transfected with 
pre-miRs: (B) normalized number of Golgi fragments/cell, (C) normalized average size of Golgi 
fragments, (D) normalized maximum distance of Golgi fragment from the nucleus and (E) 
normalized average immunofluorescence intensity of GM130/cell. A detailed description of 
quantifications is available in Methods. 
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transfected with each of eight pre-miRs. As shown in Fig. R.10 E, overexpression of selected 
miRNAs did not alter GM130 protein level, independently of Golgi complex fragmentation. 
 By combining the results obtained from pre-miR library screening and the multi-
parametric analysis of the Golgi complex, we identified eight miRNAs (miR-382, -30b, -432,       
-637, -517a/b/c and -765) as potential novel biosynthetic trafficking regulators that induce 
significant changes in the Golgi complex morphology. The eight miRNAs are easier to handle for 
the follow-up analysis compared to the 44 miRNAs that were identified as primary hits in the 
screening. Importantly, none of the miRNAs that accelerated ts-O45-G transport rate (Table 2) 
were identified as effectors in the Golgi complex integrity assay. This finding suggests that 
regulatory mechanisms of these miRNAs might converge on other cellular organelles and/or 
Golgi structure-independent processes in order to accelerate biosynthetic cargo trafficking.       
 
Conclusions: To identify miRNAs involved in the regulation of biosynthetic trafficking, 
we screened 470 human miRNAs for their impact on ts-O45-G transport rate upon 
overexpression. We identified 44 miRNAs whose overexpression induce significant changes in 
cargo trafficking. Majority of arbitrarily selected inhibitory miRNAs (5 out of 6) were confirmed 
in a small-scale experimental format using pre-miRs from a different batch, demonstrating the 
reproducibility of large-scale screening data. Furthermore, comprehensive images analysis 
revealed that eight of identified hit miRNAs (miR-30b, -382, -432, -517a, -517b, -517c, -637 and 
-765) cause significant changes in Golgi complex integrity. 
 
6.3. Genome-wide identification of miRNAs expressed in HeLa cells 
 
 Large-scale experimental approaches have revealed that hundreds of miRNAs are 
expressed in highly tissue-specific patterns. Those approaches include sequencing of small RNA 
libraries (Landgraf et al, 2007) and microarray-based miRNA expression profiling (Baskerville & 
Bartel, 2005). Using purely computational methods to study the existing mRNA and miRNA 
expression data, Sood and colleagues have shown that tissue-specific miRNAs and their cognate 
targets are typically co-expressed in the same tissue; however, mRNAs are expressed at 
significantly lower levels compared to the tissues where the targeting miRNA is absent (Sood et 
al, 2006). Based on these observations, we hypothesized that introduction of miRNAs that are not 
endogenously expressed may result in stronger phenotypic effects compared to overexpression of 
endogenous miRNAs. 
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 To test this hypothesis, we performed a microarray-based miRNA expression profiling to 
identify miRNAs that are endogenously expressed in HeLa cells. Total RNA was isolated from 
wild-type HeLa cells and hybridized to microarrays that contained probes for 887 human 
miRNAs annotated in the miRBase version 14. Microarray data were analysed as described in 
Methods. In this manner, we identified 113 mature miRNAs that were endogenously expressed at 
detectable levels (Appendix II). Next, we sought to compare miRNA expression data to 
Table 3: Median-normalized linear expression 
levels of miRNAs that inhibited ts-O45-G 
transport in HeLa cells. miRNAs are listed 
according to their effect on cargo trafficking as 
in Table 1. “-“ means that either miRNA was 
not detected by microarray and/or it did not 
cause any significant changes in Golgi complex 
morphology.   
 
Table 4: Expression levels of miRNAs that 
accelerated ts-O45-G transport rate in HeLa 
cells. miRNAs are listed according to their 
effect on cargo transport as in Table 2. “-“ as 
in Table 3. 
miRNA ID
Expression 
level
S.E.M.
Effect on Golgi 
complex 
morphology?
miR-532 - - -
miR-517a - - Yes
miR-637 - - Yes
miR-517b - - Yes
miR-19b 62.64 3.42 -
miR-654 - - -
miR-218 - - -
miR-210 - - -
miR-608 - - -
miR-452* - - -
miR-647 - - -
miR-765 - - Yes
miR-125b 21.14 0.92 -
miR-365 7.90 0.87 -
miR-382 - - Yes
miR-346 - - -
miR-517c - - Yes
miR-663 - - -
miR-182 - - -
miR-124a - - -
miR-96 4.71 0.21 -
miR-604 - - -
miR-125a - - -
miR-574 - - -
miR-30b 5.49 0.35 Yes
miR-483 - - -
miR-432 - - Yes
miR-553 - - -
miR-196b 1.64 0.07 -
miR-206 - - -
miR-484 - - -
miRNA ID
Expression 
level
S.E.M.
Effect on Golgi 
complex 
morphology?
miR-128b - - -
miR-34c - - -
miR-29c 2.15 0.14 -
miR-197 1.41 0.06 -
miR-154 - - -
miR-154* - - -
miR-489 - - -
miR-595 - - -
miR-20b 9.21 0.57 -
miR-297 - - -
miR-34a 9.06 0.49 -
miR-630 - - -
miR-488 - - -
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the results of pre-miR library screening. Surprisingly, only six out of 31 miRNAs that inhibited 
ts-O45-G transport rate in the screening were expressed in HeLa cells (Table 3). Likewise, we 
found that only miR-30b was expressed endogenously of the eight miRNAs that induced 
significant changes in Golgi morphology (Table 3). In case of miRNAs that accelerated cargo 
transport, four out of 13 were expressed in HeLa cells (Table 4). Taken together, integrated data 
of miRNA microarray, pre-miR library screening and Golgi complex analyses indicate that the 
most robust cellular phenotypes are predominantly caused by miRNAs that are not endogenously 
expressed (Table 3 and 4). 
To get the insight into miRNA expression dynamics under the experimental conditions 
used in pre-miR library screening, we measured miRNA expression levels in cells incubated for 
7h at 39.5°C and either transduced or not with adenoviral vector, which encodes ts-O45-G 
protein. Experimental conditions are depicted in Fig. R.11. The analysis of miRNA expression 
profiles revealed a ~1.5-fold increase in global miRNA expression in HeLa cells incubated for 7h 
at 39.5°C (condition II) compared to the cells cultured at 37°C (condition I; data not shown). 
Upregulation of miRNA expression suggests the existence of temperature-dependent miRNA 
biogenesis and/or degradation mechanisms common to all miRNAs expressed in HeLa cells. 
Interestingly, Truettner and colleagues (Truettner et al, 2011) recently demonstrated that the 
expression of several rat miRNAs is significantly altered in hypothermia-treated brain. In plants, 
however, accumulation of miRNAs have been reported to be temperature-independent, whereas 
generation of endogenous anti-viral siRNAs is compromised at low temperature (Szittya et al, 
2003). Similar to findings of Truettner and colleagues, we identified miR-1290 and miR-1308 
which were upregulated more that other miRNAs (2.1-fold, p<0.001, and 2.8-fold, p<0.001, 
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      Figure R.11: Schematic representation 
of experimental conditions used in global 
miRNA expression analysis. 
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respesctively) in hyperthermia-treated cells, supporting a miRNA-specific response to 
temperature.  
Next, we examined the effects of hyperthermia combined with adenoviral transduction on 
miRNA expression profiles (condition III). This condition exactly matched with the experimental 
settings used in pre-miR library screening. We compared miRNA profiles in control cells 
(condition I) with miRNA expression profiles in cells treated under condition III and observed a 
modest (~20%) increase in global miRNA expression in cells maintained under condition III 
(data not shown). While for the most of miRNAs this moderate increase was not statistically 
significant, miR-1290 and miR-1308 remained consistently upregulated (2-fold, p<0.001 and 3.1-
fold, p<0.001, respectively).  
 
Conclusions: Genome-wide miRNA analysis revealed 113 miRNAs that are expressed at 
detectable levels in HeLa cells. However, only few of them are identified as effectors in pre-miR 
library screening and Golgi complex analysis, supporting the hypothesis that the introduction of 
endogenously absent miRNAs predominantly leads to stronger cellular phenotypes compared to 
the overexpression of naturally transcribed miRNAs. Moreover, we demonstrated that the 
expression two poorly characterized miRNAs, miR-1290 and miR-1308, is significantly 
upregulated by both hyperthermia (condition II) and hyperthermia combined with viral 
transduction (condition III). This highlights the need for follow-up functional studies in order to 
elucidate the roles of miRNAs in the adaptive cellular response to temperature changes and/or 
exposure to pathogens. Furthermore, future studies are required to discern the viral transduction-
specific effects on the miRNA expression levels, which was not possible under the used 
experimental settings. 
 
 6.4. miR-17 is a novel regulator of membrane trafficking 
 
As described previously, miR-17-92 cluster has been implicated in a diverse range of both 
physiological and pathological processes. However, to our knowledge, we provide the first 
experimental evidence indicating a functional interplay between members of the miR-17 family 
and membrane trafficking system. miR-17 family is composed of six miRNAs, namely, miR-17, 
miR-20a, miR-20b, miR-93, miR-106a and miR-106b, based on their identical seed sequence 
(Tanzer & Stadler, 2004). Results of our proof of principle experiments clearly showed that 
overexpression of four of these miRNAs leads to significantly accelerated ts-O45-G trafficking 
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rate (Fig. R.2 and R.4 A) and strongly inhibits internalization of DiI-LDL ligand (Fig. R.3 and 
R.4 B). Furthermore, we identified miR-20b as a hit miRNA in the pre-miR library screening 
(Table 2). Considering that miRNAs with the same seed sequences have been shown to affect 
almost identical sets of target genes (He et al, 2007), we selected miR-17 as representative 
member of the miRNA family for further investigation.    
 
6.4.1. Time-resolved gene expression profiling identifies potential targets of miR-17            
 
Recent transcriptome and ribosome profiling studies revealed that miRNA-mediated 
decrease in protein expression can mainly be attributed to target mRNA degradation, rather than 
translational repression (Baek et al, 2008; Guo et al, 2010; Hendrickson et al, 2009). These 
observations led to the successful application of gene expression microarrays as a suitable tool 
for target identification of both endogenous and ectopically introduced miRNAs (Hanina et al, 
2010; Selbach et al, 2008). Therefore, in order to identify potential miR-17 targets which could 
be responsible for the observed membrane trafficking phenotypes, we performed time-resolved 
gene expression profiling in HeLa-CD4 cells transfected with pre-miR-17 or PNC. A time-
resolved analysis was chosen to capture the temporal changes in gene expression profiles after 
transfection. For expression profiling we transfected HeLa-CD4 cells because they were initially 
used in proof of principle experiments with miR-17. Following total RNA isolation, gene 
expression profiles were anlysed on Illumina Human Sentrix-8 BeadChip
®
 arrays containing 
specific probes for 25 456 annotated human transcripts. To select differently expressed genes, 
quantile-normalized probe intensities were compared between the pre-miR-17-tranfected and the 
control-transfected samples. Considering that overexpression of miRNAs in human cells causes 
only a modest downregulation of hundreds of transcripts (Baek et al, 2008; Lim et al, 2005; 
Selbach et al, 2008), we set a conservative expression change cutoff value of -1.5 to identify 
significantly downregulated genes. The cutoff value of 1.5 was applied to select upregulated 
genes. Using these thresholds, we identified 36 genes that were downregulated and 10 
upregulated 12h after transfection; 44 genes that were downregulated and 18 upregulated 24h; 
and 44 genes that were downregulated and 35 upregulated 48h after transfection (Appendix III). 
Among downregulated genes, we found previously validated direct targets of miR-17. For 
example, TGF-beta receptor type-2 (TGFBR2; Tagawa et al, 2007; Volinia et al, 2006) was the 
most downregulated gene 12h and 24h after transfection (2.0-fold and 1.9-fold, respectively); 
Janus kinase 1 (JAK1; Doebele et al, 2010) and oligonucleotide/oligosaccharide-binding fold-
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containing protein 2A (OBFC2A; Tan et al, 2009) were also significantly downregulated by 
overexpressed miR-17 (Appendix III). Some of the known miR-17 targets, such as RUNX1 and 
NCOA3, were not affected in our experiment as miR-17 has been shown to mediate their 
translational inhibition rather than destabilization of mRNAs (Fontana et al, 2007; Hossain et al, 
2006). Importantly, almost 80% of genes downregulated 12h after transfection are predicted miR-
17 targets by at least one of the used miRNA target prediction algorithms (MicroCosm Targets 
v5, Diana-microT v3.0 and TargetScanHuman release 5.2) (Appendix III).  
Among significantly downregulated genes, we found six with well-defined functions in 
membrane trafficking system (Fig. R.12 A). Surprisingly, in line with the results of DiI-LDL 
internalization assay, we identified LDLR as potentially direct targets of miR-17. Other 
downregulated membrane trafficking-related genes were as follow: TBC1D2, M6PR, ASAP2, 
RAB32 and NKD2. Functionally, TBC1D2 and ASAP2 are GTPase-activating proteins (GAPs) 
for RAB7 GTPase (Frasa et al, 2010) and Arf GTPases (Andreev et al, 1999; Kondo et al, 2000), 
A. 
TBC1D2 LDLR M6PR ASAP2 RAB32 NKD2
12h -1.78 -1.56
24h -1.95 -1.53 -1.65 -1.51
48h -1.52 -1.64 -1.61
TBC1D2 LDLR M6PR ASAP2 RAB32 NKD2
miRNA seed 
sequence
miR-17 + + + - - -
miR-20a + + + - - -
miR-20b + + + - - -
miR-93 + + + - - -
miR-106a + + + - - -
miR-106b + + + - - -
miR-18a - - - - - -
miR-18b - - - - - -
miR-92a - - - - - -
miR-25 - - - - - -
miR-363 - - - - - -
miR-19a - + + + - -
miR-19b - + + + - -
5'-AAAGUGC-3'
5'-AAGGUGC-3'
5'-AUUGCAC-3'
5'-GUGCAAA-3'
Figure R.12: Microarray-based identification of potential miR-17 target genes. (A) 
Overexpression of miR-17 significantly downregulated the expression of six genes that are 
known  regulators of membrane trafficking system. Expression fold changes (linear scale) are 
given. Grey squares represent situations when the observed fold change was lower than the cutoff 
value of -1.5 (B) Computational prediction of TBC1D2, LDLR, M6PR, ASAP2, RAB32 and 
NKD2 genes as potential targets of miRNAs encoded by miR-17-92, miR-106b-25 and miR-106a-
363 clusters. Prediction by at least one of three algorithms (MicroCosm Targets, Diana-microT 
and TargetScanHuman) was considered as valid. miRNAs are grouped according to their seed 
sequences. 
 
B. 
 90 
respectively. Cation-independent mannose-6-phosphate receptor (M6PR) is involved in the 
transport of soluble hydrolases from the trans-Golgi to lysosomes (Stein et al, 1987). RAB32 
GTPase is implicated in the trafficking of melanogenic enzymes from the trans-Golgi network to 
the premature melanosomes (Wasmeier et al, 2006). It is also required for mitochondrial fission 
(Alto et al, 2002). Naked cuticle homolog 2 protein (NKD2) mediates the delivery of TGF-α-
loaded vesicles to the basolateral membrane in polarized MDCK cells (Li et al, 2007).  
To investigate whether these genes can be direct targets of miR-17, we next performed a 
computational miRNA target prediction analysis using the three previously mentioned prediction 
algorithms. We found that TBC1D2, LDLR and M6PR are predicted miR-17 targets by at least 
one of the prediction approaches (Fig. R.12 B). Additionally, we examined whether these genes 
are predicted targets for other miRNAs encoded by paralogous miR-17-92, miR-106b-25 and 
miR-106a-363 clusters. As anticipated, TBC1D2, LDLR and M6PR are predicted targets not only 
for miR-17, but also for other miR-17 family members (Fig. R.12 B). Conversely, TBC1D2, 
LDLR and M6PR are not among potential targets of miRNAs belonging to miR-18 or miR-92 
families. Importantly, prediction tools suggested LDLR, M6PR and ASAP2 as potential targets of 
miR-19 family miRNAs. Although modulation of miR-19a activity had no effect on Dil-LDL 
internalization, miR-19a overexpression significantly inhibited ts-O45-G transport in proof of 
principle experiments. Moreover, miR-19b was a strong inhibitor of cargo transport in pre-miR 
library screening. Taken together, all these findings provide a solid basis for follow-up studies to 
investigate the role of miR-19 family in biosynthetic membrane trafficking. 
Prediction algorithms indicated that TBC1D2, LDLR and M6PR mRNAs have one, four 
and three potential miR-17 binding sites in their 3´UTRs, respectively (Table 6). We next 
searched for motifs complementary to the seed of miR-17 in the selected mRNAs and uncovered 
one additional putative miR-17 interaction site in the 3´UTR of LDLR and four sites in ASAP2 
mRNA: three in the coding sequence and one in the 3´UTR (Table 6). These binding sites were 
“overlooked” by all three prediction tools, most probably because algorithms explore only 
3´UTRs of the transcripts and/or require particular site conservation features for the valid 
prediction of potential miRNA binding site (Alexiou et al, 2009). 
In summary, integration of gene expression profiling, computational target prediction and 
mRNA sequence analyses provided us with four membrane trafficking-related genes that are 
potential direct targets of miR-17 or other family members. 
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TBC1D1 3´UTR 247–255    5' ...CACCUCUUCCACAGAGCACUUUG... 3' 
                                     ||||||||| 
miR-17           3'    GAUGGACGUGACAUUCGUGAAAC    5' 
LDLR 
 
3´UTR 815-821    5' ...UCCCGUGGUCUCCUUGCACUUUC... 3' 
                                      |||||||  
miR-17           3'    GAUGGACGUGACAUUCGUGAAAC    5' 
3´UTR 1153-1159  5' ...ACGCCUGUAAUCCCAGCACUUUG... 3' 
                                      ||||||| 
miR-17           3'    GAUGGACGUGACAUUCGUGAAAC    5' 
3´UTR 1629-1635  5' ...ACGCCUGUAAUCCCAGCACUUUG... 3' 
                                      |||||||  
miR-17           3'    GAUGGACGUGACAUUCGUGAAAC    5' 
3´UTR 2163-2169  5' ...UUUUUUGUUAUGUUUGCACUUUG... 3' 
                                      |||||||  
miR-17           3'    GAUGGACGUGACAUUCGUGAAAC    5' 
3´UTR 2425-2430 5'  ...UCUGGGAGAUGGGUGUCACUUUU... 3' 
                                       |||||| 
miR-17           3'    GAUGGACGUGACAUUCGUGAAAC    5' 
M6PR 
3´UTR 3-9        5'              ...UUGCACUUUA... 3' 
                                      |||||||    
miR-17           3'    GAUGGACGUGACAUUCGUGAAAC    5' 
3´UTR 792-798   5'   ...CCAGAAAAGGGAAGUCACUUUA... 3'  
                                       ||||||   
miR-17          3'     GAUGGACGUGACAUUCGUGAAAC    5' 
3´UTR 899-905   5'  ...AUUUCUAAACAUGUCGCACUUUC... 3' 
                                      |||||||  
miR-17          3'     GAUGGACGUGACAUUCGUGAAAC    5' 
ASAP2 
CDS 327-334     5'  ...ACAAAGGAGUUGACAGCACUUUU... 3' 
                                     |||||||| 
miR-17          3'     GAUGGACGUGACAUUCGUGAAAC    5' 
CDS 1126-1131   5'  ...ACAUGACAGAACUUACCACUUUC... 3' 
                                       |||||| 
miR-17          3'     GAUGGACGUGACAUUCGUGAAAC    5' 
CDS 3003-3009          CCCGGUGUCAUUUGUGCACUUUA... 3' 
                                      ||||||| 
miR-17          3'     GAUGGACGUGACAUUCGUGAAAC    5' 
3´UTR 1068-1073 5'  ...AUACUCCCAAACAUCCCACUUUU... 3' 
                                       |||||| 
miR-17          3'     GAUGGACGUGACAUUCGUGAAAC    5' 
 
 
6.4.2. Analysis of potential miR-17 targets as regulators of membrane trafficking 
 
Having identified the potential miR-17 binding sites in TBC1D2, LDLR, M6PR and 
ASAP2 mRNAs, we further addressed the question whether or not these genes are functionally 
relevant to the miR-17-mediated membrane trafficking phenotypes. To this end, we performed 
DiI-LDL internalization and ts-O45-G transport assays following transfection with gene-specific 
siRNAs in order to mimic miR-17 overexpression. We reasoned that, if miR-17 induces 
trafficking phenotypes by downregulating these genes, the same effects should be at least 
partially reproduced by siRNA-mediated RNAi of biologically relevant targets. Functional assays 
were performed with two different siRNAs per gene, with a single siRNA used per well. 
Phenotypic effects caused by individual siRNAs were normalized to control siRNA and results of 
the most effective siRNA are presented.  
As shown previously, knockdown of LDLR significantly reduced cellular DiI-LDL 
uptake. Moreover, we also observed a considerably reduced amount of internalized DiI-LDL in 
TBC1D2 and M6PR siRNA-transfected cells (Fig. R.13 A and B), indicating that these genes are 
actively involved in cellular uptake, trafficking and/or degradation of DiI-LDL.  
Table 6: Potential miR-17 binding 
sites in TBC1D2, LDLR, M6PR and 
ASAP2 mRNAs. miR-17 binding sites 
identified  by search of seed binding 
motifs are marked in grey, whereas 
others are predicted by one of the 
target prediction tools. 
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We next examined whether the miR-17-mediated changes in ts-O45-G trafficking rate are 
associated with downregulation of TBC1D2, LDLR, M6PR and ASAP2. We performed a ts-O45-
G transport assay in cells transfected with siRNAs against each of these potential miR-17 targets. 
Quantification of ts-O45-G transport assay revealed that RNAi of TBC1D2 significantly inhibited 
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Figure R.13: Knockdown of potential miR-17 targets inhibits DiI-LDL 
internalization and ts-O45-G transport. (A) Representative images of DiI-LDL internalization 
assay in HeLa cells transfected with control siRNA (upper row) or siRNA against TBC1D2 
(lower row). (B) Quantification of internalized DiI-LDL fluorescence intensity in cells 
transfected with indicated siRNAs on 8-well µ-slides. (C) Representative images of ts-O45-G 
transport assay in HeLa cells transfected as in (A). (D) Quantification of ts-O45-G transport rate 
in cells transfected with indicated siRNAs on 8-well µ-slides. Data of both assays were 
normalized to control siRNA samples as described in Methods. Results are represented as means 
of normalized DiI-LDL intensity values (B) or mean values of normalized ts-O45-G transport 
rates (D) from at least three independent experiments (n ≥ 3) ± S.E.M. *, p<0.05; ***, p<0.001. 
Scale bars represent 20 μm. PM, the plasma membrane. 
C. D. 
A. B. 
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cargo trafficking 48h after transfection, whereas knockdown of other three genes had no 
significant effect (Fig. R.13 C and D). This experiment confirms an active regulatory role of 
TBC1D2 in ts-O45-G progression through the biosynthetic system, however, the siRNA-
mediated RNAi resulted in an opposite cargo trafficking phenotype to the one observed upon 
overexpression of miR-17. 
Together, these results confirmed that TBC1D2, LDLR and M6PR genes play an active 
role in membrane trafficking. Specifically, knockdown of these genes significantly reduced 
cellular DiI-LDL uptake, further suggesting that they may contribute to miR-17-mediated effect 
on endocytosis.  
 
6.4.3. Validation of novel miR-17 targets TBC1D2 and LDLR 
 
Previous studies have shown that TBC1D2 acts as GAP for RAB7, which is involved in 
late endocytic trafficking and lysosomal biogenesis (Bucci et al, 2000; Chavrier et al, 1990; Frasa 
et al, 2010). LDLR is a key player in maintaining balanced blood cholesterol level since it 
interacts with and internalizes LDL-cholesterol ester conjugates into cell via endocytosis 
machinery (Brown & Goldstein, 1986; Yamada et al, 1986). Moreover, numerous mutations in 
LDLR have been identified leading to familial hypercholesterolemia, a genetic disorder 
characterized by very high level of LDL conjugates in the plasma (Hobbs et al, 1992). Based on 
this knowledge, computational miR-17 target prediction and our experimental data, we 
considered TBC1D2 and LDLR as the most relevant genes that account for the miR-17-mediated 
effects on DiI-LDL internalization. To determine whether miR-17 can directly interact with and 
repress TBC1D2 and LDLR mRNAs via the predicted binding sites in their 3´UTRs, we 
constructed luciferase reporter vectors containing the Renilla luciferase gene fused to the full-
length TBC1D2 (~0.35kb) or LDLR (~2.5kb) 3´UTRs. Co-transfection of reporters with pre-miR-
17 resulted in a significant reduction of luciferase activity compared to reporter vectors co-
transfected with PNC. This indicates that miR-17 inhibits TBC1D2 and LDLR mRNA expression 
by binding directly to their 3´UTRs. Conversely, inhibition of miR-17 by anti-miR-17 
substantially increased luciferase expression from both TBC1D2 and LDLR reporter vectors (Fig. 
R.14 A and B). Together, these results validate a functional interplay between TBC1D2 and 
LDLR mRNAs and miR-17.  
Since TBC1D2 mRNA contains a single predicted binding site for miR-17 in its 3´UTR, 
we next generated TBC1D2_Mut and TBC1D2_Del luciferase reporter vectors by mutating miR-
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17 binding site into anti-complementary sequence or deleting it, respectively (Fig. R.14 A). In 
contrast to the wild-type TBC1D2 reporter (TBC1D2_WT), these specific mutations completely 
abolished the response of TBC1D2_Mut and TBC1D2_Del reporters to both overexpression and 
inhibition of miR-17, confirming a functionally active miR-17 binding site in the 3´UTR of 
TBC1D2 mRNA (Fig. R.14 A). 
In a more biologically relevant experimental setup, we next assayed the potency of miR-
17 to modulate the levels of endogenous TBC1D2 and LDLR mRNAs. Towards this, we 
performed a qRT-PCR analysis 12h, 24h and 48h after overexpression of miR-17. siRNAs 
targeting TBC1D2 and LDLR mRNAs were used as positive controls. Consistent with microarray 
data, we observed that overexpression of miR-17 decreased TBC1D2 mRNA level around 50% 
compared to PNC at all three time points measured (Fig. R.15 A). Importantly, transfection with 
TBC1D2 siRNA led to the same knockdown efficiency as miR-17 overexpression. Analysis of 
LDLR mRNA revealed that transfection with pre-miR-17 also reduced LDLR mRNA level to the 
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Figure R.14: miR-17 binds directly to the 3´UTRs of TBC1D2 and LDLR mRNAs. (A 
and B) miR-17 binds to the 3’UTRs of TBC1D2 and LDLR mRNAs, as determined by luciferase 
reporter assay. HeLa cells were co-transfected with TBC1D2 (A) or LDLR (B) reporters and 
indicated oligonucleotides. Mutation (TBC1D2_Mut) or deletion (TBC1D2_Mut) of predicted 
miR-17 binding site in the 3´UTR of TBC1D2 rendered reporters inert to both overexpression 
and inhibition of miR-17. Luciferase activity was measured 24h following co-transfections. 
Controls indicate the luciferase expression in cells co-transfected with reporter vectors and PNC 
or ANC. Values represent mean fold changes of Renilla luciferase activity in relation to 
respective control from three experiments (n = 3) ± S.E.M.  
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Figure R.15: miR-17 inhibits the expression of TBC1D2 and LDLR mRNAs and 
reduces protein levels. (A and B) Overexpression of miR-17 decreases the expression levels of 
both TBC1D2 (A) and LDLR (B) mRNAs as determined by qRT-PCR. Expression of TBC1D2 
and LDLR mRNAs was normalized against GAPDH mRNA level. Results are represented as 
mean mRNA expression values from two independent experiments (n = 2) ± S.E.M. (C) Western 
blot analysis of TBC1D2. Representative western blot of TBC1D2 (120kDa) and tubulin-α 
(55kDa) proteins in lysates of HeLa cells transfected with indicated oligonucleotides for 48h. 
TBC1D2 protein expression levels were normalized against tubulin-α, which served as a loading 
control in this experiment. (D) Western blot analysis of LDLR. Representative western blot of 
LDLR protein (130kDa) in lysates of HeLa cells transfected with indicated oligonucleotides. A 
cross-reacting band of the anti-LDLR antibody was used as loading control (LC, ~63kDa). 
Results are represented as normalized mean values of relative protein levels from at least three 
independent experiments (n ≥ 3) ± S.E.M. Relative expression levels of TBC1D2 and LDLR 
mRNAs and proteins in siRNA- or pre-miR-17-transfected cells were normalized against the 
respective controls (TBC1D2 and LDLR siRNAs to control siRNA, pre-miR-17 to PNC). *, 
p<0.05; **, p<0.01; ***, p<0.001. 
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same extent as LDLR siRNA (Fig. R.15 B). In line with observations that miRNAs 
predominantly induce target destabilization (Baek et al, 2008; Guo et al, 2010), our findings 
independently demonstrate that miR-17 significantly reduces TBC1D2 and LDLR mRNA levels.  
Finally, we aimed to determine the extent to which expression of TBC1D2 and LDLR 
proteins is affected by overexpression of miR-17. Western blot analyses confirmed that both 
TBC1D2 and LDLR protein levels were significantly decreased 48h after transfection with pre-
miR-17 (Fig. R.15 C and D). Like in the qRT-PCR experiments, siRNAs against TBC1D2 and 
LDLR were used as positive controls. While miR-17 reduced TBC1D2 level to the same extent as 
did specific TBC1D2 siRNA (Fig. R.15 C), overexpression of miR-17 led to around 30% 
decrease of LDLR protein compared to around 60% reduction induced by LDLR siRNA (Fig. 
R.15 D).  
In summary, our combined results of luciferase reporters, mRNA and protein 
measurements validated that TBC1D2 and LDLR are novel direct targets of miR-17. Furthermore, 
we confirmed the functionality of predicted miR-17 binding sites in 3´UTRs of TBC1D2 and 
LDLR mRNAs. We also demonstrated that single miR-17 binding motif is necessary and 
sufficient to exert the miRNA-mediated regulation on TBC1D2 mRNA. Finally, we showed that 
miR-17-mediated TBC1D2 and LDLR gene silencing is significant on both mRNA and protein 
levels. 
 
 Conclusions: In order to identify potential targets of miR-17, we performed microarray-
based gene expression profiling in cells transfected with pre-miR-17. Among downregulated, we 
found transcripts of TBC1D2, LDLR, M6PR, ASAP2, RAB32 and NKD2 genes. With the siRNA-
mediated RNAi we demonstrated that single knockdowns of TBC1D2, LDLR, M6PR phenocopy 
miR-17-mediated effect on cellular DiI-LDL internalization. The results of luciferase reporter, 
qRT-PCR and western blot analyses confirmed that TBC1D2 and LDLR are novel functional 
targets of miR-17. Further studies are needed to identify functionally relevant miR-17 targets 
which are responsible for the miRNA-governed acceleration of ts-O45-G transport to the plasma 
membrane. 
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6.5. Time-resolved gene expression profiling upon expression of miR-517a            
 
Members of the miR-517 family, namely, miR-517a, miR-517b and miR-517c, were 
among the strongest ts-O45-G transport inhibitors in pre-miR library screening (Table 1). 
Moreover, biosynthetic transport phenotypes were associated with significant fragmentation of 
Golgi complex induced by all three family members (Fig. 10). Despite recently identified 
oncogenic role of miR-517a in progression of hepatocellular carcinoma (Toffanin et al, 2011), the 
functions of this miRNA family remain elusive. Previous studies have shown that miR-517 
family miRNAs are encoded in the largest human miRNA cluster C19MC; this cluster contains 
46 primate-specific miRNA genes that ultimately yields up to 59 mature miRNAs (Borchert et al, 
2006). C19MC cluster is mainly, if not exclusively, transcribed in undifferentiated tissues 
including placenta, human hematopoietic and embryonic stem cells (Bar et al, 2008; Laurent et 
al, 2008; Ren et al, 2009). Since all three miR-517a/b/c have identical seed sequence (5´-
UGCACGA-3´) and were among the strongest effectors in our assays, we sought to investigate 
further this miRNA family. We selected miR-517a as representative member of the family on a 
basis of more pronounced phenotypic effects compared to other two miRNAs. 
Similar to gene expression profiling with miR-17, we performed a time-resolved 
microarray analysis in order to identify potential miR-517a target genes that are functionally 
relevant to membrane trafficking. Total RNA was isolated from HeLa cells 12h, 24h and 48h 
after transfection with pre-miR-517a or PNC. Gene expression profiles were analysed on 
HumanHT-12 v4 BeadChip
®
 arrays (Illumina) containing probes for 48 107 transcripts derived 
from RefSeq Release 38. The microarray data of the pre-miR-517a-transfected samples were 
compared to the PNC-transfected samples as decribed in Methods. In contrast to a relatively low 
number of miR-17-affected transcripts, we found that substantially more mRNAs were 
deregulated by miR-517a (Table 7, Appendix IV).  
 
 
Table 7: Number of transcripts affected 12h, 24h 
and 48h after transfection with pre-miR-517a. 
Expression fold change cutoff values of -1.5 and 1.5 
(in linear scale) corresponding to an adjusted p-
value ≤ 0.01 were used as criteria to identify 
significantly downregulated and upregulated genes, 
respectively. 
Down-regulated Up-regulated
12h 83 51
24h 360 379
48h 978 1111
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We next aimed to determine how many affected genes have known functions in regulation 
of membrane trafficking. To this end, we first compiled a list of human genes that were directly 
annotated to the Gene Ontology (GO) terms of “Protein transport” (GO:0015031), “Endocytosis” 
(GO:0006897) and “Protein secretion” (GO:0009306) by two independent databases, namely, 
AmiGO and Ensembl. The list of 617 unique genes was then compared with genes affected upon 
expression of miR-517a. Comparative analysis revealed that 32 genes associated with membrane 
trafficking were significantly downregulated by miR-517a (Appendix V A). Interestingly, we 
found more (72) trafficking-related genes among upregulated by miR-517a (Appendix V B). The 
following computational miRNA target prediction analysis (MicroCosm Targets, Diana-microT 
and TargetScanHuman algorithms) indicated that among 32 downregulated genes, AP1S2, 
ATG10, HRAS, INPPL1, NUPL2 and LDLR are potential direct targets of miR-517a. Among 
upregulated membrane trafficking-associated genes, only GOLT1B and NUP35 were predicted as 
miR-517a targets. Strikingly, we have previously validated LDLR as a novel functional target of 
miR-17, suggesting an active post-transcriptional LDLR expression regulation by both miR-17 
and miR-517a. 
Besides LDLR, integration of gene expression profiling data uncovered relatively few 
downregulated genes with direct functions in membrane trafficking (Table 8). For example, 
AP1S2 encodes subunit sigma-2 of AP-1 adaptor complex, which is implicated in the formation 
of clathrin-coated vesicles at trans-Golgi network (TGN) and involved in TGN-to-endosome 
traffic (Robinson, 2004). Previous studies have reported that siRNA-mediated knockdown of 
AP1S2 stimulates DiI-LDL uptake, but inhibits transferrin internalization in HeLa cells (Bartz et 
al, 2009), suggesting an active role of miR-517a also in endocytosis. The TGN-localized ADP-
ribosylation factor (ARF3) is involved in the assembly of COPI and clathrin coat complexes onto 
budding vesicles, however, ARF3 knockdown does not alter biosynthetic ts-O45-G transport to 
the plasma membrane and has no effect on the TGN morphology (Manolea et al, 2010; 
Volpicelli-Daley et al, 2005). Therefore, miR-517a-induced phenotypes are unlikely to be 
explained by direct targeting of ARF3 mRNA. We also identified a group of poorly characterized 
Rab GTPase genes (RAB26, RAB35, RAB40B and RAB40C) that were significantly 
downregulated throughout the 48h expression profiling experiment. 
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Among upregulated membrane trafficking-related genes (Table 9), we found COG3, 
COG5 and COG6 genes encoding three subunits of the conserved oligomeric Golgi (COG) 
tethering complex that is essential for establishing and maintaining the normal structure and 
function of the Golgi apparatus (Ungar et al, 2002; Ungar et al, 2005). The transfection with pre-
miR-517a also increased the expression of well-described genes like ARF1, ARF4, ARFGAP1, 
ARFGAP3, COPE that either play regulatory roles in the formation of protein transport vesicles 
on the Golgi membrane or encode structural components of these vesicles (Donaldson & Jackson, 
2011; Hsu & Yang, 2009; Yang et al, 2002; Kartberg et al, 2010). YIP family member 5, 
(YIPF5, also known as YIP1A) co-localizes with COPII coatomer components SEC31A and 
SEC13 at ER exit sites (ERES). Moreover, overexpression of N terminus of YIPF5 blocks ER-
Golgi transport of ts-O45-G and induces fragmentation of the Golgi complex (Stagg et al, 2006; 
Tang et al, 2001). Several genes of well-characterized Rab GTPases, including RAB5A that 
regulates early steps in endocytosis, RAB6A that acts on intra-Golgi transport, RAB8A that 
mediates anterograde transport from the TGN to the plasma membrane and RAB22 that controls 
bi-directional vesicular trafficking between the TGN and the early endosomes (Hutagalung & 
Novick, 2011) were among upregulated by miR-517a. 
A number of recent bioinformatics studies have proposed the existence of mutual 
regulatory networks between miRNAs and transcription factors (TFs). The TFs seem to regulate 
miRNA, or to be regulated by the miRNA, forming a range of diverse feed-forward loops 
(Martinez & Walhout, 2009; Shalgi et al, 2007; Tran et al, 2010; Tu et al, 2009). Consistently, 
experimental evidence indicate that some transcription regulators, which are targets of miRNAs, 
can exert both positive and negative transcription regulation (van Rooij et al, 2007). Considering 
that the majority of membrane trafficking-related genes were upregulated only at 48h after 
transfection, we speculate that most of the functionally relevant genes to exert miR-517a-
Table 8: List of representative membrane trafficking-related genes that were downregulated in 
pre-miR-517a-transfected HeLa cells. Genes are listed alphabetically. 
12h 24h 48h
1 AP1S2 -2.21 -2.31 -2.02 Yes NM_003916.3
2 ARF3 -1.53 NM_001659.1
3 LDLR -1.99 Yes NM_000527.2
4 RAB26 -1.75 -2.98 NM_014353.4
5 RAB35 -1.74 -1.57 NM_006861.4
6 RAB40B -1.95 -2.77 -2.95 NM_006822.1
7 RAB40C -1.74 -1.53 NM_021168.2
Gene accession 
number
Number
Gene 
symbol
Fold-change Predicted 
target?
 100
mediated phenotypes are secondary targets of this miRNA. However, the structure of miR-517a-
governed regulatory networks remains to be identified in future studies.   
   
 
 
Conclusions: In order to identify potential targets of miR-517a, we performed a 
microarray-based gene expression profiling in HeLa cells transfected with pre-miR-517a. 
Bioinformatics analysis of microarray data yielded a set of genes with previously described 
functions in membrane trafficking, however, their functional interactions with miR-517a remains 
to be identified in future studies. 
 
6.6. Bioinformatics analysis of miR-17 and miR-517a microarray data 
 
The most compelling evidence that the downregulated transcripts are direct miRNA 
targets is the presence of miRNA binding sites in their 3´UTRs (Grimson et al, 2007; Lim et al, 
2005). Therefore, we sought to investigate whether the transcripts downregulated upon 
overexpression of miR-17 and miR-517a are enriched in the potential binding motifs for these 
miRNAs. In other words, this analysis addressed the question whether the downregulated 
transcripts are direct targets of the respective miRNA. For this purpose, we employed a Sylamer 
algorithm (van Dongen et al, 2008) to perform an unbiased analysis for overrepresented 
nucleotide motifs in 3´UTRs of the transcripts affected by miR-17 or miR-517a. Sylamer 
Table 9: List of representative membrane trafficking-related genes that were upregulated in pre-
miR-517a-transfected HeLa cells. Genes are listed alphabetically. 
 
12h 24h 48h
1 ARF1 1.87 NM_001024228.1
2 ARF4 2.71 NM_001660.2
3 ARFGAP1 2.11 3.43 NM_018209.2
4 ARFGAP3 1.62 2.06 NM_014570.3
5 COG3 2.04 NM_031431.2
6 COG5 2.17 NM_006348.2
7 COG6 2.22 NM_020751.1
8 COPE 1.62 NM_199442.1
9 RAB18 1.57 NM_021252.3
10 RAB22A 2.25 2.14 NM_020673.2
11 RAB32 1.74 NM_006834.2
12 RAB5A 1.54 NM_004162.3
13 RAB6A 1.83 NM_198896.1
14 RAB8B 2.21 2.26 2.81 NM_016530.2
15 SEC31A 2.02 NM_014933.2
16 YIPF5 1.77 2.32 NM_030799.6
Gene accession 
number
Number
Gene 
symbol
Fold-change Predicted 
target?
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algorithm determines over- or underrepresented nucleotide motifs in a ranked transcript list and 
assigns the log10-transformed enrichment p-value to each of tested motifs (van Dongen et al, 
2008). Therefore, prior to analysis, we ranked all transcripts analysed miR-17 or miR-517a 
microarray experiments from the most downregulated to the most upregulated according to their 
expression fold change values. Using a word size of seven nucleotides, Sylamer identified 
significantly overrepresented motifs in both miRNA overexpression experiments at all three time 
points (Fig. R.16). For miR-17 12h experiment, the enrichment curve of seven nucleotides 
GCACUUU (p<1 x 10
-27
), which are complementary to the seed region of miR-17 (positions 2-8), 
was peaking approximately at transcript 1 500 in the ranked list (Fig. R.16 A). This indicates that 
the set of approximately 1 500 most downregulated transcripts, located to the left of the 
significance peak, were significantly enriched for miR-17 binding sites in relation to the 
remaining transcripts. In turn, this suggests that these transcripts are likely direct targets of miR-
17. Consistent with observations by Grimson and colleagues (Grimson et al, 2007), the 
overrepressented motif corresponds to a canonical 7mer-m8 type of miRNA binding sites.  
Analysis of miR-517a microarray data indicated three different heptamers with very 
similar enrichment patterns across all time points, especially at 12h (Fig. R.16 D-F). All three 
motifs contained the core hexamer (GCACGA) complementary to the seed sequence of miR-
517a. Like in case of miR-17, the hexamer flanked by additional complementary nucleotide at its 
5´ end (UGCACGA, 7mer-m8 type of binding site) was the most significantly overrepresented 
motif among the miR-517a-downregulated mRNAs. We also observed the enrichment of other 
two closely related heptamers GCACGAU (complementary to positions 1-7 of miR-517a) and 
GCACGAA (7mer-A1 type, hexamer seed match augmented by an A at target position 1). The 
enrichment of these two motifs indicates that nucleotides outside the minimal seed region 
(hexamer GCACGA) are less important for miR-517a to induce target degradation; the 
enrichment of single motif in miR-17-deregulated transcripts suggests that only the presence of 
this motif permits the destabilization of miR-17-bound transcripts. This observation might 
partially explain why miR-517a deregulates much more transcripts than miR-17 when tranfected 
to cells. 
In case when stringent expression change cutoff values are applied to select differently 
expressed transcripts, secondary miRNA-mediated effects are usually considered to occur later 
than 24h after transfection with exogenous miRNA (Tu et al, 2009). Consistently, our Sylamer 
analysis of miR-17 and miR-517a microarray data resulted in a broader motif enrichment profiles 
48h after transfection with respective pre-miRs (Fig. R.16 C and F) compared to the data 
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Figure R.16: Motif enrichment analysis of miR-17 and miR-517a microarray data. 
(A-C) Motif enrichment landscape plots of miR-17 microarray data 12h (A), 24h (B) and 48h (C) 
after transfection. (D-F) Motif enrichment landscape plots of miR-517a microarray data 12h (D), 
24h (E) and 48h (F) after transfection. The x axes represent the sorted gene list from most 
downregulated (left) to most upregulated (right). Positive values on y axes indicate enrichment 
and negative values, depletion for each tested motif. The horizontal dotted lines indicate a 
multiple-testing E-value (Bonferroni-corrected) threshold of 0.01, whereas vertical dotted lines 
show significance peaks across the gene list for a given word. Coloured lines represent three 
most enriched and three most depleted motifs. Heptamers complementary to the seed regions of 
miRNAs of interest are represented in each plot. Significance peaks observed below E-value 
threshold are not considered as statistically significant. 
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from earlier time points. This type of motif enrichment profiles, peaking closer to the middle of 
the sorted transcript list, potentially represents situations when secondary miRNA targets 
compose a large fraction of the affected transcripts and thereby dilute the significance of motif 
enrichment (van Dongen et al, 2008). 
 To test this hypothesis with our microarray data, we selected sets of downregulated and 
upregulated transcripts with a fold change higher or equal to 1.5 at each time point and searched 
for miR-17 and miR-517a binding sites in their 3´UTRs. Analysing miR-17 microarray data, we 
found GCACUUU motif at least once in 76% of the 3´UTRs of the transcripts downregulated 12h 
after transfection. For comparison, the same heptamer was found only in 19% of all annotated 
human 3´UTRs (Fig. R. 17 A and B, background rate). In contrast to 12h time point, the 
frequency of miR-17 binding sites in the 3´UTRs of transcripts downregulated at 48h was similar 
to the background rate. As anticipated, we found the intermediate frequency of GCACUUU 
heptamer at 24h time point (Fig. R.17 A). Analysis of the 3´UTRs of transcripts downregulated 
by miR-517a revealed similar trend of miR-517a binding site UGCACGA frequencies over the 
experimental period (Fig. R.17 C). Taken together, these results confirmed that the majority of 
the downregulated transcripts at early time points are most likely direct targets of miR-17 or miR-
517a.  
We further searched the 5´UTRs and protein-coding sequences (CDS) of downregulated 
and the entire sequences of upregulated transcripts for heptamers complementary to the seeds of 
miR-17 or miR-517a. Searching for miR-17 or miR-517a seed-matched motifs in the 5´UTRs and 
in the CDS of downregulated transcripts did not yield any significant enrichment compared to the 
genome-wide frequency of these motifs (Fig R.17 A and C). These results are in line with the 
concept that metazoan miRNAs target 3´UTRs more frequently and more efficiently than other 
regions of transcripts (Lai, 2002; Lee et al, 1993; Lim et al, 2005). Sequence analysis of miR-17-
upregulated transcripts revealed enrichment for the miR-17 binding motif GCACUUU in the 
3´UTRs. However, enrichment of this motif was much more pronounced in the downregulated 
transcripts (Fig R.17 A and B). Interestingly, the miR-517a binding motif UGCACGA was 
underrepresented in the CDS and the 3´UTRs of miR-517a-upregulated transcripts compared to 
the genome-wide frequency (Fig R.17 D). Although this finding further indicates that 
upregulated transcripts are likely indirect miR-517a targets, the miRNA-mediated regulatory 
networks that lead to increased gene expression remain to be elucidated. In summary, motif 
enrichment analysis confirmed that miRNAs, through direct interactions with their targets, act as 
predominantly negative post-transcriptional regulators of gene expression (Lai, 2002).  
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Computational miRNA target prediction is one of the most commonly used approaches 
for a rapid identification of potential miRNA targets. The main feature used in various prediction 
algorithms is the sequence alignment of the miRNA seed sequence to the 3´UTR of the transcript. 
Additionally, prediction specificity is increased using different combinations of other parameters, 
including evolutionary conservation, structural accessibility, nucleotide composition and location 
of the binding sites within the 3´UTR (Alexiou et al, 2009; Sethupathy et al, 2006). In order to 
evaluate the prediction quality of these algorithms, we selected three commonly used programs 
(MicroCosm Targets v5, Diana-microT v3.0 and TargetScanHuman release 5.2) and analyzed 
how many transcripts downregulated by miR-17 or miR-517a are predicted as potential targets at 
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Figure R.17: Search of miR-17 and miR-517a binding motifs in the sequences of 
transcripts affected by overexpression of the miRNAs. (A, B) Transcripts affected by 
overexpression of miR-17 and (C, D) miR-517a. Only transcripts with an expression fold change 
higher or equal to 1.5 corresponding to an adjusted p-value ≤0.05 (miR-17) or ≤0.01 (miR-517a) 
and with annotated 3´UTR sequence were used for analysis. The most significantly enriched 
heptamers in Sylamer algorithm-based analysis (GCACUUU for miR-17a and UGCACGA for 
miR-517a; Fig. R.16) were used as search words. Transcripts with at least one word in a given 
region are represented as percentage in relation to all either downregulated (A, C) or upregulated 
(B, D) mRNAs at the indicated time points after transfection. Background rates were calculated 
by searching the given motifs within all annotated human 5´UTRs, coding sequences and 
3´UTRs. 
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least by one of the mentioned programs. The analysis of microarray data showed that 58% of the 
transcripts, which are downregulated by fold change ≤ -1.5 12h after transfection, are predicted 
miR-17 targets. For miR-517a, only 26% of the transcripts downregulated at 12h after 
transfection are predicted targets. Surprisingly, the simple search of miRNA binding motifs in the 
3´UTRs of the downregulated transcripts indicated that 76% and 32% of the transcripts affected 
12h after transfection are potential targets of miR-17 and miR-517a, respectively (Fig R.17 A 
and C). These results indicate that the straightforward motif search outperforms more complex 
computational methods.  
 
Conclusions: Applying global analysis of miR-17 and miR-517a microarray data we 
showed that many transcripts are downregulated through direct miRNA:target interactions. On 
the other hand, upregulated transcripts are most likely indirect secondary targets of the 
investigated miRNAs. We also demonstrated that the searching of potential miRNA binding 
motif outperforms complex computational prediction programs and can be used as an alternative 
for a fast identification of putative miRNA targets. 
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7. DISCUSSION 
 
 The list of physiological and pathological processes where miRNAs play important 
regulatory roles is constantly growing. In this context, the area of membrane trafficking in 
eukaryotic cells has attracted little interest from the scientific miRNA community. To our 
knowledge, there are only three publications available that report the effects of miR-375 (Poy et 
al, 2004), miR-9 (Plaisance et al, 2006), miR-124a and miR-96 (Lovis et al, 2008) on regulated 
insulin secretion in murine pancreatic β-cells. Moreover, Kanzaki and colleagues (Kanzaki et al, 
2011) recently demonstrated that miR-92a regulates the expression of RAB14, which is involved 
in surfactant secretion in lung cells. These observations suggest that miRNAs might constitute a 
new regulatory level of complex membrane trafficking process. However, no large-scale studies 
to elucidate the effects of known miRNAs on membrane trafficking in human cells have been 
performed. In this study, we established an integrative platform of different experimental 
approaches that allowed us to identify miRNAs and their biologically relevant target genes 
involved in the regulation of membrane trafficking. 
 
7.1. Proof of principle: functional activity of pre-miRs and anti-miRs 
 
Effective and reliable approaches to modulate miRNA activity are crucial for 
understanding the biological importance of miRNAs. Generally, overexpression by introducing 
synthetic miRNAs (gain-of-function) and miRNA inhibition by antisense inhibitory 
oligonucleotides (loss-of-function) are the most straightforward and commonly used strategies 
for investigating miRNA functions. In this study, we first of all evaluated the potency of miRNA 
mimicking (pre-miRs) and antisense oligonucleotides (anti-miRs) to enhance or to inhibit the 
activity of specific miRNAs in cell cultures, respectively. Noteworthy, pre-miRs and anti-miRs 
are patent pending products of Ambion company and, therefore, the formulation of chemical 
modifications of these molecules is undisclosed. As previously showed by U. Neniškytė 
(previous member of Screening of Cellular Networks laboratory), synthetic pre-miRs and anti-
miRs can be efficiently introduced into four adherent cell lines by using commercially available 
Lipofectamine 2000 transfection reagent. Furthermore, oligonucleotides could be successfully 
delivered by liquid-phase and solid-phase reverse transfections. The latter approach is of 
particular relevance in order to perform large-scale screenings of miRNA libraries (Erfle et al, 
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2007). In order to evaluate functionality of pre-miRs and anti-miRs, we selected three human 
miRNAs encoded by polycistronic miR-17-92 cluster, namely miR-17, miR-20a and miR-92a 
(Tanzer & Stadler, 2004), and one unrelated – miR-320a. miRNA expression profiling by qRT-
PCR showed that transfection with pre-miRs significantly increased the expression of respective 
miRNAs. These results were further confirmed by luciferase reporter assay. Except for miR-92a, 
we did not observe a significant reduction of miRNA levels in cells transfected with anti-miRs. 
Considering that inhibition of miRNA activity by anti-miRs is sometimes achieved without 
detectable miRNA degradation (Davis et al, 2009; Elmen et al, 2008), measuring miRNA level 
by qRT-PCR is not always a suitable method to assess inhibition. Moreover, Davis and 
colleagues (Davis et al, 2009) showed that some high affinity chemical modifications stabilize 
the anti-miR:miRNA complex and interfere with miRNA detection by qRT-PCR. Indeed, our 
results from the luciferase reporter assay showed that anti-miRs effectively inhibit the activity of 
endogenous miRNAs resulting in a relief of reporter gene suppression, which is reflected by 
increased luciferase protein expression. 
Consistent with previous studies (Davis et al, 2006; Lennox & Behlke, 2010; Ovcharenko 
et al, 2007), we conclude that synthetic pre-miRs and anti-miRs are functional approaches, 
respectively, to efficiently enhance or inhibit the activity of endogenous miRNAs in cultured 
cells. We also show that pre-miRs are resistant to nuclease degradation up to 72h after 
transfection. 
 
7.2. Members of the miR-17 family are novel regulators of membrane trafficking 
 
   Biosynthetic trafficking and endocytic pathways are the major intracellular membrane 
trafficking routes in eukaryotic cells. To examine whether modulation of miRNA activity by pre-
miRs or anti-miRs induces any detectable phenotypic changes in these pathways, we employed 
two well-established fluorescence-based assays. Changes in biosynthetic trafficking were 
measured by ts-O45-G protein transport assay (Starkuviene et al, 2004; Zilberstein et al, 1980), 
whereas efficiency of endocytosis was assayed by internalization of DiI-LDL ligand (Ghosh et al, 
1994). The key feature of these assays is that, in combination with automated image acquisition 
and analysis, fluorescence intensity of ts-O45-G or Dil-LDL is measured at single cell level and, 
therefore, allows statistical data analysis.  
miR-17-92 is one of the most extensively studied miRNA clusters in mammals. Aberrant 
expression of this cluster has been reported in numerous human malignancies (Coller et al, 2007; 
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Volinia et al, 2006), indicating that it is one of the most potent oncogenic clusters. According to 
their seed sequences, the six miRNAs encoded by miR-17-92 cluster can be classified into four 
families. Thus, we selected miR-17, miR-18a, miR-19a and miR-92a as representative members 
of each seed family and performed membrane trafficking assays. Surprisingly, we observed that 
overexpression of miR-17 significantly accelerated ts-O45-G transport rate and substantially 
reduced the amount of internalized DiI-LDL in HeLa cells. miRNAs with identical seed 
sequences have been predicted to modulate a highly overlapping set of target genes (Bartel, 2009; 
Lewis et al, 2005). Therefore, we hypothesized that other miR-17 seed family members encoded 
by miR-17-92 and its paralogous miR-106a-363 and miR-106b-25 clusters (Tanzer & Stadler, 
2004) could modulate similar biological processes to the ones regulated by miR-17. Indeed, 
overexpression of miR-20a, miR-20b and miR-93, miRNAs that contain the same seed sequence 
as miR-17, accelerated ts-O45-G transport rate and reduced the cellular Dil-LDL uptake to a 
similar extent as miR-17. These findings validated our hypothesis suggesting that miR-17 family 
members modulate a similar set of genes and the net outcome of this regulation is the enhanced 
biosynthetic ts-O45-G trafficking and the reduced internalization of DiI-LDL. In line with our 
results, previous studies have demonstrated functional redundancy of miR-17 family members 
since they target common genes (Doebele et al, 2010; Wu et al, 2010) or regulate the same 
biological processes (Borgdorff et al, 2010). To our knowledge, this is the first experimental 
evidence demonstrating an active role of miR-17 family members in regulation of membrane 
trafficking and, therefore, further expanding the functional repertoire of miR-17-92 cluster. 
In contrast to miRNA overexpression, we could not obtain biologically significant 
changes in biosynthetic trafficking or endocytosis upon inhibition of any tested miRNAs. Again, 
a possible explanation is that miRNAs sharing same seed sequence can be functionally 
redundant. This is exemplified by the lack of obvious phenotypes in C. elegans deficient for 
individual miRNAs whose functions are apparently compensated by other similar miRNAs 
(Miska et al, 2007). On the other hand, Brenner and colleagues (Brenner et al, 2010) were able to 
identify enhanced or synthetic phenotypes for most of the analyzed miRNAs in alg-1 mutant 
nematodes with partially disabled miRNA silencing machinery and lower total miRNA activity. 
Another example of functional miRNA redundancy comes from mice deficient for miR-106b-25 
cluster. The function of this cluster was uncovered only in the context of miR-17-92 deletion, 
suggesting that the loss of miR-106b-25 is compensated by the paralogous miRNAs from miR-
17-92 cluster (Ventura et al, 2008). Moreover, functional redundancy of miR-17 family members 
is supported by the fact that systematic inhibition of both miR-17 and miR-20a induced stronger 
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effect on neovascularization than inhibition of miR-20a alone (Doebele et al, 2010). The results 
of our luciferase reporter assay indicate significant suppression of miRNA activity by different 
inhibition approaches. This could be explained by higher sensitivity of the artificial reporter to 
miRNA of interest in comparison to other similar miRNAs that are different in some nucleotides 
outside the seed region. Although further studies are needed, we believe that miR-17 family 
members redundantly regulate a set of natural targets, which would explain the lack of significant 
phenotypes after inhibition of individual miRNAs. As mentioned before, this possibility has been 
supported by numerous experimental studies (Doebele et al, 2010; He et al, 2007; Uhlmann et al, 
2010; Wu et al, 2010).  
Taken together, we demonstrated for the first time a regulatory role of miR-17 family 
miRNAs in biosynthetic trafficking and endocytosis, further indicating that miRNAs are actively 
involved in the control of membrane trafficking processes. Despite the lack of cellular 
phenotypes after inhibition of individual miRNAs, the overexpression of miR-17 family miRNAs 
resulted in significant changes in biosynthetic ts-O45-G transport and internalization of 
extracellular Dil-LDL. 
  
7.3. Large-scale screening identifies multiple miRNAs as regulators of biosynthetic 
trafficking   
 
A number of miRNA-based screenings have been completed during the last 5 years. 
Surprisingly, in order to elucidate the biological roles of miRNAs, nearly all reported screenings 
used the gain-of-function approach. Overexpression of miRNAs often induces mutant phenotypes 
in a dominant fashion, and so they are potentially easier to evaluate compared to the ones caused 
by inhibition of miRNAs. Additionally, loss-of-function experiments are limited to the 
experimental system with endogenously expressed miRNAs of interest, whereas gain-of-function 
is in principle relevant to all tissue or cell types (Serva et al, 2011). 
Based on successful proof of principle experiments, we designed a gain-of-function 
screening of 470 miRNAs to identify the ones that are involved in the regulation of biosynthetic 
ts-O45-G trafficking. Among 470 screened miRNAs, we identified 31 whose overexpression 
significantly inhibited ts-O45-G transport to the plasma membrane, whereas overexpression of 
other 13 miRNAs substantially accelerated cargo trafficking. In comparison to the relatively large 
number of miRNAs counted as primary hits in previously reported screenings (Ovcharenko et al, 
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2007; Sirotkin et al, 2009; Whittaker et al, 2010), we selected in total 44 miRNAs which 
represent less than 10% of all screened molecules, indicating stringent cutoff values. In line with 
the data from proof of principle experiments, we identified miR-20b as hit in library screening. 
The majority of arbitrarily selected inhibitory miRNAs (5 out of 6) was then confirmed in a 
small-scale experimental format using pre-miRs from a different batch, demonstrating the 
reproducibility of large-scale screening data. Among the inhibitory miRNAs we identified three 
poorly-characterized members of miR-517 family, namely, miR-517a, miR-517b and miR-517c, 
which are mainly expressed in undifferentiated tissues (Ren et al, 2009). Recently, miR-517a has 
been identified as a novel oncogenic miRNA upregulated in human hepatocellular carcinoma 
samples (Toffanin et al, 2011). In contrast to previous finding in Huh7 cells (Toffanin et al, 
2011), overexpression of miR-517a had no significant effect on HeLa cell growth, suggesting cell 
type-dependent function of the miRNA. Among ts-O45-G transport accelerators, we found miR-
34a and miR-34c, members of miR-34 family. All three family members (including miR-34b) are 
well-known tumor suppressors and their expression is transactivated by the transcription factor 
p53 (Chang et al, 2007; He et al, 2007). Ectopic expression of miR-34 family miRNAs has been 
shown to cause cell-cycle arrest (Tarasov et al, 2007) or induce apoptosis (Raver-Shapira et al, 
2007). Consistently, we found that overexpression of miR-34a significantly inhibited cell growth. 
None of miR-517 and miR-34 family members that affected ts-O45-G transport has been 
previously implicated in regulation of membrane trafficking. Furthermore, except for miR-34a, 
overexpression of these miRNAs had no significant effect on cell growth, indicating that 
observed changes in biosynthetic ts-O45-G transport was not caused by dysregulated cell 
proliferation (Misteli & Warren, 1995; Warren, 1993) or induced apoptosis (Nozawa et al, 2002). 
These representative examples demonstrate the potency of large-scale functional screening in 
identifying miRNAs with regulatory functions in biosynthetic trafficking.  
 The Golgi complex is a highly dynamic cellular structure responsible for modifying, 
sorting and packaging secretory proteins in mammalian cells. The functionality of the Golgi 
apparatus is closely related to its structure, and so any changes in structural integrity directly 
affect biosynthetic protein transport (Tamaki & Yamashina, 2002). Therefore, we developed a 
fully automated image analysis platform for quantification of Golgi complex integrity and 
investigated the effects of hit miRNAs on Golgi structure. Surprisingly, we observed that the 
inhibition of ts-O45-G transport by miR-517a, miR-517b and miR-517c is also associated with 
significant fragmentation of Golgi complex. Apart from miR-517 family, we identified other four 
miRNAs (miR-30b, miR-637, miR-432 and miR-765) that induced Golgi fragmentation by at least 
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1.75-fold compared to control, whereas miR-382 caused condensation of the Golgi apparatus. All 
eight miRNAs identified as effectors of Golgi morphology inhibited ts-O45-G transport in the 
functional screening. Importantly, none of the miRNAs that accelerated protein transport had 
obvious effect on Golgi network, suggesting that other cellular organelles and/or Golgi 
morphology-independent regulatory mechanisms are involved in miRNA-mediated upregulation 
of biosynthetic protein transport.  
 In summary, through large-scale screening we identified 44 miRNAs regulating 
biosynthetic ts-O45-G trafficking. We also demonstrated that eight out of 31 inhibitory miRNAs 
significantly affect morphology of Golgi complex. The observed changes in Golgi structure 
suggest that functions of multiple targets that are deregulated by each of eight miRNAs converge 
on this organelle and potentially affect ts-O45-G transport in the Golgi complex. 
 
7.4. Microarray-based expression profiling identifies miRNAs expressed in 
HeLa cells 
                
 Hundreds of miRNAs have been shown to be expressed in highly tissue specific patterns 
(Baskerville & Bartel, 2005; Landgraf et al, 2007). Therefore, the introduction of a miRNA that 
is not endogenously expressed would downregulate many transcripts that are not usually targeted 
in specific tissue under natural conditions. We speculated that the transfection with endogenously 
non-expressed miRNAs can induce stronger phenotypes compared to the overexpression of 
endogenous miRNAs. In agreement with this notion, our microarray-based miRNA expression 
profiling revealed that only 10 out of the 44 hit miRNAs from functional screening are 
endogenously expressed in HeLa cells. Even a smaller fraction of miRNAs was expressed if 
considering the Golgi effectors: we only detected the expression of miR-30b. Noteworthy, miR-
30b were among the weakest hit miRNAs that inhibited ts-O45-G transport     (-1.62 Z-scores) 
and the weakest inducer of Golgi fragmentation (1.78-fold) compared to other identified hit 
miRNAs. These findings validate our hypothesis and are in part supported by a report showing a 
strong correlation between miRNA and target mRNAs expression levels (Sood et al, 2006). 
 Several recent studies have reported aberrant cellular miRNA expression profiles 
following viral infection (Marquez et al, 2010; Triboulet et al, 2007; Wang et al, 2008).  In 
parallel with the analysis of steady-state miRNA expression profiles, we examined how 
experimental conditions of ts-O45-G transport assay, which include incubation at 39.5°C and 
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adenoviral transduction (adenoviral vector encodes ts-O45-G), effect miRNA expression. We 
found that mere incubation at 39.5°C led to ~1.5-fold increase in global miRNA expression with 
miR-1290 and miR-1308 being most upregulated miRNAs. Although hyperthermia, in 
combination with adenoviral transduction, induced only a modest increase in global miRNA 
expression, the expression of poorly-characterized miR-1290 and miR-1308 remained 
significantly upregulated. The experimental settings we used did not allow to discern viral 
transduction-specific effects on cellular miRNA expression. However, constant upregulation of 
two specific miRNAs supports a previously suggested miRNA-specific response to temperature 
in mammals (Truettner et al, 2011).  
 Altogether, we detected 113 mature miRNAs expressed in HeLa cells under normal 
conditions. Integration of miRNA expression data revealed that the majority of miRNAs 
identified in our pre-miR library screening and Golgi complex integrity assay are not 
endogenously expressed. Furthermore, we identified temperature-dependent upregulation of miR-
1290 and miR-1308, providing an interesting basis for the follow-up studies to elucidate their 
upregulation mechanisms and potential effects on ts-O45-G transport. 
 
7.5. Microarray-based identification of potential miR-17 and miR-517a targets 
    
 As previously mentioned, several independent studies using different large-scale 
approaches have demonstrated that miRNA-mediated target mRNA destabilization, rather than 
translational repression, is the predominant mechanism for reduced protein levels (Baek et al, 
2008; Guo et al, 2010; Hendrickson et al, 2009). These findings were at least partially anticipated 
considering that an early transcriptome profiling study revealed a large number of transcripts 
downregulated by ectopically introduced miRNAs (Lim et al, 2005). Based on these 
observations, we performed a time-resolved microarray-based mRNA expression profiling in 
order to identify biologically relevant targets of two miRNAs, miR-17 and miR-517a. We 
selected miR-17 as representative member of the miR-17 family. miR-517a was chosen as 
representative member of the miR-517 family because of its novelty and the magnitude of 
induced ts-O45-G transport inhibition and Golgi complex fragmentation. Noteworthy, our 
miRNA expression profiling experiment showed that miR-17 is highly expressed, whereas 
members of the miR-517 family are undetectable in HeLa cells.    
Gene expression profiling identified 90 downregulated and 56 upregulated transcripts in 
the pre-miR-17-transfected cells throughout the 48h experiment. Surprisingly, we detected in 
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total 1 088 downregulated and 1 238 upregulated transcripts by enforced expression of miR-517a. 
The considerably higher number of transcripts affected by introduction of miR-517a compared to 
miR-17 is in line with our previous speculation that many transcripts, which are not co-expressed 
in the same cell type with targeting miRNA, will be downregulated by introduction of the 
respective exogenous miRNA. One could argue that the majority of potential miR-517a targets 
identified by mRNA expression profiling are biologically irrelevant. However, Lim et al. showed 
that expression of tissue-specific miRNAs in HeLa cells shifts the entire gene expression pattern 
towards that tissue (Lim et al, 2005). Nevertheless, further studies are necessary to investigate 
whether it is valid for miR-517a, comparing our microarray data with mRNA expression profiles 
in cells that endogenously express miR-517a, for example, human embryonic stem cells (Bar et 
al, 2008). 
Among miR-17 downregulated transcripts, we identified six (TBC1D2, LDLR, M6PR, 
ASAP2, RAB32 and NKD2) with described functions in membrane trafficking. Sequence analysis 
revealed that TBC1D2, LDLR, M6PR, ASAP2 mRNAs have potential miR-17 binding sites in 
their 3´UTRs or coding regions. Similar to our analysis, at least one of three miRNA target 
prediction tools (MicroCosm Targets v5, Diana-microT and TargetScanHuman) predicted 
TBC1D2, LDLR and M6PR as targets for miR-17. Further investigation of potential miR-17 
targets are discussed in the following section.  
Comparative analysis of miR-517a microarray data with a set of 167 genes assigned to 
Gene Ontology terms “Protein transport”, “Endocytosis” and “Protein secretion” identified 32 
and 72 membrane trafficking related genes downregulated and upregulated by miR-517a, 
respectively. Surprisingly, among downregulated transcripts we found LDLR, which was also 
validated as a novel miR-17 target (discussed later). Although we did not confirm LDLR as a 
target of miR-517a, mRNA expression data suggest that this gene is potentially regulated by both 
miR-17 and miR-517a. Analysis of other downregulated transcripts revealed a relatively few 
genes that exert miR-517a-mediated inhibition of ts-O45-G transport or Golgi complex 
fragmentation. One of these potential genes could be ARF3, however, Manolea and colleagues 
(Manolea et al, 2010) recently showed that ARF3 knockdown does not interfere with biosynthetic 
ts-O45-G transport and has no effect on the trans-Golgi network. In contrast to downregulated, 
we found many upregulated genes with well-described functions in membrane trafficking. Such 
genes are COG3, COG5 and COG6 encoding different subunits of the conserved multisubunit 
tethering COG complex that is essential for COPI-mediated retrograde vesicle transport within 
the Golgi complex (Oka et al, 2004). Moreover, the COG complex has been shown to be 
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involved in Golgi-specific glycosylation process (Bruinsma et al, 2004) and maintenance of 
Golgi structure (Ungar et al, 2002; Ungar et al, 2005). Another example is YIPF5 gene. Tang and 
colleagues demonstrated that overexpression of YIPF5 arrests ER-Golgi transport of ts-O45-G 
and induces Golgi complex fragmentation. It also co-localizes with COPII coatomer subunits 
SEC13 and SEC31A at ER exit sites (Tang et al, 2001). Importantly, SEC31A was also 
upregulated by miR-517a, indicating that this miRNA can potentially regulate different steps of 
ER-Golgi cargo transport. Besides well-described Rab genes (RAB5A, RAB6A, RAB8A and 
RAB22), we also detected upregulation of RAB32. In line with miR-517a effect, we recently 
demonstrated that knockdown of RAB32 results in acceleration of ts-O45-G transport to the 
plasma membrane (Sanchari Roy, personal communication). Despite experimental evidence that 
these genes can potentially play a role in miR-517a-mediated phenotypes, none of them is 
predicted to be target of miR-517a. Furthermore, all of them were upregulated and most of 
upregulation events were detected 48h after transfection, indicating that they are likely indirect 
miR-517a targets. Their upregulation might be induced through more complex miR-517a-
governed secondary regulatory mechanisms, rather than by direct interactions with the miRNA 
(Martinez & Walhout, 2009; Shalgi et al, 2007; Tu et al, 2009). 
Taken together, using time-resolved transcriptome profiling approach, in combination 
with bioinformatics analysis, we identified a set of membrane trafficking-related genes affected 
by transfection with pre-miR-17 or pre-miR-517a. While validation of novel miR-17 targets is 
discussed in the following section, further investigation is necessary to elucidate miR-517a-
mediated regulatory networks responsible for the upregulation of functionally relevant genes.  
        
7.6. miR-17 regulates membrane trafficking through novel targets TBC1D2 and 
LDLR 
 
As we demonstrated a novel function of miR-17 in regulation of membrane trafficking, it 
is of great interest to identify the target genes that are responsible for the miR-17-mediated 
phenotypes in ts-O45-G transport and DiI-LDL internalization. Given the well-know miR-17-92 
functions in tumorigenesis (Olive et al, 2010; Xiang & Wu, 2010), most of the 33 to date 
experimentally validated miR-17 targets are important cell cycle or apoptosis regulators (Hsu et 
al, 2011). In this study, integration of gene expression profiling data, transcript sequence analysis 
and computational target prediction indicated TBC1D2, LDLR, M6PR and ASAP2 genes as 
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potential miR-17 targets involved in the regulation of membrane trafficking. Among these genes, 
TBC1D2 has been studied least. Recently, Armus, a highly homologous protein of TBC1D2 
(TBC1D2 contains deletion of 11 amino acids compared to Armus), was shown to act as GTPase-
activating protein (GAP) for RAB7 and to regulate ARF6-induced internalization of E-cadherin 
from keratinocyte cell-cell contacts (Frasa et al, 2010). LDLR is one of the most intensively 
studied proteins and functions as a major regulator of plasma LDL concentration (Yamada et al, 
1986; Schneider, 1989). M6PR is required for the transport of lysosomal hydrolases from the 
TGN to pre-lysosomal compartments (Stein et al, 1987). ASAP2 functions as GAP for ARF1, 
ARF5 and ARF6 and thereby modules biosynthetic trafficking (Andreev et al, 1999). 
 To investigate whether TBC1D2, LDLR, M6PR and ASAP2 genes are functionally 
relevant to the miR-17-mediated phenotypes, we downregulated them individually by siRNA-
based RNAi and performed membrane trafficking assays. Apart from the anticipated effect of 
LDLR knockdown, RNAi of TBC1D2 and M6PR led to the significantly reduced amount of 
internalized DiI-LDL and thereby phenocopied miR-17-mediated effect. The quantification of ts-
O45-G trafficking assay showed that only the knockdown of TBC1D2 significantly inhibited the 
cargo transport. Noteworthy, the transfection with siRNAs against TBC1D2 resulted in an effect 
on ts-O45-G transport phenotype opposite to the one induced by overexpressed miR-17. This 
finding indicates that TBC1D2 is important for cargo transport; however, it is not directly 
responsible for miR-17-regulated acceleration of ts-O45-G transport. Considering that miR-17 has 
been shown to induce translational repression without detectable changes in transcript levels 
(Fontana et al, 2007; Hossain et al, 2006), we can not exclude that we could have missed some 
other biosynthetic trafficking-related targets by the gene expression profiling approach.  
 Since TBC1D2 is a GAP for RAB7, an essential regulator of late endocytic trafficking 
and lysosomal degradation (Bucci et al, 2000; Chavrier et al, 1990; Frasa et al, 2010), and LDLR 
is required for cellular LDL uptake (Brown & Goldstein, 1986), we considered TBC1D2 and 
LDLR as the most potential genes to exert miR-17 phenotype on DiI-LDL internalization. With 
the luciferase reporter assay we validated that miR-17 directly regulates the expression of both 
TBC1D2 and LDLR through binding to their 3´UTRs. Moreover, we showed that a single miR-17 
binding site in the 3´UTR of TBC1D2 mRNA is functionally active and essential for the miRNA-
mediated regulation. Finally, we demonstrated that overexpressed miR-17 significantly decreased 
mRNA and protein levels of both investigated genes, further confirming that TBC1D1 and LDLR 
are novel functional targets of this miRNA. 
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 Internalized LDL-LDLR complex is dissociated in the RAB5-positive early endosomes 
and segregated components are directed towards two different endocytic pathways: (i) LDL 
proceeds through the endosomal pathway for subsequent degradation in lysosomes (Goldstein et 
al, 1985) and (ii) LDLR receptor is recycled back to the plasma membrane via the recycling 
pathway (Anderson et al, 1982). A recent fluorescence microscopy-based study has elegantly 
showed that the degradation of LDL occurs in the lysosome-associated membrane protein 1 
(LAMP1)-positive late endosomes (Humphries et al, 2010). The formation of RAB7-positive late 
endosomes from RAB5-positive early endosomes requires the replacement of RAB5 with RAB7. 
This process, also known as Rab conversion, is mediated by the RAB5-recruited SAND-1-CCZ-1 
complex, which acts as a guanine nucleotide exchange factor (GEF) for RAB7 (Kinchen & 
Ravichandran, 2010; Poteryaev et al, 2010). In this context, TBC1D2 GAP comes as a relevant 
regulator of early-to-late endosome maturation. Despite the fact that TBC1D2 was identified as 
GAP specific for RAB7, the experimental time settings (10min time point) of the biochemical 
GAP activity assay leaves the possibility that other fast-hydrolyzing Rabs, such as RAB5, are 
potential substrates for TBC1D2 (Frasa et al, 2010). Indeed, real-time measurement of GTP 
hydrolysis revealed that TBC-2 (C. elegans homolog of human TBC1D2) displays higher 
catalytic activity with C. elegans RAB-5 than with RAB-7 (Chotard et al, 2010). Moreover, 
studies in C. elegans demonstrated that TBC-2 co-localizes with RAB-7 on late endosomes and 
suggested that it inactivates RAB-5 during endosome maturation (Chotard et al, 2010).  
Given that TBC1D2 might act as GAP for both RAB5 and RAB7 in human cells, we 
propose a potential mechanism via which TBC1D2 may regulate intracellular DiI-LDL 
trafficking. It is known that active RAB5 recruits its effector early endosome antigen 1 (EEA1) 
required for tethering and fusion of RAB5-positive endocytic vesicles to early endosomes 
(Simonsen et al, 1998; Stenmark et al, 1996). Importantly, the study by Haas et al. demonstrated 
that internalized EGF is retained in enlarged EEA1-positive structures in cells depleted for the 
RAB5-specific GAP RABGAP-5 (Haas et al, 2005). Consistently, the expression of 
constitutively active RAB5Q79L mutant has been showed to induce the formation of giant early 
endosomes with large amount of EEA1 (Lawe et al, 2002; Stenmark et al, 1994). Surprisingly, a 
recent study showed that RAB5Q79L recruits RAB7 and other late endosome markers to these 
enlarged endosomal structures (Wegner et al, 2010). Consistent with these findings, we observed 
that the knockdown of TBC1D2 resulted in Dil-LDL accumulation in large juxtanuclear 
structures. Based on these observations, we propose that downregulation of TBC1D2 increases 
the activity of both RAB5 and RAB7 which leads to the loss of endosome functional identity. As 
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a result, this potentially compromises sorting of LDLR-LDL complex, recycling of LDLR back 
to the plasma membrane and subsequent endosomal trafficking of internalized LDL. 
In conclusion, we identified and confirmed TBC1D2 and LDLR as novel functional targets 
of miR-17. Although further studies are required to delineate TBC1D2 functions in endocytosis, 
our results revealed that miR-17 is an important regulator of membrane trafficking and expanded 
the functional repertoire of the well-known oncogenic miR-17-92 cluster.    
 
7.7. Bioinformatics analysis of gene expression profiling data 
 
Numerous large-scale studies have revealed that an individual miRNA can modulate the 
expression of many target mRNAs (Giraldez et al, 2006; Guo et al, 2010; Lim et al, 2005; 
Selbach et al, 2008). Consistently, by gene expression profiling experiments, we showed that 
overexpression of miR-17 and miR-517a deregulates a large number of transcripts in HeLa cells. 
Although we also observed that many transcripts are upregulated by the investigated miRNAs, 
both transcriptome-wide miRNA binding site enrichment analysis and searching for specific miR-
17 or miR-517a binding motifs in affected transcripts indicated that only downregulated 
transcripts are potential direct targets of miRNAs (Lai, 2002). As anticipated, searching for 
binding motifs of a given miRNA demonstrated that most of the direct targets can be identified 
12h after transfection; later they are increasingly masked by indirectly affected mRNAs. 
Similar to the study that investigated the transcriptome of Huh7 cells stably expressing 
miR-517a (Toffanin et al, 2011), we found that upregulated transcripts represent more than half 
of affected mRNAs (1 238 upregulated versus 1 088 downregulated) in pre-miR-517a transfected 
HeLa cells. These observations suggest that miR-517a presumably modulates important 
transcription regulators leading to upregulation of numerous indirect targets. Although recently 
proposed mutual regulatory networks between miRNAs and transcription factors (Martinez & 
Walhout, 2009; Shalgi et al, 2007; Tu et al, 2009) support this possibility, further bioinformatics 
studies are needed in order to identify miR-517a-mediated gene activation mechanisms.                  
Identifying miRNA targets is essential for understanding miRNA functions. Various 
computational target prediction tools have been developed for rapid identification of potential 
miRNA targets (Alexiou et al, 2009). Usually, prediction algorithms are used in combination 
with other experimental approaches, for example, miRNA loss-of-function or gain-of-function 
experiments followed by transcriptome profiling. Intriguingly, we showed that simple search of 
miRNA binding site in the 3´UTRs of downregulated transcripts outperforms complex 
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computational methods used to identify potential miR-17 and miR-517a targets from gene 
expression profiling data. The lower performance of computational prediction algorithms might 
be due to the fact that some of them use artificially designed miRNA:mRNA interactions to 
validate predicted sites (Maragkakis et al, 2009). Another possibility is that combining additional 
features such as site conservation, position in the 3´UTR, and UTR length are rather detrimental 
than advantageous, because they weakly correlate with the extent of target downregulation in 
some situations (Betel et al, 2010).     
Altogether, we confirmed that the presence of miRNA seed binding site in the 3´UTRs of 
human mRNAs is an important determinant for functional miRNA:mRNA interaction. 
Additionally, we demonstrated that the sets of transcripts downregulated at early time points after 
transfection have substantially higher fractions of transcripts with potential miRNA binding sites 
in their 3´UTRs compared to the transcripts downregulated at late time points. Our results may 
also contribute to the development of more accurate miRNA target prediction tools.  
 
7.8. Conclusions and future perspectives 
 
The overall aim of this study was to identify miRNAs and their biologically relevant 
target genes involved in the regulation of membrane trafficking. To achieve this aim, we have 
established an integrative experimental platform that consists of (i) a screening module to identify 
miRNAs that affect membrane trafficking, (ii) a mRNA microarray module to identify potential 
miRNA target genes, (iii) a statistics and bioinformatics module for data analysis and integration 
and (iv) a target validation module to validate functional links between targets and miRNAs. 
 For this study, we successfully applied two quantitative fluorescence intensity-based 
functional assays that allowed us to detect miRNA-mediated changes in biosynthetic trafficking 
and endocytosis. As proof of principle, we showed for the first time that miRNAs belonging to 
the miR-17 family are novel regulators of membrane trafficking in mammalian cells. 
We next performed a gain-of-function large-scale screening and identified 44 miRNAs 
that affect the biosynthetic transport of ts-O45-G. The quantification of the Golgi complex 
integrity revealed that overexpression of eight identified hit miRNAs (miR-30b, -382, -432, -
517a, -517b, -517c, -637 and -765) significantly alters the Golgi morphology. The finding 
suggests that functions of multiple target genes modulated by each of these eight miRNAs 
converge on the Golgi complex and potentially regulate ts-O45-G transport at the level of this 
cellular organelle. Therefore, the functional miRNA screening, in combination with the Golgi 
 119 
complex integrity assay, is an efficient strategy for identification of miRNAs that function as 
novel regulators of membrane trafficking. 
Applying a genome-wide transcriptome profiling and bioinformatics, we identified 
numerous potential miR-17 and miR-517a targets relevant to membrane trafficking. The results of 
follow-up detailed analysis validated TBC1D2 and LDLR genes as novel functional miR-17 
targets and confirmed that they exert the miR-17-mediated regulation of endocytosis. Thus, our 
study revealed miR-17 as a novel regulator of membrane trafficking and further expanded the 
functional repertoire of well-known oncogenic miR-17-92 cluster. Further investigation is 
required to identify genes that play role in miR-17-mediated acceleration of ts-O45-G transport as 
well as to elucidate regulatory miR-517a networks that induce strong phenotypes observed in this 
study.  
Considering that the number of known human miRNAs increased more than threefold 
(from 470 to 1527) during this project, the establishment of integrative experimental platform is 
of great importance for identification of other miRNAs and of their targets involved in the 
membrane trafficking process. The link between defects in membrane trafficking, tumorigenesis, 
various infectious and neurological diseases reflects the fundamental role of this cellular process. 
Such defects usually compromise sorting of internalized molecules, motility of vesicles along the 
cytoskeletal tracks or result in aberrant secretion of intracellular proteases and thereby facilitate 
invasive cell motility. In this context, the results of this study provide us new insight into 
miRNAs as potential therapeutic targets or agents for treatment of membrane trafficking-related 
diseases.  
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APPENDIXES 
 
 Appendix I: Accession numbers and IDs of 470 mature human miRNAs in Pre-miR
TM
 
miRNA Precursor Library. Library contains all human miRNAs annotated in miRBase v9.2. Z-
scores of ts-O45-G trafficking rate changes and standard errors of the mean (S.E.M.) induced by 
overexpression of each miRNA are given. The median cargo transport rate is adjusted to Z-score 
of 0. The functional screen was performed in HeLa cells in 96-well µ-plate experimental format.  
 
Accesion 
number in 
miRBase v9.2 
miRNA ID Z-score S.E.M. 
MIMAT0000062 let-7a 0.16 0.12 
MIMAT0000063 let-7b -0.18 0.25 
MIMAT0000064 let-7c -0.07 0.11 
MIMAT0000065 let-7d 0.18 0.16 
MIMAT0000066 let-7e -0.44 0.35 
MIMAT0000067 let-7f 0.03 0.17 
MIMAT0000414 let-7g 0.06 0.21 
MIMAT0000415 let-7i 0.31 0.18 
MIMAT0000416 miR-1 -0.53 0.17 
MIMAT0000098 miR-100 -0.82 0.32 
MIMAT0000099 miR-101 1.18 0.01 
MIMAT0000101 miR-103 0.22 0.26 
MIMAT0000102 miR-105 0.88 0.09 
MIMAT0000103 miR-106a 1.46 0.09 
MIMAT0000680 miR-106b 1.44 0.13 
MIMAT0000104 miR-107 -0.35 0.25 
MIMAT0000253 miR-10a 0.09 0.08 
MIMAT0000254 miR-10b 0.31 0.15 
MIMAT0000422 miR-124a -1.71 0.18 
MIMAT0000443 miR-125a -2.06 0.34 
MIMAT0000423 miR-125b -1.66 0.12 
MIMAT0000445 miR-126 -0.19 0.38 
MIMAT0000444 miR-126* 1.01 0.13 
MIMAT0000446 miR-127 -0.62 0.16 
MIMAT0000424 miR-128a -0.65 0.09 
MIMAT0000676 miR-128b 3.06 0.11 
MIMAT0000242 miR-129 -0.18 0.32 
MIMAT0000425 miR-130a -1.28 0.19 
MIMAT0000691 miR-130b -0.97 0.08 
MIMAT0000426 miR-132 1.37 0.19 
MIMAT0000427 miR-133a -0.62 0.09 
MIMAT0000770 miR-133b -0.97 0.17 
MIMAT0000447 miR-134 -0.14 0.21 
MIMAT0000428 miR-135a -0.58 0.30 
MIMAT0000758 miR-135b -0.64 0.05 
MIMAT0000448 miR-136 0.47 0.12 
MIMAT0000429 miR-137 0.86 0.24 
MIMAT0000430 miR-138 0.33 0.04 
MIMAT0000250 miR-139 0.49 0.20 
MIMAT0000431 miR-140 -1.36 0.09 
MIMAT0000432 miR-141 0.39 0.25 
MIMAT0000434 miR-142-3p 0.71 0.18 
MIMAT0000433 miR-142-5p 0.61 0.37 
MIMAT0000435 miR-143 0.43 0.27 
MIMAT0000436 miR-144 0.63 0.10 
Accesion 
number in 
miRBase v9.2 
miRNA ID Z-score S.E.M. 
MIMAT0000437 miR-145 -0.63 0.53 
MIMAT0000449 miR-146a 1.20 0.49 
MIMAT0002809 miR-146b 0.51 0.24 
MIMAT0000251 miR-147 -0.73 0.23 
MIMAT0000243 miR-148a 0.43 0.10 
MIMAT0000759 miR-148b 0.07 0.40 
MIMAT0000450 miR-149 -0.06 0.13 
MIMAT0000451 miR-150 0.48 0.46 
MIMAT0000757 miR-151 -0.12 0.13 
MIMAT0000438 miR-152 1.16 0.24 
MIMAT0000439 miR-153 0.15 0.25 
MIMAT0000452 miR-154 1.81 0.18 
MIMAT0000453 miR-154* 1.68 0.49 
MIMAT0000646 miR-155 0.64 0.44 
MIMAT0000068 miR-15a 0.38 0.05 
MIMAT0000417 miR-15b -0.20 0.24 
MIMAT0000069 miR-16 0.49 0.39 
MIMAT0000071 miR-17-3p -0.07 0.04 
MIMAT0000070 miR-17-5p 0.97 0.10 
MIMAT0000256 miR-181a 1.23 0.09 
MIMAT0000270 miR-181a* -0.28 0.11 
MIMAT0000257 miR-181b -0.30 0.06 
MIMAT0000258 miR-181c -0.61 0.11 
MIMAT0002821 miR-181d -1.05 0.16 
MIMAT0000259 miR-182 -1.73 0.12 
MIMAT0000260 miR-182* -0.49 0.28 
MIMAT0000261 miR-183 -0.12 0.28 
MIMAT0000454 miR-184 -0.68 0.33 
MIMAT0000455 miR-185 0.92 0.33 
MIMAT0000456 miR-186 -0.06 0.19 
MIMAT0000262 miR-187 0.06 0.15 
MIMAT0000457 miR-188 -0.03 0.15 
MIMAT0000079 miR-189 -0.26 0.26 
MIMAT0000072 miR-18a -0.30 0.02 
MIMAT0002891 miR-18a* -0.51 0.09 
MIMAT0001412 miR-18b 0.44 0.18 
MIMAT0000458 miR-190 -0.16 0.65 
MIMAT0000440 miR-191 -1.27 0.43 
MIMAT0001618 miR-191* -0.36 0.29 
MIMAT0000222 miR-192 1.01 0.08 
MIMAT0000459 miR-193a 0.16 0.26 
MIMAT0002819 miR-193b -0.14 0.43 
MIMAT0000460 miR-194 0.52 0.18 
MIMAT0000461 miR-195 -1.20 0.29 
MIMAT0000226 miR-196a 0.95 0.18 
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Accesion 
number in 
miRBase v9.2 
miRNA ID Z-score S.E.M. 
MIMAT0001080 miR-196b -1.55 0.53 
MIMAT0000227 miR-197 2.01 0.25 
MIMAT0000228 miR-198 0.18 0.31 
MIMAT0000231 miR-199a 0.18 0.31 
MIMAT0000232 miR-199a* 0.64 0.11 
MIMAT0000263 miR-199b 0.02 0.13 
MIMAT0000073 miR-19a -1.34 0.41 
MIMAT0000074 miR-19b -2.59 0.91 
MIMAT0000682 miR-200a 0.96 0.28 
MIMAT0001620 miR-200a* -0.10 0.47 
MIMAT0000318 miR-200b -1.04 0.29 
MIMAT0000617 miR-200c -0.99 0.26 
MIMAT0002811 miR-202 0.10 0.26 
MIMAT0002810 miR-202* 0.01 0.27 
MIMAT0000264 miR-203 -0.27 0.27 
MIMAT0000265 miR-204 -0.43 0.28 
MIMAT0000266 miR-205 0.78 0.03 
MIMAT0000462 miR-206 -1.54 0.18 
MIMAT0000241 miR-208 0.49 0.05 
MIMAT0000075 miR-20a 0.49 0.10 
MIMAT0001413 miR-20b 1.65 0.22 
MIMAT0000076 miR-21 -0.02 0.39 
MIMAT0000267 miR-210 -2.42 0.28 
MIMAT0000268 miR-211 -0.20 0.10 
MIMAT0000269 miR-212 0.76 0.16 
MIMAT0000271 miR-214 -0.20 0.18 
MIMAT0000272 miR-215 0.09 0.16 
MIMAT0000273 miR-216 0.37 0.29 
MIMAT0000274 miR-217 0.45 0.44 
MIMAT0000275 miR-218 -2.43 0.24 
MIMAT0000276 miR-219 -0.42 0.25 
MIMAT0000077 miR-22 0.00 0.04 
MIMAT0000277 miR-220 -0.27 0.20 
MIMAT0000278 miR-221 -0.09 0.18 
MIMAT0000279 miR-222 0.53 0.08 
MIMAT0000280 miR-223 1.09 0.13 
MIMAT0000281 miR-224 -0.42 0.33 
MIMAT0000078 miR-23a 0.52 0.10 
MIMAT0000418 miR-23b 0.70 0.15 
MIMAT0000080 miR-24 -0.28 0.39 
MIMAT0000081 miR-25 0.87 0.14 
MIMAT0000082 miR-26a -1.33 0.32 
MIMAT0000083 miR-26b -0.78 0.39 
MIMAT0000084 miR-27a 0.40 0.18 
MIMAT0000419 miR-27b 0.45 0.15 
MIMAT0000085 miR-28 -1.25 0.22 
MIMAT0000690 miR-296 0.60 0.33 
MIMAT0004450 miR-297 1.62 1.02 
MIMAT0000687 miR-299-3p -1.35 0.29 
MIMAT0002890 miR-299-5p 1.03 0.59 
MIMAT0000086 miR-29a 1.22 0.61 
MIMAT0000100 miR-29b 0.93 0.47 
MIMAT0000681 miR-29c 2.07 0.10 
MIMAT0000688 miR-301 -0.33 0.38 
MIMAT0000684 miR-302a -0.12 0.38 
MIMAT0000683 miR-302a* -0.04 0.14 
Accesion 
number in 
miRBase v9.2 
miRNA ID Z-score S.E.M. 
MIMAT0000715 miR-302b 0.16 0.03 
MIMAT0000714 miR-302b* -0.40 0.33 
MIMAT0000717 miR-302c 0.80 0.19 
MIMAT0000716 miR-302c* 0.45 0.11 
MIMAT0000718 miR-302d 0.52 0.31 
MIMAT0000088 miR-30a-3p -1.29 0.92 
MIMAT0000087 miR-30a-5p -0.66 0.27 
MIMAT0000420 miR-30b -1.62 0.26 
MIMAT0000244 miR-30c -1.14 0.11 
MIMAT0000245 miR-30d 0.22 0.19 
MIMAT0000693 miR-30e-3p -0.02 0.17 
MIMAT0000692 miR-30e-5p -1.47 0.17 
MIMAT0000089 miR-31 0.62 0.11 
MIMAT0000090 miR-32 -0.28 0.23 
MIMAT0000510 miR-320 -0.05 0.46 
MIMAT0000755 miR-323 -0.06 0.20 
MIMAT0000762 miR-324-3p -0.29 0.34 
MIMAT0000761 miR-324-5p 0.95 0.15 
MIMAT0000771 miR-325 -1.29 0.10 
MIMAT0000756 miR-326 -0.23 0.38 
MIMAT0000752 miR-328 0.14 0.53 
MIMAT0001629 miR-329 -1.45 0.10 
MIMAT0000091 miR-33 0.52 0.29 
MIMAT0000751 miR-330 1.22 0.18 
MIMAT0000760 miR-331 -0.01 0.37 
MIMAT0000765 miR-335 0.47 0.05 
MIMAT0000754 miR-337 -0.05 0.13 
MIMAT0000763 miR-338 0.28 0.18 
MIMAT0000764 miR-339 0.18 0.05 
MIMAT0003301 miR-33b 1.18 0.40 
MIMAT0000750 miR-340 0.97 0.19 
MIMAT0000753 miR-342 0.28 0.28 
MIMAT0000772 miR-345 0.45 0.29 
MIMAT0000773 miR-346 -1.89 0.30 
MIMAT0000255 miR-34a 1.61 0.24 
MIMAT0000685 miR-34b 0.26 0.28 
MIMAT0000686 miR-34c 2.17 0.33 
MIMAT0000703 miR-361 -1.01 0.62 
MIMAT0000705 miR-362 -0.45 0.44 
MIMAT0000707 miR-363 -0.23 0.28 
MIMAT0003385 miR-363* -0.43 0.14 
MIMAT0000710 miR-365 -2.04 0.07 
MIMAT0000719 miR-367 0.76 0.34 
MIMAT0000720 miR-368 0.44 0.17 
MIMAT0000721 miR-369-3p -0.04 0.43 
MIMAT0001621 miR-369-5p 0.49 0.26 
MIMAT0000722 miR-370 0.47 0.28 
MIMAT0000723 miR-371 -0.74 0.51 
MIMAT0000724 miR-372 0.67 0.31 
MIMAT0000726 miR-373 0.75 0.06 
MIMAT0000725 miR-373* -0.13 0.11 
MIMAT0000727 miR-374 0.96 0.22 
MIMAT0000728 miR-375 0.47 0.44 
MIMAT0000729 miR-376a 1.32 0.38 
MIMAT0003386 miR-376a* 1.42 0.10 
MIMAT0002172 miR-376b 1.12 0.16 
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MIMAT0000730 miR-377 0.27 0.36 
MIMAT0000731 miR-378 -0.51 0.24 
MIMAT0000733 miR-379 1.16 0.16 
MIMAT0000735 miR-380-3p -0.11 0.24 
MIMAT0000734 miR-380-5p 1.22 0.39 
MIMAT0000736 miR-381 -0.28 0.04 
MIMAT0000737 miR-382 -1.90 0.19 
MIMAT0000738 miR-383 0.64 0.29 
MIMAT0001075 miR-384 0.32 0.23 
MIMAT0001639 miR-409-3p -0.35 0.22 
MIMAT0001638 miR-409-5p 1.00 0.16 
MIMAT0002171 miR-410 -0.50 0.05 
MIMAT0003329 miR-411 0.15 0.38 
MIMAT0002170 miR-412 -0.32 0.11 
MIMAT0003339 miR-421 -0.01 0.24 
MIMAT0001339 miR-422a -0.24 0.32 
MIMAT0000732 miR-422b -0.23 0.16 
MIMAT0001340 miR-423 -0.01 0.37 
MIMAT0001341 miR-424 -0.14 0.18 
MIMAT0001343 miR-425-3p 1.10 0.13 
MIMAT0003393 miR-425-5p -0.46 0.19 
MIMAT0001536 miR-429 -0.66 0.19 
MIMAT0001625 miR-431 1.02 0.18 
MIMAT0002814 miR-432 -1.58 0.38 
MIMAT0002815 miR-432* -0.03 0.34 
MIMAT0001627 miR-433 0.70 0.16 
MIMAT0001532 miR-448 0.75 0.13 
MIMAT0001541 miR-449 0.08 0.12 
MIMAT0003327 miR-449b -0.03 0.41 
MIMAT0001545 miR-450 -0.13 0.13 
MIMAT0001631 miR-451 0.61 0.30 
MIMAT0001635 miR-452 -0.55 0.36 
MIMAT0001636 miR-452* -2.31 0.32 
MIMAT0001630 miR-453 0.50 0.42 
MIMAT0003885 miR-454-3p -0.70 0.31 
MIMAT0003884 miR-454-5p -0.83 0.41 
MIMAT0003150 miR-455 -0.99 0.26 
MIMAT0002173 miR-483 -1.62 0.57 
MIMAT0002174 miR-484 -1.54 0.27 
MIMAT0002176 miR-485-3p 1.07 0.37 
MIMAT0002175 miR-485-5p -0.11 1.02 
MIMAT0002177 miR-486 -0.61 0.73 
MIMAT0002178 miR-487a 0.42 0.12 
MIMAT0003180 miR-487b 0.44 0.58 
MIMAT0002804 miR-488 1.54 0.16 
MIMAT0002805 miR-489 1.68 0.41 
MIMAT0002806 miR-490 0.41 0.21 
MIMAT0002807 miR-491 0.32 0.41 
MIMAT0002812 miR-492 0.39 0.20 
MIMAT0003161 miR-493-3p 0.31 0.18 
MIMAT0002813 miR-493-5p 0.16 0.24 
MIMAT0002816 miR-494 -0.26 0.07 
MIMAT0002817 miR-495 0.43 0.13 
MIMAT0002818 miR-496 0.53 0.05 
MIMAT0002820 miR-497 -0.20 0.06 
MIMAT0002824 miR-498 0.54 0.12 
Accesion 
number in 
miRBase v9.2 
miRNA ID Z-score S.E.M. 
MIMAT0002870 miR-499 0.32 0.12 
MIMAT0002871 miR-500 -0.34 0.35 
MIMAT0002872 miR-501 0.15 0.26 
MIMAT0002873 miR-502 0.24 0.19 
MIMAT0002874 miR-503 -0.56 0.36 
MIMAT0002875 miR-504 0.39 0.07 
MIMAT0002876 miR-505 -0.16 0.05 
MIMAT0002878 miR-506 0.29 0.19 
MIMAT0002879 miR-507 0.44 0.25 
MIMAT0002880 miR-508 0.02 0.09 
MIMAT0002881 miR-509 0.34 0.18 
MIMAT0002882 miR-510 0.37 0.32 
MIMAT0002808 miR-511 -1.41 0.67 
MIMAT0002823 miR-512-3p 0.56 0.05 
MIMAT0002822 miR-512-5p 0.63 0.37 
MIMAT0002877 miR-513 -0.32 0.18 
MIMAT0002883 miR-514 0.39 0.02 
MIMAT0002827 miR-515-3p -0.21 0.24 
MIMAT0002826 miR-515-5p 0.16 0.18 
MIMAT0002860 miR-516-3p 0.36 0.18 
MIMAT0002859 miR-516-5p 0.34 0.37 
MIMAT0002851 miR-517* -0.12 0.24 
MIMAT0002852 miR-517a -3.70 0.76 
MIMAT0002857 miR-517b -3.16 0.22 
MIMAT0002866 miR-517c -1.86 0.48 
MIMAT0002863 miR-518a 0.44 0.02 
MIMAT0002844 miR-518b 0.38 0.10 
MIMAT0002848 miR-518c -0.09 0.34 
MIMAT0002847 miR-518c* -1.13 0.06 
MIMAT0002864 miR-518d -0.01 0.20 
MIMAT0002861 miR-518e 0.73 0.10 
MIMAT0002842 miR-518f 0.31 0.06 
MIMAT0002841 miR-518f* 0.20 0.04 
MIMAT0002869 miR-519a 0.14 0.04 
MIMAT0002837 miR-519b -0.01 0.35 
MIMAT0002832 miR-519c -0.34 0.21 
MIMAT0002853 miR-519d 0.36 0.49 
MIMAT0002829 miR-519e 0.73 0.19 
MIMAT0002828 miR-519e* 0.25 0.14 
MIMAT0002834 miR-520a 0.76 0.08 
MIMAT0002833 miR-520a* 0.12 0.39 
MIMAT0002843 miR-520b 0.20 0.29 
MIMAT0002846 miR-520c -0.16 0.23 
MIMAT0002856 miR-520d 0.17 0.11 
MIMAT0002855 miR-520d* 0.23 0.17 
MIMAT0002825 miR-520e 0.27 0.05 
MIMAT0002830 miR-520f -0.48 0.07 
MIMAT0002858 miR-520g 1.05 0.28 
MIMAT0002867 miR-520h 1.28 0.29 
MIMAT0002854 miR-521 -0.34 0.28 
MIMAT0002868 miR-522 0.05 0.31 
MIMAT0002840 miR-523 -1.29 0.24 
MIMAT0002850 miR-524 -0.79 0.18 
MIMAT0002849 miR-524* 0.88 0.53 
MIMAT0002838 miR-525 0.40 0.23 
MIMAT0002839 miR-525* -0.36 0.09 
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MIMAT0002845 miR-526a 0.12 0.32 
MIMAT0002835 miR-526b 0.35 0.14 
MIMAT0002836 miR-526b* 0.22 0.35 
MIMAT0002831 miR-526c -0.07 0.24 
MIMAT0002862 miR-527 0.41 0.45 
MIMAT0002888 miR-532 -4.14 0.61 
MIMAT0003163 miR-539 -0.16 0.44 
MIMAT0003389 miR-542-3p 1.30 0.48 
MIMAT0003340 miR-542-5p -1.15 0.41 
MIMAT0003164 miR-544 0.69 0.15 
MIMAT0003165 miR-545 0.06 0.61 
MIMAT0003251 miR-548a -0.25 0.62 
MIMAT0003254 miR-548b 0.46 0.08 
MIMAT0003285 miR-548c 0.48 0.38 
MIMAT0003323 miR-548d -0.03 0.42 
MIMAT0003333 miR-549 -0.41 0.56 
MIMAT0003257 miR-550 0.05 0.37 
MIMAT0003214 miR-551a 0.13 0.17 
MIMAT0003233 miR-551b -0.53 0.02 
MIMAT0003215 miR-552 0.97 0.28 
MIMAT0003216 miR-553 -1.55 0.33 
MIMAT0003217 miR-554 -0.26 0.21 
MIMAT0003219 miR-555 -1.21 0.23 
MIMAT0003220 miR-556 -0.62 0.22 
MIMAT0003221 miR-557 0.19 0.33 
MIMAT0003222 miR-558 0.57 0.26 
MIMAT0003223 miR-559 0.75 0.30 
MIMAT0003224 miR-560 0.48 0.27 
MIMAT0003225 miR-561 0.36 0.66 
MIMAT0003226 miR-562 -0.19 0.67 
MIMAT0003227 miR-563 0.90 0.70 
MIMAT0003228 miR-564 -0.21 0.55 
MIMAT0003229 miR-565 -0.80 0.10 
MIMAT0003230 miR-566 -0.33 0.21 
MIMAT0003231 miR-567 -0.65 0.48 
MIMAT0003232 miR-568 -0.20 0.22 
MIMAT0003234 miR-569 -0.50 0.20 
MIMAT0003235 miR-570 -0.22 0.51 
MIMAT0003236 miR-571 -0.38 0.27 
MIMAT0003237 miR-572 -0.25 0.17 
MIMAT0003238 miR-573 0.49 0.38 
MIMAT0003239 miR-574 -1.65 0.35 
MIMAT0003240 miR-575 0.34 0.20 
MIMAT0003241 miR-576 0.26 0.44 
MIMAT0003242 miR-577 0.24 0.22 
MIMAT0003243 miR-578 0.08 0.60 
MIMAT0003244 miR-579 -0.72 0.34 
MIMAT0003245 miR-580 0.12 0.32 
MIMAT0003246 miR-581 -0.01 0.32 
MIMAT0003247 miR-582 0.11 0.97 
MIMAT0003248 miR-583 0.70 0.35 
MIMAT0003249 miR-584 -0.55 0.33 
MIMAT0003250 miR-585 -1.00 0.66 
MIMAT0003252 miR-586 1.20 0.49 
MIMAT0003253 miR-587 0.72 0.10 
MIMAT0003255 miR-588 -0.14 0.61 
Accesion 
number in 
miRBase v9.2 
miRNA ID Z-score S.E.M. 
MIMAT0003256 miR-589 1.24 0.10 
MIMAT0003258 miR-590 0.70 0.61 
MIMAT0003259 miR-591 -0.57 0.46 
MIMAT0003260 miR-592 0.67 0.35 
MIMAT0003261 miR-593 -0.18 0.60 
MIMAT0003263 miR-595 1.68 0.14 
MIMAT0003264 miR-596 -1.03 0.04 
MIMAT0003265 miR-597 0.56 0.19 
MIMAT0003266 miR-598 0.09 0.23 
MIMAT0003267 miR-599 0.25 0.91 
MIMAT0003268 miR-600 -0.11 0.86 
MIMAT0003269 miR-601 0.26 0.29 
MIMAT0003270 miR-602 -0.52 0.28 
MIMAT0003271 miR-603 1.19 0.18 
MIMAT0003272 miR-604 -1.67 0.97 
MIMAT0003273 miR-605 -0.20 0.48 
MIMAT0003274 miR-606 0.78 0.31 
MIMAT0003275 miR-607 0.45 0.20 
MIMAT0003276 miR-608 -2.35 0.43 
MIMAT0003277 miR-609 0.29 0.37 
MIMAT0003278 miR-610 0.26 0.27 
MIMAT0003279 miR-611 0.40 0.28 
MIMAT0003280 miR-612 0.26 0.07 
MIMAT0003281 miR-613 -1.18 0.11 
MIMAT0003282 miR-614 -0.52 0.37 
MIMAT0003283 miR-615 -0.42 0.18 
MIMAT0003284 miR-616 0.05 0.16 
MIMAT0003286 miR-617 -0.52 0.23 
MIMAT0003287 miR-618 0.33 0.09 
MIMAT0003288 miR-619 0.05 0.11 
MIMAT0003289 miR-620 0.41 0.04 
MIMAT0003290 miR-621 0.61 0.79 
MIMAT0003291 miR-622 0.69 0.27 
MIMAT0003292 miR-623 0.07 0.31 
MIMAT0003293 miR-624 0.63 0.23 
MIMAT0003294 miR-625 -0.83 0.18 
MIMAT0003295 miR-626 -0.06 0.13 
MIMAT0003296 miR-627 0.29 0.14 
MIMAT0003297 miR-628 0.34 0.42 
MIMAT0003298 miR-629 0.58 0.33 
MIMAT0003299 miR-630 1.56 0.20 
MIMAT0003300 miR-631 -0.41 0.41 
MIMAT0003302 miR-632 0.45 0.21 
MIMAT0003303 miR-633 0.25 0.07 
MIMAT0003304 miR-634 -0.45 0.22 
MIMAT0003305 miR-635 0.56 0.22 
MIMAT0003306 miR-636 -0.51 0.10 
MIMAT0003307 miR-637 -3.20 0.14 
MIMAT0003308 miR-638 0.03 0.09 
MIMAT0003309 miR-639 -0.34 0.26 
MIMAT0003310 miR-640 0.36 0.18 
MIMAT0003311 miR-641 0.96 0.19 
MIMAT0003312 miR-642 0.49 0.08 
MIMAT0003313 miR-643 0.21 0.29 
MIMAT0003314 miR-644 0.56 0.42 
MIMAT0003315 miR-645 1.03 0.28 
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MIMAT0003316 miR-646 -0.53 1.20 
MIMAT0003317 miR-647 -2.15 0.12 
MIMAT0003318 miR-648 0.51 0.49 
MIMAT0003319 miR-649 0.07 0.19 
MIMAT0003320 miR-650 0.33 0.28 
MIMAT0003321 miR-651 0.45 0.49 
MIMAT0003322 miR-652 -0.43 0.09 
MIMAT0003328 miR-653 0.94 0.37 
MIMAT0003330 miR-654 -2.54 0.79 
MIMAT0003331 miR-655 0.80 0.06 
MIMAT0003332 miR-656 0.50 0.05 
MIMAT0003335 miR-657 0.42 0.10 
MIMAT0003336 miR-658 0.12 0.28 
MIMAT0003337 miR-659 0.17 0.12 
MIMAT0003338 miR-660 -0.01 0.66 
MIMAT0003324 miR-661 -0.69 0.29 
MIMAT0003325 miR-662 -0.63 0.56 
MIMAT0003326 miR-663 -1.83 0.37 
MIMAT0003881 miR-668 -1.46 0.12 
MIMAT0003880 miR-671 -0.61 0.33 
MIMAT0004284 miR-675 -1.11 0.26 
MIMAT0000252 miR-7 -0.11 0.08 
Accesion 
number in 
miRBase v9.2 
miRNA ID Z-score S.E.M. 
MIMAT0003879 miR-758 -0.35 0.50 
MIMAT0003945 miR-765 -2.09 0.52 
MIMAT0003888 miR-766 -0.11 0.76 
MIMAT0003883 miR-767-3p -0.38 0.22 
MIMAT0003882 miR-767-5p -0.01 0.20 
MIMAT0003947 miR-768-3p -0.08 0.10 
MIMAT0003946 miR-768-5p -0.20 0.21 
MIMAT0003887 miR-769-3p 0.01 0.17 
MIMAT0003886 miR-769-5p -1.28 0.71 
MIMAT0003948 miR-770-5p 0.55 0.41 
MIMAT0004209 miR-801 -1.12 0.39 
MIMAT0004185 miR-802 -0.05 0.17 
MIMAT0000441 miR-9 0.17 0.44 
MIMAT0000442 miR-9* 0.14 0.71 
MIMAT0000092 miR-92 -0.12 0.32 
MIMAT0003218 miR-92b 0.00 0.37 
MIMAT0000093 miR-93 0.12 0.21 
MIMAT0000094 miR-95 0.23 0.37 
MIMAT0000095 miR-96 -1.67 0.19 
MIMAT0000096 miR-98 -0.68 0.06 
MIMAT0000097 miR-99a -0.09 0.46 
MIMAT0000689 miR-99b -0.46 0.24 
 
 
Appendix II: Accession numbers and IDs of 113 mature human miRNAs that were 
detected in HeLa cells by expression profiling analysis. Microarrays were designed for profiling 
all miRNAs annotated in miRBase v14. Median-normalized expression levels (in linear scale) 
and standard errors of the mean (S.E.M.) are given. The median signal intensity of each 
microarray is adjusted to “1”. 
 
Accesion 
number in 
miRBase v14 
miRNA ID 
Expression 
level 
S.E.M 
MIMAT0000062 let-7a 97.68 4.15 
MIMAT0000063 let-7b 57.19 1.18 
MIMAT0000064 let-7c 16.45 0.62 
MIMAT0000065 let-7d 11.27 0.52 
MIMAT0000066 let-7e 12.00 0.29 
MIMAT0000067 let-7f 68.45 3.18 
MIMAT0000414 let-7g 17.72 0.89 
MIMAT0000415 let-7i 76.44 2.89 
MIMAT0000098 miR-100 8.85 0.27 
MIMAT0000099 miR-101 2.04 0.17 
MIMAT0000101 miR-103 8.27 0.34 
MIMAT0000680 miR-106b 13.65 0.89 
MIMAT0000104 miR-107 8.86 0.51 
MIMAT0005865 miR-1202 1.66 0.09 
MIMAT0005898 miR-1246 8.63 0.16 
MIMAT0000443 miR-125a-
5p 
4.05 0.09 
MIMAT0000423 miR-125b 21.14 0.92 
MIMAT0005911 miR-1260 44.10 3.29 
MIMAT0005927 miR-1274a 23.88 1.68 
MIMAT0005938 miR-1274b 153.88 10.82 
MIMAT0005946 miR-1280 3.02 0.19 
Accesion 
number in 
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S.E.M 
MIMAT0005880 miR-1290 1.17 0.05 
MIMAT0005893 miR-1305 1.22 0.07 
MIMAT0005947 miR-1308 1.17 0.09 
MIMAT0000425 miR-130a 10.14 0.48 
MIMAT0000691 miR-130b 2.42 0.09 
MIMAT0000448 miR-136 3.25 0.21 
MIMAT0000431 miR-140-5p 2.66 0.18 
MIMAT0000759 miR-148b 1.34 0.10 
MIMAT0000757 miR-151-3p 1.68 0.06 
MIMAT0004697 miR-151-5p 6.89 0.21 
MIMAT0000068 miR-15a 18.68 1.09 
MIMAT0000417 miR-15b 44.05 1.55 
MIMAT0000069 miR-16 36.33 1.58 
MIMAT0000070 miR-17 22.06 1.11 
MIMAT0000071 miR-17* 4.91 0.26 
MIMAT0000256 miR-181a 5.05 0.23 
MIMAT0000257 miR-181b 3.07 0.14 
MIMAT0000455 miR-185 1.26 0.07 
MIMAT0000072 miR-18a 3.56 0.23 
MIMAT0001412 miR-18b 1.22 0.08 
MIMAT0007892 miR-1915 1.81 0.13 
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MIMAT0000459 miR-193a-
3p 
5.41 0.37 
MIMAT0002819 miR-193b 14.62 0.79 
MIMAT0000226 miR-196a 6.49 0.32 
MIMAT0001080 miR-196b 1.64 0.07 
MIMAT0000227 miR-197 1.41 0.06 
MIMAT0009449 miR-1974 812.96 56.92 
MIMAT0009454 miR-1979 1.87 0.12 
MIMAT0000073 miR-19a 26.34 1.62 
MIMAT0000074 miR-19b 62.64 3.42 
MIMAT0000075 miR-20a 50.29 1.91 
MIMAT0001413 miR-20b 9.21 0.57 
MIMAT0000076 miR-21 1082.09 45.52 
MIMAT0004494 miR-21* 3.17 0.20 
MIMAT0000077 miR-22 36.57 1.54 
MIMAT0000278 miR-221 3.25 0.24 
MIMAT0000281 miR-224 8.29 0.54 
MIMAT0000078 miR-23a 85.07 5.22 
MIMAT0000418 miR-23b 21.34 1.17 
MIMAT0000080 miR-24 59.26 3.31 
MIMAT0000081 miR-25 7.80 0.26 
MIMAT0000082 miR-26a 3.13 0.20 
MIMAT0000083 miR-26b 2.95 0.15 
MIMAT0000084 miR-27a 114.31 6.11 
MIMAT0000419 miR-27b 33.99 1.67 
MIMAT0000085 miR-28-5p 2.11 0.14 
MIMAT0000086 miR-29a 16.87 0.91 
MIMAT0000100 miR-29b 14.17 0.88 
MIMAT0000681 miR-29c 2.15 0.14 
MIMAT0000688 miR-301a 4.29 0.21 
MIMAT0000087 miR-30a 16.33 0.94 
MIMAT0000088 miR-30a* 4.02 0.22 
MIMAT0000420 miR-30b 5.49 0.35 
MIMAT0000244 miR-30c 8.58 0.23 
MIMAT0000245 miR-30d 3.17 0.12 
MIMAT0000692 miR-30e 1.96 0.16 
MIMAT0000693 miR-30e* 1.30 0.06 
Accesion 
number in 
miRBase v14 
miRNA ID 
Expression 
level 
S.E.M 
MIMAT0000089 miR-31 7.76 0.67 
MIMAT0004504 miR-31* 11.31 0.61 
MIMAT0000510 miR-320a 2.26 0.11 
MIMAT0005792 miR-320b 5.95 0.28 
MIMAT0005793 miR-320c 6.14 0.33 
MIMAT0006764 miR-320d 9.12 0.37 
MIMAT0000762 miR-324-3p 4.39 0.29 
MIMAT0000761 miR-324-5p 2.51 0.08 
MIMAT0000760 miR-331-3p 3.59 0.19 
MIMAT0000091 miR-33a 1.84 0.16 
MIMAT0000753 miR-342-3p 1.35 0.04 
MIMAT0000255 miR-34a 9.06 0.49 
MIMAT0000703 miR-361-5p 2.85 0.11 
MIMAT0000710 miR-365 7.90 0.87 
MIMAT0000727 miR-374a 2.51 0.18 
MIMAT0000720 miR-376c 1.84 0.09 
MIMAT0000730 miR-377 1.62 0.09 
MIMAT0001341 miR-424 4.25 0.19 
MIMAT0003393 miR-425 1.71 0.10 
MIMAT0001635 miR-452 1.10 0.06 
MIMAT0004784 miR-455-3p 2.23 0.10 
MIMAT0003233 miR-551b 2.14 0.12 
MIMAT0003239 miR-574-3p 3.14 0.22 
MIMAT0004795 miR-574-5p 2.40 0.14 
MIMAT0003247 miR-582-5p 4.43 0.22 
MIMAT0003258 miR-590-5p 3.11 0.14 
MIMAT0004814 miR-654-3p 1.24 0.09 
MIMAT0005954 miR-720 491.34 17.46 
MIMAT0004906 miR-886-3p 33.14 2.64 
MIMAT0000092 miR-92a 15.84 0.80 
MIMAT0000093 miR-93 8.24 0.51 
MIMAT0000095 miR-96 4.71 0.21 
MIMAT0000096 miR-98 2.49 0.14 
MIMAT0000097 miR-99a 6.52 0.29 
MIMAT0000689 miR-99b 2.25 0.10 
 
 
Appendix III: Genes affected by overexpression of miR-17. An expression change cutoff 
values of -1.5 and 1.5 (in linear scale) corresponding to an adjusted p-value ≤ 0.05 were used as 
criteria to identify significantly downregulated and upregulated genes, respectively. Genes are 
listed from the most to the least affected according to the time point at which individual gene was 
identified as significantly deregulated for the first time. “Yes” indicates that gene is a predicted 
target of miR-17 by at least one of the three computational prediction programs (MicroCosm 
Targets v5, Diana-microT v3.0, TargetScanHuman release 5.2). 
(A) Genes downregulated by overexpressed miR-17 
 
Number 
Gene 
symbol 
Expression change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
1 TGFBR2 -2.00 -1.90  Yes NM_001024847.1 
2 DAZAP2 -1.92 -1.87  Yes NM_014764.2 
3 MICA -1.85 -1.71 -1.58 Yes NM_000247.1 
4 TBC1D2 -1.78 -1.95 -1.52 Yes NM_018421.2 
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target? 
Gene accession 
number 12h 24h 48h 
5 NKIRAS1 -1.75 -1.62  Yes NM_020345.3 
6 SQSTM1 -1.72 -1.67  Yes NM_003900.3 
7 NETO2 -1.72    NM_018092.3 
8 HDHD1A -1.69 -1.93   NM_012080.3 
9 FLJ31438 -1.69    NM_152385.1 
10 JAK1 -1.65 -2.00  Yes NM_002227.1 
11 CYBRD1 -1.63   Yes NM_024843.2 
12 IL6 -1.63 -2.12 -3.49  NM_000600.1 
13 TMEM64 -1.61   Yes NM_001008495.2 
14 RNH1 -1.60 -2.01 -1.56 Yes NM_203385.1 
15 FYCO1 -1.60 -1.68 -1.52 Yes NM_024513.1 
16 TNFRSF21 -1.59   Yes NM_014452.3 
17 FAM79A -1.59 -1.64   NM_182752.3 
18 TMEM9B -1.58 -1.57   NM_020644.1 
19 MKRN1 -1.57   Yes NM_013446.2 
20 FASTK -1.57   Yes NM_033015.2 
21 C2ORF29 -1.57    NM_017546.3 
22 ASAP2 -1.56 -1.65   NM_003887.1 
23 C21ORF25 -1.55 -1.61 -1.53 Yes NM_199050.1 
24 NLRP8 -1.55    NM_176811.2 
25 SLC28A1 -1.54    NM_201651.1 
26 KATNAL1 -1.54    NM_032116.3 
27 FNBP1L -1.53   Yes NM_017737.3 
28 KIF23 -1.53   Yes NM_004856.4 
29 PNKD -1.53 -1.56   NM_022572.2 
30 IRAK2 -1.53 -1.55 -1.87  NM_001570.3 
31 PSCD1 -1.53    NM_017456.2 
32 FBXO18 -1.52   Yes NM_032807.3 
33 ZFP91 -1.52   Yes NM_053023.2 
34 TNFRSF10B -1.51   Yes NM_003842.3 
35 LIMA1 -1.51   Yes NM_016357.3 
36 LOC205251 -1.50 -1.68   NM_174925.1 
37 C9ORF152  -1.87 -1.51  NM_001012993.1 
38 MT2A  -1.78   NM_005953.2 
39 FAM18B  -1.74   NM_016078.3 
40 DNAJB6  -1.72   NM_005494.2 
41 TNFAIP1  -1.71  Yes NM_021137.3 
42 EGR1  -1.69   NM_001964.2 
43 FAM46C  -1.65  Yes NM_017709.2 
44 ETS2  -1.64   NM_005239.4 
45 DNAJC12  -1.59 -1.54  NM_021800.2 
46 MRPL24  -1.59  Yes NM_024540.2 
47 OBFC2A  -1.59  Yes NM_022837.1 
48 CYR61  -1.58 -1.91  NM_001554.3 
49 WDR4  -1.57   NM_018669.4 
50 BIRC3  -1.54 -1.68  NM_001165.3 
51 M6PR  -1.53  Yes NM_002355.2 
52 WBSCR22  -1.53  Yes NM_017528.2 
53 DCPS  -1.52   NM_014026.3 
54 C9ORF40  -1.52  Yes NM_017998.1 
55 PFKP  -1.52  Yes NM_002627.3 
56 CASP1  -1.52   NM_033294.2 
57 MT1A  -1.51   NM_005946.2 
58 RAB32  -1.51   NM_006834.2 
59 EPAS1  -1.50   NM_001430.3 
60 KRT17   -2.11  NM_000422.1 
61 C1QTNF1   -1.97  NM_198594.1 
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62 C8ORF4   -1.93  NM_020130.2 
63 CCL20   -1.92  NM_004591.1 
64 S100P   -1.91  NM_005980.2 
65 SLC16A6   -1.86  NM_004694.2 
66 HSF2BP   -1.79  NM_007031.1 
67 MMP12   -1.74  NM_002426.2 
68 TMEM16B   -1.74  NM_020373.1 
69 TESC   -1.69 Yes NM_017899.1 
70 WDR69   -1.66  NM_178821.1 
71 IL32   -1.64  NM_001012633.1 
72 CA9   -1.64  NM_001216.1 
73 LDLR   -1.64 Yes NM_000527.2 
74 RGS2   -1.61  NM_002923.1 
75 CXCR7   -1.61  NM_001047841.1 
76 NKD2   -1.61  NM_033120.2 
77 GDF15   -1.59  NM_004864.1 
78 CMKOR1   -1.57  NM_020311.1 
79 WDR54   -1.57  NM_032118.2 
80 AOX1   -1.55  NM_001159.3 
81 CTGF   -1.53  NM_001901.2 
82 SRGN   -1.53  NM_002727.2 
83 ADAM9   -1.52 Yes NM_003816.2 
84 PITPNC1   -1.52  NM_181671.1 
85 SERPINB8   -1.52  NM_001031848.1 
86 C1S   -1.51  NM_001734.2 
87 MUC1   -1.51  NM_001018021.1 
88 TFPI   -1.51  NM_001032281.1 
89 KRT16   -1.51  NM_005557.2 
90 GNS   -1.51 Yes NM_002076.2 
 
 
(B) Genes upregulated by overexpressed miR-17 
 
Number 
Gene 
symbol 
Expression change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
1 BAT2D1 1.70 1.52   NM_015172.2 
2 PPIF 1.63    NM_005729.3 
3 ICMT 1.62   Yes NM_012405.2 
4 LOC285636 1.57 1.66   NM_175921.4 
5 PMM2 1.57 1.58   NM_000303.1 
6 ETF1 1.53   Yes NM_004730.1 
7 TSC22D3 1.53 1.75   NM_004089.3 
8 TMEM41A 1.52   Yes NM_080652.2 
9 UBE2O 1.51    NM_022066.2 
10 B4GALT4 1.50    NM_003778.3 
11 ARID3A  1.69   NM_005224.1 
12 SNRPC  1.66 1.60  NM_003093.1 
13 DDAH1  1.62   NM_012137.2 
14 GNB1  1.62   NM_002074.2 
15 SLC35A1  1.61   NM_006416.2 
16 PPM1B  1.60   NM_177968.2 
17 PSAT1  1.58  Yes NM_021154.3 
18 EML4  1.56   NM_019063.2 
19 TRIM2  1.56   NM_015271.2 
20 ARID5B  1.55   NM_032199.1 
21 SLC11A2  1.55   NM_000617.1 
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22 PLCXD1  1.54  Yes NM_018390.1 
23 CITED2  1.54   NM_006079.3 
24 ARPC4  1.54   NM_001024960.1 
25 TAC3   3.75  NM_001006667.1 
26 ACTA2   2.01  NM_001613.1 
27 KRT86   1.95  NM_002284.3 
28 KRTHB1   1.89  NM_002281.2 
29 OLFML1   1.86  NM_198474.2 
30 ALDH1A3   1.86  NM_000693.1 
31 SLC1A3   1.85  NM_004172.3 
32 CLCA2   1.84  NM_006536.4 
33 S100A4   1.77  NM_002961.2 
34 CRYAB   1.77  NM_001885.1 
35 SPINK4   1.77  NM_014471.1 
36 SNCG   1.64  NM_003087.1 
37 KRT8   1.63  NM_002273.2 
38 TNFSF9   1.62  NM_003811.2 
39 ZNF467   1.62  NM_207336.1 
40 LOC91461   1.61  NM_138370.1 
41 ENO3   1.60  NM_001976.2 
42 VAV3   1.60  NM_006113.4 
43 MGP   1.59  NM_000900.2 
44 SUSD2   1.58  NM_019601.3 
45 SLC12A3   1.55  NM_000339.1 
46 PPFIBP2   1.55  NM_003621.1 
47 FGFR3   1.55  NM_000142.2 
48 RPESP   1.53  NM_153225.2 
49 STEAP4   1.53  NM_024636.1 
50 GPR37   1.53  NM_005302.2 
51 TST   1.52  NM_003312.4 
52 SCNN1A   1.51  NM_001038.4 
53 VAMP5   1.51  NM_006634.2 
54 GAS1   1.51  NM_002048.1 
55 REEP6   1.51  NM_138393.1 
56 CRIP1   1.50  NM_001311.3 
 
 
Appendix IV: Genes affected by miR-517a. An expression change cutoff values of -1.5 
and 1.5 (in linear scale) corresponding to an adjusted p-value ≤ 0.01 were used as criteria to 
identify significantly downregulated and upregulated genes, respectively. Genes are listed from 
the most to the least affected according to the time point at which individual gene was identified 
as significantly deregulated for the first time. “Yes” indicates that gene is a predicted target of 
miR-517a by at least one of the three computational prediction programs (MicroCosm Targets v5, 
Diana-microT v3.0, TargetScanHuman release 5.2).   
(A) Genes downregulated by miR-517a 
 
Number Gene symbol 
Fold change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
1 EPDR1 -3.26 -6.06 -5.21  NM_017549.3 
2 STUB1 -3.13 -4.03 -3.90  NM_005861.2 
3 TNIP1 -2.73 -2.50 -1.91 Yes NM_006058.3 
4 DBN1 -2.64 -2.45 -2.13 Yes NM_004395.2 
5 CARM1 -2.61 -3.68 -3.84  NM_199141.1 
6 TOMM5 -2.58 -3.93 -4.59  NM_001001790.2 
7 TMEM30A -2.51 -2.15 -1.96  NM_018247.2 
Number Gene symbol 
Fold change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
8 PDXP -2.49 -3.52 -3.89  NM_020315.4 
9 SLC7A5 -2.45 -2.73 -2.42  NM_003486.5 
10 LOC390298 -2.45 -3.41 -2.56  XR_019644.1 
11 CDKN1C -2.45 -3.46 -3.03 Yes NM_000076.1 
12 NCLN -2.44 -2.46 -1.82  NM_020170.3 
13 NFIA -2.40 -2.65 -3.03  NM_005595.1 
14 ELFN2 -2.40 -2.02 -2.27 Yes NM_052906.3 
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15 AKIRIN1 -2.30 -1.95 -2.26 Yes NM_024595.1 
16 PTGES -2.25 -1.57  Yes NM_004878.3 
17 TIMM17B -2.24 -3.10 -2.37 Yes NM_005834.1 
18 CERK -2.23 -2.58 -2.45  NM_022766.4 
19 AP1S2 -2.21 -2.31 -2.02  NM_003916.3 
20 CABLES1 -2.18 -3.04 -2.45  NM_138375.1 
21 SLC3A2 -2.05 -1.91 -1.54  NM_001013251.1 
22 LOC730455 -2.03 -3.68 -3.34  XM_001125904.1 
23 PACS1 -2.01 -2.64 -2.36  NM_018026.2 
24 LOC100134182 -2.00  -1.53  XM_001715185.1 
25 KATNAL1 -1.99 -1.87 -1.67  NM_001014380.1 
26 NFIC -1.97 -1.72 -1.95  NM_205843.1 
27 RAB40B -1.95 -2.77 -2.95  NM_006822.1 
28 CDK2AP1 -1.93 -2.46 -1.98 Yes NM_004642.2 
29 NTAN1 -1.93 -3.35 -3.36  NM_173474.2 
30 TSKU -1.93 -1.57   NM_015516.3 
31 WDR45L -1.92 -2.06 -1.77 Yes NM_019613.2 
32 CDS2 -1.92 -2.63 -2.51  NM_003818.2 
33 MAPK6 -1.91 -2.03   NM_002748.2 
34 EFHD2 -1.90 -2.50 -1.89  NM_024329.4 
35 FAM189B -1.90 -3.00 -3.13  NM_006589.2 
36 CHRAC1 -1.89 -2.01 -1.97  NM_017444.3 
37 STK39 -1.83 -1.58 -1.72  NM_013233.2 
38 HYAL1 -1.82 -2.20 -2.04  NM_153282.1 
39 CBX6 -1.82 -1.97 -1.96  NM_014292.3 
40 UBR7 -1.81 -2.33 -2.57  NM_001100417.1 
41 TMEM87A -1.81    NM_015497.2 
42 ADAM9 -1.80 -2.39 -2.59  NM_003816.2 
43 ASB13 -1.80 -1.88 -1.60  NM_024701.2 
44 FOXJ3 -1.80 -2.14 -1.78 Yes NM_014947.3 
45 ETNK1 -1.79 -1.91 -1.53  NM_018638.4 
46 CTBP1 -1.79 -1.77 -1.81  NM_001328.2 
47 SEPHS1 -1.78 -2.20 -2.54 Yes NM_012247.3 
48 CSNK2A2 -1.78 -1.87 -1.80  NM_001896.2 
49 NUPL2 -1.78 -1.56 -1.79 Yes NM_007342.1 
50 ARCN1 -1.76 -1.71  Yes NM_001655.3 
51 CEP55 -1.75 -1.89 -3.58  NM_018131.3 
52 CSK -1.74 -1.85 -1.54  NM_004383.1 
53 C5ORF46 -1.74 -2.16 -3.39  NM_206966.2 
54 LOC100129828 -1.74 -1.77 -2.14  XM_001724980.1 
55 GRAMD1A -1.74 -1.71 -1.81 Yes NM_020895.2 
56 RAB35 -1.74  -1.57  NM_006861.4 
57 RAB40C -1.74 -1.53   NM_021168.2 
58 SLC6A9 -1.73 -1.62  Yes NM_001024845.1 
59 TOB1 -1.72 -1.69 -1.88  NM_005749.2 
60 METRNL -1.72    XM_941466.2 
61 AES -1.72 -2.99 -2.94  NM_001130.5 
62 USP1 -1.72 -2.02 -2.40 Yes NM_001017416.1 
63 C22ORF9 -1.71  -1.77  NM_015264.1 
64 YDJC -1.70 -2.35 -2.51  NM_001017964.1 
65 RPS23 -1.70 -1.72 -1.85   
66 C12ORF49 -1.70 -1.94 -1.88 Yes NM_024738.1 
67 TRAK1 -1.69    NM_014965.2 
68 DVL3 -1.69 -1.73 -1.83  NM_004423.3 
69 DOK4 -1.68 -1.99 -2.36  NM_018110.2 
70 MRRF -1.68 -2.59 -2.56 Yes NM_199177.1 
71 NFIB -1.68 -1.91 -2.77 Yes NM_005596.2 
Number Gene symbol 
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72 CCNK -1.67 -1.59  Yes NM_003858.3 
73 LRSAM1 -1.67 -1.59   NM_138361.3 
74 TSPYL6 -1.67    NM_001003937.2 
75 LYSMD2 -1.66 -2.11 -2.20  NM_153374.1 
76 PLAGL2 -1.64 -1.77 -1.99  NM_002657.2 
77 PSMF1 -1.64 -2.52 -2.75  NM_178579.1 
78 ZFAND6 -1.64 -1.77 -1.82  NM_019006.2 
79 FGFRL1 -1.64 -1.98 -1.98  NM_021923.3 
80 C20ORF11 -1.62 -1.95 -1.71  NM_017896.2 
81 TMEM203 -1.62 -2.01 -2.22  NM_053045.1 
82 C17ORF49 -1.62 -2.01 -2.33 Yes NM_174893.1 
83 SMYD3 -1.58 -1.87 -1.51 Yes NM_022743.1 
84 EPDR1  -6.06 -5.21  NM_017549.2 
85 LOC392437  -3.04 -1.95  XR_037197.1 
86 LPL  -2.75 -4.42  NM_000237.1 
87 UBP1  -2.45 -2.24  NM_014517.2 
88 ANKRD29  -2.36 -2.50  NM_173505.2 
89 VTI1B  -2.35 -2.15  NM_006370.1 
90 PANX2  -2.31   NM_052839.2 
91 GINS2  -2.31 -3.67  NM_016095.1 
92 RRP1B  -2.21 -2.07  NM_015056.1 
93 REEP5  -2.21 -2.06  NM_005669.3 
94 CDCA7L  -2.21 -2.27  NM_018719.2 
95 C4orf34  -2.20  Yes NM_174921.1 
96 CMBL  -2.18 -1.84  NM_138809.2 
97 LOC440731  -2.14 -2.42  XM_933693.1 
98 TMEM109  -2.11 -2.12  NM_024092.1 
99 CAP2  -2.10 -1.87 Yes NM_006366.2 
100 SLC25A23  -2.08 -2.41  NM_024103.2 
101 JPH1  -2.08 -2.12  NM_020647.2 
102 DYM  -2.06  Yes NM_017653.2 
103 GOLSYN  -2.06 -2.35  NM_017786.2 
104 SRM  -2.06 -1.58  NM_003132.2 
105 MUTED  -2.04 -1.99  NM_201280.1 
106 RPS6KA4  -2.01 -1.62  NM_003942.2 
107 KIAA1671  -2.01 -1.92  XM_371461.4 
108 C1orf43  -2.00 -1.59  NM_015449.1 
109 ZDHHC4  -2.00 -1.92  NM_018106.3 
110 FAM3A  -2.00 -2.08  NM_021806.1 
111 DCAF6  -1.99 -2.05  NM_018442.2 
112 ABHD14B  -1.97 -1.67   
113 WSB2  -1.96 -1.52  NM_018639.3 
114 RPLP1  -1.96 -2.89  NM_001003.2 
115 LOC728640  -1.95   XR_015400.1 
116 FREQ  -1.94   NM_014286.2 
117 NA  -1.93 -3.56  Hs.370359 
118 CYBASC3  -1.92 -1.54  NM_153611.3 
119 ARL5A  -1.92 -1.57  NM_012097.2 
120 SFRS1  -1.91 -1.93 Yes NM_006924.3 
121 RAC1  -1.91 -4.11  NM_018890.2 
122 USP13  -1.91 -2.67  NM_003940.1 
123 SDCBP  -1.90   NM_001007067.1 
124 HOXA10  -1.90 -1.99  NM_153715.1 
125 MYC  -1.89 -2.04 Yes NM_002467.3 
126 RUNX3  -1.89 -1.52  NM_004350.1 
127 LOC652685  -1.88   XM_942289.1 
128 PHF13  -1.87 -1.68 Yes NM_153812.1 
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129 TERF2  -1.87 -1.95  NM_005652.2 
130 KIF26A  -1.87   NM_015656.1 
131 TLN2  -1.87  Yes NM_015059.1 
132 FAM171A1  -1.87 -1.79  NM_001010924.1 
133 MARCKSL1  -1.86 -3.01  NM_023009.4 
134 B4GALT2  -1.85 -1.71  NM_001005417.1 
135 RIPK2  -1.84   NM_003821.4 
136 TNFRSF11B  -1.84 -3.80  NM_002546.2 
137 TCEAL1  -1.83 -1.85  NM_001006639.1 
138 SMU1  -1.82 -1.74  NM_018225.1 
139 SEPT11  -1.82 -2.36  NM_018243.2 
140 LOC647349  -1.82   NM_001284.2 
141 HOXC4  -1.82   NM_153633.1 
142 PARVB  -1.81 -1.83  NM_013327.3 
143 MGAT4B  -1.81 -1.52   
144 AGPAT3  -1.80   NM_020132.3 
145 LOC652233  -1.80 -2.62  XM_941627.1 
146 TMEM111  -1.80 -1.59 Yes NM_018447.1 
147 GOLGA8A  -1.80 -1.81  NM_181077.2 
148 LUZP1  -1.79 -1.72  NM_033631.2 
149 PPP6C  -1.79 -1.74  NM_002721.3 
150 PLEKHA9  -1.78 -1.51  NM_015899.1 
151 LOC653383  -1.78 -1.69  XM_927177.1 
152 IRAK1  -1.78 -2.20 Yes NM_001025243.1 
153 LYRM7  -1.77 -2.33  NM_181705.2 
154 BCAP31  -1.77 -1.75  NM_005745.6 
155 C6orf211  -1.77 -1.54  NM_024573.1 
156 PSME4  -1.76   NM_014614.1 
157 ABCD1  -1.76 -1.82  NM_000033.2 
158 EXOSC6  -1.76 -1.83  NM_058219.2 
159 PRUNE  -1.76 -1.67  NM_021222.1 
160 EI24  -1.75 -1.61  NM_004879.3 
161 TYSND1  -1.75 -3.11  NM_173555.1 
162 RAB26  -1.75 -2.98  NM_014353.4 
163 PABPC1L  -1.75 -1.99  XM_001722078.1 
164 KIF3B  -1.75 -1.66  NM_004798.2 
165 C8orf33  -1.75 -1.93  NM_023080.1 
166 LOC100134361  -1.75 -2.39  XM_001726827.1 
167 LOC283267  -1.75 -1.69  NR_015451.1 
168 CCNE1  -1.75 -1.89  NM_001238.1 
169 ALDH3A2  -1.74 -2.11  NM_001031806.1 
170 FANCE  -1.74   NM_021922.2 
171 FBXL16  -1.74   NM_153350.2 
172 IGF2R  -1.73   NM_000876.1 
173 PREPL  -1.73 -1.87  NM_006036.2 
174 TMEM5  -1.73 -2.42  NM_014254.1 
175 FLJ20674  -1.72 -2.02  NM_019086.2 
176 YAP1  -1.72 -1.71  NM_006106.2 
177 GDE1  -1.72 -1.70  NM_016641.3 
178 ELL2  -1.72   NM_012081.3 
179 CAMKK2  -1.71   NM_172215.1 
180 ALG3  -1.71 -1.62  NM_001006940.1 
181 CPSF4  -1.71 -1.89  NM_006693.1 
182 POLR1D  -1.71 -2.31  NM_015972.1 
183 EIF2C2  -1.71   NM_012154.2 
184 ATG10  -1.70 -1.65  NM_031482.3 
185 ICAM2  -1.70   NM_000873.2 
Number Gene symbol 
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186 WNT5A  -1.69 -2.39  NM_003392.3 
187 SNORD83B  -1.69 -1.94  NR_000028.1 
188 OLR1  -1.69   NM_002543.2 
189 PRMT6  -1.68 -1.60  NM_018137.1 
190 C17orf85  -1.68 -1.56  NM_018553.1 
191 HIST2H2AA4  -1.68 -2.98  NM_001040874.1 
192 ECEL1  -1.68 -2.13  NM_004826.1 
193 CCNJL  -1.68 -1.50  NM_024565.5 
194 JAG2  -1.68   NM_002226.3 
195 LOC389816  -1.68 -2.17  NM_001013653.1 
196 TTYH3  -1.67   NM_025250.2 
197 FBXO9  -1.67  Yes NM_033480.1 
198 LOC645781  -1.67   XM_933141.1 
199 FAM133B  -1.67 -1.98  NM_152789.2 
200 ALCAM  -1.67   NM_001627.2 
201 ARMC1  -1.66 -2.03  NM_018120.3 
202 STX11  -1.66   NM_003764.2 
203 DHX40  -1.66   NM_024612.3 
204 RBPMS2  -1.66 -1.75  NM_194272.1 
205 IFIT2  -1.66 -1.54  NM_001547.3 
206 KCTD12  -1.66 -1.85  NM_138444.2 
207 HPD  -1.66 -3.05  NM_002150.2 
208 TAF6  -1.66   NM_139122.1 
209 ATF1  -1.65 -1.91  NM_005171.2 
210 OBFC2A  -1.65 -1.53  NM_022837.1 
211 TMEM201  -1.65 -2.01  NM_001010866.1 
212 FNBP1  -1.65   NM_015033.2 
213 POLDIP2  -1.65 -1.83  NM_015584.2 
214 MAT2B  -1.65 -1.71  NM_182796.1 
215 URM1  -1.64   NM_030914.1 
216 C12orf65  -1.64 -1.60 Yes NM_152269.1 
217 SNX5  -1.64 -1.89  NM_152227.1 
218 STAC2  -1.64 -1.71  NM_198993.2 
219 CTSZ  -1.64 -2.06 Yes NM_001336.2 
220 PLD6  -1.64   NM_178836.2 
221 E2F2  -1.64 -1.93  NM_004091.2 
222 UROS  -1.64 -1.96  NM_000375.1 
223 LOC100129673  -1.64 -3.61  XM_001715544.1 
224 RYBP  -1.63 -1.99 Yes NM_012234.3 
225 ZNF783  -1.63   NM_001004302.2 
226 TTLL12  -1.63 -2.00  NM_015140.2 
227 AP3S1  -1.63   NM_001002924.1 
228 RPP25  -1.63 -1.59  NM_017793.1 
229 PVT1  -1.63 -2.14  XM_944465.1 
230 SLC6A10P  -1.62   NM_198857.1 
231 PLCD3  -1.62   NM_133373.2 
232 OPN3  -1.62 -2.05  NM_001030012.1 
233 MANSC1  -1.62 -1.70  NM_018050.2 
234 B3GALT6  -1.62   NM_080605.2 
235 RAPGEF2  -1.62 -1.56  NM_014247.2 
236 ACAA1  -1.62  Yes NM_001607.2 
237 LOC389641  -1.62 -1.68  XM_374260.3 
238 KIAA0101  -1.62 -3.00  NM_014736.4 
239 GOLGA8B  -1.62 -1.71  NM_001023567.2 
240 PDSS1  -1.62 -1.95  NM_014317.3 
241 OSBPL5  -1.62   NM_020896.2 
242 IFITM1  -1.62 -2.08 Yes NM_003641.2 
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243 SQRDL  -1.61   NM_021199.2 
244 TMEM150A  -1.61   NM_001031738.1 
245 MORF4L1  -1.61 -1.59  NM_006791.2 
246 NBEAL2  -1.61 -1.67  XM_941211.1 
247 LOC644033  -1.61 -1.93  XM_927280.1 
248 SNHG9  -1.61 -2.80  NR_003142.2 
249 LRRC26  -1.61 -2.11  XM_939320.1 
250 LOC653308  -1.61   XM_928675.1 
251 CDS1  -1.61   NM_001263.2 
252 SMG7  -1.61 -1.84 Yes NM_014837.3 
253 EIF2S3  -1.60   NM_001415.2 
254 BOLA1  -1.60 -1.85  NM_016074.1 
255 FANCG  -1.60 -2.63  NM_004629.1 
256 C3orf72  -1.60 -1.66  XM_376269.2 
257 SEC11A  -1.60 -1.51  NM_014300.2 
258 CXCR4  -1.60   NM_003467.2 
259 CSRP2BP  -1.60 -1.64  NM_020536.2 
260 HMOX1  -1.60   NM_002133.1 
261 ZNF581  -1.60   NM_016535.3 
262 POLR2D  -1.60   NM_004805.2 
263 HIST2H2AA3  -1.60 -3.00  NM_003516.2 
264 UHRF1BP1  -1.59   NM_017754.3 
265 LOC728715  -1.59 -1.94  XM_931759.1 
266 LOC100129866  -1.59 -1.53  XR_037532.1 
267 STOM  -1.59 -1.50  NM_004099.4 
268 FAM119B  -1.59 -1.55  NM_206914.1 
269 LOC286208  -1.59 -1.55  XM_379668.3 
270 ELAC2  -1.58 -2.17   
271 RFNG  -1.58  Yes NM_002917.1 
272 MGST1  -1.58  Yes NM_145792.1 
273 C1orf107  -1.58   NM_014388.5 
274 TXNRD1  -1.58   NM_182743.1 
275 CTSC  -1.58   NM_001814.2 
276 LOC440927  -1.58 -1.68  XM_944816.1 
277 C9orf46  -1.57   NM_018465.1 
278 CNN2  -1.57 -2.33  NM_201277.1 
279 LOC729887  -1.57 -2.36  XR_040891.1 
280 JDP2  -1.57   NM_130469.2 
281 FLJ11235  -1.57 -1.75  XR_000626.1 
282 DAB2  -1.57 -1.62  NM_001343.1 
283 CPNE8  -1.57 -1.85  NM_153634.2 
284 LOC648526  -1.56 -1.64  XM_937579.1 
285 LOC90624  -1.56 -1.64  NM_181705.1 
286 ZIC2  -1.56 -1.66  NM_007129.2 
287 HIST2H2AC  -1.56 -3.25  NM_003517.2 
288 MEIS2  -1.56 -1.85  NM_020149.2 
289 FLJ20021  -1.56   XM_028217.4 
290 MCOLN2  -1.55 -1.95  NM_153259.2 
291 CPA4  -1.55 -1.94  NM_016352.2 
292 LOC100129028  -1.55 -1.88  XM_001722134.1 
293 SLC6A8  -1.55   NM_005629.1 
294 CCDC92  -1.55 -1.53  NM_025140.1 
295 PGAM5  -1.55 -1.80  XM_942043.1 
296 CLIC4  -1.55   NM_013943.1 
297 SNORA10  -1.55 -1.90  NR_002327.1 
298 LOC407835  -1.55   NR_002144.1 
299 WRB  -1.55 -1.84  NM_004627.2 
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300 ILF3  -1.55 -1.66  NM_004516.2 
301 GJC2  -1.55   NM_020435.2 
302 RPL17  -1.55   NM_000985.2 
303 HSPB3  -1.54 -2.33  NM_006308.1 
304 GRPEL1  -1.54 -1.95  NM_025196.2 
305 CNRIP1  -1.54 -1.74  NM_015463.2 
306 HDAC4  -1.54   NM_006037.2 
307 F12  -1.54   NM_000505.2 
308 RNF41  -1.54   NM_194359.1 
309 PKP3  -1.54   NM_007183.2 
310 ACY1  -1.54   NM_000666.1 
311 TRIM23  -1.54   NM_001656.3 
312 TMEM64  -1.54   NM_001008495.2 
313 DNAJB4  -1.54   NM_007034.3 
314 ADCY9  -1.54   NM_001116.2 
315 ANKRD10  -1.53   NM_017664.2 
316 RRM2  -1.53 -2.06  NM_001034.1 
317 DUS3L  -1.53 -1.60  NM_020175.1 
318 EMR2  -1.53 -1.53  NM_152916.1 
319 SULT1A3  -1.53  Yes NM_001017389.1 
320 SNHG4  -1.53 -3.16  NM_199189.1 
321 TTC9C  -1.53 -1.53 Yes NM_173810.3 
322 ARF3  -1.53   NM_001659.1 
323 LOC401397  -1.53   Hs.117929 
324 KITLG  -1.53 -1.54  NM_000899.3 
325 TEAD4  -1.53 -1.95  NM_201441.1 
326 LOC645236  -1.53 -1.62  XM_928275.1 
327 TCEA3  -1.53 -2.31  NM_003196.1 
328 FKBP4  -1.53 -1.97  NM_002014.2 
329 FAR2  -1.53   NM_018099.3 
330 BLCAP  -1.53   NM_006698.2 
331 MT1E  -1.52   NM_175617.3 
332 CDC42SE2  -1.52   NM_001038702.1 
333 KIF1C  -1.52 -1.61  NM_006612.3 
334 ATN1  -1.52 -1.97  NM_001007026.1 
335 TXNDC15  -1.52   NM_024715.2 
336 MYO9B  -1.52   NM_004145.2 
337 GLS  -1.52   NM_014905.2 
338 KCTD14  -1.52 -1.55  NM_023930.2 
339 BFAR  -1.52    
340 ITGA2  -1.52   NM_002203.2 
341 UBAP2  -1.52  Yes NM_018449.2 
342 FOXC1  -1.52   NM_001453.1 
343 INPPL1  -1.52  Yes NM_001567.2 
344 ITPRIPL2  -1.51 -1.93  XM_943094.1 
345 RALGAPA1  -1.51 -1.91  NM_194301.2 
346 PDPR  -1.51   NM_017990.3 
347 ZNF514  -1.51   NM_032788.1 
348 FJX1  -1.51 -2.26  NM_014344.2 
349 PPL  -1.51 -2.22  NM_002705.3 
350 VAMP2  -1.51 -1.99  NM_014232.1 
351 C5orf25  -1.51 -1.77  NM_198567.1 
352 YWHAZ  -1.51 -1.75  NM_003406.2 
353 LOC340274  -1.51   XR_017256.2 
354 SLC25A19  -1.51 -1.79 Yes  
355 NARS2  -1.51 -1.54  NM_024678.3 
356 HNRNPU  -1.51 -2.38 Yes NM_031844.2 
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357 SACS  -1.51   NM_014363.3 
358 NCRNA00152  -1.51 -1.80  NR_024204.1 
359 ANAPC7  -1.51   NM_016238.1 
360 DLX1  -1.51 -1.50  NM_178120.3 
361 PRKAR1B  -1.50   NM_002735.1 
362 SLC25A40  -1.50   NM_018843.2 
363 MGC61598  -1.50 -1.99  XM_939432.1 
364 PTGFRN  -1.50 -2.02  NM_020440.2 
365 C13orf25  -1.50 -2.08  XM_931068.1 
366 SEMA4D  -1.50 -1.62  NM_006378.2 
367 DIP2A  -1.50   NM_015151.2 
368 PEX5  -1.50   NM_000319.3 
369 CCL2   -3.07  NM_002982.3 
370 PLAC8   -2.90  NM_016619.1 
371 H2AFJ   -2.84  NM_177925.2 
372 AOX1   -2.81  NM_001159.3 
373 MATR3   -2.70  NM_199189.1 
374 LOC440957   -2.68  NM_001124767.1 
375 TNS3   -2.64  NM_022748.10 
376 NMU   -2.64  NM_006681.1 
377 HIST2H4A   -2.59  NM_003548.2 
378 EBPL   -2.58  NM_032565.2 
379 C18orf56   -2.53  NM_001012716.1 
380 PRR11   -2.46  NM_018304.2 
381 CD83   -2.44 Yes NM_004233.3 
382 CRB1   -2.40  NM_201253.1 
383 SNORD80   -2.40  NR_003940.1 
384 HIST3H2A   -2.40  NM_033445.2 
385 MOSC1   -2.39 Yes NM_022746.2 
386 PEG10   -2.37  NM_001040152.1 
387 MAPKAP1   -2.36  NM_001006618.1 
388 NUSAP1   -2.35  NM_018454.5 
389 RPL39L   -2.34  NM_052969.1 
390 FAM179A   -2.31  NM_199280.2 
391 HIST1H2AC   -2.28  NM_003512.3 
392 STMN1   -2.27  NM_203401.1 
393 ACYP1   -2.27  NM_001107.3 
394 TMOD1   -2.27  NM_003275.2 
395 FOXM1   -2.25  NM_021953.2 
396 MYLIP   -2.23  NM_013262.3 
397 DHFR   -2.23 Yes NM_000791.3 
398 DHRS11   -2.21  NM_024308.3 
399 IFIT1   -2.20  NM_001548.3 
400 AFAP1   -2.20 Yes NM_021638.4 
401 AGMAT   -2.20  NM_024758.3 
402 FBL   -2.20  NM_001436.2 
403 NME1   -2.18  NM_198175.1 
404 HIST1H1C   -2.18  NM_005319.3 
405 ADCY3   -2.17  NM_004036.3 
406 AGAP3   -2.17  NM_001042535.1 
407 SCARA3   -2.17  NM_016240.2 
408 CENPA   -2.15  NM_001042426.1 
409 ZNF548   -2.14  NM_152909.2 
410 KIF11   -2.14  NM_004523.2 
411 CRISPLD2   -2.14  NM_031476.2 
412 CSTF3   -2.12  NM_001033506.1 
413 LARP6   -2.12 Yes NM_197958.1 
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414 FAM81A   -2.12  NM_152450.2 
415 CENPM   -2.11  NM_001002876.1 
416 CDC2   -2.10  NM_001786.2 
417 CALML4   -2.09  NM_001031733.1 
418 COBL   -2.08  NM_015198.2 
419 SKP2   -2.08  NM_005983.2 
420 TPR   -2.08  NM_003292.2 
421 FERMT2   -2.07  NM_006832.1 
422 C7orf11   -2.07  NM_138701.1 
423 LOC729217   -2.07  XR_015614.2 
424 ID1   -2.07  NM_181353.1 
425 EXO1   -2.06  NM_006027.3 
426 TACSTD1   -2.06  NM_002354.1 
427 HIST1H2BG   -2.05 Yes NM_003518.3 
428 BOP1   -2.05  NM_015201.3 
429 TTF2   -2.05  NM_003594.3 
430 HIST2H4B   -2.04  NM_001034077.4 
431 TUBD1   -2.04  NM_016261.2 
432 SFRS7   -2.03  NM_001031684.1 
433 ASF1B   -2.03  NM_018154.2 
434 PARD6A   -2.03  NM_001037281.1 
435 SNHG3-RCC1   -2.03  NM_001048197.1 
436 COQ2   -2.03 Yes NM_015697.6 
437 RAD51C   -2.03  NM_002876.2 
438 ADAMTS8   -2.03  NM_007037.3 
439 TPM2   -2.02  NM_003289.3 
440 CENPK   -2.01  NM_022145.3 
441 SPC24   -2.01  NM_182513.1 
442 C9orf103   -2.01  NM_001001551.1 
443 ASPM   -2.01  NM_018136.3 
444 NR2F1   -2.01  NM_005654.4 
445 OLFM1   -2.01  NM_006334.3 
446 AGBL5   -2.00  NM_001035507.2 
447 FARP1   -2.00  NM_005766.2 
448 DIS3L   -2.00  NM_133375.2 
449 ALDH5A1   -1.99  NM_001080.3 
450 LDLR   -1.99  NM_000527.2 
451 LHX2   -1.99  NM_004789.3 
452 C21orf58   -1.98  NM_199071.2 
453 CTDSPL2   -1.97  NM_016396.2 
454 PNN   -1.97  NM_002687.3 
455 HIST1H3G   -1.96  NM_003534.2 
456 RNU1G2   -1.95  NR_004426.1 
457 SNRPD3   -1.95  NM_004175.3 
458 LOC388564   -1.95  XM_498725.3 
459 DIO2   -1.95  NM_001007023.2 
460 SLC1A3   -1.95  NM_004172.3 
461 PDE7B   -1.94  NM_018945.3 
462 IGSF10   -1.94  NM_178822.3 
463 GTSE1   -1.94  NM_016426.4 
464 FUBP1   -1.94  NM_003902.3 
465 FAH   -1.94  NM_000137.1 
466 SERPINI1   -1.93  NM_005025.3 
467 UNG   -1.93  NM_003362.2 
468 MCM10   -1.93  NM_018518.3 
469 PHF19   -1.93  NM_001009936.1 
470 LOC387841   -1.92  XM_932678.1 
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471 PIF1   -1.92  NM_025049.2 
472 WNT10B   -1.91  NM_003394.2 
473 RPL8   -1.91  NM_033301.1 
474 APOA1BP   -1.91  NM_144772.1 
475 TACC3   -1.91  NM_006342.1 
476 C21orf34   -1.91  NM_001005734.1 
477 FLJ35934   -1.91  NM_207453.1 
478 LOC731049   -1.91  XM_001129232.1 
479 MYO5C   -1.91  NM_018728.2 
480 OGG1   -1.91  NM_002542.4 
481 FAM72D   -1.90  NM_207418.2 
482 LOC644254   -1.90  XM_932079.1 
483 SLC16A10   -1.90  NM_018593.3 
484 MND1   -1.90  NM_032117.2 
485 METTL7A   -1.89  NM_014033.3 
486 TRIM7   -1.89  NM_033342.2 
487 C20orf72   -1.89  NM_052865.2 
488 LOC652235   -1.89  XM_941629.1 
489 NCRNA00085   -1.89  NR_024330.1 
490 PSRC1   -1.89  NM_001032290.1 
491 KRT13   -1.88  NM_002274.3 
492 SNCA   -1.88  NM_007308.1 
493 SNORD36A   -1.88  NR_002448.1 
494 CHAF1B   -1.88  NM_005441.2 
495 AGXT2L1   -1.88  NM_031279.2 
496 PAFAH1B3   -1.87  NM_002573.2 
497 AK2   -1.87  NM_001625.2 
498 SLC27A2   -1.87  NM_003645.2 
499 HIST2H2AB   -1.87  NM_175065.2 
500 RNU1-5   -1.87  NR_004400.1 
501 DDX54   -1.87  NM_024072.3 
502 PPIL5   -1.87 Yes NM_203467.1 
503 ZNF787   -1.87  NM_001002836.2 
504 RNF212   -1.87  NM_194439.1 
505 GCHFR   -1.87  NM_005258.2 
506 CCNB1   -1.87  NM_031966.2 
507 FAM133A   -1.87  NM_173698.1 
508 LOC100130506   -1.86  XM_001724500.1 
509 LOC730101   -1.86  NR_024403.1 
510 LMNB1   -1.86  NM_005573.2 
511 GPATCH4   -1.85  NM_182679.1 
512 TMEM56   -1.85  NM_152487.1 
513 NRG4   -1.85  NM_138573.2 
514 SLC27A5   -1.85  NM_012254.1 
515 BCAT2   -1.85  NM_001190.2 
516 VAMP1   -1.85  NM_199245.1 
517 EFHD1   -1.85  NM_025202.2 
518 TRAP1   -1.85  NM_016292.1 
519 CDCA3   -1.84  NM_031299.3 
520 CHAC2   -1.84  NM_001008708.1 
521 RDM1   -1.83  NM_001034836.1 
522 CAMK1D   -1.83  NM_153498.2 
523 LOC143543   -1.83  NR_002197.1 
524 LOC100133328   -1.83  XR_038620.1 
525 C11orf83   -1.83  NM_001085372.1 
526 DPM3   -1.83  NM_153741.1 
527 ATRIP   -1.83  NM_032166.2 
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528 GSTM1   -1.83  NM_000561.2 
529 C6orf176   -1.83  XR_017929.2 
530 KIF2C   -1.82  NM_006845.2 
531 MCM3APAS   -1.82  NR_002776.1 
532 LOC401152   -1.82  NM_001001701.1 
533 CXorf61   -1.82  NM_001017978.1 
534 RAD51AP1   -1.82  NM_006479.3 
535 NMB   -1.82  NM_021077.3 
536 HIST1H2AG   -1.82  NM_021064.3 
537 LOC100130921   -1.82  XM_001723862.1 
538 LOC541471   -1.82  XR_001013.1 
539 PDE8B   -1.81  NM_001029851.1 
540 C1orf135   -1.81  NM_024037.1 
541 KIAA0114   -1.81  NR_024031.1 
542 HIST2H2BE   -1.80  NM_003528.2 
543 NUP62CL   -1.80  NM_017681.1 
544 TROAP   -1.80  NM_005480.2 
545 C19orf48   -1.80  NM_199250.1 
546 ANKRD32   -1.80  NM_032290.2 
547 CDK6   -1.80  NM_001259.5 
548 LOC653610   -1.80  XM_928387.1 
549 PAK2   -1.80  XM_001126110.1 
550 LOC93622   -1.79  XR_017952.1 
551 ZDHHC3   -1.79  NM_016598.1 
552 LYAR   -1.79  NM_017816.1 
553 NR2C2AP   -1.79  NM_176880.4 
554 TUB   -1.79  NM_177972.1 
555 BZW2   -1.79  NM_014038.1 
556 IMPDH2   -1.78  NM_000884.2 
557 LOC645726   -1.78  XR_018230.2 
558 MSH5   -1.78  NM_172166.2 
559 C9orf140   -1.78  NM_178448.2 
560 HAUS4   -1.78  NM_017815.1 
561 SMOC1   -1.78  NM_001034852.1 
562 SRRM4   -1.78  NM_194286.2 
563 LOC653820   -1.78  XM_930579.2 
564 MEGF9   -1.78  NM_001080497.1 
565 LXN   -1.77  NM_020169.2 
566 POLA1   -1.77  NM_016937.2 
567 PRDX3   -1.77  NM_006793.2 
568 BRCA1   -1.77  NM_007299.2 
569 ANXA2   -1.77  NM_001002857.1 
570 DSCC1   -1.77  NM_024094.1 
571 ZNF556   -1.77  NM_024967.1 
572 DCTPP1   -1.77  NM_024096.1 
573 CENPF   -1.77  NM_016343.3 
574 PLCXD1   -1.76  NM_018390.2 
575 LOC346887   -1.76  XM_943533.1 
576 ASB9   -1.76  NM_024087.1 
577 RFK   -1.76  NM_018339.3 
578 INPP5E   -1.76  NM_019892.3 
579 GPR37   -1.75  NM_005302.2 
580 LOC651816   -1.75  XM_941060.1 
581 RAD54L   -1.75 Yes NM_003579.2 
582 UGT8   -1.75  NM_003360.2 
583 SMC2   -1.75  NM_001042550.1 
584 IL17RB   -1.75  NM_018725.3 
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585 CDC45L   -1.75  NM_003504.3 
586 KRT18P13   -1.75  XM_001726959.1 
587 NGEF   -1.75 Yes NM_019850.1 
588 HIST1H2BD   -1.74  NM_138720.1 
589 PDE12   -1.74  NM_177966.4 
590 C1orf86   -1.74  NM_182533.1 
591 HPDL   -1.74  NM_032756.2 
592 IMPA2   -1.74  NM_014214.1 
593 VAV3   -1.74  NM_006113.4 
594 MESP1   -1.74  NM_018670.2 
595 PTP4A1   -1.74  NM_003463.3 
596 PUS7   -1.74  NM_019042.3 
597 DFFA   -1.74  NM_004401.2 
598 RACGAP1   -1.73  NM_013277.2 
599 PRMT3   -1.73  NM_005788.1 
600 CDCA7   -1.73  NM_031942.4 
601 HSPC111   -1.73  NM_016391.3 
602 EPCAM   -1.73  NM_002354.2 
603 MRI1   -1.73  NM_001031727.2 
604 RNU1-3   -1.73  NR_004408.1 
605 SUV39H1   -1.72  NM_003173.2 
606 HIST1H3H   -1.72  NM_003536.2 
607 C5orf36   -1.72  NM_173665.1 
608 HN1   -1.72 Yes NM_016185.2 
609 KDELC2   -1.72  NM_153705.4 
610 DUT   -1.72  NM_001025248.1 
611 KIF15   -1.72  NM_020242.1 
612 SLC16A14   -1.72  NM_152527.3 
613 TMEM106C   -1.72  NM_024056.2 
614 RCCD1   -1.72  NM_001017919.1 
615 KIAA1688   -1.72  NM_025251.1 
616 CHCHD7   -1.72  NM_001011671.1 
617 BICD2   -1.72  NM_001003800.1 
618 APOBEC3B   -1.71  NM_004900.3 
619 C7orf55   -1.71  NM_197964.3 
620 HSDL2   -1.71 Yes NM_032303.3 
621 ABL1   -1.71  NM_007313.2 
622 MNS1   -1.71  NM_018365.1 
623 OSR2   -1.71  XM_001126824.1 
624 SSBP3   -1.71  NM_018070.3 
625 RBM4   -1.71 Yes NM_002896.2 
626 LOC727761   -1.71  XM_001126211.1 
627 NHP2   -1.71  NM_001034833.1 
628 LOC100128191   -1.71  XM_001718586.1 
629 LSM5   -1.71  NM_012322.1 
630 IL7R   -1.71  XM_937367.1 
631 DBNDD1   -1.71  NM_001042610.1 
632 ADD3   -1.71  NM_016824.3 
633 NR4A2   -1.71  NM_006186.2 
634 C15orf23   -1.71  NM_033286.2 
635 ZWINT   -1.71  NM_001005413.1 
636 CCDC34   -1.70  NM_030771.1 
637 IFI44   -1.70  NM_006417.3 
638 H1FX   -1.70  NM_006026.2 
639 HIST1H3F   -1.70  NM_021018.2 
640 MGC3731   -1.69  NM_024313.1 
641 ADAP2   -1.69  NM_018404.2 
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642 MKI67   -1.69  NM_002417.3 
643 C5orf34   -1.69  NM_198566.1 
644 ESPL1   -1.69  NM_012291.4 
645 ANLN   -1.69  NM_018685.2 
646 GSTT2   -1.69  NM_000854.2 
647 NCAPG   -1.69  NM_022346.3 
648 RAVER2   -1.69  NM_018211.2 
649 FAM107B   -1.69  NM_031453.2 
650 ABCA7   -1.69  NM_019112.3 
651 NOP56   -1.69  NM_006392.2 
652 C13orf3   -1.69  NM_145061.3 
653 OIP5   -1.69  NM_007280.1 
654 C16orf53   -1.69  NM_024516.2 
655 CSE1L   -1.69 Yes NM_177436.1 
656 TMEM47   -1.69  NM_031442.2 
657 PTBP2   -1.69  NM_021190.1 
658 FHL1   -1.69  NM_001449.3 
659 FBXO43   -1.68  NM_001029860.2 
660 ZNF207   -1.68  NM_001032293.2 
661 THOP1   -1.68  NM_003249.3 
662 DCXR   -1.68  NM_016286.2 
663 LOC442727   -1.68  XR_017503.2 
664 NRM   -1.68  NM_007243.1 
665 PTCD1   -1.68  NM_015545.2 
666 ETS2   -1.68  NM_005239.4 
667 URB2   -1.68  NM_014777.2 
668 RNU11   -1.68  NR_004407.1 
669 CCNF   -1.68  NM_001761.1 
670 NOTCH2NL   -1.68  NM_203458.3 
671 FAM86A   -1.68  NM_201598.1 
672 NTHL1   -1.68  NM_002528.4 
673 PSMG4   -1.68  NM_001128591.1 
674 LOC650029   -1.68  XM_941861.1 
675 SLC25A15   -1.68  NM_014252.1 
676 LOC100131735   -1.68  XR_038716.1 
677 CDC25B   -1.68  NM_004358.3 
678 CCNO   -1.68  NM_021147.3 
679 CCDC74B   -1.68  NM_207310.1 
680 PPA2   -1.68  NM_176866.2 
681 MGP   -1.68  NM_000900.2 
682 KLHDC8B   -1.67  NM_173546.1 
683 DHRS4   -1.67  NM_021004.2 
684 BCL7C   -1.67  NM_004765.2 
685 ABCB10   -1.67  NM_012089.1 
686 NUDT3   -1.67 Yes NM_006703.2 
687 SHROOM3   -1.67  NM_020859.3 
688 LOC100128221   -1.67  XM_001713928.1 
689 UHRF1   -1.67  NM_001048201.1 
690 CCDC14   -1.67  NM_022757.3 
691 LOC729421   -1.67  XM_001133682.1 
692 PMS2L4   -1.67  NR_022007.1 
693 CTSL2   -1.67 Yes NM_001333.2 
694 CENPE   -1.67  NM_001813.2 
695 CCDC152   -1.66  NM_001134848.1 
696 C17orf90   -1.66  NM_001039842.1 
697 C12orf24   -1.66  NM_013300.1 
698 HIST1H4K   -1.66   
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699 ERCC1   -1.66  NM_001983.2 
700 MXD3   -1.66  NM_031300.2 
701 C17orf89   -1.66  NM_001086521.1 
702 TAP2   -1.66  NM_000544.3 
703 MCM3   -1.66  NM_002388.3 
704 PMS2   -1.66  NR_003085.1 
705 C16orf59   -1.66  NM_025108.2 
706 PLK4   -1.66  NM_014264.3 
707 LOC399959   -1.66  NR_024430.1 
708 RFXAP   -1.66  NM_000538.2 
709 BUB1B   -1.66  NM_001211.4 
710 KIF18A   -1.66  NM_031217.2 
711 PLK1   -1.66  NM_005030.3 
712 LOC345041   -1.66  XR_038458.1 
713 PDDC1   -1.66  NM_182612.1 
714 CTNNAL1   -1.65  NM_003798.1 
715 ATOH8   -1.65  NM_032827.4 
716 FBXO5   -1.65  NM_012177.2 
717 CNKSR3   -1.65  NM_173515.2 
718 RFWD3   -1.65  NM_018124.3 
719 LOC100133747   -1.65  XM_001719129.1 
720 SURF2   -1.65  NM_017503.2 
721 AMOT   -1.65  NM_133265.2 
722 C12orf48   -1.65  NM_017915.2 
723 RFC1   -1.65  NM_002913.3 
724 RFC3   -1.65  NM_002915.3 
725 CMTM4   -1.65  NM_181521.2 
726 ACOT4   -1.65  NM_152331.2 
727 LOC643918   -1.65  XM_933328.1 
728 SAC3D1   -1.65  NM_013299.3 
729 NCAPG2   -1.65  NM_017760.5 
730 POLR1E   -1.65  NM_022490.1 
731 C21orf51   -1.65  NM_001042401.1 
732 FANCI   -1.65  NM_018193.2 
733 RRP1   -1.64  NM_003683.5 
734 ZNF121   -1.64  NM_001008727.1 
735 CHAF1A   -1.64  NM_005483.2 
736 BTF3   -1.64  NM_001037637.1 
737 RNU1F1   -1.64  NR_004402.1 
738 LOC100128266   -1.64  XR_037888.1 
739 ISL1   -1.64 Yes NM_002202.1 
740 LOC100131609   -1.64  XR_038433.1 
741 NICN1   -1.64  NM_032316.3 
742 TGIF2   -1.64  NM_021809.5 
743 BARD1   -1.64 Yes NM_000465.1 
744 dJ222E13.2   -1.64  NR_002184.1 
745 ADRA2A   -1.64  NM_000681.2 
746 PSMB10   -1.64  NM_002801.2 
747 ASTE1   -1.64  NM_014065.2 
748 SHQ1   -1.64  NM_018130.2 
749 PA2G4   -1.64  NM_006191.2 
750 FABP5L2   -1.63  XM_001134012.2 
751 WDR4   -1.63 Yes NM_033661.3 
752 ZBTB22   -1.63  NM_005453.3 
753 BID   -1.63  NM_197966.1 
754 TMX4   -1.63  NM_021156.2 
755 PALM2   -1.63  NM_001037293.1 
Number Gene symbol 
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756 UCP2   -1.62  NM_003355.2 
757 NSBP1   -1.62  NM_030763.1 
758 CCDC88C   -1.62  NM_001080414.2 
759 EFCAB4A   -1.62  NM_173584.3 
760 LAMA3   -1.62  NM_198129.1 
761 DAZAP1   -1.62  NM_170711.1 
762 ZNF789   -1.62  NM_213603.2 
763 TRIM5   -1.62  NM_033093.1 
764 C10orf2   -1.62  NM_021830.3 
765 ACN9   -1.62  NM_020186.1 
766 RBM12B   -1.62  NM_203390.2 
767 TUBGCP4   -1.62  NM_014444.2 
768 NAAA   -1.62  NM_014435.3 
769 MAST4   -1.62  NM_198828.2 
770 NUFIP1   -1.62  NM_012345.1 
771 SNAPC5   -1.62  NM_006049.2 
772 C14orf167   -1.62  NR_023921.1 
773 RBMX   -1.62  NM_002139.2 
774 CENPQ   -1.61  NM_018132.3 
775 SNHG6   -1.61  NR_002599.1 
776 MGC27348   -1.61  XM_171158.5 
777 C9orf10OS   -1.61  NM_198841.1 
778 LRP3   -1.61  NM_002333.1 
779 RANBP1   -1.61  NM_002882.2 
780 TOMM40   -1.61  NM_006114.1 
781 SYT15   -1.61  NM_181519.2 
782 MTCP1   -1.61  NM_014221.3 
783 APEX1   -1.61  NM_080649.1 
784 HADH   -1.61  NM_005327.2 
785 NME4   -1.61  NM_005009.2 
786 TRAFD1   -1.61  NM_006700.1 
787 SCG2   -1.61  NM_003469.3 
788 DEPDC1B   -1.61  NM_018369.1 
789 LRRN2   -1.61  NM_201630.1 
790 GEMIN4   -1.61  NM_015721.2 
791 STXBP6   -1.61  NM_014178.6 
792 LGSN   -1.61  NM_016571.1 
793 HNRNPA1   -1.61  NM_031157.2 
794 MORC2   -1.60  NM_014941.1 
795 LSMD1   -1.60  NM_032356.3 
796 CHDH   -1.60  NM_018397.3 
797 LOC643287   -1.60  XM_928075.2 
798 SLC29A1   -1.60  NM_001078174.1 
799 WEE1   -1.60 Yes NM_003390.2 
800 THUMPD2   -1.60  NM_025264.3 
801 GTPBP6   -1.60  NM_012227.1 
802 LOC728572   -1.60  XR_039595.1 
803 SGOL2   -1.60  NM_152524.3 
804 KIF23   -1.60  NM_138555.1 
805 LOC440498   -1.60  XM_938817.2 
806 DLEU1   -1.60  NR_002605.1 
807 TAOK1   -1.60  NM_020791.1 
808 RFX7   -1.60  NM_022841.5 
809 WASPIP   -1.60  NM_003387.3 
810 CCDC47   -1.60  NM_020198.1 
811 SKA2   -1.60  NM_182620.3 
812 BUB1   -1.60  NM_004336.2 
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813 SERBP1   -1.59  NM_001018069.1 
814 ADAMTS1   -1.59  NM_006988.3 
815 LOC646993   -1.59  XM_001717725.1 
816 ATOX1   -1.59  NM_004045.3 
817 CCDC85B   -1.59  NM_006848.2 
818 RTN4IP1   -1.59  NM_032730.4 
819 ECHDC2   -1.59  NM_018281.2 
820 KRT19   -1.59  NM_002276.3 
821 ARHGAP23   -1.59  XM_290799.7 
822 SETMAR   -1.59  NM_006515.1 
823 C15orf38   -1.59  NM_182616.1 
824 SNORD87   -1.59  NR_002598.1 
825 FAM165B   -1.59  NM_058182.4 
826 LOC400304   -1.59  XM_375152.3 
827 RPL36   -1.59  NM_015414.2 
828 ZWILCH   -1.59  NM_017975.3 
829 CIAO1   -1.59  NM_004804.2 
830 CDK2   -1.59  NM_001798.2 
831 HMGA1   -1.59  NM_145899.1 
832 C12orf30   -1.59  NM_024953.2 
833 PODXL2   -1.59  NM_015720.1 
834 C9orf142   -1.59  NM_183241.1 
835 KCNIP3   -1.59 Yes NM_013434.4 
836 SHMT1   -1.59  NM_004169.3 
837 BTBD3   -1.59  NM_014962.2 
838 NFX1   -1.59  NM_002504.3 
839 H2AFY   -1.59  NM_138609.2 
840 SHRM   -1.59  NM_020859.1 
841 SLC44A2   -1.59  NM_020428.2 
842 LOC728006   -1.59  XM_001128698.1 
843 LOC282997   -1.58  XR_041083.1 
844 LOC100132774   -1.58  XM_001725935.1 
845 BRI3BP   -1.58  XM_941876.1 
846 SNORD104   -1.58  NR_004380.1 
847 CCNG1   -1.58  NM_199246.1 
848 RNU1A3   -1.58  NR_004430.1 
849 FAM38B   -1.58  NM_022068.1 
850 RANBP3   -1.58  NM_007320.1 
851 SLC43A3   -1.58  NM_017611.2 
852 GRB14   -1.58  NM_004490.2 
853 MCM7   -1.58  NM_005916.3 
854 REPIN1   -1.57  NM_014374.1 
855 TCF3   -1.57  NM_003200.1 
856 LOC286467   -1.57  XR_015266.1 
857 NPR3   -1.57  NM_000908.2 
858 SDCCAG3   -1.57  NM_001039708.1 
859 KAT2A   -1.57  NM_021078.2 
860 FEN1   -1.57  NM_004111.4 
861 FERMT1   -1.57  NM_017671.4 
862 SP110   -1.57  NM_004510.2 
863 TMEM80   -1.57   
864 FLJ40504   -1.57  NM_173624.1 
865 LOC641746   -1.57  XR_036993.1 
866 SMC4   -1.57  NM_001002800.1 
867 NT5C3L   -1.57  NM_052935.2 
868 CCNB2   -1.57  NM_004701.2 
869 UBE2C   -1.57  NM_181803.1 
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870 ADAL   -1.57  NM_001012969.1 
871 MDC1   -1.57  NM_014641.1 
872 NUDCD2   -1.57  NM_145266.4 
873 LOC729057   -1.57  XR_042044.1 
874 NFYC   -1.57 Yes NM_014223.2 
875 C3orf26   -1.57  NM_032359.2 
876 MANEAL   -1.57  NM_001031740.1 
877 CDC25A   -1.57  NM_001789.2 
878 IQCC   -1.56  NM_018134.1 
879 TMEM14B   -1.56  NM_030969.2 
880 POLR3G   -1.56  NM_006467.2 
881 FOXRED2   -1.56  NM_024955.4 
882 CDCA5   -1.56  NM_080668.2 
883 DLGAP5   -1.56  NM_014750.3 
884 BIVM   -1.56  NM_017693.2 
885 PDCD2   -1.56  NM_144781.1 
886 TMEM149   -1.56  NM_024660.2 
887 C16orf13   -1.56  NM_001040161.1 
888 LOC728408   -1.56  XR_039142.1 
889 RBBP7   -1.56  NM_002893.2 
890 LOC730323   -1.56  XM_001722097.1 
891 WNT7B   -1.56  NM_058238.1 
892 FAM64A   -1.56  NM_019013.1 
893 KIF22   -1.56  NM_007317.1 
894 ARL17P1   -1.56  NM_016632.1 
895 SAMD1   -1.56  NM_138352.1 
896 LOC339290   -1.56  NR_015389.1 
897 PTGES2   -1.56  NM_198938.1 
898 NOP2   -1.56  NM_006170.2 
899 TSTD1   -1.56  NM_001113206.1 
900 ADCK2   -1.56  NM_052853.3 
901 LOC644029   -1.56  XR_017397.1 
902 PKN3   -1.56  NM_013355.3 
903 LOC391532   -1.56  XR_017653.1 
904 MTHFD1   -1.56  NM_005956.2 
905 GXYLT2   -1.56  NM_001080393.1 
906 TUBG1   -1.56  NM_001070.3 
907 TAF7L   -1.56  NM_024885.2 
908 DR1   -1.56  NM_001938.2 
909 ZNF274   -1.55  NM_016324.2 
910 ARL17B   -1.55  NM_001103154.1 
911 PEMT   -1.55  NM_148172.1 
912 PTMA   -1.55  NM_001099285.1 
913 EPHX1   -1.55  NM_000120.2 
914 XPO5   -1.55  NM_020750.1 
915 PPP2R3B   -1.55  NM_013239.3 
916 RUSC1   -1.55  NM_014328.2 
917 UBA52   -1.55  NM_003333.3 
918 UBXN2B   -1.55  NM_001077619.1 
919 KIAA1618   -1.55  NM_020954.2 
920 RPL14   -1.55  NM_001034996.1 
921 LOC652837   -1.55  XM_942529.1 
922 LOC391019   -1.55  XR_019605.1 
923 TATDN2   -1.55  NM_014760.2 
924 C13orf37   -1.55  NM_001071775.2 
925 LOC100129585   -1.55  XM_001720509.1 
926 MACROD1   -1.55  NM_014067.2 
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927 ABCF2   -1.55  NM_005692.3 
928 LOC642934   -1.55  XM_942991.2 
929 RNFT2   -1.55  NM_032814.3 
930 LOC400986   -1.55  XM_001126815.1 
931 BLM   -1.55  NM_000057.2 
932 SKAP2   -1.55  NM_003930.3 
933 CDKN3   -1.55  NM_005192.2 
934 KLC1   -1.55  NM_005552.4 
935 SSBP4   -1.55  NM_032627.2 
936 FAM104A   -1.55  NM_032837.1 
937 HCP5   -1.55  NM_006674.2 
938 LOC100130009   -1.55  XM_001720338.1 
939 DHX34   -1.55  NM_014681.4 
940 GPD2   -1.55  NM_001083112.1 
941 LOC649841   -1.54  XM_938906.2 
942 CENPN   -1.54  NM_018455.3 
943 B3GALNT1   -1.54  NM_033168.2 
944 HRAS   -1.54 Yes NM_005343.2 
945 KIAA1644   -1.54  XM_936510.2 
946 AMFR   -1.54  NM_001144.4 
947 HIST1H2BH   -1.54  NM_003524.2 
948 BAZ1A   -1.54  NM_182648.1 
949 KRT86   -1.54  NM_002284.3 
950 TOP2A   -1.54  NM_001067.2 
951 SLC47A1   -1.54  NM_018242.2 
952 RBMS1   -1.54  NM_002897.3 
953 RPS7   -1.54  NM_001011.3 
954 LOC100133923   -1.54  XM_001714921.1 
955 LOC645691   -1.54  XM_928701.3 
956 CD320   -1.54  NM_016579.2 
957 LOC100129267   -1.54  XR_037397.1 
958 TOE1   -1.54  NM_025077.2 
959 CKB   -1.54  NM_001823.3 
960 MCM5   -1.54  NM_006739.3 
961 TMEM133   -1.54  NM_032021.2 
962 SNORD96A   -1.54  NR_002592.1 
963 RAD54B   -1.54  NM_012415.2 
964 REXO4   -1.54  NM_020385.2 
965 C9orf100   -1.54  NM_032818.1 
966 HIST1H2BJ   -1.54  NM_021058.3 
967 H1F0   -1.54  NM_005318.2 
968 NPM3   -1.54  NM_006993.1 
969 LRRCC1   -1.54  NM_033402.3 
970 HMG20B   -1.54  NM_006339.1 
971 LRRC14   -1.54  NM_014665.1 
972 HIST1H4C   -1.54  NM_003542.3 
973 LOC100134648   -1.53  XM_001724681.1 
974 ACAT1   -1.53  NM_000019.2 
975 SIGMAR1   -1.53  NM_005866.2 
976 SELENBP1   -1.53  NM_003944.2 
977 C6orf167   -1.53  NM_198468.2 
978 RAP1GDS1   -1.53  NM_021159.3 
979 CDC42EP3   -1.53  NM_006449.3 
980 KRT18P17   -1.53  XR_037953.1 
981 MPRIP   -1.53  NM_015134.2 
982 CCDC97   -1.53  NM_052848.1 
983 ZBTB47   -1.53  NM_145166.2 
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984 NRGN   -1.53  NM_006176.1 
985 MCM4   -1.53  NM_182746.1 
986 OBFC1   -1.53  NM_024928.3 
987 RFX5   -1.53  NM_001025603.1 
988 NME3   -1.53 Yes NM_002513.2 
989 CDC25C   -1.53  NM_001790.3 
990 GCSH   -1.53  NM_004483.3 
991 TPX2   -1.53  NM_012112.4 
992 FABP5   -1.53  NM_001444.1 
993 EXOSC9   -1.53  NM_001034194.1 
994 CYTSB   -1.53  NM_001033553.1 
995 GRHPR   -1.53  NM_012203.1 
996 LOC646044   -1.53  XR_037328.1 
997 COBRA1   -1.53  NM_015456.2 
998 CCNE2   -1.53  NM_057735.1 
999 OXA1L   -1.53  NM_005015.1 
1000 ABHD15   -1.52  NM_198147.1 
1001 KIF20A   -1.52  NM_005733.1 
1002 C1QBP   -1.52  NM_001212.3 
1003 C2orf68   -1.52  NM_001013649.3 
1004 SLC16A9   -1.52  NM_194298.1 
1005 CTAG2   -1.52  NM_020994.2 
1006 PRC1   -1.52  NM_199413.1 
1007 POLQ   -1.52  NM_199420.3 
1008 AURKB   -1.52  NM_004217.2 
1009 GINS4   -1.52  NM_032336.1 
1010 GEMIN6   -1.52  NM_024775.9 
1011 MSX1   -1.52  NM_002448.3 
1012 DDX39   -1.52 Yes NM_005804.2 
1013 NEK2   -1.52  NM_002497.2 
1014 WDR51A   -1.52  NM_015426.2 
1015 MKRN3   -1.52  NM_005664.3 
1016 AIF1L   -1.52  NM_031426.2 
1017 FAM83D   -1.52 Yes NM_030919.2 
1018 SNORD15B   -1.52  NR_000025.1 
1019 LOC648164   -1.52  XM_936503.1 
1020 TRIM28   -1.52  NM_005762.2 
1021 PRTFDC1   -1.52  NM_020200.5 
1022 ZNF32   -1.52  NM_006973.2 
1023 HIST1H2AE   -1.52  NM_021052.2 
1024 PEBP1   -1.52  NM_002567.2 
1025 POLD1   -1.52 Yes NM_002691.1 
1026 PARP1   -1.52  NM_001618.2 
1027 CISD1   -1.52  NM_018464.2 
1028 KIAA1545   -1.52  XM_495939.3 
1029 PABPC1   -1.52  NM_002568.3 
1030 CNOT7   -1.52  NM_013354.5 
1031 C11orf58   -1.52  NM_001142705.1 
1032 NEFH   -1.52 Yes NM_021076.2 
1033 PYCARD   -1.52  NM_013258.3 
1034 TMEM160   -1.52  NM_017854.1 
1035 CCDC77   -1.52  NM_032358.2 
1036 KIAA0495   -1.52  NM_207306.1 
1037 EML3   -1.52  NM_153265.2 
1038 MRPS27   -1.51  NM_015084.1 
1039 LSM2   -1.51  NM_021177.3 
1040 FBXL20   -1.51  NM_032875.1 
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1041 C3orf31   -1.51  NM_138807.2 
1042 GPC4   -1.51  NM_001448.2 
1043 ZNF302   -1.51  NM_018443.2 
1044 LOC643995   -1.51  XM_934410.1 
1045 TMSB15A   -1.51  NM_021992.2 
1046 DTL   -1.51  NM_016448.1 
1047 LOC728153   -1.51  XM_001128002.1 
1048 AADAT   -1.51  NM_182662.1 
1049 LOC100128060   -1.51  XM_001723512.1 
1050 MTA2   -1.51  NM_004739.2 
1051 ZHX1   -1.51  NM_007222.3 
1052 SRPK1   -1.51  NM_003137.3 
1053 UCK2   -1.51  NM_012474.3 
1054 AKR1C2   -1.51 Yes NM_001354.4 
1055 PXMP2   -1.51  NM_018663.1 
1056 GPN3   -1.51  NM_016301.2 
1057 C9orf40   -1.51  NM_017998.1 
1058 C10orf54   -1.51  NM_022153.1 
1059 CENPO   -1.51  NM_024322.1 
1060 RALBP1   -1.51  NM_006788.3 
1061 NHP2L1   -1.51  NM_005008.2 
1062 SNORD99   -1.51  NR_003077.1 
1063 LOC440145   -1.51  NM_001071775.1 
1064 C4orf32   -1.51  NM_152400.1 
Number Gene symbol 
Fold change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
1065 MRPL40   -1.51  NM_003776.2 
1066 SYCE1L   -1.51  NM_001129979.1 
1067 DDX12   -1.51  XM_931833.1 
1068 PMS2L5   -1.51  NM_174930.2 
1069 SLC2A4RG   -1.51  NM_020062.3 
1070 ZNF462   -1.51  NM_021224.4 
1071 SMYD2   -1.51  NM_020197.1 
1072 C17orf58   -1.51  NM_181656.3 
1073 SNORD65   -1.50  NR_003054.1 
1074 TMEM97   -1.50  NM_014573.2 
1075 SPTAN1   -1.50  NM_003127.1 
1076 GBAS   -1.50  NM_001483.1 
1077 MRPL24   -1.50  NM_145729.1 
1078 XRCC3   -1.50  NM_001100118.1 
1079 BCOR   -1.50 Yes NM_020926.2 
1080 FLJ35776   -1.50  NR_024101.1 
1081 IREB2   -1.50  NM_004136.2 
1082 C6orf155   -1.50  NM_024882.1 
1083 LOC728312   -1.50  XR_042333.1 
1084 AMD1   -1.50  NM_001033059.1 
1085 KLF10   -1.50  NM_005655.1 
1086 C5orf21   -1.50  NM_032042.3 
1087 GNG11   -1.50  NM_004126.3 
1088 ZNF580   -1.50  NM_016202.2 
 
 
(B) Genes upregulated by miR-517a 
 
Number Gene symbol 
Fold change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
1 DDAH1 2.75 3.46 1.80  NM_012137.2 
2 
TMEM189-
UBE2V1 
2.53 2.90 2.45  NM_003349.4 
3 RDX 2.51 3.04 2.61  NM_002906.3 
4 RAB8B 2.21 2.26 2.81  NM_016530.2 
5 IDI1 2.18 2.74   NM_004508.2 
6 RAB11FIP1 2.16 3.08 3.00  NM_001002814.1 
7 ERLIN2 2.13 3.08 3.02  NM_007175.5 
8 SLC35A1 2.10 1.78 2.03  NM_006416.3 
9 SYPL1 2.10 1.65 1.82  NM_182715.1 
10 ARL8B 2.02 2.20 3.90  NM_018184.2 
11 PKIA 2.01 1.99 2.54  NM_006823.2 
12 TMEM2 2.00 3.03 2.86  NM_013390.1 
13 FGF2 1.98 1.70 2.95  NM_002006.4 
14 INSIG1 1.94 1.97 1.65  NM_198336.1 
15 C5ORF51 1.93 2.43 3.54  NM_175921.4 
16 NUP35 1.91 1.92 1.88 Yes NM_138285.3 
17 PFTK1 1.87  1.54 Yes NM_012395.2 
18 BTG3 1.85 2.03 2.27 Yes NM_006806.3 
19 FAM116A 1.85 2.75 2.12  XM_001132771.1 
20 HMGCR 1.83 1.66   NM_000859.1 
21 ERLIN1 1.82 2.23 2.06  NM_006459.2 
22 RBM12 1.82 2.00   NM_006047.4 
23 SNRPC 1.81 3.28 2.96  NM_003093.1 
24 HMGCS1 1.81 1.51   NM_002130.6 
25 LOC730052 1.80 2.72 2.45  XR_038933.1 
Number Gene symbol 
Fold change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
26 HNRNPR 1.78    NM_005826.3 
27 PPIF 1.77 1.58 1.83  NM_005729.3 
28 TMTC3 1.77    NM_181783.2 
29 SLC4A7 1.75 1.74   NM_003615.3 
30 PPM1B 1.74 1.91 1.77  NM_177968.2 
31 NPTN 1.74 2.53 2.32  NM_012428.2 
32 RAP1B 1.73 2.14 2.67  NM_015646.4 
33 HS.21177 1.72    AJ420516 
34 EIF2A 1.72 2.07 2.03  NM_032025.3 
35 UBLCP1 1.71 2.15 1.99  NM_145049.1 
36 IRF2BP2 1.71 1.93 2.30  NM_182972.2 
37 IL8 1.70 1.89 5.35  NM_000584.2 
38 SRI 1.69 2.20 1.54  NM_198901.1 
39 HS.127310 1.68    AL137257 
40 HNRPR 1.67 1.81   NM_005826.2 
41 CTNNB1 1.66 1.76 1.93  NM_001098209.1 
42 GXYLT1 1.66    NM_001099650.1 
43 SH3RF1 1.65 1.58   NM_020870.3 
44 SEC24A 1.65 1.95 2.69  NM_021982.1 
45 RP2 1.65 1.89 1.91  NM_006915.1 
46 FAS 1.65    NM_152877.1 
47 ST5 1.64    NM_213618.1 
48 CYBRD1 1.64 1.72 2.54  NM_024843.2 
49 STBD1 1.63    NM_003943.2 
50 MBNL1 1.62    NM_207295.1 
51 ZFYVE20 1.60 1.85 1.66  NM_022340.2 
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52 DDAH1  3.46 1.80  NM_012137.2 
53 COMMD10  3.17 2.66  NM_016144.2 
54 LOC100129566  3.06 3.10  XM_001718519.1 
55 ACTC1  2.94   NM_005159.3 
56 PMM2  2.83 3.40  NM_000303.1 
57 FSTL1  2.67 2.52  NM_007085.3 
58 RDH11  2.57 2.03  NM_016026.2 
59 WIPI1  2.44 8.40  NM_017983.3 
60 C12orf23  2.35 2.63  NM_152261.1 
61 SEC24D  2.34 2.71  NM_014822.1 
62 IL11  2.34 4.38  NM_000641.2 
63 NXNL2  2.33 2.08  NM_145283.1 
64 TNFSF9  2.32 3.14  NM_003811.2 
65 RAB22A  2.25 2.14  NM_020673.2 
66 SPOCD1  2.23 2.83  NM_144569.3 
67 TUBB3  2.22 2.06  NM_006086.2 
68 CAV2  2.21   NM_001233.3 
69 STK38L  2.20 1.56  NM_015000.1 
70 KIAA0367  2.17 2.06  NM_015225.1 
71 TGM2  2.14 2.55  NM_004613.2 
72 C14orf45  2.14 4.18   
73 ACSS2  2.14 1.61  NM_001076552.1 
74 NT5E  2.13 5.70  NM_002526.1 
75 SERPINE1  2.12 4.41 Yes NM_000602.1 
76 LOC158160  2.10   NM_001031744.1 
77 TMEM154  2.10 3.75  NM_152680.1 
78 LARP6  2.08 3.71 Yes NM_018357.2 
79 SRA1  2.08 3.42  NM_001035235.2 
80 HSPA5  2.06 2.27  NM_005347.2 
81 MEX3B  2.06   NM_032246.3 
82 TMEM181  2.05 2.62  XM_941693.1 
83 LOC648742  2.05 2.70  XM_001714210.1 
84 EIF2S1  2.01 1.58  NM_004094.4 
85 TPST1  2.01 2.15  NM_003596.2 
86 H3F3B  2.01 1.50  NM_005324.3 
87 IKBIP  1.99 2.20  NM_153687.2 
88 UBE2V1  1.99 1.53  NM_001032288.1 
89 ARPC4  1.98 2.51  NM_001024960.1 
90 KIAA0494  1.98 2.44  NM_014774.1 
91 OPTN  1.97 2.71  NM_001008213.1 
92 CPOX  1.97 1.58  NM_000097.4 
93 MTAP  1.97   NM_002451.3 
94 GPR180  1.97 2.38  NM_180989.3 
95 RAP1BL  1.97 2.28  NM_001089704.3 
96 PCSK9  1.96   NM_174936.2 
97 IDH1  1.96 2.54  NM_005896.2 
98 PRRC1  1.95 2.11  NM_130809.2 
99 LOC650517  1.95 2.03  XM_496202.2 
100 LPIN1  1.93   NM_145693.1 
101 LOC653631  1.92 2.20  XM_930476.1 
102 SLC39A14  1.91 2.50  NM_015359.1 
103 CD70  1.91 2.78  NM_001252.2 
104 PDGFRL  1.91 3.03  NM_006207.1 
105 XBP1  1.90 2.64  NM_005080.2 
106 SC4MOL  1.90 1.54  NM_006745.3 
107 ATPAF1  1.89   NM_001042546.1 
108 SLCO1B3  1.88 2.51  NM_019844.1 
Number Gene symbol 
Fold change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
109 PNMA1  1.88   NM_006029.4 
110 FAM69A  1.87 1.69  NM_001006605.3 
111 SELT  1.87   NM_016275.3 
112 FAM114A1  1.85 2.14  NM_138389.1 
113 GLIPR1  1.85 1.86  NM_006851.1 
114 SNAI2  1.85 2.55  NM_003068.3 
115 NEDD4  1.85 2.12  NM_198400.1 
116 PLA2G3  1.83   NM_015715.2 
117 LOC645313  1.83 1.57  XR_017585.2 
118 MAP1LC3B  1.83 2.82  NM_022818.3 
119 CCPG1  1.83 3.56  NM_004748.3 
120 YWHAG  1.83 1.67  NM_012479.2 
121 AIDA  1.83 2.89  NM_022831.2 
122 PDGFRB  1.83 2.27  NM_002609.3 
123 TRIM2  1.82 2.49  NM_015271.2 
124 PDIA5  1.82 4.07  NM_006810.1 
125 C14orf32  1.81 1.77  NM_144578.2 
126 ETF1  1.80 1.60  NM_004730.1 
127 VKORC1L1  1.80 1.75  NM_173517.3 
128 GFPT2  1.80 1.72 Yes NM_005110.1 
129 B4GALT4  1.80 2.42  NM_003778.3 
130 CDK2AP2  1.79 2.98  NM_005851.3 
131 GABPB1  1.78   NM_181427.3 
132 FAM3C  1.77 1.57  NM_014888.1 
133 INO80C  1.77 1.82  NM_194281.2 
134 ARHGAP19  1.77   NM_032900.4 
135 SLCO2A1  1.77 1.95  NM_005630.1 
136 ITGA6  1.77 1.80  NM_000210.2 
137 GABPB2  1.77   NM_181427.2 
138 C17orf91  1.77 2.27  NM_001001870.1 
139 YIPF5  1.77 2.32  NM_030799.6 
140 APPL2  1.76  Yes NM_018171.2 
141 UCN2  1.76 2.90  NM_033199.3 
142 ICMT  1.76 1.72  NM_012405.2 
143 POFUT2  1.76 3.41  NM_133635.3 
144 DNAJC25  1.76 2.35  NM_001015882.1 
145 MVK  1.75   NM_000431.1 
146 NARF  1.75 1.69  NM_001038618.1 
147 TMED7  1.75 1.80  NM_181836.3 
148 LOC402232  1.75   XM_499226.2 
149 KDELR2  1.75 3.10  NM_006854.2 
150 FECH  1.75   NM_000140.2 
151 RTCD1  1.74 1.99  NM_003729.1 
152 BMPR2  1.74 2.00  NM_001204.5 
153 MOBKL2B  1.74   NM_024761.3 
154 RCE1  1.74   NM_001032279.1 
155 DCP2  1.74 1.76  NM_152624.4 
156 SCD  1.74   NM_005063.4 
157 LIPG  1.74 1.72  NM_006033.2 
158 SUGT1  1.74   NM_006704.2 
159 GNA13  1.74 2.25  NM_006572.3 
160 DRAM1  1.74 3.43  NM_018370.1 
161 TXNDC5  1.74 2.43  NM_022085.3 
162 USP47  1.74   NM_017944.3 
163 CACHD1  1.73 2.21  NM_020925.1 
164 C20orf20  1.73 1.68  NM_018270.3 
165 GPX8  1.72 2.74  NM_001008397.2 
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166 ARFGAP1  1.72 3.43  NM_175609.1 
167 GBP1  1.72   NM_002053.1 
168 DEDD2  1.72 2.02  NM_133328.2 
169 KDELR3  1.72 4.42  NM_016657.1 
170 ACLY  1.72 1.74  NM_198830.1 
171 SOX9  1.72   NM_000346.2 
172 DNAJB11  1.71 2.04  NM_016306.4 
173 C12orf31  1.70 1.83  NM_032338.2 
174 COPS8  1.69 1.66  NM_198189.2 
175 SLC11A2  1.69 2.08  NM_000617.1 
176 IGFBP3  1.69 1.97  NM_001013398.1 
177 PGM3  1.69 3.15  NM_015599.1 
178 KRT17P3  1.69 1.95  XR_015626.2 
179 FRMD6  1.69 2.58  NM_152330.3 
180 LSS  1.68 1.59  NM_002340.3 
181 ALDH9A1  1.68 1.59  NM_000696.2 
182 MED8  1.68 2.12  NM_001001651.1 
183 GFM1  1.68 1.52  NM_024996.5 
184 KLHL13  1.68   NM_033495.2 
185 SLC26A2  1.68 2.20  NM_000112.2 
186 C10orf75  1.68   XR_041972.1 
187 ASF1A  1.68   NM_014034.1 
188 FURIN  1.68 2.06  NM_002569.2 
189 JUN  1.68 2.39  NM_002228.3 
190 CUL4B  1.67 1.89  NM_001079872.1 
191 SEMA4F  1.66 2.36 Yes NM_004263.2 
192 GNB1  1.66 1.77  NM_002074.2 
193 ERI1  1.66   NM_153332.3 
194 HDAC1  1.66 1.50  NM_004964.2 
195 C2orf30  1.66 2.08  NM_015701.2 
196 IVNS1ABP  1.66 1.60  NM_006469.4 
197 NDUFA6  1.66  Yes NM_002490.3 
198 PJA2  1.65 2.05  NM_014819.2 
199 GPR1  1.65 2.32  NM_005279.2 
200 TNFRSF12A  1.65 2.13  NM_016639.1 
201 ITFG2  1.65 1.67  NM_018463.2 
202 ING3  1.65 1.75  NM_198267.1 
203 ASPH  1.65 1.93  NM_032468.2 
204 FDFT1  1.65   NM_004462.3 
205 FDPS  1.64   NM_002004.2 
206 AURKA  1.64   NM_198434.1 
207 ACBD3  1.64 2.70  NM_022735.3 
208 ROD1  1.64 1.71  NM_005156.4 
209 SLC2A6  1.64 1.82  NM_017585.2 
210 MAP1B  1.64 1.52  NM_032010.1 
211 TMEM231  1.64   NM_001077419.1 
212 TMEM39A  1.64 2.19  NM_018266.1 
213 CAB39  1.63 1.70  NM_016289.2 
214 CRIPT  1.63 1.69  NM_014171.3 
215 CYB5R4  1.63 1.65  NM_016230.2 
216 ARFGAP3  1.62 2.06  NM_014570.3 
217 DUSP5  1.62 3.18  NM_004419.3 
218 IPO11  1.62   NM_016338.3 
219 WDR25  1.62 2.58  NM_024515.3 
220 MCFD2  1.62 1.91  NM_139279.3 
221 RBM7  1.62   NM_016090.2 
222 ANXA7  1.62 1.74  NM_004034.1 
Number Gene symbol 
Fold change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
223 SLC35B3  1.62 1.82  NM_015948.2 
224 ZFAND2A  1.62 1.95  NM_182491.1 
225 ZYX  1.62  Yes NM_003461.4 
226 TNFAIP8  1.62 1.89  NM_001077654.1 
227 ANKRD1  1.62 2.03  NM_014391.2 
228 MORN4  1.61 2.17  NM_178832.2 
229 TSPAN13  1.61 3.08  NM_014399.3 
230 ULK1  1.61 2.89  XM_942125.1 
231 NRBF2  1.61 1.72  NM_030759.3 
232 MGC18216  1.61 1.80  XM_927732.1 
233 RNF14  1.61 2.21  NM_004290.3 
234 LSM14A  1.61   NM_015578.1 
235 DHCR7  1.61 1.51 Yes NM_001360.2 
236 CYP51A1  1.61   NM_000786.2 
237 PTPRR  1.61 2.41  NM_002849.2 
238 EML1  1.61   NM_004434.2 
239 SLC35B4  1.61 1.87  NM_032826.3 
240 TMEM45A  1.61 4.06  NM_018004.1 
241 LOC731999  1.61 1.62  XM_942260.1 
242 KLHL2  1.61 1.65  NM_007246.2 
243 LOC649679  1.60   XM_945045.1 
244 DNAJC15  1.60 1.55  NM_013238.2 
245 P2RX1  1.60 1.89  NM_002558.2 
246 TRIM29  1.60 2.38  NM_058193.1 
247 LEPRE1  1.60 2.58 Yes NM_022356.2 
248 DNAJB9  1.60 4.00  NM_012328.1 
249 TRIOBP  1.60 1.64  NM_138632.1 
250 INTS2  1.60   NM_020748.1 
251 FADS1  1.60   NM_013402.3 
252 HACL1  1.60 1.51  NM_012260.1 
253 PROSC  1.60   NM_007198.2 
254 SAR1A  1.60 1.95  NM_020150.3 
255 SERP1  1.60 1.92  NM_014445.2 
256 ARL6IP1  1.60   NM_015161.1 
257 SYVN1  1.60 2.41  NM_032431.2 
258 PDGFC  1.59   NM_016205.1 
259 PCNP  1.59 1.53  NM_020357.1 
260 SPINK5L3  1.59   XM_376433.2 
261 CDKN2B  1.59   NM_078487.2 
262 GPN1  1.59   NM_007266.1 
263 C5orf15  1.59 1.94  NM_020199.1 
264 RAN  1.59   NM_006325.2 
265 ZNF365  1.59 1.80  NM_014951.1 
266 ZBTB9  1.59   NM_152735.3 
267 ITGA5  1.59 2.98  NM_002205.2 
268 ATG4A  1.59 1.74  NM_178270.1 
269 EPHB2  1.59   NM_004442.6 
270 LRRC1  1.59 1.85  NM_018214.3 
271 LOX  1.59 2.37  NM_002317.3 
272 MVD  1.59   NM_002461.1 
273 FOXP1  1.58 1.73  NM_032682.4 
274 FHL2  1.58   NM_001450.3 
275 YPEL5  1.58 3.22  NM_016061.1 
276 KLF9  1.58 2.42  NM_001206.2 
277 C10orf88  1.58   NM_024942.1 
278 VLDLR  1.58 3.23  NM_001018056.1 
279 RRBP1  1.57 2.17  NM_001042576.1 
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280 ACTA2  1.57 3.14  NM_001613.1 
281 PBK  1.57   NM_018492.2 
282 ARID3A  1.57 1.87  NM_005224.1 
283 TM4SF1  1.57 1.64  NM_014220.2 
284 GEM  1.57 1.60  NM_181702.1 
285 MCEE  1.57 1.62  NM_032601.2 
286 LSM8  1.57   NM_016200.2 
287 RER1  1.57 1.51  NM_007033.3 
288 PDCD4  1.57   NM_145341.2 
289 C6orf62  1.57 1.66  NM_030939.3 
290 GDF15  1.57 7.46  NM_004864.1 
291 KAT2B  1.57   NM_003884.4 
292 TIMP3  1.57 1.53  NM_000362.4 
293 LOC652846  1.57 2.19  XM_942545.1 
294 STAG2  1.56   NM_006603.3 
295 KRT16  1.56 1.93  NM_005557.2 
296 MED31  1.56   NM_016060.2 
297 ADAM17  1.56 1.72  NM_003183.4 
298 TMEM41B  1.56   NM_015012.1 
299 STAT3  1.56 1.89  NM_139276.2 
300 ID2  1.56   NM_002166.4 
301 CALD1  1.56 1.57  NM_004342.5 
302 C9orf123  1.56   NM_033428.1 
303 XRCC4  1.56   NM_022406.1 
304 ANKRD13C  1.56 1.80  NM_030816.2 
305 NPC1  1.56 2.23  NM_000271.1 
306 USO1  1.56 1.96  NM_003715.1 
307 MAPK1  1.56 2.31  NM_138957.2 
308 ALDOC  1.56 2.23  NM_005165.2 
309 ZC3H14  1.56   NM_024824.3 
310 ARNT  1.56   NM_178426.1 
311 RWDD2A  1.56 1.64  NM_033411.2 
312 LOC652175  1.56   XM_941526.1 
313 CCDC99  1.56   NM_017785.2 
314 SERF2  1.55 2.38  NM_001018108.2 
315 SLC7A1  1.55 1.66  NM_003045.3 
316 FNDC3B  1.55 1.90  NM_022763.3 
317 HCCS  1.55 1.89  NM_005333.2 
318 TROVE2  1.55   NM_001042369.1 
319 METAP2  1.55   NM_006838.2 
320 LOC440093  1.55 1.55  NM_001013699.1 
321 RGL1  1.55   NM_015149.2 
322 MRPS36  1.55   NM_033281.5 
323 RCAN1  1.55 1.75  NM_203418.1 
324 CXorf26  1.54 1.52  NM_016500.3 
325 RELL1  1.54 1.60  NM_001085400.1 
326 HNRNPH3  1.54   NM_012207.2 
327 TRA1P2  1.54 1.65  XR_000203.3 
328 LOC729372  1.54   XM_001720639.1 
329 SERPINH1  1.54 2.48  NM_001235.2 
330 CRELD2  1.54 2.54  NM_024324.2 
331 SMAD7  1.54   NM_005904.2 
332 LOC285550  1.54   XR_001250.1 
333 HIF1A  1.54   NM_001530.2 
334 AKAP12  1.54   NM_005100.2 
335 BAT2D1  1.54 2.01  NM_015172.2 
336 ISCU  1.54 2.27 Yes NM_014301.2 
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337 DOCK11  1.53   NM_144658.2 
338 PMEPA1  1.53 1.62  NM_199169.1 
339 WAC  1.53   NM_100486.1 
340 PELI2  1.53 2.01  NM_021255.1 
341 HNRNPM  1.53   NM_031203.2 
342 KPNA2  1.53   NM_002266.2 
343 UBE2Q2  1.53 1.68  NM_173469.1 
344 CDA  1.53 3.19  NM_001785.1 
345 DUSP12  1.53 1.59  NM_007240.1 
346 MRS2  1.53   NM_020662.1 
347 UBE2E3  1.53 1.51  XM_944996.1 
348 SQLE  1.52   NM_003129.3 
349 FHL3  1.52   NM_004468.3 
350 SPAG1  1.52  Yes NM_003114.3 
351 LOC400759  1.52   XR_000992.1 
352 NA  1.52 3.49  Hs.194225 
353 LOC283050  1.52 2.09  XM_944265.1 
354 IFNE  1.52   NM_176891.4 
355 CAPZA1  1.52   NM_006135.1 
356 SLITRK5  1.52   NM_015567.1 
357 LOC100131261  1.52   XM_001723141.1 
358 CKAP2  1.52   NM_018204.2 
359 DCBLD1  1.52 2.02  NM_173674.1 
360 ENAH  1.52   NM_018212.4 
361 SEC13  1.52 2.69  NM_001136232.1 
362 NEDD9  1.52   NM_006403.2 
363 KIAA1539  1.52 2.58  NM_025182.2 
364 PRKCB1  1.52   NM_002738.5 
365 TPM4  1.51   NM_003290.1 
366 EPS8  1.51 1.61  NM_004447.4 
367 SLC7A6  1.51   NM_001076785.1 
368 FLJ22447  1.51 1.95  XM_379075.3 
369 ANXA10  1.51 2.52 Yes NM_007193.3 
370 LPAR1  1.51 1.84  NM_001401.3 
371 NSDHL  1.51   NM_015922.1 
372 POPDC3  1.51   NM_022361.3 
373 PMM1  1.51   NM_002676.1 
374 CD47  1.51   NM_001025080.1 
375 LAMP2  1.51 2.06  NM_013995.1 
376 EML4  1.51   NM_019063.2 
377 DMBT1  1.51 1.94  NM_017579.1 
378 TNFRSF10B  1.51 2.53  NM_003842.3 
379 HERPUD1  1.51 4.76  NM_001010990.1 
380 PJA1  1.51 2.08  NM_001032396.1 
381 ARMCX3  1.51 2.25  NM_177947.2 
382 MIR21  1.51 1.69  NR_029493.1 
383 B9D2  1.51   NM_030578.2 
384 LRIG1  1.51 2.26  NM_015541.2 
385 RNF19A  1.50   NM_015435.3 
386 RHOBTB1  1.50   NM_198225.1 
387 HSD17B7P2  1.50   NM_182829.1 
388 LOC650132  1.50   XM_939218.1 
389 FAM36A  1.50   NM_198076.4 
390 CSGALNACT1  1.50   NM_018371.3 
391 DDIT3   5.24  NM_004083.4 
392 GCNT3   4.53  NM_004751.1 
393 ETV5   4.29  NM_004454.1 
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394 BEX2   3.96  NM_032621.2 
395 TNFRSF14   3.86  NM_003820.2 
396 INHBE   3.66  NM_031479.3 
397 LRRC32   3.53  NM_005512.1 
398 TOM1   3.33  NM_005488.1 
399 ASNS   3.25  NM_133436.1 
400 STC2   3.16  NM_003714.2 
401 TSPAN10   3.13  NM_031945.3 
402 P4HA2   3.06  NM_001017973.1 
403 KCNK6   3.01  NM_004823.1 
404 SLC35A2   3.00  NM_001032289.1 
405 NTN4   2.94  NM_021229.3 
406 ABCA1   2.92  NM_005502.2 
407 PTGS2   2.91  NM_000963.1 
408 VEGFC   2.91  NM_005429.2 
409 TMEM50B   2.88  NM_006134.5 
410 ARHGEF4   2.88  NM_015320.2 
411 CD68   2.86  NM_001251.1 
412 CRELD1   2.84  NM_001031717.2 
413 UBAP2L   2.83 Yes NM_014847.2 
414 RNY1   2.82  NR_004391.1 
415 LOXL4   2.80  NM_032211.6 
416 SPINK1   2.76  NM_003122.2 
417 RABAC1   2.74  NM_006423.1 
418 ARF4   2.71  NM_001660.2 
419 MFGE8   2.71  NM_005928.1 
420 DNAJB6   2.71  NM_058246.3 
421 IER3   2.70  NM_003897.3 
422 RSPO3   2.70 Yes NM_032784.3 
423 SLC10A7   2.69  NM_001029998.2 
424 SELM   2.69  NM_080430.2 
425 SLC22A18   2.66  NM_002555.3 
426 CTH   2.65  NM_153742.3 
427 NDRG4   2.64  NM_022910.1 
428 ENO2   2.63  NM_001975.2 
429 C15orf48   2.63  NM_032413.2 
430 KLHL24   2.63  NM_017644.3 
431 ADM2   2.61  NM_024866.4 
432 ARMCX1   2.61  NM_016608.1 
433 STAT2   2.60  NM_005419.2 
434 CREB5   2.56  NM_182898.2 
435 OKL38   2.55  NM_013370.2 
436 UAP1L1   2.53  NM_207309.1 
437 HK2   2.53  NM_000189.4 
438 LAMB3   2.51  NM_000228.2 
439 CDRT4   2.49  NM_173622.3 
440 SLC39A11   2.48  NM_139177.2 
441 HS1BP3   2.47  NM_022460.3 
442 WARS   2.47  NM_173701.1 
443 NOV   2.46  NM_002514.2 
444 DUSP10   2.46  NM_144729.1 
445 DKK3   2.46  NM_013253.4 
446 GPR137B   2.45  NM_003272.1 
447 LOC387763   2.45  XM_941665.2 
448 SLC33A1   2.45  NM_004733.2 
449 NDRG1   2.45  NM_006096.2 
450 CLDN1   2.43  NM_021101.3 
Number Gene symbol 
Fold change Predicted 
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451 ANXA8   2.42  NM_001630.1 
452 TIMP4   2.39  NM_003256.2 
453 GMPPB   2.38  NM_021971.1 
454 RNF145   2.37  NM_144726.1 
455 ABTB1   2.37  NM_032548.2 
456 PRKCDBP   2.37  NM_145040.2 
457 ANTXR2   2.36  NM_058172.3 
458 CFB   2.36  NM_001710.4 
459 YIF1A   2.36  NM_020470.1 
460 GPRC5C   2.36  NM_018653.3 
461 P4HA1   2.35  NM_000917.2 
462 BCAT1   2.35  NM_005504.4 
463 PCSK1   2.33  NM_000439.3 
464 PPP1R15A   2.33  NM_014330.2 
465 IGFBP6   2.32  NM_002178.2 
466 ZMAT3   2.30  NM_152240.1 
467 ALDH1L2   2.29  XM_927536.1 
468 CTHRC1   2.28  NM_138455.2 
469 SEMA4B   2.28  NM_198925.1 
470 COPB2   2.27  NM_004766.1 
471 YPEL3   2.27  NM_031477.4 
472 HYOU1   2.27  NM_006389.2 
473 C5orf41   2.27  NM_153607.1 
474 GMPPA   2.27  NM_205847.1 
475 PCK2   2.26  NM_004563.2 
476 YIPF2   2.26  NM_024029.3 
477 MOGS   2.26  NM_006302.2 
478 TMBIM1   2.26  NM_022152.4 
479 EPPB9   2.25  NM_015681.2 
480 SLC37A3   2.24  NM_032295.2 
481 CTSD   2.23  NM_001909.3 
482 CHAC1   2.23  NM_024111.2 
483 FAM102A   2.23  NM_001035254.1 
484 COG6   2.22  NM_020751.1 
485 ETS1   2.22  NM_005238.2 
486 FAM113B   2.20  NM_138371.1 
487 SEC61A1   2.20  NM_013336.3 
488 TMEM214   2.20  NM_017727.4 
489 SLC12A8   2.20  NM_024628.4 
490 RHOQ   2.20  NM_012249.3 
491 C19orf4   2.20  NM_012109.1 
492 ASS1   2.19  NM_000050.4 
493 C3orf52   2.19  NM_024616.1 
494 RBKS   2.18  NM_022128.1 
495 TRIB3   2.17  NM_021158.3 
496 PTK6   2.17  NM_005975.2 
497 COG5   2.17  NM_006348.2 
498 PFKFB4   2.17  NM_004567.2 
499 PTGES   2.16 Yes NM_004878.3 
500 SRGN   2.15  NM_002727.2 
501 MAGED2   2.15  NM_201222.1 
502 CTSL1   2.15  NM_001912.3 
503 PRKAG2   2.14  NM_024429.1 
504 MLPH   2.14  NM_001042467.1 
505 PELO   2.14  NM_015946.4 
506 DGKA   2.14  NM_201554.1 
507 CLDN12   2.12  NM_012129.2 
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508 VEGFA   2.12  NM_003376.4 
509 RNMT   2.12 Yes NM_003799.1 
510 SLC1A1   2.11  NM_004170.4 
511 LOC344887   2.11  XR_038616.1 
512 RRAGB   2.11  NM_006064.3 
513 SIRPA   2.10  NM_001040023.1 
514 FNIP1   2.09  NM_001008738.2 
515 TBC1D2   2.09  NM_018421.2 
516 TMED9   2.09  NM_017510.4 
517 PPAPDC1B   2.09  NM_032483.2 
518 GMPR2   2.09  NM_001002000.1 
519 PLAUR   2.08  NM_001005376.1 
520 BNIP3L   2.08   
521 PIP4K2C   2.08  NM_024779.3 
522 FICD   2.08  NM_007076.2 
523 NCF2   2.07  NM_000433.2 
524 SEMA3B   2.07  NM_001005914.1 
525 STYXL1   2.07  NM_016086.2 
526 ITGB3   2.07  NM_000212.2 
527 FAP   2.07  NM_004460.2 
528 MICAL1   2.07  NM_022765.2 
529 TP53INP1   2.06  NM_033285.2 
530 IFT20   2.06  NM_174887.2 
531 SEL1L3   2.06  NM_015187.3 
532 VAMP5   2.06  NM_006634.2 
533 EEF1A1   2.05  NM_001402.5 
534 PHLDA1   2.05  NM_007350.3 
535 B9D1   2.05  NM_015681.3 
536 MYLK   2.05  NM_053032.2 
537 COG3   2.04  NM_031431.2 
538 GABARAPL1   2.04  NM_031412.2 
539 ORAI3   2.04  NM_152288.1 
540 OAT   2.04  NM_000274.1 
541 PDIA3P   2.03  NR_002305.1 
542 SLC35E1   2.03  NM_024881.4 
543 S100P   2.02  NM_005980.2 
544 RIT1   2.02  NM_006912.4 
545 CHN2   2.02  NM_004067.2 
546 LOC339192   2.02  XM_001726300.1 
547 SEC31A   2.02  NM_014933.2 
548 CD55   2.01  NM_000574.2 
549 C6orf223   2.01  NM_153246.3 
550 YIPF1   2.01  NM_018982.3 
551 RNASE4   2.01  NM_194431.1 
552 YIPF3   2.01  NM_015388.2 
553 DOM3Z   2.01 Yes NM_005510.3 
554 WISP2   2.00  NM_003881.2 
555 NPAS2   2.00  NM_002518.3 
556 BBS9   1.99  NM_001033604.1 
557 MCOLN1   1.99  NM_020533.1 
558 SSR1   1.99  NM_003144.2 
559 GOLT1B   1.99 Yes NM_016072.3 
560 LOC729768   1.98  XR_016076.2 
561 MEG3   1.98  NR_002766.1 
562 ACTG2   1.98  NM_001615.3 
563 CLIP4   1.97  NM_024692.3 
564 NGF   1.97  NM_002506.2 
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565 KRT80   1.97  NM_182507.2 
566 ABHD3   1.97  NM_138340.3 
567 SERPINB5   1.97  NM_002639.3 
568 CDKN1A   1.97  NM_000389.2 
569 SCYL1   1.97  NM_020680.3 
570 HHAT   1.97  NM_018194.2 
571 SCYL1BP1   1.97  NM_152281.1 
572 RAB11FIP5   1.97  NM_015470.2 
573 SH2D5   1.96  XM_375698.3 
574 PID1   1.96  NM_017933.3 
575 LACTB   1.96  NM_032857.2 
576 GOLGA5   1.96  NM_005113.2 
577 LOC493869   1.96  NM_001008397.1 
578 CMAS   1.96  NM_018686.3 
579 TPP1   1.96  NM_000391.3 
580 LOC400750   1.95  XR_039444.1 
581 GADD45A   1.95  NM_001924.2 
582 ABLIM3   1.95  NM_014945.2 
583 THSD4   1.95  NM_024817.1 
584 UGDH   1.95  NM_003359.2 
585 C16orf45   1.95  NM_033201.1 
586 PAPSS2   1.95  NM_004670.3 
587 RPL34   1.95  NM_000995.2 
588 TMEM97   1.95  NM_014573.2 
589 DPY19L3   1.95  NM_207325.1 
590 GPT2   1.95  NM_133443.1 
591 OTUD1   1.95  XM_001134465.1 
592 TAGLN   1.95  NM_003186.3 
593 UGCG   1.95  NM_003358.1 
594 LEPREL2   1.95  NM_014262.2 
595 LOC648399   1.95  XM_937448.1 
596 CANX   1.94  NM_001746.3 
597 GALNT10   1.94  NM_017540.3 
598 COPB1   1.94  NM_016451.3 
599 PLEKHM1   1.94  XM_001128220.1 
600 C9orf169   1.94  NM_199001.1 
601 SURF4   1.93  NM_033161.2 
602 DNER   1.93  NM_139072.3 
603 DHDDS   1.93  NM_024887.2 
604 SELS   1.93  NM_018445.4 
605 C1orf85   1.93  NM_144580.1 
606 SDF2L1   1.93  NM_022044.2 
607 STX5   1.93  NM_003164.3 
608 WDSUB1   1.93  NM_152528.1 
609 PTPRF   1.93  NM_002840.3 
610 GCNT2   1.92  NM_001491.2 
611 CATSPER1   1.92  NM_053054.2 
612 USP36   1.92  NM_025090.2 
613 KLF4   1.92  NM_004235.3 
614 SERPINB8   1.91  NM_002640.3 
615 SARS   1.91  NM_006513.2 
616 UBC   1.91  NM_021009.3 
617 PYCR1   1.91  NM_153824.1 
618 C9orf119   1.91  NM_001040011.1 
619 STS-1   1.91  NM_032873.3 
620 IL32   1.91  NM_001012636.1 
621 PLAU   1.91  NM_002658.2 
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622 CPZ   1.91  NM_001014447.1 
623 ANKRD33   1.91  NM_182608.2 
624 F3   1.90  NM_001993.2 
625 ATF4   1.90  NM_182810.1 
626 CYB561   1.90  NM_001017917.1 
627 GPR175   1.90  NM_016372.1 
628 IFNGR1   1.90  NM_000416.1 
629 CALU   1.90  NM_001219.2 
630 PPPDE1   1.90  NM_016076.3 
631 LGALS8   1.89  NM_006499.3 
632 IL6   1.89  NM_000600.1 
633 LOC730996   1.89  XM_001128017.1 
634 RPS29   1.89  NM_001030001.1 
635 ATXN1   1.89  NM_000332.2 
636 FAM134B   1.89  NM_001034850.1 
637 COPG   1.88 Yes NM_016128.3 
638 WBP5   1.87  NM_001006612.1 
639 TPRG1L   1.87  NM_182752.3 
640 ALS2   1.87  NM_020919.2 
641 COPA   1.87  NM_004371.3 
642 CNN1   1.87  NM_001299.4 
643 SRP54   1.87  NM_003136.2 
644 ARF1   1.87  NM_001024228.1 
645 PIM1   1.87  NM_002648.2 
646 LOC401805   1.87  XR_038835.1 
647 SPAG9   1.86  NM_172345.1 
648 LOC392871   1.86  XR_018049.2 
649 HSPA13   1.86  NM_006948.4 
650 BIRC2   1.86  NM_001166.3 
651 CAPRIN2   1.86  NM_001002259.1 
652 NUDT18   1.86  NM_024815.3 
653 SLC30A5   1.86  NM_022902.2 
654 TPMT   1.85  NM_000367.2 
655 C20orf100   1.85  NM_032883.1 
656 SDSL   1.85  NM_138432.2 
657 BHLHB2   1.85  NM_003670.1 
658 QPRT   1.85  NM_014298.3 
659 DOCK2   1.85 Yes NM_004946.1 
660 KRT81   1.85  NM_002281.2 
661 PEPD   1.85  NM_000285.2 
662 CTNS   1.85  NM_004937.2 
663 PHTF1   1.85  NM_006608.1 
664 PTPRE   1.85  NM_130435.2 
665 UFC1   1.84  NM_016406.1 
666 IRS2   1.84  NM_003749.2 
667 PDE2A   1.84  NM_002599.1 
668 RUNX2   1.84  NM_001024630.2 
669 ATG2A   1.84  NM_015104.1 
670 SLC7A11   1.83  NM_014331.3 
671 C7orf10   1.83  NM_024728.1 
672 KCNMB1   1.83  NM_004137.2 
673 LPPR2   1.83  NM_022737.1 
674 TNFRSF25   1.83  NM_148973.1 
675 BTBD7   1.83  NM_001002860.2 
676 LOC100128077   1.83  XM_001721943.1 
677 ETV4   1.83  NM_001986.1 
678 SLC2A1   1.83  NM_006516.1 
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679 GOLGB1   1.83  NM_004487.3 
680 JUB   1.83  NM_198086.1 
681 CDCP1   1.83  NM_022842.3 
682 RAB6A   1.83  NM_198896.1 
683 DKK1   1.83  NM_012242.2 
684 MTMR2   1.82  NM_201281.1 
685 CHPF   1.82  NM_024536.4 
686 NAGK   1.82  NM_017567.2 
687 PNPLA8   1.82  NM_015723.2 
688 IFRD1   1.82  NM_001550.2 
689 SSR2   1.82  XM_945430.1 
690 LMAN2   1.82  NM_006816.1 
691 RRAGC   1.82  NM_022157.2 
692 NEU1   1.82  NM_000434.2 
693 TCP11L2   1.82  NM_152772.1 
694 ARMET   1.82  NM_006010.2 
695 SLC25A46   1.82  NM_138773.1 
696 TRPC4AP   1.82  NM_015638.2 
697 C6orf85   1.82  NM_021945.4 
698 PTRH1   1.82  NM_001002913.1 
699 LOC284988   1.82  XR_017252.1 
700 RIOK3   1.81  NM_003831.3 
701 SLC25A20   1.81  NM_000387.3 
702 PHLDA3   1.81 Yes NM_012396.3 
703 LCN2   1.81  NM_005564.3 
704 UFM1   1.81  NM_016617.1 
705 INSIG2   1.80  NM_016133.2 
706 TCEAL8   1.80  NM_153333.2 
707 NUPR1   1.80  NM_001042483.1 
708 ECM2   1.80  NM_001393.2 
709 SLC38A2   1.80  NM_018976.3 
710 RND3   1.80  NM_005168.3 
711 ANGPTL4   1.80  NM_139314.1 
712 MAP2K1   1.80  NM_002755.2 
713 EPHA2   1.80  NM_004431.2 
714 FKBP10   1.80  NM_021939.2 
715 EPOR   1.80  NM_000121.2 
716 SLC38A10   1.80  NM_138570.2 
717 MUC1   1.80  NM_001044390.1 
718 EIF2AK3   1.80  NM_004836.4 
719 DKFZp451A211   1.80  NM_001003399.1 
720 MBNL2   1.80  NM_207304.1 
721 STMN3   1.80  NM_015894.2 
722 RSL24D1   1.79  NM_016304.2 
723 STX3   1.79  NM_004177.3 
724 TMEM151A   1.79  NM_153266.2 
725 C12orf57   1.79  NM_138425.2 
726 AGPAT9   1.79  NM_032717.3 
727 DNAJB2   1.79  NM_006736.5 
728 CYB5R1   1.78  NM_016243.2 
729 LMAN1   1.78  NM_005570.2 
730 RHOU   1.78  NM_021205.4 
731 COQ10B   1.78  NM_025147.3 
732 DUSP4   1.78  NM_001394.5 
733 LOC730820   1.78  XM_001127763.1 
734 SYT11   1.78  NM_152280.2 
735 GARS   1.78  NM_002047.2 
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736 FAM18B   1.78  NM_016078.4 
737 NAGLU   1.78  NM_000263.3 
738 TNC   1.78  NM_002160.2 
739 C6orf1   1.78  NM_001008704.1 
740 JUP   1.78  NM_021991.1 
741 FOXQ1   1.78  NM_033260.3 
742 MYL9   1.78  NM_006097.3 
743 PDXDC1   1.78  NM_015027.2 
744 CALCOCO1   1.78  NM_020898.1 
745 BCL2L1   1.78  NM_138578.1 
746 RENBP   1.77  NM_002910.4 
747 TRIP11   1.77  NM_004239.1 
748 ERRFI1   1.77  NM_018948.2 
749 SMPDL3A   1.77  NM_006714.2 
750 NME7   1.77  NM_013330.3 
751 CPEB4   1.77  NM_030627.1 
752 LIPA   1.77  NM_000235.2 
753 LAT   1.77  NM_001014987.1 
754 HMGCL   1.77  NM_000191.2 
755 DAP   1.77  NM_004394.1 
756 TGDS   1.77  NM_014305.2 
757 COL4A1   1.77  NM_001845.4 
758 CEBPG   1.77  NM_001806.2 
759 OCIAD2   1.76  NM_001014446.1 
760 CYFIP2   1.76  NM_014376.2 
761 LIF   1.76  NM_002309.2 
762 C8orf83   1.76  NR_015339.1 
763 COL15A1   1.76  NM_001855.3 
764 HBP1   1.76  NM_012257.3 
765 C1S   1.76  NM_001734.2 
766 ISG20L1   1.76  NM_022767.2 
767 LOC401317   1.76  XM_379479.3 
768 MOBKL2C   1.76  NM_145279.4 
769 SEPX1   1.76  NM_016332.2 
770 NAMPT   1.76  NM_005746.2 
771 GRN   1.76  NM_002087.2 
772 GALNT12   1.75  NM_024642.3 
773 MAMLD1   1.75  NM_005491.2 
774 KLHL30   1.75  NM_198582.2 
775 UNC84B   1.75  NM_015374.1 
776 WDR45   1.75  NM_007075.3 
777 RRAGD   1.75  NM_021244.3 
778 AUH   1.75  NM_001698.1 
779 KIAA0251   1.75  XM_001125924.1 
780 ECE1   1.75  NM_001397.1 
781 ORMDL3   1.75  NM_139280.1 
782 HPS3   1.75  NM_032383.3 
783 TWF2   1.75  NM_007284.3 
784 PARP3   1.75  NM_005485.3 
785 TBC1D8B   1.75  NM_017752.2 
786 IL1A   1.75  NM_000575.3 
787 CHIC2   1.75  NM_012110.2 
788 CGNL1   1.75  NM_032866.3 
789 DNAJC10   1.75  NM_018981.1 
790 CDH13   1.75  NM_001257.3 
791 CLCN7   1.75  NM_001287.3 
792 SUMF1   1.74  NM_182760.2 
Number Gene symbol 
Fold change Predicted 
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793 POL3S   1.74  NM_001039503.2 
794 CCRK   1.74  NM_012119.3 
795 VAT1   1.74  NM_006373.3 
796 PDIA4   1.74  NM_004911.3 
797 FBXL13   1.74  NM_145032.2 
798 RAB32   1.74  NM_006834.2 
799 MBD1   1.74  NM_015845.2 
800 CALCOCO2   1.74  NM_005831.3 
801 PPP2R5B   1.74  NM_006244.2 
802 HK1   1.74  NM_033500.1 
803 LOC653994   1.73  XM_944439.2 
804 ZNF622   1.73  NM_033414.2 
805 IL24   1.73  NM_006850.2 
806 COMMD3   1.73  NM_012071.2 
807 FLJ20254   1.73  NM_017727.3 
808 GNPDA1   1.73  NM_005471.3 
809 TICAM2   1.72  NM_021649.3 
810 MTMR10   1.72  NM_017762.2 
811 B3GNT5   1.72  NM_032047.4 
812 MBTPS1   1.72  NM_003791.2 
813 SH3BGRL3   1.72  NM_031286.3 
814 PSCA   1.72  NM_005672.3 
815 GALK2   1.72  NM_002044.2 
816 GOLGA2   1.72  NM_004486.4 
817 CLDN23   1.72  NM_194284.2 
818 C10orf118   1.72  NM_018017.2 
819 FUCA1   1.72  NM_000147.3 
820 CD24   1.72  NM_013230.2 
821 MARS   1.72  NM_004990.2 
822 THBS3   1.72  NM_007112.3 
823 RNF13   1.72  NM_183381.1 
824 KIAA0913   1.72  NM_015037.2 
825 AKAP13   1.72  NM_007200.3 
826 EXT1   1.71  NM_000127.2 
827 STK19   1.71 Yes NM_004197.1 
828 CAPN7   1.71  NM_014296.2 
829 DERL2   1.71  NM_016041.3 
830 LOC143666   1.71  XM_001127524.1 
831 C10orf11   1.71  NM_032024.3 
832 BMP1   1.71  NM_006129.2 
833 C7orf23   1.71  NM_024315.2 
834 ALDH18A1   1.71  NM_002860.3 
835 MLEC   1.71  NM_014730.2 
836 OSMR   1.71  NM_003999.1 
837 YIPF6   1.71  NM_173834.2 
838 CCND1   1.71  NM_053056.2 
839 LOC390557   1.71  XM_001726973.1 
840 CMPK1   1.71  NM_016308.1 
841 KRT17   1.71  NM_000422.1 
842 OSBPL9   1.71  NM_148906.1 
843 PHGDH   1.70  NM_006623.2 
844 GBA   1.70  NM_001005742.1 
845 ZMIZ1   1.70  NM_020338.2 
846 C15orf39   1.70  NM_015492.4 
847 HSDL1   1.70  NM_031463.3 
848 CCDC90B   1.70  NM_021825.3 
849 PPIB   1.70  NM_000942.4 
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850 LOC340274   1.70  XR_017256.2 
851 TBX3   1.70  NM_005996.3 
852 ITPRIP   1.69  NM_033397.2 
853 BAX   1.69  NM_138765.2 
854 GOSR2   1.69  NM_004287.3 
855 SLC31A2   1.69  NM_001860.2 
856 TBC1D20   1.69  NM_144628.2 
857 SDC4   1.69  NM_002999.2 
858 BAD   1.69  NM_004322.2 
859 FTH1   1.69  NM_002032.2 
860 CDH2   1.69  NM_001792.2 
861 PNKD   1.69  NM_022572.2 
862 SULF2   1.69  NM_018837.2 
863 PSG4   1.69  NM_002780.3 
864 MTHFD2   1.69  NM_006636.3 
865 CD276   1.69  NM_001024736.1 
866 SECISBP2   1.69  NM_024077.3 
867 SPTLC1   1.68 Yes NM_178324.1 
868 FAM55C   1.68  NM_145037.1 
869 BRI3P1   1.68  XR_015539.2 
870 WSB1   1.68  NM_134264.2 
871 LOC645638   1.68  XR_040455.1 
872 MAPK13   1.68  NM_002754.3 
873 ZBTB43   1.68  NM_014007.2 
874 ECM1   1.68  NM_022664.1 
875 KIAA0363   1.68  XM_001133202.1 
876 CDH15   1.68  NM_004933.2 
877 IRF9   1.68  NM_006084.4 
878 FVT1   1.68  NM_002035.1 
879 FMNL2   1.68  NM_052905.3 
880 SLC35C1   1.68  NM_018389.3 
881 NFIL3   1.68  NM_005384.2 
882 PCTP   1.68  NM_021213.1 
883 TMF1   1.68  NM_007114.2 
884 UNC50   1.68  NM_014044.4 
885 SIL1   1.68  NM_001037633.1 
886 SLC31A1   1.68  NM_001859.2 
887 CD59   1.68  NM_203331.1 
888 LOC729779   1.68  XR_019592.2 
889 PARP4   1.68  NM_006437.3 
890 ALDH2   1.67  NM_000690.2 
891 LAMA1   1.67  NM_005559.2 
892 PLOD1   1.67  NM_000302.2 
893 ASAP2   1.67  NM_003887.2 
894 CHPF2   1.67  NM_019015.1 
895 IL18BP   1.67  NM_173042.2 
896 C9orf21   1.67  NM_153698.1 
897 LOC100132564   1.67  XM_001713808.1 
898 TMEM59   1.66  NM_004872.3 
899 CGB5   1.66  NM_033043.1 
900 CHKA   1.66  NM_212469.1 
901 B3GNT6   1.66  NM_006876.1 
902 SLC36A1   1.66  NM_078483.2 
903 HSPBAP1   1.66  NM_024610.4 
904 LOC441711   1.66  XR_037852.1 
905 GNPTAB   1.66  NM_024312.3 
906 COL4A2   1.66  NM_001846.2 
Number Gene symbol 
Fold change Predicted 
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907 APBB3   1.66  NM_133172.2 
908 ARHGEF18   1.66  NM_015318.2 
909 ANKRA2   1.66  NM_023039.2 
910 EDEM1   1.66  NM_014674.1 
911 PSPH   1.66  NM_004577.3 
912 HM13   1.66  NM_178580.1 
913 CYP4V2   1.66  NM_207352.2 
914 SESN1   1.66  NM_014454.1 
915 TIMP2   1.66  NM_003255.4 
916 SEC61G   1.65  NM_014302.3 
917 UBR4   1.65  NM_020765.2 
918 SLC35C2   1.65  NM_173073.2 
919 SPINK6   1.65  NM_205841.2 
920 EBI3   1.65  NM_005755.2 
921 FOXD1   1.65  NM_004472.2 
922 SLC2A5   1.65  NM_003039.1 
923 ZFPL1   1.65  NM_006782.3 
924 ATP6V0E1   1.65  NM_003945.3 
925 ZNF697   1.65  NM_001080470.1 
926 TBC1D7   1.65  NM_016495.2 
927 AARS   1.65  NM_001605.2 
928 COL7A1   1.65  NM_000094.2 
929 TTC3   1.65  NM_003316.3 
930 PPT2   1.65  NM_138717.1 
931 DCUN1D3   1.65  NM_173475.1 
932 STARD3NL   1.65  NM_032016.2 
933 PRDX5   1.65  NM_181652.1 
934 PPP1CB   1.65 Yes NM_206876.1 
935 LPIN2   1.65  NM_014646.2 
936 OSTCL   1.64  NM_145303.3 
937 MANBA   1.64  NM_005908.3 
938 FLNB   1.64  NM_001457.1 
939 NECAP2   1.64  NM_018090.3 
940 RGS20   1.64  NM_170587.1 
941 CSPG4   1.64  NM_001897.4 
942 TERF1   1.64  NM_017489.1 
943 VPS18   1.64  NM_020857.2 
944 C19orf10   1.64  NM_019107.3 
945 LOC644496   1.64  XR_039005.1 
946 RETSAT   1.64  NM_017750.2 
947 GPX7   1.64  NM_015696.3 
948 ATXN2L   1.64  XM_939199.1 
949 IFI16   1.64  NM_005531.1 
950 TAX1BP3   1.64  NM_014604.2 
951 PSAT1   1.64  NM_021154.3 
952 KDSR   1.64  NM_002035.2 
953 OSBPL2   1.64  NM_144498.1 
954 CHMP2B   1.64  NM_014043.2 
955 CGB1   1.64  NM_033377.1 
956 COL4A3BP   1.64  NM_005713.1 
957 CD82   1.64  NM_001024844.1 
958 TFG   1.63  NM_001007565.1 
959 CCDC50   1.63 Yes NM_174908.2 
960 NPC2   1.63  NM_006432.3 
961 COL5A1   1.63  NM_000093.3 
962 CLIC3   1.63  NM_004669.2 
963 FAM98A   1.63  NM_015475.3 
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964 SND1   1.63  NM_014390.2 
965 DTWD1   1.63  NM_020234.4 
966 KIAA1715   1.63  NM_030650.1 
967 CKAP4   1.63  NM_006825.2 
968 LOC646567   1.63  XM_929503.2 
969 B4GALNT1   1.63  NM_001478.3 
970 ZNF295   1.62  NM_001098402.1 
971 ANKDD1A   1.62  NM_182703.3 
972 APCDD1L   1.62  NM_153360.1 
973 CHST15   1.62  NM_015892.2 
974 TLE1   1.62  NM_005077.3 
975 GLT8D1   1.62  NM_018446.2 
976 GRAMD4   1.62  NM_015124.2 
977 TPBG   1.62  NM_006670.3 
978 SPSB1   1.62  NM_025106.2 
979 NUB1   1.62  NM_016118.3 
980 C10orf58   1.62  NM_032333.4 
981 COPE   1.62  NM_199442.1 
982 MAGED4B   1.62 Yes NM_030801.2 
983 LRP1   1.62  NM_002332.2 
984 SH3RF2   1.62  NM_152550.2 
985 F2RL1   1.62  NM_005242.3 
986 VASN   1.62  NM_138440.2 
987 JMY   1.62  NM_152405.3 
988 ULBP2   1.62  NM_025217.2 
989 JMJD1A   1.62  NM_018433.3 
990 DUSP11   1.62  NM_003584.1 
991 MATN2   1.62  NM_002380.3 
992 TRIO   1.61  NM_007118.2 
993 TPD52   1.61  NM_005079.2 
994 C12orf5   1.61  NM_020375.2 
995 IQGAP1   1.61  NM_003870.3 
996 GAB2   1.61  NM_080491.1 
997 TESK2   1.61  NM_007170.2 
998 ADORA2B   1.61  NM_000676.2 
999 TANC2   1.61  NM_025185.3 
1000 TOX2   1.61  NM_001098797.1 
1001 RRM2B   1.61  NM_015713.3 
1002 TINAGL1   1.61  NM_022164.1 
1003 ABHD10   1.61  NM_018394.1 
1004 RINT1   1.61  NM_021930.4 
1005 TP53BP1   1.61  NM_005657.1 
1006 ERMAP   1.61  NM_001017922.1 
1007 LOC653566   1.61  XM_934796.2 
1008 C1orf54   1.61  NM_024579.2 
1009 TMEM144   1.61  NM_018342.3 
1010 PTDSS2   1.61  NM_030783.1 
1011 REPS2   1.61  NM_004726.2 
1012 C1orf56   1.61  NM_017860.3 
1013 TPCN2   1.61  NM_139075.2 
1014 ARFGEF1   1.61  NM_006421.3 
1015 DIRC2   1.60  NM_032839.1 
1016 TCEAL3   1.60  NM_001006933.1 
1017 SYNC1   1.60  NM_030786.1 
1018 TTPAL   1.60  NM_001039199.1 
1019 MACF1   1.60  NM_012090.3 
1020 ARID5B   1.60  NM_032199.1 
Number Gene symbol 
Fold change Predicted 
target? 
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1021 DCBLD2   1.60  NM_080927.3 
1022 SRPR   1.60  NM_003139.2 
1023 PLDN   1.60  NM_012388.2 
1024 CYB561D2   1.60  NM_007022.3 
1025 ENC1   1.60  NM_003633.1 
1026 LRRC59   1.60  NM_018509.2 
1027 TMEM131   1.60  NM_015348.1 
1028 AMDHD2   1.60  NM_015944.2 
1029 EXOC2   1.60  NM_018303.4 
1030 SYNGR3   1.60  NM_004209.4 
1031 NFKB2   1.60  NM_001077493.1 
1032 KIAA0194   1.60  XM_001714730.1 
1033 LINGO2   1.59  NM_152570.1 
1034 NGRN   1.59  NM_016645.2 
1035 WASF2   1.59  NM_006990.2 
1036 GCGR   1.59  NM_000160.2 
1037 ERP29   1.59  NM_006817.3 
1038 LOC730278   1.59  XM_001126471.1 
1039 RPS27L   1.59  NM_015920.3 
1040 ACYP2   1.59  NM_138448.2 
1041 WBP2   1.59  NM_012478.3 
1042 GLG1   1.59  NM_012201.4 
1043 CLIP2   1.59  NM_032421.2 
1044 RALA   1.59  NM_005402.2 
1045 TBL2   1.59  NM_012453.2 
1046 CYLN2   1.59  NM_032421.1 
1047 TMEM184B   1.59  NM_012264.3 
1048 KLF6   1.59  NM_001300.4 
1049 P8   1.59  NM_012385.1 
1050 TMEM22   1.59  NM_001097599.1 
1051 ARMCX2   1.58  NM_177949.1 
1052 CARS   1.58  NM_001014438.1 
1053 ERCC5   1.58  NM_000123.2 
1054 YIF1B   1.58  NM_001031731.1 
1055 WDR26   1.58  NM_025160.4 
1056 OSTC   1.57  NM_021227.2 
1057 DNASE2   1.57  NM_001375.2 
1058 MBP   1.57  NM_001025100.1 
1059 ATM   1.57  NM_000051.3 
1060 PKIB   1.57  NM_032471.4 
1061 SPIRE1   1.57  NM_020148.2 
1062 BET1   1.57  NM_005868.4 
1063 ATP6V0D1   1.57  NM_004691.4 
1064 RAB18   1.57  NM_021252.3 
1065 SERPINE2   1.57  NM_006216.2 
1066 ADM   1.57  NM_001124.1 
1067 SELI   1.57  NM_033505.2 
1068 NHLRC3   1.57  NM_001017370.1 
1069 CCDC28A   1.57  NM_015439.2 
1070 EVI5L   1.57  NM_145245.2 
1071 GBE1   1.57  NM_000158.2 
1072 MAFB   1.57  NM_005461.3 
1073 LOC100132394   1.57  XM_001713809.1 
1074 AHCYL1   1.57  NM_006621.4 
1075 HSPC171   1.56  NM_014187.2 
1076 EBI2   1.56  NM_004951.3 
1077 RP11-529I10.4   1.56  NM_015448.1 
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1078 C2orf43   1.56  NM_021925.2 
1079 BECN1   1.56  NM_003766.2 
1080 LOC652968   1.56  NM_001037666.1 
1081 CHURC1   1.56  NM_145165.2 
1082 IRS1   1.56  NM_005544.1 
1083 BAG1   1.56  NM_004323.4 
1084 TMTC1   1.56  NM_175861.2 
1085 LOC646463   1.56  XM_001130106.1 
1086 FAM70B   1.56  XM_001130122.1 
1087 PTGS1   1.56  NM_080591.1 
1088 ASB1   1.56  NM_016114.3 
1089 THUMPD1   1.56  NM_017736.3 
1090 MAMDC4   1.56  NM_206920.2 
1091 LGALS1   1.56  NM_002305.3 
1092 TRIM25   1.56  NM_005082.4 
1093 HRASLS3   1.56  NM_007069.2 
1094 TOM1L2   1.56  NM_001082968.1 
1095 HERC3   1.56  NM_014606.1 
1096 ATP6V1E1   1.56  NM_001039367.1 
1097 TIPARP   1.56  NM_015508.3 
1098 ATP8B2   1.56  NM_020452.2 
1099 DACT1   1.56  NM_016651.4 
1100 GGT1   1.56  NM_005265.2 
1101 SRPK2   1.56  NM_182691.1 
1102 GPX1   1.56  NM_201397.1 
1103 UBE2H   1.56  NM_003344.2 
1104 SLC15A4   1.55  NM_145648.1 
1105 SYNJ2   1.55  NM_003898.2 
1106 TES   1.55  NM_152829.1 
1107 LOC731007   1.55  XM_001132080.1 
1108 PICALM   1.55  NM_007166.2 
1109 C12orf44   1.55  NM_001098673.1 
1110 FOXO1   1.55  NM_002015.3 
1111 ADAMTSL5   1.55  NM_213604.1 
1112 GSTO1   1.55  NM_004832.1 
1113 TM9SF1   1.55  NM_006405.5 
1114 RCN3   1.55  NM_020650.2 
1115 ABHD5   1.55  NM_016006.3 
1116 OSBP   1.55  NM_002556.2 
1117 TMED2   1.55  NM_006815.3 
1118 ZHX2   1.55  NM_014943.3 
1119 CD63   1.55  NM_001040034.1 
1120 FST   1.55  NM_013409.1 
1121 ANXA5   1.55  NM_001154.2 
1122 XPR1   1.55  NM_004736.2 
1123 CTSB   1.55  NM_147780.2 
1124 HSP90B1   1.55  NM_003299.1 
1125 CHST7   1.55  NM_019886.2 
1126 SFXN3   1.55  NM_030971.3 
1127 OSBP2   1.55  NM_030758.3 
1128 TM9SF4   1.55  NM_014742.2 
1129 LTBP2   1.55  NM_000428.2 
1130 SENP2   1.55  NM_021627.2 
1131 PKD2   1.54  NM_000297.2 
1132 APH1B   1.54  NM_031301.2 
1133 IGFL1   1.54  NM_198541.1 
1134 CBLB   1.54  NM_170662.3 
Number Gene symbol 
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1135 P2RY2   1.54  NM_002564.2 
1136 BDNF   1.54  NM_001709.3 
1137 RNF160   1.54  NM_015565.1 
1138 ARL1   1.54  NM_001177.3 
1139 NISCH   1.54  NM_007184.3 
1140 EXOSC1   1.54  XM_001131367.1 
1141 MED23   1.54  NM_004830.2 
1142 PSG5   1.54  NM_002781.2 
1143 SLC22A15   1.54  NM_018420.1 
1144 LOC338758   1.54  XM_931359.2 
1145 C19orf63   1.54  NM_175063.4 
1146 MIA3   1.54  NM_198551.2 
1147 RAB5A   1.54  NM_004162.3 
1148 RAC2   1.54  NM_002872.3 
1149 C3   1.54  NM_000064.1 
1150 CMTM3   1.53  NM_144601.2 
1151 BRI3   1.53  NM_015379.3 
1152 NOTCH3   1.53  NM_000435.1 
1153 LOC730358   1.53   
1154 AHNAK   1.53  NM_001620.1 
1155 OSTM1   1.53  NM_014028.3 
1156 KDELR1   1.53  NM_006801.2 
1157 FAM50A   1.53 Yes NM_004699.1 
1158 STAM2   1.53  NM_005843.3 
1159 IER5L   1.53  NM_203434.2 
1160 FKBP14   1.53  NM_017946.2 
1161 SLC41A2   1.53  NM_032148.2 
1162 CDC42EP2   1.53  NM_006779.2 
1163 RNF146   1.53  NM_030963.2 
1164 SQSTM1   1.53  NM_003900.3 
1165 KLHL21   1.53  NM_014851.2 
1166 GGTLC2   1.53  NM_199127.1 
1167 ABHD4   1.53  NM_022060.2 
1168 TMEM106B   1.53  NM_018374.2 
1169 FKBP2   1.52  NM_004470.2 
1170 CENTB2   1.52  NM_012287.3 
1171 IBTK   1.52  NM_015525.2 
1172 SAR1B   1.52 Yes NM_001033503.1 
1173 OSBPL7   1.52  NM_145798.2 
1174 GK   1.52  NM_203391.1 
1175 CORO1C   1.52  NM_014325.2 
1176 C1R   1.52  NM_001733.4 
1177 WTAP   1.52  NM_152858.1 
1178 C2orf29   1.52  NM_017546.3 
1179 C9orf150   1.52  NM_203403.1 
1180 FOSL1   1.52  NM_005438.2 
1181 USP4   1.52  NM_003363.2 
1182 TMEM55A   1.52  NM_018710.1 
1183 IL13RA1   1.52  NM_001560.2 
1184 TGFA   1.52  NM_003236.1 
1185 SEC63   1.52  NM_007214.3 
1186 CD58   1.52  NM_001779.1 
1187 CXCL2   1.52  NM_002089.3 
1188 ABLIM2   1.52  NM_032432.3 
1189 GGT2   1.52  XM_001129425.1 
1190 GGPS1   1.52  NM_001037277.1 
1191 DDEF2   1.52  NM_003887.1 
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1192 TAF9L   1.52  NM_015975.3 
1193 MGAT1   1.52  NM_002406.2 
1194 SLC22A23   1.52  NM_015482.1 
1195 CA12   1.51  NM_001218.3 
1196 SEC16A   1.51  NM_014866.1 
1197 ATP6AP1   1.51  NM_001183.4 
1198 PSMD9   1.51  NM_002813.4 
1199 HSPA12A   1.51  NM_025015.2 
1200 MAP4K2   1.51  NM_004579.2 
1201 SAT1   1.51  NM_002970.1 
1202 NUCB2   1.51  NM_005013.2 
1203 LOC653354   1.51  XM_927053.2 
1204 LAMC1   1.51  NM_002293.2 
1205 GORASP2   1.51  NM_015530.3 
1206 SLC30A1   1.51  NM_021194.2 
1207 FOXO3   1.51  NM_201559.2 
1208 PRKAR1A   1.51  NM_002734.3 
1209 ASAH1   1.51  NM_177924.2 
1210 C16orf7   1.51  NM_004913.2 
1211 HINT3   1.51  NM_138571.4 
1212 TMED3   1.51  NM_007364.2 
1213 LMBRD1   1.51  NM_018368.2 
1214 FNDC3A   1.51  NM_001079673.1 
1215 LIMS2   1.51  NM_017980.3 
Number Gene symbol 
Fold change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
1216 NUAK1   1.51  NM_014840.2 
1217 A2LD1   1.51  NM_033110.1 
1218 LFNG   1.51  NM_001040167.1 
1219 ZDHHC13   1.51  NM_001001483.1 
1220 CIB1   1.51  NM_006384.2 
1221 PINK1   1.51  NM_032409.2 
1222 C1orf128   1.51  NM_020362.3 
1223 TBC1D23   1.51  NM_018309.1 
1224 SCPEP1   1.51  NM_021626.1 
1225 C5orf28   1.51  NM_022483.3 
1226 LZTFL1   1.51  NM_020347.2 
1227 ADAM19   1.50  NM_033274.2 
1228 S100A11   1.50  NM_005620.1 
1229 ENTPD7   1.50  NM_020354.2 
1230 DFFB   1.50  NM_004402.2 
1231 CIR1   1.50  NM_004882.3 
1232 ARMCX5   1.50  NM_022838.2 
1233 DNAJC1   1.50  NM_022365.3 
1234 TGIF1   1.50  NM_170695.2 
1235 ASB3   1.50  NM_145863.1 
1236 LOC650128   1.50  XM_945833.1 
1237 SRPRB   1.50  NM_021203.2 
1238 HIPK2   1.50  NM_022740.2 
 
 
 
Appendix V: Membrane trafficking-related genes affected in pre-miR-517a-transfected 
HeLa cells. Genes are listed alphabetically.   
(A) Membrane trafficking-related genes downregulated by miR-517a. 
 
Number 
Gene 
symbol 
Expression change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
1 ABL1   -1.71  NM_007313.2 
2 AGAP3   -2.17  NM_001042535.1 
3 AP1S2 -2.21 -2.31 -2.02 Yes NM_003916.3 
4 AP3S1  -1.63   NM_001002924.1 
5 ARF3  -1.53   NM_001659.1 
6 ARL17B   -1.55  NM_001103154.1 
7 ATG10  -1.70 -1.65 Yes NM_031482.3 
8 CENPF   -1.77  NM_016343.3 
9 FNBP1  -1.65   NM_015033.2 
10 HRAS   -1.54 Yes NM_005343.2 
11 INPPL1  -1.52  Yes NM_001567.2 
12 KIF18A   -1.66  NM_031217.2 
13 KIF20A   -1.52  NM_005733.1 
14 LDLR   -1.99 Yes NM_000527.2 
15 LRSAM1 -1.67 -1.59   NM_138361.3 
16 NME1   -2.18  NM_198175.1 
17 NUP62CL   -1.80  NM_017681.1 
18 NUPL2 -1.78 -1.56 -1.79 Yes NM_007342.1 
19 PEX5  -1.50   NM_000319.3 
20 RAB26  -1.75 -2.98  NM_014353.4 
21 RAB35 -1.74  -1.57  NM_006861.4 
22 RAB40B -1.95 -2.77 -2.95  NM_006822.1 
23 RAB40C -1.74 -1.53   NM_021168.2 
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24 RAC1  -1.91 -4.11  NM_018890.2 
25 RANBP3   -1.58  NM_007320.1 
26 SCG2   -1.61  NM_003469.3 
27 SELENBP1   -1.53  NM_003944.2 
28 SNX5  -1.64 -1.89  NM_152227.1 
29 TAP2   -1.66  NM_000544.3 
30 TOMM40   -1.61  NM_006114.1 
31 TPR   -2.08  NM_003292.2 
32 TRIM23  -1.54   NM_001656.3 
 
 
(B) Membrane trafficking-related genes upregulated by miR-517a. 
 
Number 
Gene 
symbol 
Expression change Predicted 
target? 
Gene accession 
number 12h 24h 48h 
1 ARF1   1.87  NM_001024228.1 
2 ARF4   2.71  NM_001660.2 
3 ARFGAP1  2.11 3.43  NM_018209.2 
4 ARFGAP3  1.62 2.06  NM_014570.3 
5 ARL1   1.54  NM_001177.3 
6 ARL8B 2.02 2.20 3.90  NM_018184.2 
7 ATG4A  1.59 1.74  NM_178270.1 
8 BET1   1.57  NM_005868.4 
9 CANX   1.94  NM_001746.3 
10 CHMP2B   1.64  NM_014043.2 
11 COG3   2.04  NM_031431.2 
12 COG5   2.17  NM_006348.2 
13 COG6   2.22  NM_020751.1 
14 COPE   1.62  NM_199442.1 
15 DMBT1  1.51 1.94  NM_017579.1 
16 DNER   1.93  NM_139072.3 
17 ERP29   1.59  NM_006817.3 
18 EXOC2   1.60  NM_018303.4 
19 GEM  1.57 1.60  NM_181702.1 
20 GNPTAB   1.66  NM_024312.3 
21 GOLT1B   1.99 Yes NM_016072.3 
22 GOSR2   1.63  NM_001012511.1 
23 HSP90B1   1.55  NM_003299.1 
24 KDELR3  1.84 4.42  NM_016657.1 
25 LMAN1   1.78  NM_005570.2 
26 LMAN2   1.82  NM_006816.1 
27 LTBP2   1.55  NM_000428.2 
28 MAMDC4   1.56  NM_206920.2 
29 MCFD2  1.62 1.91  NM_139279.3 
30 MIA3   1.54  NM_198551.2 
31 NECAP2   1.64  NM_018090.3 
32 NUP35 2.08 2.43 1.88 Yes NM_138285.3 
33 PDIA4   1.74  NM_004911.3 
34 RAB11FIP1 2.16 3.08 3.00  NM_001002814.1 
35 RAB11FIP5   1.97  NM_015470.2 
36 RAB18   1.57  NM_021252.3 
37 RAB22A  2.25 2.14  NM_020673.2 
38 RAB32   1.74  NM_006834.2 
39 RAB5A   1.54  NM_004162.3 
40 RAB6A   1.83  NM_198896.1 
41 RAB8B 2.21 2.26 2.81  NM_016530.2 
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42 RAC2   1.54  NM_002872.3 
43 RALA   1.59  NM_005402.2 
44 RAN  1.59   NM_006325.2 
45 RAP1B 1.73 2.14 2.67  NM_015646.4 
46 RHOBTB1  1.50   NM_198225.1 
47 RHOQ   2.20  NM_012249.3 
48 RHOU   1.78  NM_021205.4 
49 RINT1   1.61  NM_021930.4 
50 RIT1   2.02  NM_006912.4 
51 RND3   1.80  NM_005168.3 
52 RRBP1  1.57 2.17  NM_001042576.1 
53 SEC16A   1.51  NM_014866.1 
54 SEC31A   2.02  NM_014933.2 
55 SEC61A1   2.20  NM_013336.3 
56 SEC61G   1.65  NM_014302.3 
57 SEC63   1.52  NM_007214.3 
58 SENP2   1.55  NM_021627.2 
59 SERP1  1.60 1.92  NM_014445.3 
60 SLC15A4   1.55  NM_145648.1 
61 TM9SF1   1.55  NM_006405.5 
62 TMED2   1.55  NM_006815.3 
63 TMED3   1.51  NM_007364.2 
64 TOM1   3.33  NM_005488.1 
65 UNC50   1.68  NM_014044.4 
66 VLDLR  1.58 3.23  NM_001018056.1 
67 VPS18   1.64  NM_020857.2 
68 WASF2   1.59  NM_006990.2 
69 YIF1A   2.36  NM_020470.1 
70 YIPF5  1.77 2.32  NM_030799.6 
71 ZFYVE20 1.60 1.85 1.66  NM_022340.2 
72 ZMAT3   2.30  NM_152240.1 
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